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Résumé
Depuis plusieurs décennies, les médecins peuvent accéder aux organes creux avec des méthodes
endoscopiques, qui remplissent à la fois la fonction d’outil diagnostique et chirurgical dans nom-
bre de disciplines de la médecine moderne (par ex. en urologie, pneumologie, gastroentérologie).
Malheureusement, l’endoscopie conventionnelle en lumière blanche (LB) montre une sensibilité
limitée pour les lésions cancéreuses précoces. Par conséquent, plusieurs méthodes endoscopiques
utilisant l’imagerie de ﬂuorescence ont été développées pour surmonter cette limitation. La
ﬂuorescence endogène et exogène-induite a été étudiée, menant à des produits commercialisés.
En eﬀet, la bronchoscopie en autoﬂuorescence, et la cystoscopie utilisant la ﬂuorescence des
porphyrines sont maintenant sur le marché.
Les méthodes de dépistage endoscopiques utilisant la ﬂuorescence montrent une sensibilité
très élevée pour les lésions pré-cancéreuses, souvent invisibles en LB, mais elles souﬀrent encore
d’une spéciﬁcité limitée, principalement due au taux élevé de faux-positifs. Bien que la plupart de
ces faux-positifs puissent être facilement rejetés en observation LB, il est plus diﬃcile d’identiﬁer
des anomalies tissulaires telles que les zone inﬂammatoires, les hyperplasies et les métaplasies.
Cela se traduit souvent en des biopsies supplémentaires, péjorant encore la spéciﬁcité. Par
conséquent, le but de cette thèse est d’étudier une méthode novatrice, rapide et commode pour
caractériser in situ les zones positives en ﬂuorescence pendant l’endoscopie et, plus généralement,
pour optimiser l’appareillage endoscopique existant. Dans cette thèse, plusieurs évaluations
cliniques ont été eﬀectuées soit dans l’arbre trachéo-bronchique, soit dans la vessie.
Dans la vessie, l’imagerie de ﬂuorescence pour la détection des tumeurs superﬁcielles utilise
la production et l’accumulation sélective dans les tissus cancéreux de porphyrines ﬂuorescentes,
principalement la protoporphyrine IX (PpIX), après une instillation de Hexvix R© pendant une
heure. Dans cette thèse, nous avons adapté un cystoscope rigide pour observer la muqueuse
vésicale avec un grossissement élevé (GE), ceci aﬁn de distinguer les vrais- des faux-positifs dé-
tectés par ﬂuorescence. L’optique permettant le GE peut-être utilisée soit avec lumière blanche,
soit en ﬂuorescence, avec un grossissement variant entre 30× – pour l’observation standard – et
650×. Une molette permet l’ajustement continu in situ du grossissement pendant la cystoscopie.
Dans le régime élevé de grossissement, le plus petit diamètre du champ visuel est de 600 microns
et la résolution est de 2.5 microns, le cystoscope étant dans ce cas précis au contact avec la
muqueuse vésicale. Avec ce cystoscope CGE, nous avons caractérisé – avec un éclairement en
lumière blanche 370–700 nm – la vascularisation superﬁcielle des zones positives en ﬂuorescence
aﬁn de distinguer les tissus cancéreux des non-cancéreux. Ce procédé nous a permis d’établir une
classiﬁcation utilisant les motifs vasculaires observés. 72 patients examinés avec la cystoscopie
de ﬂuorescence Hexvix R© ont été inclus dans l’étude. La comparaison de la classiﬁcation GE
avec les résultats d’histopathologie a conﬁrmé 32/33 (97%) de biopsies cancéreuses, et a rejeté
17/20 (85%) de lésions non-cancéreuses. Aucun changement vasculaire n’a pu être visualisé sur
la seule lésion positive qui était négative GE, parce que ce carcinome sarcomatoïde trouvait son
origine ailleurs que dans l’urothélium. Nous avons montré avec cette étude qu’un grossissement
de l’ordre de 80–100× pouvait constituer un bon compromis entre l’endoscopie macroscopique
en ﬂuorescence et microscopie en réﬂectance. Aﬁn de rendre cette approche plus quantitative,
des algorithmes de traitement d’images (segmentation, extraction de squelette, extraction de
l’information globale) ont été également implémentés dans cette thèse.
Aﬁn de mieux visualiser les vaisseaux, nous avons augmenté leur contraste par rapport à
l’arrière-plan par des méthodes optiques. Puisque l’hémoglobine est un absorbeur puissant,
nous avons visé ses deux pics d’absorption en plaçant deux ﬁltres passe-bande (405±50 nm
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bleu, 550±50 nm vert) dans la fontaine de lumière. La cystoscopie CGE a été alors exécutée
séquentiellement avec l’illumination blanche, bleue et verte. Les deux dernières ont montré un
contraste plus élevé des vaisseaux par rapport au fond, mettant en évidence la vascularisation à
plusieurs profondeurs grâce à la pénétration diﬀérenciée des longeurs d’onde utilisées.
Pendant la cystoscopie de ﬂuorescence, nous avons souvent observé que les images sont
ﬂoutées par un écran bleu-vert entre l’extrémité de l’endoscope et la muqueuse vésicale. Puisque
cet eﬀet est augmenté par la production d’urine, il est encore plus marqué avec les endo-
scopes ﬂexibles (qui disposent d’un rinçage limité) et les imageurs qui utilisent seulement
l’autoﬂuorescence comme arrière-plan. En eﬀet, quand la vessie n’est pas rinsée régulièrement,
on observe facilement des écoulements bleu-vert sortant des uretères. Pour cette raison, on a
supposé que quelques ﬂuorophores contenus dans l’urine sont excités par la lumière d’excitation,
et apparaissent bleu-vert à l’écran. Cet eﬀet peut altérer la visualisation de la muqueuse vési-
cale et les lésions cancéreuses. Par conséquent, la sensibilité de la cystoscopie de ﬂuorescence
est diminuée. Dans cette thèse, nous avons identiﬁé les principaux produits responsables de la
ﬂuorescence du liquide, et avons optimisé la conception spectrale en conséquence.
Dans l’arbre trachéo-bronchique, le contraste de ﬂuorescence utilise la forte diminution
d’autoﬂuorescence (AF) de la bande spectrale verte (environ 500 nm) sur les lésions cancéreuses
précoces et une diminution relative moins importante de la bande spectrale rouge (> 600 nm),
lorsque la muqueuse bronchique est excitée avec de la lumière bleu violet (environ 410 nm). Il a
été montré au cours des dernières années que ce contraste peut être attribué à un eﬀet combiné
de l’épithélium épaissi et à une concentration plus élevée d’hémoglobine dans le tissu sous-jacent
des lésions cancéreuses précoces.
Dans cette thèse, nous avons contribué à la conception de plusieurs nouveaux prototypes, qui
ont été plus tard évalués en clinique. En premier lieu, nous avons prouvé que l’excitation à bande
étroite dans le bleu-violet pourrait augmenter le contraste tumeur-tissu sain dans la bande spec-
trale verte. Puis, nous avons mesuré les variations en intensité d’AF intra- et inter-patients aﬁn
d’optimiser la réponse spectrale de l’imageur endoscopique. A cette ﬁn, nous avons développé
une référence endoscopique à placer près de la muqueuse bronchique pendant la bronchoscopie.
Finalement, nous avons évalué sur 144 patients un bronchoscope AF nouvellement équipé avec
la lumière bleu-rétrodiﬀusée. Ce nouveau dispositif a montré une sensibilité augmentée pour les
lésions pré-néoplasiques.
A l’instar de ce que nous avons observé dans la vessie, il est très probable que les nouveaux
développements en imagerie (y compris l’imagerie vasculaire) facilitent la distinction des vrais et
faux-positifs dans la bronchoscopie en AF. Dans cette étude, nous avons montré que le grossisse-
ment permettait de résoudre des vaisseaux d’un diamètre d’environ 30 microns. Cette résolution
est probablement suﬃsante pour identiﬁer les critères vasculaires de Shibuya (boucles, mailles,
vaisseaux pointillés) sur les lésions positives en AF. Ces critères lui permettent d’identiﬁer les
lésions précancéreuses, et potentiellement permettrait d’abaisser le taux de faux-positifs avec
notre imageur AF. Ce grossissement a également amélioré la bronchoscopie de routine, puisqu’il
fournit des images plus structurées à l’opérateur.
Mots-clés: tumeurs vésicales, cystoscopie de ﬂuorescence, endoscopie à grossissement, im-
agerie vasculaire, Hexvix R©, CysviewTM, hexylester d’acide aminolévulinique, motifs vasculaires,
angiogenèse, cancer bronchique, bronchoscopie, autoﬂuorescence, imagerie et spectroscopie de
ﬂuorescence, phantomes optiques, évaluation clinique.
Abstract
Since several decades, the physicians are able to access hollow organs with endoscopic methods,
which serve both as diagnostic and surgical means in a wide range of disciplines of the modern
medicine (e.g. urology, pneumology, gastroenterology). Unfortunately, white light (WL) en-
doscopy displays a limited sensitivity to early pre-cancerous lesions. Hence, several endoscopic
methods based on ﬂuorescence imaging have been developed to overcome this limitation. Both
endogenous and exogenously-induced ﬂuorescence have been investigated, leading to commer-
cial products. Indeed, autoﬂuorescence bronchoscopy, as well as porphyrin-based ﬂuorescence
cystoscopy, are now on the market.
As a matter of fact, ﬂuorescence-based endoscopic detection methods show very high sensi-
tivity to pre-cancerous lesions, which are often overlooked in WL endoscopy, but they still lack
speciﬁcity mainly due to the high false-positive rate. Although most of these false positives can
easily be rejected under WL observation, tissue abnormalities such as inﬂammations, hyper-
plasia, and metaplasia are more diﬃcult to identify, often resulting in supplementary biopsies.
Therefore, the purpose of this thesis is to study novel, fast, and convenient method to charac-
terize ﬂuorescence positive spots in situ during ﬂuorescence endoscopy and, more generally, to
optimize the existing endoscopic setup. In this thesis, several clinical evaluations were conducted
either in the tracheo-bronchial tree and the urinary bladder.
In the urinary bladder, ﬂuorescence imaging for detection of non-muscle invasive bladder
cancer is based on the selective production and accumulation of ﬂuorescing porphyrins, mainly
protoporphyrin IX (PpIX), in cancerous tissues after the instillation of Hexvix R© during one hour.
In this thesis, we adapted a rigid cystoscope to perform high magniﬁcation (HM) cystoscopy
in order to discriminate false from true ﬂuorescence positive ﬁndings. Both white light and
ﬂuorescence modes are possible with the magniﬁcation cystoscope, allowing observation of the
bladder wall with magniﬁcation ranging between 30× – for standard observation – and 650×.
The optical zooming setup allows adjusting the magniﬁcation continuously in situ. In the high
magniﬁcation regime, the smallest diameter of the ﬁeld of view is 600 microns and the resolution
is 2.5 microns, when in contact with the bladder wall. With this HM cystoscope, we characterized
the superﬁcial vascularization of the ﬂuorescing sites in WL (370–700 nm) reﬂectance imaging
in order to discriminate cancerous from non-cancerous tissues. This procedure allowed us to
establish a classiﬁcation based on observed vascular patterns. 72 patients subject to Hexvix R©
ﬂuorescence cystoscopy were included in the study. Comparison of HM cystoscopy classiﬁcation
with histopathology results conﬁrmed 32/33 (97%) cancerous biopsies, and rejected 17/20 (85%)
non-cancerous lesions. No vascular alteration could be observed on the only positive lesion that
was negative in HM mode, probably because this sarcomatoid carcinoma was not originating in
the bladder mucosa. We established with this study that a magniﬁcation ranging between 80×
and 100× is an optimal tradeoﬀ to perform both macroscopic PDD and HM reﬂectance imaging.
In order to make this approach more quantitative, diﬀerent algorithms of image processing (vessel
segmentation and skeletonisation, global information extraction) were also implemented in this
thesis.
In order to better visualize the vessels, we improved their contrast with respect to the
background. Since hemoglobin is a very strong absorber, we targeted the two hemoglobin
absorption peaks by placing appropriate bandpass ﬁlters (blue 405±50 nm, green 550±50 nm)
in the light source. HM cystoscopy was then performed sequentially with WL, blue and green
illumination. The two latter showed higher vessel-to-background contrast, identifying diﬀerent
layers of vascularization due to the light penetration depth.
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During ﬂuorescence cystoscopy, we often observed that the images are somehow “blurred”
by a greenish screen between endoscope tip and bladder mucosa. Since this eﬀect is enhanced
by the urine production, it is more visible with ﬂexible scopes (lower ﬂushing capabilities) and
imaging systems that collect only autoﬂuorescence as background. Indeed, when the bladder
is not ﬂushed regularly, greenish ﬂows coming out of the ureters can easily be observed. For
this reason, it is supposed that some ﬂuorophores contained in the urine are excited by the
photodetection excitation light, and appear greenish on the screen. This eﬀect may impair the
visualization of the bladder mucosa, and thus cancerous lesions, and lowers sensitivity of the
ﬂuorescence cystoscopy. In this thesis, we identiﬁed the main metabolites responsible for the
liquid ﬂuorescence, and optimized the spectral design accordingly.
In the tracheo-bronchial tree, the ﬂuorescence contrast is based on the sharp autoﬂuorescence
(AF) decrease on early cancerous lesions in the green spectral region (around 500 nm) and a
relatively less important decrease in the red spectral region (> 600 nm) when excited with blue-
violet light (around 410 nm). It has been shown over the last years, that this contrast may be
attributed to a combined eﬀect of epithelium thickening and higher concentration of hemoglobin
in the tissues underneath the (pre-)cancerous lesions.
In this thesis, we contributed to the deﬁnition of the input design of several new prototypes,
that were subsequently tested in the clinical environment. We ﬁrst showed that narrow-band
excitation in the blue-violet could increase the tumor-to-normal spectral contrast in the green
spectral region. Then, we quantiﬁed the intra- and inter-patient variations in the AF intensities
in order to optimize the spectral response of the endoscopic ﬂuorescence imaging system. For
this purpose, we developed an endoscopic reference to be placed close to the bronchial mucosa
during bronchoscopy. Finally, we evaluated a novel AF bronchoscope with blue-backscattered
light on 144 patients. This new device showed increased sensitivity for pre-neoplastic lesions.
Similar to what we observed in the bladder, it is likely that developing new imaging capa-
bilities (including vascular imaging) will facilitate discriminating true from false positive in AF
bronchoscopy. Here, we demonstrated that this magniﬁcation allowed us to resolve vessels with
a diameter of about 30 µm. This resolution is likely to be suﬃcient to identify Shibuya’s vascular
criteria (loops, meshes, dotted vessels) on AF positive lesions. This criteria allow him to rec-
ognize pre-cancerous lesions, and thus can potentially decrease the false-positive rate with our
AF imaging system. This magniﬁcation was also showed to be better for routine bronchoscopy,
since it delivers sharper and more structured images to the operator.
Keywords: bladder cancer, ﬂuorescence cystoscopy, high magniﬁcation, vascular imaging,
Hexvix R©, CysviewTM, hexaminolevulinate, vessel patterns, angiogenesis, bronchial cancer, aut-
oﬂuorescence, bronchoscopy, ﬂuorescence imaging and spectroscopy, optical phantoms, clinical
evaluation.
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Foreword
This manuscript is the ﬁnal report about my research activity as a PhD student in the Biomedical
Photonics Group of Prof. Hubert van den Bergh, under the supervision of Dr. Georges Wagnières,
at the Ecole Polytechnique Fédérale de Lausanne in Switzerland. Some parts of this report have
been published or submitted during the course of my Ph.D. thesis. I therefore included the text
of the publications with a brief introduction instead of an original chapter whenever relevant.
In such a case, the reference is clearly stated.
As will be seen in the author’s list of the published sections of this work, many studies
has been done in close collaboration with other people. Whenever relevant (i.e. whenever I
don’t appear as the ﬁrst author of a paper that has been include in my report), I stated in
the introduction what my exact contribution was. It should be understood that those papers
have been included in my report with full knowledge and agreement from my co-authors and
supervisor.
This work is the result of multidisciplinary research approaches intended to contribute to
improved management of a major heath problem: cancer. In this report, we will focus on
the lesions of the tracheo-bronchial tree and the urinary bladder. They are frequent cancers
but, unfortunately, they are still diﬃcult to diagnose in the early stages of development with
conventional detection methods. Interestingly, over the last decades, several endoscopic methods
based on ﬂuorescence imaging have been reported. Both endogenous and exogenously-induced
ﬂuorescence have been investigated, leading to commercial products. Indeed, autoﬂuorescence
bronchoscopy, as well as porphyrin-based ﬂuorescence cystoscopy, are now commercialized.
Both methods have been reported to have a high sensitivity, but still suﬀer from a limited
speciﬁcity, mainly attributed to the high rate of false-positive lesions. This thesis is focused
on the optimization of endoscopic visual contrast between cancerous lesions and healthy tissue,
and on the rejection of false-positive in both organs, mainly with the help of high magniﬁcation
vascular imaging.
Chapter 1 gives a brief overview on tissue optics, describing the light-tissue interactions
(dispersion, absorption, and scattering). It also introduces some ﬂuorescence basic concepts.
Chapter 2 deals with the issue of clinical cancer detection by optical imaging. It describes
the principles of reﬂectance and ﬂuorescence endoscopic imaging, and their applications to cancer
diagnostic. After a short technical review about instrumentation aspects, we describe the state-
of-the-art in high magniﬁcation imaging. The special case of confocal endoscopy is discussed
separately. Finally, we explain some statistical concepts that often intervene in clinical studies
(sensitivity, speciﬁcity, likelihood and odds ratios).
Part I (Chapter 3, 4, 5 and 6) deals with bladder cancer. Chapter 3 is a brief sum-
mary of some facts about bladder cancer, the current methods of detection and their limits,
as well as the current methods of management of the disease. It also summarizes the devel-
opment of porphyrin-based photodetection of bladder cancer. It reviews the methods of false-
positive characterization, and describes the mechanisms underlying angiogenesis in bladder can-
cer. Chapter 4 describes the optimization of the spectral design for ﬂuorescence cystoscopy,
with a dedicated interest to the ﬂuorescing metabolites present in the liquid ﬁlling the bladder.
Chapter 5 deals with the development of high magniﬁcation (HM) reﬂectance imaging
in the bladder. After the optical characterization of the dedicated cystoscope, we present the
results of a clinical study, evaluating the potential to reject false-positive lesions with the help
of HM cystoscopy. In order to make this approach more quantitative, the next sections deal
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with diﬀerent algorithms of image processing (vessel segmentation and skeletonisation, global
information extraction). Chapter 6 sums up all the contributions related to bladder cancer,
and outlooks some future prospects.
Part II (Chapter 7, 8, 9, 10, 11, and 12) deals with bronchial cancer. Chapter 7 is a
brief summary of some facts about bronchial cancer, as well as the current methods of manage-
ment of the disease. It also summarizes the development of autoﬂuorescence photodetection of
bronchial cancer, and describes the mechanisms underlying angiogenesis in the bronchi.
Chapter 8 evaluates if narrow-band imaging improves the spectral contrast in autoﬂuores-
cence imaging. Chapter 9 quantiﬁes the inter-patients variations in autoﬂuorescence intensity
in order to scale the dynamic range of future endoscopic setup accordingly. For this purpose,
it also describes the development and characterization of an endoscopic reference, that can be
placed close to the bronchial mucosa.
Chapter 10 summarizes a clinical study evaluating the performance of a new autoﬂuores-
cence bronchoscope prototype on 147 patients. This new device has shown a high sensitivity
for (pre-)neoplasia. Chapter 11 introduces the high magniﬁcation imaging concept in the
bronchi with preliminary clinical tests, providing a proof-of-concept of vascular imaging in the
tracheo-bronchial tree. Chapter 12 sums up all the contributions related to bronchial cancer.
Some appendices have been added to this manuscript summarizing some minor contributions.
Appendix A reviews a clinical study with autoﬂuorescence bronchoscopy showing a great
beneﬁt for Head&Neck cancer patients. Appendix B lists the morphological criteria for bladder
cancer classiﬁcation. It also reviews an interesting scoring system, that predicts prognosis and
recurrence in bladder cancer patients. Appendix C introduces narrow-band excitation in the
bladder to improve tumor-to-healthy contrast. Appendix D illustrates the development of a
ﬂuorescence validation sample to assess the correct functioning of endoscopic instrumentation.
Appendix E deals with the color presentation of optical contrasts in endoscopy and its inﬂuence
on tumor detectability. Finally, Appendix F presents some attempts of spectral optimization
in HM endoscopy.
As stated above, the common thread of all these studies is the use of ﬂuorescence imaging with
the addition of reﬂectance high magniﬁcation imaging. We showed that the combination of these
two techniques allows a higher sensitivity and a better rejection of false-positive lesions.
Finally, I would like to apologize to the native English speaker reader for my less that perfect
command of their language.
Introduction

Chapter 1
Introduction to Tissue Optics
The ﬁrst part of this chapter gives an introduction to the physical basics of tissue optics (dis-
persion, absorption, scattering, and diﬀusion). The second part gives an overview of the optical
properties of biological tissues, dominated by absorption, scattering and ﬂuorescence emission.
Interactions of light with biological tissues and structures was at the origin of all optical
diagnostic or therapeutic tool, leading to the common topic of photomedicine. Light propagation
in a turbid medium (e.g. in a biological tissue) is ruled by reﬂection and refraction, absorption,
and scattering. These four interaction mechanisms deﬁne the optical properties of the medium.
In the framework of photomedicine, the study of these interactions allows to ﬁnd how much
light energy per unit area per unit time reaches a target chromophore, and, thus, to develop
characterization and therapeutic methods based on the tissue optical properties.
The absorption coeﬃcient µa, the scattering coeﬃcient µs, the index of refraction n and the
phase function Φ are referred to as the fundamental or “microscopic” optical parameters. Each
type of tissue has its speciﬁc optical parameters, which can lead to specialized diagnostic and
therapeutic applications. The macroscopic parameters, µeﬀ, δ, R, and T are generally measured
from thick tissue samples. The microscopic parameters can be evaluated from the macroscopic
ones using theoretical models for light propagation. Table 1.1 summarizes the tissue optical
parameters.
1.1 Dispersion
The present section will treat microscopic origin of the dispersion. The refractive index n of a
medium is deﬁned to be the ratio between light velocity in the vacuum co (2.99793 × 108 m/s)
and in the medium c. The refractive index n is frequency-dependent, and thus wavelength-de-
pendent.
n = co/c with c = λ · ν
If one applies an external electric ﬁeld onto a molecule, its surrounding electron cloud is distorted.
The internal charge distribution is thus modiﬁed and a dipole moment is generated. In case of
an incident harmonic electromagnetic (EM) wave, time-varying forces and torques act upon
internal charge distribution and generate oscillating dipoles. When excited by a light wave, the
electron will oscillate at the driving frequency, and emit light at this frequency. If one considers
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Fundamental microscopic parameters
µa Absorption coeﬃcient [cm−1]
µs Scattering coeﬃcient [cm−1]
n Refraction index dimensionless
g Anisotropy factor dimensionless
Dependent microscopic parameters
a µs/µa Optical albedo
µt µa + µs Total extinction coeﬃcient [cm−1]
Lt 1/µt Free optical path length [cm]
µ′s (1 − g)µs Reduced scattering coeﬃcient [cm−1]
Macroscopic parameters
µeﬀ
√
3µa · (µa + µ′s) Eﬀective attenuation coeﬃcient [cm−1]
δ 1/µeﬀ Eﬀective penetration depth [cm]
R Diﬀuse reﬂectance
T Diﬀuse transmittance
Table 1.1: Tissue optical parameters. The fundamental optical parameters are the absorption coef-
ﬁcient µa, the scattering coeﬃcient µs, and the refraction index n. The other parameters can be deduced
from these parameters.
the electron to be elastically bound to the nucleus, like a harmonic oscillator with a natural
or resonant frequency ωo, the restoring force F is linear for small displacement, according to
Hooke’s law, with k being a positive constant, and me the electron mass (9.109 × 10−31 kg):
F = −k · x
The resonance frequency will be
ωo =
√
k
me
In this model, one assumes that the electron cloud is elastically bound to the nucleus isotropically
(i.e. with the same force in all directions), and one only considers the harmonic response of the
electron cloud to the driving force of the incident E-ﬁeld. Assuming such a linear response
is correct, while the induced displacements are small. Conversely, larger EM ﬁelds (e.g. high
intensity laser pulses) can induce larger displacements, and non-linear restoring forces. Thus,
higher order, anharmonic terms should be added to this expression, leading to non-linear optics.
In complex materials, the molecular spring constant can change for diﬀerent polarization of the
E-ﬁeld. This will lead to diﬀerent indices of refraction for diﬀerent E-ﬁeld polarizations (n‖,n⊥),
deﬁned as birefringence.
If one considers an electron with position xe(t) and driven by a light wave, Eoe−iωt:∑
i
−→
Fi = driving force + restoring force = mass · acceleration
eEoe
−iωt − meω2oxe = me
d2xe
dt2
(1.1)
The solution is :
xe(t) =
[
e/me
ω2o − ω2
]
Eoe
−iωt (1.2)
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Vacuum (or air) 
n1=1
Medium 
n2
Absorption depth = 1/α
wavelength decreasesλ λ/n
nkk
-γ/2
Frequency ω
α n-1
0 0
γ/2
ωο
Figure 1.1: Light propagation between two diﬀerent media and resonance peaks
The amplitude of oscillation is frequency-dependent, with the maximum displacement occurring
at ωo, the resonance frequency. xe(t) is the displacement of each charge vs. time, e is the
electron charge (1.602×10−19 coulombs), me the electron mass, and ω the oscillating frequency.
In this context, a damped forced oscillator would ﬁt as a more realistic model though. The
harmonic oscillator experiences thus a sinusoidal force and viscous drag γ (friction). One should
add a viscous drag term meγdxe/dt to Equation 1.1:
me
d2xe
dt2
+ meγ
dxe
dt
+ meω2oxe = eEoe−iωt
The solution is now:
xe(t) =
1
ω2o − ω2 − iωγ
e
me
Eoe
−iωt (1.3)
The electron still oscillates at the driving frequency of the light wave, but with an amplitude
and a phase that depend on the relative frequencies. It can be rewritten as:
xe(t) = xoe−i(ωt−φ)
where xo = Eo
e
me
1√
(ω2o − ω2)2 + γ2ω2
, the amplitude (1.4)
and φ = arctan
(
γω
ω2o − ω2
)
, the phase lag (1.5)
The incident light wave will induce a polarization in the medium deﬁned as
P (t) = N · e · xe(t)
where N is the number density of charges.
It can be shown (as illustrated in Figure 1.1) that the electric ﬁeld in the vacuum is given by
E(z, t) = Eoei(kz−ωt)
and in the medium
E(z, t) = Eoe(−α/2)zei(nkz−ωt)
We can also show that absorption causes attenuation of the ﬁeld:
α = Ne
2
4meoco
γ/2
(ωo − ω)2 + (γ/2)2
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Refractive index n changes the k-vector:
n − 1 = Ne
2
4meo
ωo − ω
(ωo − ω)2 + (γ/2)2
Figure 1.1 illustrates the inﬂuence of the incident light frequency ω on the absorption coeﬃcient
α and the refractive index n:
ωo  ω ⇒ n hardly depends on λ  transparency of the medium (i.e. colorless)
ω → ωo ⇒ n increases with λ  normal dispersion
ω ≈ ωo ⇒ n is dominated by absorption & viscous drag
 anomalous dispersion between −γ/2 and γ/2
1.2 Absorption
t t
I IIo Io
ε, c, µa ε, c, µs
Figure 1.2: Absorption and scattering through a turbid medium
In tissue optics, one calls absorption the extraction of energy from light by matter. The
absorption of light energy is the primary mechanism that allows light from a source (e.g. laser)
to produce physical eﬀects on tissue in light-based therapeutic applications. Since numerous
chromophores lie in the tissue and act as light absorbers, one can often link them to the phys-
iological status of the tissue. Transitions between two energy levels of a molecule could serve
as spectral ﬁngerprint of the molecule in diagnostic applications [Tuch02]. These energy transi-
tions are quantized (i.e. discrete) and correspond to speciﬁc wavelengths. The Planck-Einstein
equation links these quantities:
∆E = E2 − E1 = h(ν2 − ν1) = hν = h2πω = ω = h ·
c
λ
(1.6)
with h the Planck constant (6.626 × 10−34 J s), ν the frequency, ω the angular frequency, λ the
wavelength, and c the speed of light.
The absorption coeﬃcient µa[cm−1] is deﬁned as µa = Na · σa where σa is the eﬀective
cross-section [m2] and Na is the amount of absorbers per volume unit [m−3]. This deﬁnition is
valid with the assumptions that (i) the cross section is independent of the relative orientation
of the incident light and absorbers, and (ii) that the distribution of identical absorbing particles
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is uniform. The average travel distance of a photon before being absorbed is deﬁned as the
absorption mean free path la = 1/µa [m].
An absorbing medium is characterized by the absorption coeﬃcient µa, the transmission
coeﬃcient T , and the absorbance A (also called optical density OD). The Lambert-Beer1 law
describes the eﬀect of either thickness or concentration of the sample on absorption:
I = Ioe−µa · t (1.7)
A = ε · c · t
c is the chromophore concentration [mol l−1], t is the sample thickness [cm], and ε the molar
extinction coeﬃcient given in [l mol−1cm−1]. Io and I are the intensities entering or leaving the
sample, respectively (see Figure 1.2). Equation 1.7 can be combined using these deﬁnitions:
A = − log( I
Io
) with ln(x) = log(x)log(e) = 2.303 · log(x) (1.8)
T = I
Io
= 10−A = 10−ε · c · t (1.9)
ln( I
Io
) = ln(10−ε · c · t) = −2.303 · ε · c · t = −µa · t (1.10)
µa = 2.303 · ε · c (1.11)
By measuring the transmission T or the absorbance A for a given c, we can obtain ε usually
ex vivo. If ε is known, and if we can measure µa in vivo, we can quantify the concentration of
the chromophores.
1.3 Scattering and Diﬀusion
Diﬀusion assumes that the quantity that is diﬀusing (e.g. optical or radiant energy) does not have
a preferential direction of travel. Light scattering arises from the presence of heterogeneities, re-
sulting in non-uniform temporal/spatial distribution of refractive index n within a bulk medium.
Incident EM wave sets electric charges into oscillatory motion and can excite vibrational modes.
Scattered light is re-radiated by acceleration of these charges and/or relaxation of vibrational
transition. The scattering is said to be elastic if the energy (and therefore the wavelength) of the
incident photon is conserved and only its direction is changed (e.g. Rayleigh, Mie). Conversely,
the scattering is said to be inelastic where the scattered photon either gives energy to or takes
energy from the medium (e.g. ﬂuorescence or Raman, respectively). The main parameters that
aﬀect scattering: (i) wavelength, (ii) relative refractive index, (iii) particle radius and (iv) shape
and orientation.
The scattering coeﬃcient µs[cm−1] is deﬁned as µs = Ns · σs where σs is the eﬀective cross-
section [m2] and Ns is the amount of scatterers per volume unit [m−3]. The scattering mean free
path (mfp), deﬁned as ls = 1/µs [m], is the average distance a photon travels between scattering
events.
Rayleigh scattering arises from very small particles (≈ λ/10). Scattering at right angles is
half the forward intensity (see Figure 1.3). The strong wavelength dependence enhances the
1Pierre Bouguer (1698-1758), Johann Heinrich Lambert (1728-1777), and August Beer (1825-1863) are at the
origin of these equations.
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short wavelengths. It depends on the size, morphology, and structure of the components
in tissues. The scattered intensity is equal to:
I = Io
8π4Nα2
λ4R2
(1 + cos2 θ) ∝ 1
λ4
(1.12)
Rayleigh scattering is inversely related to the fourth power of the wavelength of the incident
light I ∝ 1/λ4.
Mie scattering predominates if the encountered particles is comparable or larger than the
wavelength. Because of the relative particle size, Mie scattering is poorly wavelength
dependent, but is rather forward directional scattering.
Rayleigh scattering
incident light
Mie scattering Mie scattering, larger particles
Figure 1.3: Direction of propagation in Rayleigh and Mie scattering
Due to various size of scatterers in biological tissues, neither Rayleigh nor Mie theories
completely describe scattering in biological tissue. Therefore, one needs to establish a new
model for scattering calculation. One assumes that a photon is scattered by a particle so that
its trajectory is deﬂected by an angle θ (see Figure 1.4). The projection of its new trajectory on
the direction of original traveling path is cos θ.
incident photon
scatterer
scattered photon
scattering
     angle (θ)
cos(θ)
dΩ
s‘
s
Figure 1.4: Scattering anisotropy g
The anisotropy g is deﬁned as the mean cosine 〈cos θ〉 of the deﬂection angle and is a measure
of the forward direction retained after a single scattering event.
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The proper deﬁnition for g is the expectation value of cos(θ):
g = 〈cos θ〉 =
∫
p(s · s′)s · s′dΩ∫
p(s · s′)dΩ
=
∫ π
0
p(θ)2π cos θ sin θdθ
The angular dependence of scattering is called the scattering phase function, p(θ), which has
units of [sr−1]. It describes the probability of a photon to be scattered into a unit solid angle,
oriented at an angle θ relative to the original trajectory. An isotropic scattering function would
scatter light with equal eﬃciency into all possible directions. Such a scattering function has the
form:
p(θ) = 14π , such that
∫ π
0
p(θ)2π cos θ sin θdθ = 1
The Heyney-Greenstein scattering phase function is an analytical expression which mimics the
angular dependence of light scattering by small particles and is based on the anisotropy factor g
(see Figure 1.5).
p(θ) = 14π
1 − g2
(1 + g2 − 2g cos θ)3/2 (1.13)
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Figure 1.5: Heyney Greenstein approximation of the scattering anisotropy g
The function does not represent true scattering phase functions in biological tissues, but it is
a fairly good approximation. Typical values for g are ranging between 0.65 and 0.95 [Niem07].
The absorption and scattering coeﬃcients, µa and µs, are the probability of absorption and
scattering occurring per unit path length. The other microscopic parameters listed in Table 1.1
can all be deduced from the three fundamental ones.
The optical albedo a is deﬁned by the ratio a = µs/µt. For a = 0, attenuation is exclusively
due to absorption, whereas only scattering occurs in the case of a = 1.
The eﬀective scattering coeﬃcient µ′s is a lumped property incorporating the scattering
coeﬃcient µs and the anisotropy g:
µ′s = µs(1 − g)
The purpose of µ′s is to describe the diﬀusion of photons in a random walk of step size of 1/µ′s,
where each step involves isotropic scattering. Such a description is equivalent to description of
photon movement using many small steps 1/µs, that each involves only a partial deﬂection angle
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if there are many scattering events before an absorption event, i.e. µa 	 µ′s. This situation of
scattering-dominated light transport is called the diﬀusion regime. µ′s is commonly encountered
when treating how visible and near-infrared light propagates through biological tissues.
µ′s < 10µa Strong absorption regime  Lambert-Beer Law ( λ < 300nm; λ > 2000nm)
µ′s  µa Diﬀusion approximation regime (600nm < λ < 1000nm)
µa  µ
′
s Equation of radiative transfer (300nm < λ < 600nm; 1000nm < λ < 2000nm)
The total extinction coeﬃcient µt is the inverse of the mean free optical path Lt of incident
photons in turbid media and is given by
µt =
1
Lt
= µa + µ′s
The optical penetration depth δ is the depth at which the incident spatial irradiance has
decreased to 1/e in the tissue. The eﬀective attenuation coeﬃcient µeﬀ is the inverse of δ. The
relation between µeﬀ and the microscopic parameters µa and µ′s can be derived from photon
transport theory:
µeﬀ =
1
δ
=
√
3µaµt =
√
3µa · (µa + µ′s) (1.14)
1.4 Fluorescence Basics
Most of the biological tissues do ﬂuoresce when they are excited by visible or ultraviolet (UV)
light. This ﬂuorescence is emitted by numerous bio-molecules. In this section, one will describe
the physical mechanisms underlying ﬂuorescence emission.
Luminescence occurs as a light emission during electronic transitions of a physical system,
i.e. atoms or molecules, from its excited states back to a lower state. Various excitation ways
lead an electron into an excited state: chemically, biologically, electronically, light-based, etc...
Chemoluminescence: chemical reactions provides the necessary excitation energy. An ex-
ample would be a “glow-in-the-dark” plastic tube. Zinc Sulﬁde and Strontium Aluminate
are the two most commonly used phosphors.
Bioluminescence: the excitation energy is provided by biochemical, mainly enzymatical,
reactions in living organisms. Examples for bioluminescence are the glow of lightning bugs
lampyridae and sea plankton dinoﬂagellat noctiluca scintillans observed in summer nights.
Electroluminescence is activated by electrical current. Examples are numerous : ﬂuorescence
tubes, light emitting diodes (LED), auroras (polar lights) and lightening. The same phe-
nomenon is observed in cathode ray tube (CRT) screens, where electrons are accelerated
towards a light-emitting screen.
Photoluminescence is the luminescence from systems excited with ultraviolet (UV), visible
(VIS) or infrared (IR) light. Depending on the nature of the system’s excited state, two
forms of photoluminescence are deﬁned : ﬂuorescence and phosphorescence. Fluorescence
is the emission resulting from the decay of an excited singlet state, while phosphorescence
is the emission resulting from the decay of an excited triplet state. Molecules showing
ﬂuorescence and phosphorescence behavior are also called ﬂuorochromes or ﬂuorophores.
The electronic transitions occurring in a molecule are schematically illustrated with the
classical Jablonski diagram, ﬁrst proposed by Professor Alexander Jabłoński in 1935 [Jabl35] to
1.4. Fluorescence Basics 9
describe absorption and emission of light (see Figure 1.6). The energy levels of a molecule are
shown as horizontal lines on a vertical, schematic energy scale. Each of these electronic levels is
subdivided in a number of vibrational sublevels, which themselves consist of diﬀerent rotational
sublevels (not shown here). The total intrinsic energy of a molecule state is the sum of the
electronic, vibrational, and rotational contributions. Transitions between the energy levels are
depicted by vertical arrows. Prior to excitation, the electronic conﬁguration of the molecule is
described as being in the ground state, i.e. the most stable energy conﬁguration, typically a
singlet state (S0). Upon absorbing a photon of excitation light, usually of short wavelengths
(i.e high energy), electrons may be raised to a higher vibrational energy level in the ﬁrst excited
state (S1) in about a femtosecond (10−15 s) before rapidly relaxing to the lowest energy level.
This event depicted in Figure 1.6 as a transition from the upper to lower bars in S1, is termed
vibrational relaxation and occurs in about a picosecond (10−12 s) or less. Because of this rapid
relaxation, emission spectra are usually independent of the excitation wavelength. Fluorescence
lifetimes (10−9 s) are typically four orders of magnitude slower than vibrational relaxation. This
gives the molecules suﬃcient time to achieve a thermally equilibrated lowest-energy excited state
(i.e. the lowest vibrational level of Sl) prior to ﬂuorescence emission. Except for atoms in the
vapor phase, one invariably observes a shift to lower wavelength (i.e. a loss of energy) of the
emission relative to the absorption. This phenomenon is called Stokes’ shift, and is named after
Irish physicist George G. Stokes, who observed it ﬁrst in 1852. Internal conversion (IC) can
occur between two excited states (e.g. S2 → S1) under certain conditions [Lako06].
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Figure 1.6: Jablonski diagram shows the ground (S0), ﬁrst (S1) and second (S2) excited electronic singlet
states of a molecule, as well as the ﬁrst excited triplet state (T1) with ﬂuorescence and phosphorescence
emission.
Phosphorescence decay is similar to ﬂuorescence, except that the electron undergoes a spin
conversion (↓↑  ↑↑) into a “forbidden” triplet state T1 instead of S0. This process is known as
intersystem crossing (ISC) . Emission from the triplet state occurs with lower energy relative to
ﬂuorescence, hence emitted photons have longer wavelengths. Typical phosphorescence lifetimes
are in the order of millisecond (10−3s), thus much longer than ﬂuorescence lifetimes.
It is interesting to note that the emission spectrum of a ﬂuorophore is typically a mirror im-
age of the S0 to S1 absorption spectrum transition. According to the Franck-Condon principle,
all electronic transitions are vertical. Thus, electronic excitation does not seriously alter the
geometry of the nucleus and the spacing of excited state vibrational levels is similar to that of
the ground state, that is, they occur without change in the position of the nuclei. As a result,
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if a particular transition probability between the 0th and 2nd vibrational levels is largest in ab-
sorption, the reciprocal transition is also most probable in emission. Consequently, ﬂuorescence
emission spectra often display similar, but reversed, vibrational structures to those observed in
the absorption spectra. This is called the mirror image rule
The quantum yield of a ﬂuorophore describes the number of emitted photons divided by the
number of absorbed photons. Consequently, ﬂuorochromes with large quantum yields display
the brightest emissions.
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Chapter 2
Clinical cancer detection
and tissue characterization
by optical imaging
In this chapter, we will address the optical tissue characterization, leading us to introduce
the clinical cancer detection by optical methods. In Section 2.1, we will focus on reﬂectance
imaging, where only scattering and absorption play a signiﬁcant role. In this context, we will
present shortly the main non-ﬂuorescing absorbers, called chromophores. The latter are either
contained in the biological tissue – the endogenous chromophores –, or applied externally – the
exogenous chromophores. In Section 2.2, we will address the ﬂuorescence photodetection. In
this context, we will present the main ﬂuorophores involved, and the instrumentation aspects.
In Section 2.3, we will review the technical concepts of high magniﬁcation shortly, and present
their implementation in the endoscopic imaging apparatus. In Section 2.4, we will focus on
confocal endoscopy. In the last Section 2.5, we will introduce some basic statistical concepts
that underly our clinical studies.
2.1 Reﬂectance endoscopic imaging
2.1.1 Major absorbing chromophores
2.1.1.1 Endogenous chromophores
As described thoroughly in Section 1.2, absorption plays an important role in photomedical
applications. The major light absorbing molecules in mammalian tissues are oxy- and deoxyhe-
moglobin, melanin, myoglobin and water. The absorption spectra of these molecules are shown
in Figure 2.1 adapted from [Boul86]. We can observe a lower absorption between 600 nm and
1000 nm. In this so-called therapeutic window, scattering predominates over absorption and
light is deep-penetrating into the tissue. Since we are working in hollow organs (i.e. not skin),
we will focus on the main absorbers in soft tissue for visible light, namely hemoglobin.
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Figure 2.1: Major light absorbing molecules in soft mammalian tissues.
Hemoglobin absorption Healthy functioning of all tissues depends on an adequate blood
supply, and thus suﬃcient oxygen delivery. In the normal adult, blood is composed of (i) plasma
(∼ 55% by volume), (ii) red blood cells (∼ 44% by volume for an adult, 1 cm3 blood = 5 billion
rbc), and (iii) white blood cells and platelets (< 1% by volume, leucocytes - 1 per 100 rbc).
Red blood cells can be considered simply as small sacks containing hemoglobin. They attach
oxygen in the lungs, becoming oxyhemoglobin (HbO2), and then deliver oxygen to tissues. At
the tissue, the oxygen dissociates to leave deoxyhemoglobin (Hb). Figure 2.2 shows oxy- and
deoxy- hemoglobin absorption spectra (adapted from [Grat60], cited by Scott Prahl1). The cir-
culating blood is almost fully saturated with oxygen (≈ 98%), so that the hemoglobin absorption
spectrum is dominated by the oxyhemoglogin component.
Hemoglobin has a normal concentration of 150g/liter of blood, which permits the whole
blood to carry 65 times more oxygen than does plasma at a pO2 of 100 mmHg. The hemoglobin
molecule can bind up to four oxygens molecules. The oxygen saturation gives the statistical
average of all oxygen bound to hemoglobin molecules relative to the total amount that can be
bound. One gram of functional hemoglobin can combine with 1.34ml O2, yielding
150g Hb/liter × 1.34ml O2/ g Hb = 200ml O2/liter
Then to convert the molar extinction coeﬃcient ε(λ) to an absorption coeﬃcient µa:
µa(λ) = 2.303 · ε(λ) · 150 g Hb/liter64500 g Hb/mole = 0.0054 · ε(λ)
In vascular imaging, one may either use an intravenous contrast agent (e.g. ICG or FITC)
or target hemoglobin absorption peaks to maximize the contrast between blood vessels and sur-
rounding tissue. Narrow-band imaging (NBI) has been developed over the last decade [Gono03]
to exploit this latter property (see Section 2.1.2). In this thesis, we will present a spectral design
optimization of our high-magniﬁcation setup also based on these properties.
1http://omlc.ogi.edu/spectra/hemoglobin/
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Figure 2.2: Hemoglobin absorption in the near ultraviolet, visible and near infrared (NIR) range. Normal
and logarithmic scales are presented.
2.1.1.2 Exogenous chromophores
In the unstained mucosa, meticulous attention is required for the initial detection of abnor-
malities, looking for subtle changes in color, topography, and vasculature [DaCo05]. With the
development of endoscopy, new techniques have been implemented to enhance the detection of
early cancers. The use of a chromogenic contrast agent that accumulates (or not) in cancerous
tissues helps to determine the boundary of the lesion and to determine whether it is elevated,
ﬂat, or depressed. As a common term, one calls this imaging procedure chromoendoscopy, based
on the Greek words chromo (color), endon (within), and skopein (to examine).
Intravital staining techniques are not new. In fact, it dates back to Schiller (1933), who
used Lugol’s solution to improve diagnosis in the uterine cervix [Schi33]. In the 1960s and
1970s, endoscopic staining techniques were employed for oropharyngeal and esophageal tu-
mors [Voeg66, Endo72]. However, since then, the knowledge about the diﬀerent dyes has in-
creased dramatically [Kies04a, Eise04]. Furthermore, the renaissance of chromoendoscopy was
accelerated by the rapid improvement of endoscopic image resolution. In the last decade, a
signiﬁcant increase in published data about chromo- and high resolution endoscopy has been
observed.
Chromoendoscopy means to stain certain areas with several dyes. Generally, the dye is
distributed in a homogenous fashion by the help of a spraying catheter which is passed through
the working channel of the endoscope [Jung99]. Intravital staining of suspected lesions in the
colon oﬀers the possibility to deﬁne the macroscopic type and to delineate the exact borders.
Additionally, the surface structure can be analyzed by the help of magnifying endoscopes. The
eﬃciency of magnifying endoscopy is often determined in conjunction with intravital staining
techniques. Chromoendoscopy ﬁrst helps to identify small, circumscribed lesions. Subsequent
surface analysis is done by the help of magnifying endoscopy [Kies03].
The diﬀerent dyes are categorized according to their staining mechanisms :
Absorbtive dyes are taken up by speciﬁc epithelial cells, thereby making it possible to specif-
ically characterize the mucosa, e.g. Lugol’s solution (0.5-3%), methylene blue (0.1-1%),
toluidine blue and Cresyl violet (0.2%).
Contrast dyes are not absorbed but accumulate in pits and valleys between cells, highlighting
mucosal architecture, e.g. indigo carmine (0.1-0.4%).
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Reactive stains induce a chemical reaction at the cell level, e.g. Congo red (0.3%) and phenol
red react to changing conditions of acid secretion and carry a potential with regard to the
early detection of gastric cancer and helicobacter pylori infection [Jung99, Brun03].
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Figure 2.3: Extinction coeﬃcients of two absorptive dyes: Methylene blue and Cresyl violet [Du98].
In the following, one will describe the main exogenous chromophore and their applications:
Methylene blue is a heterocyclic aromatic compound with molecular formula C16H18N3SCl.
At room temperature it appears as a solid, odorless, dark green powder, that yields a blue
solution when dissolved in water. Usually a concentration of 0.5% of methylene blue is
used. It requires a mucus clearance prior to examination with e.g. acetic acid. A lot of
results have been obtained in the gastrointestinal (GI) tract to highlight metaplasia on
Barret’s esophagus. Tests have also been performed in the urinary bladder. Mufti et al.
used in vivo staining of the bladder mucosa with 0.1% methylene blue in normal saline
in 23 randomly selected patients, with known and previously treated transitional cell
tumors of the bladder, in whom routine check cystoscopy failed to demonstrate any mucosal
abnormality. Cold cup biopsies were obtained from stained (n = 21) as well as unstained
areas (n = 2). Although positive staining did not prove the presence of a pre-malignant or
malignant area, lack of staining was more likely to exclude mucosal abnormalities [Muft90].
Creagh et al. studied 39 patients newly diagnosed with bladder tumors and followed for a
minimum of 2 years. Potential biopsy sites were identiﬁed by staining intravesically with
a 1% methylene blue solution and compared with random biopsy sites. Biopsy directed
by methylene blue staining detected carcinoma in situ more often than random biopsy,
but rates of recurrence were similar in both stained and unstained groups. These authors
concluded that methylene blue staining does not add signiﬁcantly to the management of
patients presenting with bladder tumors [Crea95].
Toluidine blue is an acidophilus metachromatic nuclear stain that colors sites of squamous
cell carcinoma, but not adjacent normal mucosal surfaces. Whether or not toluidine blue
actually stains tumor nuclei is still not proven, but dye may diﬀuse into larger intercellular
canaliculi present in the tumor cells.
Cresyl violet is also an absorptive dye, that is used to visually emboss the relief of planar
polyps [Jung99]. It is often used in combination with indigo carmine. Regular staining
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patterns are often seen in hyperplastic polyps or normal mucosa, whereas unstructured
surface architecture was associated with malignancy [Kudo94]. Also the kind of adenoma
(tubular vs. villous) can be seen by detailed inspection. This experience has lead to
a categorization of the diﬀerent staining patterns in the colon. The so-called pit-pattern
classiﬁcation diﬀerentiated 5 types and several subtypes of colonic mucosa [Kudo96]. With
the help of this classiﬁcation, the endoscopist is allowed to predict histology with good
accuracy [Huan04].
Indigo carmine is a contrast stain that is not taken up by cells. Instead, it accumulates in
pits and valleys between cells highlighting the mucosal architecture that becomes even
more apparent with the use of magniﬁcation or high resolution endoscopy, or both. In
general, a concentration of 0.5% to 1% is used. It contributes to contrasting and accen-
tuating changed mucosal processes [Fu04]. It has been used to diagnose Barrett’s esopha-
gus [Aman05, Curv08], and diagnose and discriminate polypoid and non-polypoid lesions
in the colon [Kudo97]. Endo et al. have developed an outpatient procedure to resect uri-
nary bladder cancer using a blue dye-mixed local anesthetic (2% xylocaine:indigo carmine
8:2), that was injected into the tumor base prior to resection [Endo10].
Lugol’s solution contains potassium iodine and iodine that reacts with glycogen in non-kera-
tinized squamous epithelium. Usually a concentration of 2% to 3% is used. Normal
squamous epithelium stains deeply brown giving the esophagus a snake skin-like appear-
ance while areas with inﬂammation, dysplasia, or (early) cancer lack appropriate staining
because of a depletion of glycogen. Lugol’s solution has been used to delineate the extent
of Barrett’s esophagus [Wool89], to screen for squamous cell cancer in the esophagus in
high risk populations [Inou01], and to detect (standard) endoscopy negative reﬂux disease
in combination with high resolution endoscopy [Tam02].
2.1.2 Narrow-band imaging, FICE and Chromoendoscopy
Since the initial development of white light endoscopy, several attempts have been made to
improve sensitivity. Among them, Hürzeler placed some color ﬁlter in front of the light source
to better delineate the tumor margins [Hürz75]. Other optical modiﬁcations were investigated
to develop the so-called virtual chromoendoscopy, i.e. staining without the need of any dyes.
Two main technologies have been developed by two distinct Japanese groups.
Narrow-Band Imaging (NBI) has been in use since 1999 and was developed as a part of the
joint research between the Japanese National Cancer Center Hospital East and Olympus
Medical Systems Corporation (Tokyo, Japan). Gono et al. revealed that the use of 415 nm
narrowband light could improve the capillary images, which are diﬃcult to observe under
conventional white light cystoscopy (WLC) [Gono03, Gono04]. The NBI technology is an
optical image enhancement technique designed for endoscopy to enhance the contrast be-
tween mucosal surfaces and microvascular structures without the use of dyes. With NBI,
the tissue surface is illuminated with light of a narrow bandwidth, with center wavelengths
in the blue (415 nm) and green (540 nm) spectrum of light (see Figure 2.4). The penetra-
tion depth for these wavelengths is 170 µm, and 240 µm, respectively. Since these speciﬁc
wavelengths are strongly absorbed by hemoglobin (see Section 2.1.1), the vascular struc-
tures appear dark brown or green against a pink-whitish mucosal background. Several
investigators have demonstrated that this modiﬁcation of spectral features emphasizes the
contrast of both the capillary pattern and the pit pattern, so providing imaging features ad-
ditional to those of both conventional endoscopy and chromoendoscopy [Kara05, Sano09].
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Systems that have integrated NBI and WLC are already commercially available. With the
push of a button, the NBI mode is activated by mechanical insertion of the narrow-band
ﬁlter in front of the white-light source.
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Figure 2.4: Narrow-band imaging (NBI) is based on the phenomenon that the depth of light penetration
increases with wavelength. The blue light (415 nm) enhances the superﬁcial capillary network, whereas
the green light (540 nm) enhances the visibility of deeper vessels [Caub09].
Fujinon Intelligent Color Enhancement (FICE) was invented by Yohishi Miyake (Fac-
ulty of Engineering, Chiba University Japan) [Miya89, Shio95] and introduced by Fujinon
Inc. in 2005. Like NBI, the FICE technology (sometimes called Optimal Band Imaging,
OBI) is based on the selection of spectral transmittance with a dedicated wavelength. In
contrast to NBI, in which the bandwidth of the spectral transmittance is narrowed by
optical ﬁlters, this system is based on a new spectral estimation technique that replaces
the need for optical ﬁlters. The FICE system takes an ordinary endoscopic image from the
video processor and arithmetically processes the reﬂected photons to reconstitute virtual
images for a choice of diﬀerent wavelengths. Because the spectra of pixels are known, it is
possible to implement imaging on a single wavelength. Such single-wavelength images are
carefully selected, and assigned to red, green, and blue to build and display an enhanced
color image. There are 10 pre-programmed ﬁlters which are switched on the keyboard,
each of which has diﬀerent settings for estimated RGB channels (see Table 2.1). Although
each spectral image is a monochromatic image, their combination brings a view similar to
a color image produced under conventional video endoscopy and improves visibility in the
spectral image [P.-B09, Pohl07, Pohl08, Osaw09, Camm08]. Figure 2.5 shows an evalua-
tion of the vascular patterns with the help of FICE virtual ﬁlters (adapted from [P.-B09]).
FICE emphasizes increased vascular density, which can be appreciated as a darkening of
the mucosal pattern, or as a ﬁne meshwork of brown/bluish vessels.
The FICE design has not been yet implemented in the urinary tract, whereas the NBI system has
been adapted to cystoscopy [Brya07, Herr08, Herr09, Nase10]. These authors concluded that NBI
cystoscopy improved the detection of recurrent non-muscle-invasive bladder tumors as compared
to standard WLC. NBI cystoscopy also provided a much clearer view of papillary tumors than
with WLC, in particular their delicate capillary architecture. Moreover, NBI better deﬁned the
margins of carcinoma in situ (CIS) lesions with surrounding normal appearing mucosa. Since
NBI can be implemented in magniﬁcation or high resolution endoscope, it is also possible to
visualize small vessel structures on detected carcinomas. For instance, Shibuya et al. revealed
vascular patterns on squamous cell carcinoma in the bronchi [Shib10], but nothing similar has
been up-to-now implemented in the bladder.
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NBI 1st generation
NBI-blue ﬁlter 395-445nm
NBI-green ﬁlter 530-550nm
NBI 2nd generation
R 500 ± 15nm
G 445 ± 15nm
B 415 ± 15nm
FICE virtual set of ﬁlters
R G B
set 0 500 445 415
set 1 550 470 580
set 2 550 500 470
set 3 400 450 480
set 4 520 500 405
set 5 500 480 420
set 6 580 520 460
set 7 650 550 450
set 8 540 415 415
set 9 550 500 400
Table 2.1: NBI optical ﬁlters and FICE virtual ﬁlters
DCBA
E F G H
I J K
Figure 2.5: Evaluation of the vascular pattern without magniﬁcation with the FICE system. [A] Con-
ventional WL endoscopy [B] Filter 0 [C] Filter 1 [D] Filter 2 [E] Filter 3 [F] Filter 4 [G] Filter 5
[H] Filter 6 [I] Filter 7 [J] Filter 8 [K] Filter 9.
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Similarly, as NBI is a reﬂectance imaging technology, it cannot be implemented on the same
detector with ﬂuorescence detection at the present time, because the latter requires a ﬁlter in
front of the CCD, that blocks e.g. the blue backscattered light.
We present here some results obtained in the urinary bladder. Bryan et al. performed ﬂexible
WLC and subsequent NBI cystoscopy in 29 patients with recurrent non-muscle invasive bladder
cancer (NMIBC) [Brya07]. NBI cystoscopy revealed 15 additional tumors in 12 patients.
Herr et al. performed WLC with subsequent NBI cystoscopy in 427 consecutive patients with
a history of NMIBC [Herr08]. Recurrence was found in 103 patients. In 58/103 (56%) patients
with a recurrence, additional tumors were detected by NBI, and in 13/103 (12%) patients, the
bladder tumors were detected only due to NBI. A limitation of this study is the possible observer
bias, since WLC and NBI were performed subsequently by the same urologist. Whether the
speciﬁcity of NBI will be negatively inﬂuenced by previous intravesical instillation, inﬂammation,
or scarring, was not known in this study.
Naselli et al. reviewed 47 consecutive patients with newly diagnosed high-grade NMIBC
in a prospective observational study [Nase10]. About one month after the ﬁrst transurethral
resection (TUR), NBI cold-cup biopsies were taken from areas suspicious for urothelial cancer
at the end of an extensive white-light second TUR protocol including: (i) resection of the scar of
the primary tumor; (ii) resection of any overt or suspected urothelial lesions; and (iii) six random
cold-cup biopsies of healthy mucosa. Nine patients (19%) had macroscopic or microscopic high-
grade NMI urothelial cancer, whereas one was reassessed as having muscle-invasive disease at
the white-light second TUR plus the six random biopsies. NBI biopsies were taken in 40 of the
47 patients and detected six more patients with high-grade cancerous tissue (13%).
Summarily, these studies shows that NBI and FICE endoscopy are superior in sensitivity
to white-light endoscopy. However, since these technologies are quite new, the surgeons often
need to get trained by “typical” images, because often they don’t have any feeling about how
to interpret the presented colorized patterns.
The size of the observed vascular patterns highly depends on the model of endoscope. Obvi-
ously, in the GI tract, the large diameter of the scopes (≈ 15 mm) allows to integrate an optical
zooming setup (up to 150×), whereas in urology and pneumology, the small scope diameter (≈
5–6 mm) does not leave much space for a mechanical zoom. Therefore, high resolution scope
are preferred because it is possible to perform electronic zoom on the regions of interest. For
instance, in a recent study, Shibuya et al. used a high-resolution endoscope (850 kPixels), and
observed vascular patterns down to 30 µm [Shib10]. Section 2.3 will treat high-magniﬁcation
endoscopy in details.
2.2 Cancer detection by endoscopic ﬂuorescence imaging
The fundamental principle of tissue characterization or cancer detection by ﬂuorescence is to
exploit the optical contrast between the (cancerous) lesions and their surrounding healthy tissue.
As the lesions often remain invisible in conventional white light (WL) examination, one needs an
additional method to produce a better contrast. The ﬂuorescence contrast is said to be intrinsic
in case one exploits the inherent tissue optical properties (i.e autoﬂuorescence) or induced if
the ﬂuorescence comes from a selective accumulation of an exogenous or exogenously-induced
ﬂuorophore. The contrast itself may originate from the ﬂuorescence brightness, spectral shape,
lifetime or a combination of them. Spectroscopic measurements (space or time-resolved) or
imaging are of great help in order to visualize this contrast quantitatively or qualitatively.
In this thesis, we will concentrate on two applications of the photodetection in hollow organs:
bronchial and urinary bladder cancers. We left intentionally detection and treatment of cancers
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of the GI tract, the gynecological tract, the skin, the liver, the pancreas, and aﬀections of the
eye aside.
2.2.1 Endogenous ﬂuorophore
All biological tissues emit ﬂuorescence when excited by ultra-violet (UV) or visible light. This
ﬂuorescence is emitted by naturally-occurring ﬂuorophores and is therefore often called autoﬂu-
orescence (AF) . This phenomenon has been intensively studied in the last decades, whereas
pioneering work was performed in the beginning of 20th century by Policard et al. [Poli24].
The main endogenous ﬂuorochromes in human tissue are listed in Table 2.2. Figure 2.6 shows
the ﬂuorescence absorption and emission spectra of the main tissue ﬂuorochromes (adapted
from [Wagn98b]). It can easily be seen, that the absorption maxima of endogenous ﬂuorochromes
predominately lay in the UV and the blue-violet visible wavelength range.
Chromophore Absorptionmaxima
Excitation
maxima
Emission
maxima
Molar
extinction
coeﬃcient
Fluorescence
quantum yield
Tryptophan 280 280 350 5.6× 10−3 0.2
Tyrosine 275 275 300 1.4× 10−3 0.1
Phenylalanine 260 280 2× 10−4 0.04
NADH 260 290 440 14.4×10
−3
340 340 450 6.2× 10−3
NAD+ 260 not ﬂuorescing 18× 10−3
FAD 450 515
FADH not ﬂuorescing
HP, collagen, elastin 325 325 400LP, collagen, elastin 325 400
4-Pyridoxic acid 307 315 425
Hematoporphyrin derivatives (HpD) 405 610 0.11544 675 0.32
Protoporphyrin IX (PpIX) 415,582 634
Table 2.2: Endogenous ﬂuorophores at physiologic pH adapted from [R.-K96]
A biological tissue is containing ﬂuorescing and absorbing molecules. Intrinsic ﬂuorescence
spectra emitted from the tissue are often distorted by scattering and absorption. Most of
the proteins exhibiting ﬂuorescence are those containing the aromatic amino acids tryptophan,
tyrosine, and phenylalanine, or a combination thereof [Wolf93]. Their chemical structure is
depicted in Figure 2.7. The excitation maxima for those molecules all lay in the UV wavelength
region below 295 nm and their maximal ﬂuorescence emission occurs between 280 nm and 350
nm.
Most endogenous ﬂuorochromes are involved in cellular metabolic processes or are con-
stituents of the structural matrix of the tissues [Utzi01, R.-K96], and thus are under certain
conditions aﬀected by environmental factors. They can be classiﬁed in four groups, namely the
aromatic amino acids and proteins, the pyridine nucleotides, the ﬂavins, and the porphyrins. The
principal ﬂuorescing proteins are collagen and elastin, which are both involved in the structural
matrix of numerous tissues. Their ﬂuorescence stems from cross-links between their composing
amino-acids. In load-bearing tissues, two types of cross-links are found: hydroxylysyl pyridino-
line (HP) , and lysyl pyridinoline (LP). Both HP and LP are emitting autoﬂuorescence with an
excitation maximum at 325 nm and an emission maximum at 400 nm [Eyre84]. Collagen has an
inextensible ﬁbrous structure and is the main protein in connective tissue (cartilage, ligaments,
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Figure 2.6: Excitation and emission spectra of the main tissue ﬂuorophores (adapted from [Wagn98b])
Phenylalanine Tyrosine Tryptophane
Figure 2.7: Most of the ﬂuorescing proteins contains phenylalanine (Phe), tyrosine (Tyr), tryptophan
(Trp), or a combination thereof.
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tendons, bones). The absorption maximum of collagen ﬁbres is around 325 nm with a maximal
ﬂuorescence emission around 400 nm [Kirk07].
Flavins and pyridine nucleotides are strong electron acceptors and play an important role
in cellular energy metabolism. Flavin adenine dinucleotide (FAD) is the major ﬂavin-related
electron carrier. Its oxidized form (FAD) is ﬂuorescent, while its reduced form (FADH) is
not. The ﬂuorescence excitation maximum of FAD lies around 450 nm and the emission max-
imum around 530 nm [R.-K96]. The other main electron acceptors are nicotinamide adenine
dinucleotide (NAD). This molecule emits ﬂuorescence in its reduced form, NADH. Fluorescence
excitation and emission maxima can be found around 340 nm and 450 nm, respectively. Oxidiza-
tion plays an important role over their respective ﬂuorescence yield. Their relative ﬂuorescence
intensities, often deﬁned as redox ratio, can be used as a metabolic indicator, and thus as a
diagnostic mechanism in case of cancerous lesions [Brew02].
2.2.1.1 Autoﬂuorescence in Pneumology
In the 1970’s, Hürzeler et al. carried out some theoretical, then practical tests in order to
heighten the contrast observed in endoscopy [Hürz75]. Filters (red, green, yellow and light blue)
were placed in front of the light source and the subjective perceptible changes in contrast were
examined. These tests showed that the light blue ﬁlter gave a heightened contrast between light
and dark red as well as between yellow and red. With this illumination, pre-cancerous lesions
were more visible in the mucous membrane.
In the early 1980’s, Alfano et al. developed laser-induced autoﬂuorescence spectroscopy to
diﬀerentiate normal from tumor tissues. This work was initiated on rat tissues [Alfa84], and later
extended to human breast and lung tissues [Alfa91] and eventually to the gynecological tract
(uterus, cervix, ovary) [Glas92]. In these studies, 300 nm appeared to be the most appropriate
excitation wavelength, while the ratio of the emitted ﬂuorescence at 340 and 440nm provided
the most prominent diﬀerences between the normal and malignant tissues.
Several papers report a sharp autoﬂuorescence decrease on early cancerous lesions in the
bronchi around 500 nm and/or a relatively less important decrease after 600 nm when excited
between 400 and 450 nm [Anth89, Palc91, Hung91]. This serve as a basis for most autoﬂuores-
cence imaging systems. Indeed, the authors observed a sharp decrease (around a factor of 10)
in the green tissue autoﬂuorescence on the CIS with respect to healthy mucosa. However, the
spectral shape of the signal is not changed.
Anthony et al. reported autoﬂuorescence spectra of bronchial tissue in vivo [Anth89]. They
showed that the tissue, when excited around 410±5 nm displays an emission peak around 500
nm and a monotonically decreasing spectrum for λ > 500 nm. Moreover, they reported that
the spectra of the tumor and the healthy tissue were, after normalization, very well overlapped
between 500 and 600 nm but then the spectrum from the tumor displayed an increase in the
red region that could not be found in the spectrum of the healthy tissue.
Zellweger et al. studied the autoﬂuorescence of human healthy, metaplastic and dysplas-
tic/CIS bronchial tissue, covering excitation wavelengths from 350 to 480 nm [Zell01a]. Typical
spectra of bronchial mucosa are depicted in Figure 2.8. These measurements were performed
with a spectroﬂuorometer whose distal end is designed to simulate the spectroscopic response of
an imaging system using routine bronchoscopes. They also maximized the tumor vs. healthy and
the tumor vs inﬂammatory/metaplastic contrast in detecting pre-/early malignant lesions. They
found that the excitation wavelengths yielding the highest contrast are between 400 and 480 nm
with a peak at 405 nm [Zell01b]. In a more recent publication, Tercelj et al. mentioned similar
results obtained with an integrated endoscopic imaging and spectroscopy system [Terc05].
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Figure 2.8: Typical in vivo AF spectra from healthy bronchial mucosa, reactive changes and pre-
neoplastic lesions (dysplasia and CIS). The spectra were measured with a non-contact optical ﬁbre based
spectroﬂuorometer using a 405 nm wavelength for excitation. These data were adapted from [Zell01a].
At the beginning of the 2000’s, several authors hypothesized the diﬀerences in the AF spectra
between normal and abnormal tissues due to the variations of the following parameters :
1. the intrinsic ﬂuorochrome concentration
2. the metabolic status of the ﬂuorochromes [R.-K96, Wolf93]
3. the biochemical and biophysical micro-environment [Uehl09]
4. the loss of tissue layered architecture, due to e.g. mucosal thickening [Qu95]
5. the wavelength-dependent light attenuation due to the concentration and distribution of
(non-ﬂuorescent) chromophores, particularly hemoglobin [Qu95, Qu94, Gabr07]
In the next paragraphs, we will review the literature that shows that the latter two mechanisms
are most likely to be at the origin of the contrasts.
Bard et al. developed a ﬁberoptic instrument allowing the measurement of autoﬂuorescence
spectroscopy (AFS) , diﬀuse reﬂectance spectroscopy, and diﬀerential path length spectroscopy
during bronchoscopy [Bard05, Bard06]. Autoﬂuorescence and reﬂectance spectra were analyzed
in ranges from 435 to 700 nm and 435 to 900 nm, respectively. These authors commented about
the variations in the autoﬂuorescence spectra. Large natural variations in ﬂuorophore concen-
trations seem to have less relevance for tissue diagnostics. Scattering modiﬁcations are related
to changes in tissue architecture such as thickening of the epithelial layer and to cellular changes
such as an increase of the nucleus chromatin content, variations in the nucleus-cytoplasmic ra-
tio. Qu et al. described parallel changes in the mean thickness of the bronchial epithelium from
46±3 µm in normal epithelium, to 70±7 µm in a dysplasia to 116±16 µm for CIS [Qu95].
Absorption modiﬁcations are mostly related to modiﬁcations of the concentration and dis-
tribution of light absorbers such as hemoglobin. Such increased blood content is related to
the increased density of microvessels and the blood stasis occurring in tumoral tissue [Shij03].
Shibuya et al. identiﬁed an marked increase of the microvessel density observed ﬁrst on angio-
genic squamous dysplasia (ASD) [Shib02, Shib03], and then on every type of early squamous
cell carcinoma [Shib10].
Kobayashi et al. observed a clear blue peak located at around 483 nm along with a green
peak at around 560 nm in the normal tissue excited at 400nm with a gallium-nitride (GaN)
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based UV-laser diode [Koba02, Koba03]. Weak intensities were observed on the tumor tissues.
The AF imaging and spectrum analysis were performed along with a histopathological study.
The spatial distribution of the elastin in the bronchial tissue aﬀected the intensity of the AF
whereas the spectrum shape was not aﬀected.
Bourg-Eckly et al. modiﬁed the Cellvizio R© confocal system adding spectroscopic analysis
capability with 488 nm excitation [Jean07, B.-H08]. They simultaneously acquired images and
emission spectra using a ﬂexible miniprobe. In the normal bronchi, reproducible images were
obtained, characterized by a highly organized ﬁbrous network. Precancerous lesions exhibited
alterations of this ﬁbrous network. Microscopic and spectral analysis showed that the signal
mainly originates from the elastin component of the bronchial subepithelial layer.
Uehlinger et al. performed time-resolved measurements of bronchial tissue AF excited at
405 nm with an optical-ﬁber-based spectrometer [Uehl09]. These authors analyzed whether the
ﬂuorescence lifetime could serve as a new tumor/normal (T/N) tissue contrast parameter. A
secondary end-point was to explain the origin of the contrasts observed when using AF-based
cancer detection imaging systems. No signiﬁcant change in the AF lifetimes was found. These
results suggest that the spectral contrast might be due to an enhanced blood concentration
just below the epithelial layers of the lesion. The intensity contrast probably results from the
thickening of the epithelium in the lesions. The absence of T/N lifetime variations indicates that
the quenching is not at the origin of the ﬂuorescence intensity and spectral contrasts. These
lifetimes were consistent for all the examined sites. It is very likely that there is only one
dominant ﬂuorophore since the measured lifetimes were the same for diﬀerent emission domains
ranging between 430 and 680 nm. The measured lifetimes suggest that this ﬂuorophore is elastin,
which is in good agreement with Bourg-Eckly et al.
In a recent study, Gabrecht et al. compared spectral measurement acquired in vivo during
bronchoscopy and ex vivo on samples ﬁxed in formalin [Gabr07]. These authors showed that the
spectral contrast between healthy and cancerous bronchial tissue observed in vivo disappears
completely when the samples are ﬁxed in formalin (10% buﬀered). Indeed, the normalized
spectra acquired ex vivo on healthy, pre-neoplastic lesions (squamous metaplasia, mild dysplasia,
CIS, invasive SCC) and invasive lesions can be fairly superposed. In contrast to this, the
mechanisms responsible for the intensity contrast are altered, but not destroyed by tissue death
and/or the formalin ﬁxation process. The thickening of the epithelium in the measured tissue
samples is likely to be the cause of this intensity decrease on pre-neoplastic lesions. These results
indicate that epithelial thickening and blood supply in the adjacent lamina propria are likely to
play a key role in the generation of the AF contrast in bronchial tissues.
In a later study, Gabrecht et al. [Gabr08] investigated the potential of using blue backscat-
tered light to reduce the numbers of false-positive in AF bronchial photodetection. These authors
showed (pre-)neoplastic mucosa displays a clear wavelength dependence of the blue-violet light
backscattering properties, whereas the reﬂectivity of normal, metaplastic and hyperplastic aut-
oﬂuorescence positive mucosa was wavelength independent. Again, this may be attributed to
the higher hemoglobin content in the pre-neoplastic mucosa as compared to the normal tissue
due to the neoangiogenesis.
2.2.1.2 Autoﬂuorescence in Urology
The normal urothelium thickness of the bladder is estimated to be 150 µm [Reut92], and the
300-400 nm light is able to excite bladder tissue layers on the order of 500 µm. As a result,
tissue autoﬂuorescence (AF) signals from bladder tissue include contributions not only from
the urothelium but also from deeper tissue layers, such as the collagen located in the lamina
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propria and the NADH in muscle layers. In contrast to the lamina propria and muscle, there
is no collagen and only a small amount of NADH compounds in the urothelium [Koen96]. The
increased thickness of the urothelium in malignant lesions thus led to the decrease of the collagen
and NADH signals (390 nm and 470 nm, respectively) by attenuating the autoﬂuorescence from
deeper tissue layers.
In a study about bladder tissue autoﬂuorescence following excitation at 308, 337 or 480
nm, Anidjar et al. reported a marked decrease in autoﬂuorescence for CIS with respect to
normal bladder mucosa when excited at 337 or 480 nm [Anid96, Anid98], whereas the spectral
shape of the autoﬂuorescence underwent no change. At 308 nm excitation wavelength, they
observed not only a change in intensity but also a change in spectral shape between the normal
bladder mucosa and the CIS. They related these changes to the emission of oxidized ﬂavoproteins
(480 nm), tryptophan (selectively excited by 308 nm) and NADH (337 nm). They report that
these results make it possible to distinguish normal bladder mucosa from CIS.
This is in partial agreement with Koenig et al. , who also used 337 nm as an excitation wave-
length (N2 laser) but found a spectrum with a diﬀerent shape. Indeed, these authors found not
only a diﬀerence in ﬂuorescence intensity but also a modiﬁcation of the spectral shape between
the healthy mucosa and the CIS [Koen98]. The disagreements might be due to diﬀerences in
data manipulation. Indeed, Anidjar et al. provided no explanation on how and whether their
spectra were corrected for background ﬂuorescence, the spectral response of their setup. They
were also diﬀerences in their acquisition system, as Anidjar used a long pass ﬁlter centered at
400 nm whereas Koenig used a gated intensiﬁer [Koen96, Koen98]. Moreover, Koenig’s results
rely on a larger series of random biopsies. Their explanation about the autoﬂuorescence changes
is that the spectrum is inﬂuenced by the epithelial thickness. Their idea is that the AF photons
are reabsorbed on their way out by the thicker tissues. Their imaging system combined AF and
blue backscattered light to enhance the contrast, as originally proposed by Hürzeler, although
without the use of ﬂuorescence [Hürz75].
Zaak et al. carried out AF excitation with a xenon chloride (XeCl) excimer laser operating
at 308 nm [Zaak02]. For the evaluation of the AF spectra, an intensity ratio (335/430 nm) was
calculated and correlated with the histologic results of the biopsies taken. They also highlighted
a spectral distortion between spectra of the healthy mucosa, the inﬂammatory bladder mucosa
and the CIS. They analyzed the AF spectra of 114 biopsies (21 malignant, 93 benign). The AF
intensity ratios for the benign lesions were a factor of 2 to 7 higher than CIS and neoplastic
tissue. Therefore, 20 of 21 neoplastic lesions were detected as true positive by AF. They combine
it to the photodetection of 5-ALA induced ﬂuorescence to improve its speciﬁcity.
Zheng et al. determine the optimal excitation and emission wavelengths for AF diagnosis
of bladder cancer [Zhen03]. A total of 52 bladder tissue specimens were analyzed ex vivo from
samples obtained with cystoscopic biopsy or surgical resection. The tissue specimens were rinsed,
placed in bottles with physiologic saline solution (pH = 7.4) and delivered for spectroscopic
measurements immediately. Fluorescence excitation wavelengths varying from 220 to 500 nm
(10 nm step) were used to induce tissue AF, and emission spectra were measured in the 280–
700 nm range (5 nm step). These spectra were then combined to construct 2-dimensional
ﬂuorescence excitation-emission matrices (EEMs). Signiﬁcant changes in ﬂuorescence intensity
of EEMs were observed between normal and tumor bladder tissues, the most marked diﬀerences
being at the excitation wavelengths of 280 and 330 nm. Their diagnostic algorithm is based on
the combination of the ﬂuorescence peak intensity ratios of I350/I470 at 280 nm excitation and
I390/I470 at 330 nm excitation. One threshold per ratio was set to 3.5 and 1.18, respectively,
and the combination of the two ratios yielded a sensitivity of 100% [95% conﬁdence interval
(CI) 0.95-1.0] and speciﬁcity of 100% (95% CI 0.90-1.0). This study is not fully comparable
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with the studies described above, as the spectra were acquired ex vivo. Indeed, the hemoglobin
absorption doesn’t play a signiﬁcant role anymore, since the samples are rinsed with saline before
EEMs acquisition. Nevertheless, their results demonstrate increased ﬂuorescence at 350 and 635
nm emission and a decrease at 390, 470 and 520 nm emission associated with bladder tumors
(see Figure 2.9). The ﬂuorescence peaks observed in ﬂuorescence EEMs are close to the emission
spectra of pure tryptophan (emission peak approx. 340 nm), collagen (emission peak approx.
385 nm), NADH (emission peak approx. 460 nm), FAD (emission peak approx. 510-530 nm)
and porphyrins (emission peak 635 nm) as listed in Table 2.2.
Figure 2.9: Contour plots of the average ﬂuorescence EEMs of (a) normal and (b) tumor bladder
tissues [Zhen03].
2.2.2 Exogenous ﬂuorochromes
The use of ﬂuorescence imaging and spectroscopy for in vivo and ex vivo characterization of
biological materials has been well established for several decades, based on the speciﬁc localiza-
tion of administered ﬂuorescent molecules (ﬂuorophores) in tissue or cell structures. Techniques
frequently used clinically include ﬂuorescein angiography to image the retinal vasculature and
for guidance of surgical resections. Most exogenously administered ﬂuorochromes currently
being investigated for endoscopic oncologic applications have been developed primarily as pho-
tosensitizers (PS) for the photodynamic therapy (PDT). Therefore, most compounds have been
designed with speciﬁc PDT characteristics, such as strong absorption at longer red wavelengths
(and thus high penetration depth) and high triplet state quantum yield. These properties are
not relevant for ﬂuorescence detection. Furthermore, the selectivity of these PS has been rather
poor for detection of pre-neoplastic and early cancerous lesions. Consequently, over the last
years, one has designed exogenous ﬂuorochromes with better targeting strategies, since they can
be characterized in vitro regarding their photophysical and pharmacokinetics properties.
The ﬂuorescence originating from an exogenous ﬂuorophore has often a higher intensity than
autoﬂuorescence. This results in a simpler instrumentation (e.g. no need of image intensiﬁer)
and thus reduces the manufacturing costs. In contrast, the use of exogenous ﬂuorochromes for
detection raises concerns about safety and toxicity, whereas the time delay between administra-
tion and light delivery, deﬁned as drug-time interval, has to be optimized, since the ﬂuorescence
brightness and contrasts often do not peak at the same time in diﬀerent tissues.
Some existing non- or weakly phototoxic drugs are already available clinically. Fluorescein
(FITC) and Indocyanine Green (ICG) have well-known applications in ophthalmology, but also
explorative results in endoscopy [Kimu08]. Speciﬁcally, ﬂuorescein (often coupled to dextran,
FITC-dextran) has been reported to be suitable for tumor imaging [Brag93], but this seems
unlikely because it is highly water soluble and very rapidly cleared in vivo. On the other
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hand, coupling of ﬂuorescein to a monoclonal antibody makes it quite useful for ﬂuorescence
diagnostics [Foll92] and the same may be true for ICG and similar compounds [Ball97].
2.2.2.1 PpIX : build-up and spectroscopy
Under certain circumstances, a non-ﬂuorescing exogenous substance, that will be activated in-
side the cancerous tissue with the help of a biochemical modiﬁcation, is used as a precursor
of a ﬂuorescing photosensitizer. In this case, one speaks of exogenously induced ﬂuorescence.
Aminolevulinic acid (ALA) derivatives belong to this category, since they are not ﬂuorescent in
themselves, but they are part of the biosynthetic pathway of heme as shown in Figure 2.10. In
this biochemical reaction chain, the protoporphyrin IX (PpIX) is ﬂuorescing. PpIX belong to
the group of porphyrins which play an important role in the formation of key macromolecules
like hemoglobin, myoglobin,and cytochromes. The PpIX precursor is delta- or 5-aminolevulinic
acid (5-ALA) or one of its derivatives. Certain types of cells have a large capacity to synthesize
PpIX when exposed to an adequate concentration of exogenous ALA. The systemic administra-
tion of an adequate dose of ALA to experimental animals leads to the development of strong
PpIX ﬂuorescence in certain tissues but not in others [Kenn92, Kenn90]. In particular, it was
observed by ﬂuorescence microscopy, that skin, bladder, and uterus showed strong ﬂuorescence
in the epidermis, endometrium, and urothelium without signiﬁcant ﬂuorescence in the dermis,
the elastic cartilage of the ear, the myometrium, or the muscles of the bladder [Diva90].
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Figure 2.10: The biosynthesis of heme, with the ﬂuorescing PpIX in red (adapted from [Foti06]).
Figure 2.10 shows the biosynthesis of heme. The initial step in this process is the condensa-
tion of glycine and succinyl coenzyme A (succinyl CoA) to 5-aminolevulinic acid (5-ALA) in the
mitochondrion. 5-ALA production is regulated by heme in a negative feedback mechanism, i.e.
the presence of heme in the cell inhibits the production of 5-ALA. The 5-ALA molecule passes
into the cytoplasm where it undergoes several chemical reactions regulated by various enzymes
to produce the so-called coproporphyrinogen III. The latter re-enters the mitochondrion and is
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converted to protoporphyrinogen IX and ﬁnally to the PpIX. The last step is the chelation of an
iron ion into the porphyrin ring, resulting in the non-ﬂuorescent heme molecule. This chelation
is enabled by the ferrochelatase. The heme molecule is then transformed into hemoglobin.
In 1951, Berlin et al. demonstrated that excess administration of exogenous ALA bypasses
the cellular feedback control mechanism in normal organisms and leads to abnormally large
quantities of protoporphyrin IX (PpIX) in humans [Berl56a, Berl56b]. Thus, the external ap-
plication of 5-ALA (or one of its derivatives) can lead to a temporary accumulation of PpIX. In
cancerous cells, one observes a higher accumulation of PpIX after administration of exogenous
5-ALA, because (i) the up-take of ALA is increased so that one ﬁnds ALA in excess into the cell,
and (ii) the ferrochelatase activity is reduced, so that PpIX can accumulate within the cell. It
results a ﬂuorescence intensity contrast between healthy tissues and lesions, which can be used
in ALA-induced PpIX ﬂuorescence detection of dysplasia and early neoplasia.
The excitation and emission properties of PpIX are well known (see Figure 2.11), but are
strongly dependent on the medium (solution, cell culture, in vivo organs). One excites its ﬂu-
orescence between 405 nm and 632 nm (depending on the applications, i.e. desired penetration
depth), resulting in a typical red emission in the 625nm-725 nm region. ALA-induced PpIX
ﬂuorescence detection has been used for various cancerous and non-cancerous conditions, in-
cluding port-wine stains treatment [Li10], actinic keratosis and basal cell carcinoma [Foti06]
endometriosis [Mali98, Hill00], ovarian carcinoma metastases [Löni04, Lüdi03], Barrett’s esoph-
agus [Fell03, Bran02], and bladder [Jich97].
In section 3.6.2, we will discuss in details the development of ALA-derivatives for the de-
tection of non-muscle invasive bladder cancer. Pioneering research has been performed by our
group in Lausanne in order to enhance the porphyrin production inside the cancer cells. In the
next section, we will introduce some other exogenous ﬂuorophores that have also been used for
cancer photodetection.
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Figure 2.11: PpIX excitation and emission spectrum with maximum at 405 nm and 632 nm, respectively.
2.2.2.2 Various photosensitizers used in photodetection
Hematoporphyrin derivatives The accumulation of hematoporphyrin (HP) in various types
of cancers was discovered and exploited during the 1950’s [Peck55]. In attempting to purify
commercially available HP-hydrochloride, Schwartz et al. found that the fraction containing
impurities accumulated preferentially in tumors better than the partially puriﬁed, HP-rich ma-
terial [Schw92]. This so-called hematoporphyrin derivative (HpD) was evaluated subsequently
for localization of cancers in various organs, including the esophagus, tracheo-bronchial tree and
cervix, and for characterizing suspicious head and neck lesions [Wagn98a].
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The ﬁrst cystoscopic observations of HpD ﬂuorescence in urinary bladder tumors were re-
ported by Kelly and Snell in 1976, but indicated that the ﬂuorescence was too weak for eﬀective
direct-viewing endoscopy [Kell76]. Subsequently, Proﬁo and Doiron [Prof77] and Kinsey et
al. [Kins78] pioneered the development of dedicated ﬂuorescence instrumentation using photo-
electronic detectors. This, and the initial clinical and animal model studies of HpD-mediated
PDT by Dougherty et al. [Doug78], led to ﬂuorescence diagnostic studies by many other groups
using this drug or its later commercial Photofrin (QLT Phototherapeutics, Vancouver, Canada).
Hypericin-based photodetection The botanical St. John’s wort Hypericum perforatum
is native to Europe, West Asia, and North Africa, and has been naturalized to North and
South America and Australia. The Greeks and the Romans documented its medicinal use in
the treatment of nerve-related disorders. St. John’s wort has been used to treat a variety of
conditions. Several brands are standardized for content of hypericin and hyperforin, which are
among the most researched active components of St. John’s wort [Lawv05].
Hypericin, a hydroxylated phenanthroperylenequinone, is widely used in photomedicine. It
exhibits a high ﬂuorescence quantum yield, and its presence in the tissue can easily be visual-
ized. Interestingly, when instilled into the human bladder, hypericin selectively accumulates in
bladder carcinoma lesions. Hence, the compound is now used as a ﬂuorescent diagnostic tool for
superﬁcial bladder cancer [Kamu04]. However, hypericin is also a photosensitizer with a potent
photocytotoxic activity. Indeed, it produces singlet oxygen eﬃciently upon light irradiation with
a quantum yield of 0.73 [Raci88].
d’Hallewin et al. determined the sensitivity and speciﬁcity of detecting ﬂat bladder CIS
through ﬂuorescent detection after intravesical hypericin instillation [D’Ha00]. Their study in-
cluded 40 patients, of whom 26 presented with macroscopic visible tumor, 9 had a positive
cytology without visible tumor and 5 underwent cystoscopy after bacillus Calmette-Guerin in-
stillations (n=4) or radiotherapy (n=1). A solution of hypericin (40 ml 8 µM) was instilled
intravesically for at least 2 hours. Fluorescence excitation with blue light was eﬀective up to
16 hours after termination of the instillation. All visible papillary tumors showed red ﬂuores-
cence. In addition, 134 ﬂat ﬂuorescent areas were detected. Analysis of 281 biopsies from ﬂat
bladder wall indicated 93% sensitivity and 98.5% speciﬁcity for detecting CIS. These data were
conﬁrmed in a larger series of 87 patients, where the sensitivity and speciﬁcity for detecting
CIS were found to be 94 and 95%, respectively [D’Ha02]. In both studies, there were no signs
of photobleaching of hypericin during inspection of the bladder and resection of the tumors.
Inﬂammatory reactions resulting from radiotherapy, chemotherapy or immunotherapy did not
induce ﬂuorescence or false positive readings.
Kubin et al. evaluated an hypericin derivative (PVP-hypericin), and they reach a comparable
sensitivity, but their speciﬁcity was markedly lower (53%) than that reported in other studies
(98-100%), because no biopsies were taken from healthy tissues [Kubi08a, Kubi08b].
In comparison, both hypericin and ALA-induced PpIX show similar sensitivities for detecting
CIS, but hypericin shows much higher speciﬁcity (93%). However, before a ﬁnal conclusion can
be reached, the data on sensitivity and speciﬁcity for hypericin should ﬁrst be conﬁrmed by
multicentric trials, which presently have not been carried out [Kamu04].
2.2.3 Instrumentation aspects
2.2.3.1 Video system
CCD-sensor (charge-coupled device) is a device that moves the electrical charges from within
the device to an area where the charge can be manipulated, for example conversion into a digital
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value. This is achieved by “shifting” the signals between stages within the device one at a time.
Technically, CCDs are implemented as shift registers that move charge between capacitive bins
in the device, with the shift allowing for the transfer of charge between bins. Often the device
is integrated with an image sensor, such as a photoelectric device to produce the charge that
is being read, thus making the CCD a major technology for digital imaging. Although CCDs
are not the only technology to allow for light detection, CCDs are widely used in professional,
medical, and scientiﬁc applications where high-quality image data are required.
CMOS-sensor (complementary metal-oxide-semiconductor) is an image sensor consisting of
an integrated circuit containing an array of pixel sensors, each pixel containing a photodetector
and an active ampliﬁer. CMOS-sensors solve the speed and scalability issues of the passive-pixel
sensor. They consume far less power than a CCD, have less image lag, and can be fabricated
on much cheaper and more available manufacturing lines. Unlike CCDs, CMOS sensors can
combine the image sensor function and image processing functions within the same integrated
circuit.
Historical CCD have been designed for 1-color imaging. Therefore, to reproduce color image in
a video system, one used to need 3-CCD cameras, assembled within a complex setup of prisms
and optical ﬁlters. With the development of mosaic ﬁlters to be placed in front of the CCD, only
one CCD chip is required, and missing pixels are interpolated. First “color” CCD were equipped
with primary RGB ﬁlters, whereas most of the current endoscopic cameras are equipped with
complementary CMYG ﬁlters.
Image quality depends on its resolution and contrast [Muto09]. Resolution is the capacity
to visualize minute patterns and is determined by the pixel number of each CCD. To enhance
resolution, the number of pixels in the CCD has to be increased. However, a CCD with a higher
number of pixels increases the size of the videoendoscope by expanding its outer diameter. On
the other hand, if a thinner endoscope is made, the CCD must be smaller, thereby decreasing
the number of pixels with a resulting reduction of image resolution. Contrast is the ratio of
brightness between a pattern and its background, and can be increased by modifying spectral
design or electronic ampliﬁcation.
Over the years, clip-on cameras have been designed so that they remain outside of the
patient. It worked perfect with the rigid endoscopes, but during ﬂexible endoscopy, ﬁberoptic
bundles create a honeycomb appearance. Additionally, over the time, major drawbacks and
pitfalls due the nature of optical ﬁbers (loss of transmission, breakage, . . . ) have encouraged
the manufacturers to move towards videoendoscopy, that mounts the imaging device on the
tip of the endoscope. Flexible endoscopy requires only local anesthesia, which can save costs
(examination time and involved people) in the clinical routine. Nowadays, CCDs detectors are
used almost exclusively, but in CMOS detectors may be implement in the future (smaller size,
smaller cost, higher speed). High resolution endoscopes achieve very good image quality, that
is similar or even better than rigid endoscopes. However, rigid endoscopy is still preferred for
surgery, because the surgical tools (e.g. high-frequency resectoscope for transurethral resection
of the bladder) are available only on the rigid platform yet.
2.2.3.2 Light sources, ﬁlters and spectral design
Over the last century, the world of endoscopy had a great evolution. The ability to reﬂect light
in deeply located organs was a central problem in designing open tubes. The early version
developed by Nitze used a platinum wire in a glass jacket with water-cooling. The wire was
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heated and lit by a battery for illumination. Needless to say, this was a very clumsy and
cumbersome approach, but it was modiﬁed after Edison’s invention of the ﬁlament globe (1879).
Nitze and his team were able to miniaturize the Edison-type globe to a size small enough to ﬁt
into the tip of a cystoscope.
To address the limitations of the Nitze optical system, H. Hopkins, a London physicist,
devised the prototype of a new optical system in 1954 [Hopk54]. He replaced the previous lens
and air-interspace optical relays using glass rods instead of interspersed air. He also cemented
better lenses on both ends. Hopkins created a system that had the following distinct advantages
over the Nitze system :
1. The light transmission was signiﬁcantly greater, yielding a brighter image enabled the
examiner to distinguish the features more easily and recognize slight changes more clearly.
In general, perception was improved.
2. The viewing angle, which was small with the previous optics, was wider. Therefore, the
examiner could see a larger part of the object in a single viewing ﬁeld; thus, as soon as
the telescope was introduced, orientation was faster.
3. The system included several improved optical parameters (e.g. natural color reproduction,
image quality at the edge, higher resolution).
4. The system was smaller in diameter, resulting in easier and safer introduction. With fur-
ther miniaturization, it was possible to produce telescopes measuring 2-3 mm in diameter,
including ﬁber light transmission. This improvement opened up a new chapter in pediatric
endoscopy.
5. Thanks to the brighter image and increased light transmission, the examiners were able to
document their ﬁndings by attaching 35-mm still cameras, and, later on, video systems.
Nowadays, one often uses high-pressure xenon or mercury short arc lamp as an external light
source, which is connected to the endoscope via a ﬂexible light cable. The ﬁrst prototype using
light-emitting diodes (LEDs) are now commercialized. That will allow the manufacturers to
design stand-alone wireless endoscope, since any ﬂuid light cable won’t be required anymore.
Spectral design In this thesis, we used several commercial devices as light source for the
endoscopic ﬂuorescence imaging. Figure 2.12 shows the excitation spectra of the systems mea-
sured at the distal end of the light cable with a portable spectrometer (USB2000, Ocean Optics,
Duiven, NL) :
1. DAFE (Diagnostic Autoﬂuorescence Endoscopy, Richard Wolf GmbH) for pneumology
2. Combilight system (Photodynamic Diagnostic, Richard Wolf GmbH) for urology
3. D-Light system (Photodynamic Diagnostic, Karl Storz GmbH), which has a larger excita-
tion spectrum to overlap with the long-pass ﬁlter in the blue spectral region, to allow blue
backscattered background for urology.
Both systems (Storz and Wolf) do have a yellow long-pass (LP) in the detection path to
reject the excitation light. This allows collecting autoﬂuorescence in the bronchi and porphyrins
ﬂuorescence in the urinary bladder. The LP ﬁlter (cut-on wavelength 450nm) is integrated either
in the endoscope (Storz) or directly into the camera objective (Wolf).
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Figure 2.12: Excitation spectra of the DAFE, PDD and Storz systems normalized at their maximum.
Figure 2.13: The commercial version of the Xenon light source delivering white/blue light for endoscopic
examination
32 Chapter 2. Clinical cancer detection by optical imaging
2.3 High magniﬁcation technical concepts and state-of-the-art
Magniﬁcation endoscopes have high zooming capability (allowing small areas to be magniﬁed),
whereas high resolution endoscopes have a high pixel density (allowing small details to be visu-
alized in the overview image). A non-exhaustive literature review is presented in Table 2.3 in
diﬀerent organs.
In large GI endoscopes, an optical zooming setup located in the tip of scope (typically a motor
driven movable lens) allows high magniﬁcation examination. By controlling the focal distance,
the scope can move very close to the mucosal surface providing the magniﬁed image [Brun03].
In smaller devices (e.g. bronchoscope), due to space limitations, one cannot implement an active
zooming setup. One solution that was implemented was the combination of two optical systems
in the same device : (i) a video observation system for high magniﬁcation observation, and (ii)
a ﬁber observation system for orientation of the endoscope tip within the organ [Yama07].
One of the most promising aspects of the use of high-resolution endoscopes lies in their supe-
rior ability to discriminate details in the non-magniﬁed overview image. New generation video
endoscopes are equipped with CCD-chips of more than 850 Kpixels and can distinguish points
that are several tens of µm apart (as compared to about 150 µm for the naked eye) [Brun03].
Several applications of high magniﬁcation endoscopy in gastroenteroscopy and colonoscopy
are nowadays well implemented, making use of the newly observable features that can be vi-
sualized with these new scopes: pit patterns, neo-vessels morphology, and nuclear morphome-
try. Sugano et al. have diagnosed gastric cancer and inﬂammatory changes in ulcerative coli-
tis [Suga04, Suga06]. Fortun et al. have studied diagnostic improvement of Barrett’s esophagus
with this particular technique [Fort06].
In bronchoscopic studies, Shibuya et al. stated that conventional white light bronchovideoscopy
observe only increased redness and local swelling, while high magniﬁcation bronchovideoscopes
enable visualization of the vascular network [Shib02, Shib03]. Observing increased vessel growth
and complex networks of tortuous vessels of various sizes, these authors were able to discrimi-
nate between inﬂammatory reactions and angiogenic squamous dysplasia (ASD) in the bronchi.
Indeed, they observed the complex neo-vessels structure and tortuosity in the bronchial mucosa
(magniﬁcation of up to 110×), visualizing dotted vessels (size 25–53 µm), in full agreement with
capillary blood vessel diameters in ASD as observed during histopathology analysis (size 35–
62.5 µm).
Yamada et al. developed a dual-channel bronchoscope. This ﬂexible bronchovideoscope is
equipped with a prism at the distal end, allowing the images of the bronchial mucosa to be
captured by the CCD through a magnifying objective lens. The bronchial mucosa were visualized
with a magniﬁcation power of 55–110 × according to the distance between the objective lens and
the bronchial surface. The view angle was 40o, but little distortion is seen. In addition, a forward-
viewing optical ﬁberscope was attached to act as a guide. By using this front-viewing system,
we conﬁrmed the orientation and approached the endobronchial destinations while obtaining a
high-magniﬁcation view [Yama05].
In the lower GI tract, Oba and co-workers characterized the colorectal tumors using narrow-
band imaging magniﬁcation, combining diagnosis with both pit pattern and microvessel fea-
tures [Oba10].
2.4 Confocal endoscopy
Over the last years, several groups attempted to transfer the on-bench microscope into a dedi-
cated clinical micro-endoscope to assess histopathological status in vivo with either reﬂectance
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images or ﬂuorescence images.
2.4.1 Motivation and technology
The endo-cytoscopy was suggested by observations made using the contact endoscope (Karl
Storz GmbH). In the 1980s, Hamou et al. reported observations of the surface of the genital
tract under high magniﬁcation using a microhysteroscope [Hamo81, Hamo83, Hamo84]. Since
then, several studies involving in vitro and in vivo magniﬁed observations by contact endoscopy
have been reported in the ﬁeld of otorhinolaryngology. These studies used methylene blue to
stain the surface epithelium during observation, and succeeded in making cells on the surface
epithelium visible [Andr95a, Andr95b]. However, the contact endoscope used in these studies
was a rigid endoscope, which precluded observations of most organs (e.g. GI tract).
Therefore, a new ﬂexible endo-cytoscopy system, which could be inserted into the digestive
tract, was developed by Olympus Inc. This system consisted of two ﬂexible endoscopes : (i) the
low-magniﬁcation type (XEC300, 380 cm long, 3.2 mm in diameter) provided 450× magniﬁca-
tion and a ﬁeld of view (FOV) of 300×300 µm, (ii) the high-magniﬁcation type (XEC120) that
provided 1125× magniﬁcation and a FOV of 120×120 µm. These ﬂexible probes could be passed
through the instrument channel of the Olympus gastroscope (GIF1T-240). For magniﬁed obser-
vation, vital staining, such as with methylene blue or toluidine blue, was necessary. The most
evident feature of the observation using this system is the real-time diagnosis of abnormalities of
the cell nuclei [Kuma06]. Sasajima et al. also performed real-time virtual histology of colorectal
lesions using vital staining [Sasa06].
Confocal microendoscopes provide high resolution cellular imaging in vivo in a relatively
small package. This minimally invasive technique provides instant visualization of tissue and
allows pathologists to make a diagnosis in situ without having to use traditional biopsy meth-
ods [Makh08]. Therefore, this technology has often been named optical biopsy, since it replaces
the conventional tissue sampling. Confocal microendoscopy can be performed in reﬂectance or
ﬂuorescence modes [Flus05], and has been used for the detection and diagnosis of diseases in a
broad variety of organs such as cervix [Sung02, Carl05], colon [Kies04b], oral cavity [Thon07],
lung [Thib07, Thib09b], esophagus [Goet06], bladder [Sonn09a], and ovary [Brew04].
Two companies are currently on the market with a microendoscopic confocal device [Dunb08]:
Optiscan Pty Ltd. licenses its tip-integrated confocal laser endomicroscope to Pentax Corp.,
so that the confocal probe is fully integrated into an endoscope. Optiscan miniaturized the
microscope and integrates the whole xy-scanning device at the distal tip of the endoscope,
which contains a rigid part of 5 cm at the distal tip. Images have a lateral resolution of
0.7 µm and an axial resolution of 7 µm within a ﬁeld of view of 475×475 µm. The setup
only achieves a slow speed (0.7 frame/sec). The excitation light (488-nm laser) is coupled
into a single optical ﬁber that acts as both a point source and a point detection pinhole for
confocal imaging. z-sectioning can be achieved by rotating a knob on the handle, which
moves the entire scanning mechanism (including both magnetic coils and the tuning fork)
axially along the tube. This provides a mechanical range of almost 300 µm below the
surface [Thon07]. For optimum image contrast, the laser power can be adjusted between
0 to 1000 mW at the distal tip of the probe in contact with the tissue.
MaunaKea Technologies Inc. licenses its ﬂexible ﬁber-based confocal miniprobe to Leica for
the small animal applications, and market it on its own for human clinical applications.
The Cellvizio R© probe is inserted into the working channel of any standard endoscope
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and is thus not device-dependent. The ultrafast xy-scanning device is located outside
the patient within the laser light source (488nm or 660 nm). A coherent multi-core ﬁber
(30’000 cores) is scanned with the laser device and collects the ﬂuorescence image back
from the tissue [Laem04]. The software associated with the probe is providing rapid
image capture and stitching of adjacent images to create an image mosaic in real-time.
Three mini-probes are available with diﬀerent imaging depth, ﬁeld of view, and lateral
resolution. A quasi video rate (12 frames/s) is achieved with a lateral resolution depending
on the probe (1-3.5 µm). The imaging depth (0-120 µm), as well as the ﬁeld of view
(130×130 µm- 600×600 µm), can be obtained thanks to a set of ﬂexible optical microprobes
whose diameters vary from 0.16 to 1.5 mm, but no z-sectioning is possible yet [Verc08].
Bhuvaneswari et al. used the last generation of the Optiscan probe to acquire in vivo ﬂuorescence
microscopic imaging of tumor blood vessels [Bhuv10]. The images were acquired 30 min. after
intravenous administration of FITC dextran. The new Optiscan FIVE 1 system features the
same basic design with improved speciﬁcations. They demonstrated that by using laser confocal
endomicroscopy, responses to antiangiogenic therapies can be evaluated successfully by in vivo
imaging of tumor vasculature.
An interesting clinical study was recently reported by Thiberville et al. who imaged bronchial
wall microstructure using a ﬁbered confocal ﬂuorescence microscope [Thib07]. They used the
Cellvizio R© optical microprobe to image the autoﬂuorescence up to the alveoli [Thib09a]. They
observed speciﬁc basement membrane alterations associated with premalignant bronchial lesions
in vivo. The technique may also be useful to study the bronchial wall remodeling in nonmalignant
chronic bronchial diseases (e.g ﬁbrosis).
Sonn et al. used the same device in the urinary bladder [Sonn09a, Sonn09b]. After standard
cystoscopy, ﬂuorescein was administered intravesically and/or intravenously as a contrast dye.
A 2.6 mm probe based confocal laser endomicroscope was passed through a 26 Fr resectoscope
to image normal and abnormal appearing areas. The endomicroscopic images were compared
with standard hematoxylin and eosin (H&E) analysis of transurethral resection of bladder tumor
specimens. Endomicroscopic images demonstrated clear diﬀerences between normal mucosa, and
low and high grade tumors. In normal urothelium larger umbrella cells are seen most superﬁcially
followed by smaller intermediate cells and the less cellular lamina propria (as to be seen in
Figure 2.14 adapted from [Sonn09a]). In contrast, low grade papillary tumors demonstrate
densely arranged but normal-shaped small cells extending outward from ﬁbrovascular cores.
High grade tumors show markedly irregular architecture and cellular pleomorphism.
2.4.2 Limitations of current confocal endoscopy
This MaunaKea approach suﬀers several limitations. The shape of an object is a morphological
quantiﬁcation. However, images in the ﬁeld of view, smaller than the pixel resolution of the
microprobe can only be viewed as accurately as this resolution permits. In terms of intensity, the
signal is directly proportional to the amount of light detected (if below the detector saturation
limit). If the detector is saturated, the linear relationship is not valid anymore. In terms of
temporal analysis, since the frame rate is ﬁxed, the time elapsed between two frames is constant.
Thus the absolute acquisition time is indelibly associated with each frame.
In addition, image acquisition is extremely sensitive to motion introduced by the subject
(ie diaphragmatic motion or arterial pulsation) or the operator. Also, the used probe (2.6 mm
size) necessitates the use of a 26 Fr rigid resectoscope instead of a ﬂexible cystoscope. The rigid
cystoscope oﬀers less options to manipulate the probe tip. Therefore, the required perpendicular
contact with the tissue is impossible in cases where the area of interest resides on the anterior
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Figure 2.14: Comparison of H&E and confocal endomicroscopic images of normal human bladder mu-
cosa with ﬂuorescein staining [A] large, polygonal superﬁcial cells consistent with umbrella cells [B]
smaller, deeper urothelial cells consistent with intermediate cells [C] less cellular lamina propria con-
taining blood vessels ﬁlled with erythrocytes adapted from [Sonn09a].
bladder wall. Accordingly due to their location in the bladder some tumors could not be imaged.
In addition, given the 2.6 mm probe tip size with a 240 µm ﬁeld of view and the requirement
for direct contact with the urothelium, imaging the entire bladder is not practical. Rather
the proposed role of confocal laser endomicroscopy is to provide real-time histology of areas
highlighted by white light cystoscopy or other imaging modalities such as ﬂuorescence cystoscopy.
Two potential drawbacks explain why the Pentax system is not yet available for the res-
piratory and urinary tract imaging. First, because of the added sizes of the distal scan head,
working channel, conventional light guide, and CCD camera, the diameter of the distal tip of the
endoscope is currently larger than 12 mm. With this size, the exploration of the human trachea
and large main bronchi (resp. urethra and bladder) is hardly possible. Second, the miniatur-
ization of the distal scan head results in scanning rates of 1 frame/second, which needs a very
eﬃcient stabilization system of the distal tip of the endoscope onto the mucosae, to produce
crisp microscopic images of the epithelium.
Both devices are working in ﬂuorescence mode, and requires an exogenous contrast agent to
acquire images (e.g. intravenous injection of ﬂuorescein). Indeed, they are still unable to detect
the autoﬂuorescence of most tissues. Several experiments reported that only the very high
level of autoﬂuorescence in hair and adipose tissue has been detected. Therefore, the current
Cellvizio R© cannot be used for detection and imaging of autoﬂuorescence. On the other hand,
the autoﬂuorescence of the tissue does not interfere with the imaging of speciﬁc targeting of cells
by the ﬂuorophores.
Even if ﬂuorescein is widely used in ophthalmology, its clinical usage is not fully harmless.
Severe allergic reactions to this dye are extremely rare, but occasional deaths have been reported
(1/220’000). Anaphylactic shocks occur in 1/350 patients. Users of Pentax system reported an
injection of 10 ml ﬂuorescein (10%), whereas the Cellvizio R©’s users reported an injection of 5
ml ﬂuorescein (1%), which corresponds to a 50× lower dose2.
Additionally, the confocal cystoscopy may have to be limited in time because approximately
10 minutes after i.v. administration, ﬂuorescein is excreted into the bladder, potentially inter-
2More information is available on the web www.optiscan.com and www.maunakeatech.com
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fering with cystoscopic visualization.
In contrast to most other hollow organs, the bladder oﬀers a direct route for topical ad-
ministration of medications. Sonn et al. demonstrates that intravesical ﬂuorescein instillation
adequately provides cellular resolution and micro-architecture comparable to intravenous ad-
ministration [Sonn09a]. These authors also reported that quality does deteriorate after approx-
imately 15 minutes likely due to repeated bladder irrigation. However, intravesical ﬂuorescein
instillation may be repeated if necessary. Finally ﬂuorescein does not permit visualization of
cell nuclei as noted in similar studies in the GI tract [Kies04b].
2.5 Statistical calculation for cancer detection
At this point, one should deﬁne some concepts to quantify the performance of a new diagnosis
method. One usually refers to the result of an unknown test as compared to the result of a known
reference. In this context, the reference is determined by a gold standard, which is deﬁned in
medicine as “a relatively irrefutable standard that constitutes recognized and accepted evidence
that a certain disease exists” [Fouc97]. In cancer diagnosis, the gold standard is histopathology
and cellular pathology. However, the objectivity and inerrability of histopathologic diagnosis,
especially for early neoplastic pathologies, has been discussed in several scientiﬁc reports and
reviews [Rams99, Jenk01, Cros98, Farm96].
Gold standard
Positive Negative
Test
Positive True Positive TP False Positive FP → Positive predictive valueType I error, α
Negative False Negative FN True Negative TN → Negative predictive valueType II error, β
↓ ↓
Sensitivity Speciﬁcity
Table 2.4: Test vs. Gold standard. In endoscopic cancer detection, it corresponds to endoscopic
appearance vs. histopathology result [Altm94].
If the test and the reference agree on a positive or negative value, it is said to be a true
positive (TP) or a true negative (TN), respectively. If the test is positive and the reference is
negative, this is referred to a false positive (FP) result. Conversely, if the test is negative and
the reference is positive, this is called a false negative (FN) result. A summary of these values
is shown in Table 2.4.
The performance of a method is described by its sensitivity, its speciﬁcity, its positive predic-
tive value (PPV), and its negative predictive value (NPV), generally expressed in percentage [%].
These numbers are deﬁned in Table 2.5.
Statisticians speak of two signiﬁcant sorts of statistical error. Type I error α occurs observing
a diﬀerence when in truth there is none, thus indicating a test of poor speciﬁcity. An example of
this would be if a test shows that a woman is pregnant when in reality she is not. Type I error
can be viewed as the error of excessive credulity. Type II error β occurs when failing to observe
a diﬀerence when in truth there is one, thus indicating a test of poor sensitivity. An example
of this would be if a test shows that a woman is not pregnant, when in reality, she is. Type II
error can be viewed as the error of excessive skepticism. Table 2.6 deﬁnes these quantities.
In many studies, one has to be cautious with the given sensitivity and speciﬁcity, because the
number of true negative and false negative results are diﬃcult to assess correctly. Indeed, the de-
termination of these parameters would require extensive sampling from putative healthy tissues.
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Sensitivity Probability that an individual with the dis-
ease is screened positive.
TP
FN+TP
Speciﬁcity Probability that an individual without the
disease is screened negative.
TN
TN+FP
Positive Predictive Value (PPV) Probability that an individual with a pos-
itive screening result has the disease.
TP
TP+FP
Negative Predictive Value (NPV)
Probability that an individual with a nega-
tive screening result does not have the dis-
ease.
TN
TN+TP
Table 2.5: Main parameters that describe the quality of a detection and diagnostic method [Rama00].
False positive rate (Type I error) 1 - speciﬁcity α = FPFP+TN
False negative rate (Type II error) 1 - sensitivity β = FNTP+FN
Power sensitivity 1 - β = TPTP+FN
Likelihood-ratio positive LR+ sensitivity / (1 - speciﬁcity) TPFP+TP · TN+FPFP
Likelihood-ratio negative LR- (1 - sensitivity) / speciﬁcity TNTN+FP · FN+TPFN
Table 2.6: Error calculation and other related statistical values.
In case of cancer detection, we need to take biopsies to analyze the tissue with histopathology
and this procedure is considered to be invasive and not harmless for the patient. Therefore,
biopsy sampling on healthy tissues is often not defendable for medical and ethical reasons. Con-
sequently, one often prefers to speak of relative sensitivity and speciﬁcity when comparing two
concurrent methods.
The odds ratio (OR) is the ratio of the odds of an event occurring in one group to the odds
of it occurring in another group. The term is also used to refer to sample-based estimates of
this ratio. These groups might be men and women, an experimental group and a control group,
or any other dichotomous classiﬁcation. If the probabilities of the event in each of the groups
are p1 (ﬁrst group) and p2 (second group), then the odds ratio is:
p1/(1 − p1)
p2/(1 − p2) =
p1/q1
p2/q2
= p1q2
p2q1
where qx = 1 − px
An OR of 1 indicates that the condition or event under study is equally likely to occur in both
groups. An OR greater than 1 indicates that the condition or event is more likely to occur in
the ﬁrst group, and an OR less than 1 indicates that the condition or event is less likely to occur
in the ﬁrst group.
To quantify statistical tests, one needs some more deﬁnitions. The pre-test probability (or
population prevalence) is deﬁned as p1 = (TP + FN)/(TP + TN + FP + FN), related to the
pre-test odds PrTO = p1/(1 − p1). The post-test odds are deﬁned p2 = PrTO ∗ LR, related to
the post-test probability PoTP = p2/(p2 + 1).
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Part I
Bladder cancer

Chapter 3
Introduction to Bladder Cancer
In this chapter, we will ﬁrst introduce some facts and statistics about bladder cancer (BC)
(Section 3.1), in order to show that BC is an important health burden. Then, we will present the
anatomy of urinary system (Section 3.2) and histology of bladder cancer (Section 3.3) with the
classiﬁcation systems, continuously updated by the medical community. We will also illustrate
the diﬀerent evolution pathways of BC, and link them to the clinical management of BC, and
focus on screening (Section 3.4) and diagnostic procedures (Section 3.5). In Section 3.6, we will
introduce the photodetection of bladder cancer based on ALA-derivatives, and conclude this
chapter with a short review on angiogenesis related to BC (Section 3.7) to motivate the vascular
imaging, described in Chapter 5.
3.1 Facts and statistics about bladder cancer
Cancer (often deﬁned as equivalent to malignant tumor) is deﬁned a class of diseases in which a
group of cells display uncontrolled growth (division beyond the normal limits), invasion (intrusion
on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in
the body via lymph or blood). These three malignant properties of cancers diﬀerentiate them
from benign tumors, which are self-limited, and do not invade or metastasize.
In the past years, cancer statistics have been established by governmental institutes. The
most common cancers that were expected to occur in men and women in 2009 are depicted in
Figure 3.1.
Figure 3.2 shows the 5-year survival rate for the two cancers of interest in this manuscript
(namely in the tracheo-bronchial tree and in the urinary bladder). One can clearly identify that
a diagnostic procedure that would detect cancer on a localized state (i.e. not distant) would be
associated with a better survival. That is the purpose of ﬂuorescence detection.
3.2 Anatomy of the urinary system
The urinary bladder is a hollow muscular organ in the lower abdomen (see Figure 3.3). It
stores urine, the liquid waste produced by the kidneys. Urine passes from each kidney into the
bladder through a tube called a ureter. An outer layer of muscle surrounds the inner lining
of the bladder. When the bladder is full, the muscles in the bladder wall can tighten to allow
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Estimated new cases
Estimated Deaths
Figure 3.1: Ten leading cancer types for estimated new cancer cases and deaths, by sex, United States,
2009 [Jema09].
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Figure 3.2: Five-year Relative Survival Rates Among Patients Diagnosed with Selected Cancers by Race
and Stage at Diagnosis,United States, 1996-2004.
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urination. Urine leaves the bladder through another tube, the urethra. The urinary bladder is a
muscular sac lined with mucosa. Thus, it is highly distensible, with its volume varying typically
from 30 cm3 to 220 cm3 [Wood86].
The urinary bladder is shaped roughly like a tetrahedron (see Figure 3.4) when empty and
like a sphere when ﬁlled with urine. The posterior triangle of the tetrahedron forms the base
of the bladder, the anterior the apex, the inferior angle leading to the urethra is called the neck
and the two posterolateral angles admit the ureters. The smooth triangular area outlined by
the ostia of the ureters and the internal oriﬁce of the urethra is called the trigone.
Figure 3.3: Median sagittal section of male and female pelvis [Gray18].
trigone
ureters
bladder neck
urethra
left lateral wall right lateral wall
dome
Figure 3.4: Sagittal section and its corresponding tetrahedron representation of the empty blad-
der [Gray18].
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The bladder itself is made up of four layers (epithelium, lamina propria, muscularis pro-
pria, perivesical soft tissue) as shown in Figure 3.5. These layers are important landmarks in
determining the depth of tumor invasion.
Epithelium lines the bladder and is in contact with the urine. It is referred as transitional
epithelium or urothelium. Most bladder cancers originate from the cells of this transitional
epithelium. The urethra, ureters and the pelvis of the kidney are also lined by this transi-
tional epithelium, therefore, the same types of cancers seen in the bladder can also occur
in these sites.
Lamina propria lies under the epithelium, as a layer of connective tissue and blood vessels.
Within the lamina propria, there is a thin and often discontinuous layer of smooth muscle
called the muscularis mucosae. This superﬁcial layer of smooth muscle is not to be confused
with the true muscular layer of the bladder called the muscularis propria or detrusor
muscle.
Muscularis propria or detrusor muscle This deep muscle layer consists of thick smooth
muscle bundles that form the wall of the bladder. For purposes of staging bladder cancer,
the muscularis propria has been divided into a superﬁcial (inner) half and a deep (outer)
half.
Perivesical soft tissue This outermost layer consists of fat, ﬁbrous tissue and blood vessels.
When the tumor reaches this layer, it is considered out of the bladder.
Figure 3.5: Layered structure of the bladder wall
The urothelium is the most specialized epithelium and plays important and conﬂicting roles:
the urothelium must act as a permeability barrier – protecting underlying tissues against noxious
urine components – while also stretching to accommodate urine pressures. Although the urothe-
lium maintains a tight barrier to ion and solute ﬂux, a number of local factors can modulate its
barrier function (e.g. tissue pH, mechanical or chemical trauma, and bacterial infection) [Bird07].
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Urothelium is a multilayered epithelium composed of at least three layers: a basal cell layer
attached to a basement membrane, an intermediate layer, and a superﬁcial or apical layer com-
posed of large hexagonal cells (with diameters of 25-250 µm) known as umbrella cells [Drol05].
The umbrella cells are interconnected by tight junctions and are covered on their apical surface
by crystalline proteins called uroplakins which assemble into hexagonal plaques [Apod04]. The
thickness of the urothelium varies with the state of distension of the bladder (two to four cell
layers when dilated and ﬁve to seven layers when contracted) [Mont08].
3.3 Histology of bladder cancer
Approximately 75-85% of patients with bladder cancer present with the disease conﬁned to the
mucosa (stage Ta,Tis) or submucosa (stage T1) [Babj08], but as many as 50-70% of those super-
ﬁcial tumors will recur and roughly 10-20% will progress to muscularis propria invasive disease
(T2-4) [Rübb88]. A detailed description of this classiﬁcation is to be found in Section 3.3.2.1.
Three types of bladder cancer begin in cells in the lining of the bladder. These cancers are
named for the type of cells that become malignant (i.e. cancerous):
Transitional cell carcinoma begins in cells in the innermost tissue layer of the bladder (>90%).
These cells are able to stretch when the bladder is full and shrink when it is emptied.
Squamous cell carcinoma begins in squamous cells, which are thin, ﬂat cells that may form
in the bladder after a long-term infection or irritation (∼6–8%).
Adenocarcinoma begins in glandular (secretory) cells that may form in the bladder after a
long-term inﬂammation or irritation (2%).
3.3.1 Epidemiology and Risk factors
Cancer of the urinary bladder (in short bladder cancer) is frequent in the Western world. Blad-
der cancer is the 4th most common malignancy among men, the 8th most frequent among
women [Joch05]. In 2009, an estimated of 70’980 cases were diagnosed in the United States with
more than 14’330 dying from the disease [Jema09, N.-N09]. In Europe, more than 120’000 new
cases of bladder cancer are diagnosed every year. The incidence of bladder cancer increases with
age; the median age at diagnosis is 65-70 years [E.-O09].
Along with lung cancer, bladder cancer was one of the earliest cancers to undergo serious epi-
demiologic investigation [Zeeg04]. Aromatic amines were the ﬁrst to be recognized as urothelial
carcinogen [McCa97]. At-risk groups include workers in the following industries: printing, iron,
and aluminium processing, industrial painting, gas and tar manufacturing. Another prominent
risk factor is cigarette smoking, which triples the risk of developing bladder cancer and leads to
its higher mortality [Babj08, Zeeg00, Stro08].
Kaufman et al. classiﬁed the bladder cancer associated risks factors into three subsets [Kauf09]:
• genetic (oncogenes, epidermal growth factor, tumor suppressor gene) and molecular (cell
life regulatory proteins) abnormalities
• chemical (aromatic amine, aniline dyes, nitrites and nitrates, acrolein, coal, arsenic...) or
environmental (cigarette smoking) exposures
• others factors such as chronic irritation, indwelling catheters, and pelvic irradiation.
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Unfortunately, patients have often low overall knowledge regarding bladder cancer risk fac-
tors. For instance, most patients queried in the study of Nieder et al. had no idea regarding the
relationship between bladder cancer and tobacco use regardless of smoking status [Nied06].
Zeegers et al. systematically reviewed the association between smoking, beverage consump-
tion, diet and bladder cancer [Zeeg04]. Based on the results of previous epidemiologic studies and
mechanistic evidence, they concluded that the most important risk factor for bladder cancer is
cigarette smoking. In their opinion, prevention of cigarette smoking would result in a decrease of
50% of male bladder cancer cases and 23% of female bladder cancer cases. Alcohol consumption
is the only other convincing risk factor for bladder cancer, although previous research suggests
that the risk elevation for alcohol consumers is very small. Zeegers et al. stated that there is
probably no association between coﬀee, tea, vitamin A and C intake and subsequent bladder
cancer risk and a negative association with fruit consumption and selenium intake. Eventually,
these authors stated that it is possible that cigar, pipe and passive smoking slightly increase
bladder cancer risk, that total ﬂuid consumption and folate intake are not associated with blad-
der cancer risk, and that vitamin E intake decreases bladder cancer risk. Further research is
needed to conﬁrm these latter conclusions.
3.3.2 Classiﬁcation systems
The “gold standard” in endoscopy is still the histopathological analysis of biopsies. Over the
years, the pathologists have deﬁned a dedicated lexicon to classify the results. One often dis-
tinguishes between staging classiﬁcation systems, which describe the invasiveness and dissem-
ination of a tumor, and grading classiﬁcation systems, which describes the aggressiveness of a
tumor. In the following, one will present the 2002 TNM classiﬁcation (staging) and the 1973
and 2004 WHO classiﬁcation (grading).
3.3.2.1 TNM classiﬁcation
The TNM classiﬁcation is a cancer staging system that describes the extent of cancer in a
patient’s body. T describes the size of the tumor and whether it has invaded nearby tissue,
N describes regional lymph nodes that are involved, and M describes distant metastasis (spread
of cancer from one body part to another). The TNM staging system for all solid tumors was
devised by Pierre Denoix between 1943 and 1952 [Deno46]. TNM is regularly updated by the
Union Internationale Contre le Cancer (UICC) to achieve consensus on one globally recognized
standard for classifying the extent of spread of cancer. Currently, clinicians use the 2002 TNM
classiﬁcation [Babj08, Rena02, MacL07]. Table 3.1 describe the categories.
The pathological classiﬁcation (or postsurgical histopathological classiﬁcation) is designated
pTNM. This is based on the evidence acquired before treatment, supplemented or modiﬁed by
the additional evidence acquired from surgery and from pathological examination [Witt03].
3.3.2.2 1973 Classiﬁcation
The ﬁrst widely accepted grading system for papillary urothelial neoplasms was the 1973 WHO
classiﬁcation system, which divided urothelial papillary tumors into four categories: papilloma,
grade 1 carcinoma, grade 2 carcinoma and grade 3 carcinoma [Most73]. The 1973 WHO his-
tological grading of bladder cancer is one of most successful grading systems among all organ
sites and has been validated since its introduction three decades ago. An enormous amount of
data has been accumulated using this system in studies of the morphological properties, clin-
ical behavior, treatment and follow-up of urothelial tumors. Because of its relative simplicity
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T – Primary tumor
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Non-invasive papillary carcinoma
Tis Carcinoma in situ: ﬂat tumor
T1 Tumor invades subepithelial connective tissue
T2 Tumor invades muscle
T2a Tumor invades superﬁcial muscle (inner half)
T2b Tumor invades deep muscle (outer half)
T3 Tumor invades perivesical tissue:
T3a Microscopically
T3b Macroscopically (extravesical mass)
T4 Tumor invades any of the following: prostate, uterus, pelvic wall, abdominal wall
T4a Tumor invades prostate, uterus, or vagina
T4b Tumor invades pelvic wall or abdominal wall
N – Lymph nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single lymph node ≤ 2 cm in greatest dimension
N2 Metastasis in a single lymph node > 2 cm but ≤ 5 cm in greatest dimension, or
multiple lymph nodes, each ≤ 5 cm in greatest dimension
N3 Metastasis in a lymph node > 5 cm in greatest dimension
M – Distant metastasis
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Table 3.1: 2002 TNM classiﬁcation of urinary bladder cancer
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and its well-documented powerful predictive value, it has been well accepted by urologists and
used globally for several decades in making clinical decisions for management of patients with
urothelial cancer. However, in the early 1990s several factors emerged that resulted in the need
to re-evaluate this approach and update the classiﬁcation.
3.3.2.3 1998-2004 Classiﬁcation
In October 1997, Dr. F. K. Mostoﬁ assembled a group of individuals interested in bladder
neoplasia at a meeting in Washington DC. The participants included urologic pathologists,
urologists, urologic oncologists, and basic scientists with an interest in bladder neoplasia. The
purpose of this meeting was to discuss bladder terminology and make recommendations to the
World Health Organization (WHO) Committee on urothelial tumors [Epst98]. They eventually
reached a consensus, that was presented one year later in Boston. This became known as the
1998 ISUP/WHO classiﬁcation system. In 2004, this classiﬁcation system was adopted in one
of the WHO “blue books” for the classiﬁcation of tumors [Saut04]. This is known as the 2004
WHO classiﬁcation (see Table 3.2).
Normal
Normal
Hyperplasia (ﬂat or papillary)
Flat lesions with atypia
Reactive (inﬂammatory) atypia
Atypia of unknown signiﬁcance
Dysplasia (low-grade intraurothelial neoplasia)
Carcinoma in situ (high grade intraurothelial neoplasia)
Papillary neoplasms
Papilloma
Inverted papilloma
Papillary neoplasm of low malignant potential
Papillary carcinoma, low grade
Papillary carcinoma, high grade
Invasive neoplasms
Lamina propria invasion
Muscularis propria (detrusor muscle) invasion
Table 3.2: 2004 WHO/ISUP consensus classiﬁcation
According to its proponents, the 2004 WHO classiﬁcation modiﬁed the 1973 WHO classiﬁ-
cation with the following key points :
1. the description of the categories has been expanded. One group (papillary urothelial
neoplasm of low malignant potential, PUNLMP) is newly deﬁned. The PUNLMP are
lesions that do not have cytological features of malignancy but show normal urothelial
cells in a papillary conﬁguration. They have a negligible risk for progression, but still
have a tendency to recur. Since they have particularly good prognosis for the patient, the
PUNLMP do not carry the label of “cancer”.
2. it avoids use of ambiguous grading such as grade 1/2 or 2/3. The intermediate grade
(grade 2), which was the subject of controversy in the 1973 WHO classiﬁcation, has been
eliminated, such as it remains only low and high grade. The 1973 and the 2004 WHO
grading systems are compared in Table 3.3.
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1973 WHO Grading 2004 WHO Grading
Papilloma (benign) Papilloma (benign)
Grade 1: well diﬀerentiated Papillary urothelial neoplasmof low malignant potential (PUNLMP)
Grade 2: moderately diﬀerentiated Low-grade papillary urothelial carcinoma
Grade 3: poorly diﬀerentiated High-grade papillary urothelial carcinoma
Table 3.3: WHO grading in 1973 and in 2004 adapted from [Babj08]
Microphotographs showing the principal WHO classes of bladder cancer are depicted in Fig-
ure 3.6. The detailed morphological factors are listed in Table B.1 and Table B.2 (see Ap-
pendix B).
DCBA
E HGF
LKJI
A normal urothelium. B ﬂat urothelial hyperplasia. C reacve atypia. 
D urothelial dysplasia (le part of the image) adjacent to normal urothelium (right) (insert:p53 expression in dysplasia).
E urothelial carcinoma in situ (CIS), pagetoid type. 
F urothelial CIS with microinvasion (the invading cells are detected with anbody against AE1-AE3 cytokerans).
G urothelial papilloma (insert: magniﬁcaon of the lesion). 
H papillary urothelial neoplasm with low malignant potenal. I urothelial papillary carcinoma of low grade.
J urothelial papillary carcinoma of high grade (insert: microinvasion detected with anbody against AE1-AE3 cytokerans). 
K squamous cell CIS (insert 1: squamous cell metaplasia, vaginal type; insert 2: squamous cell metaplasia, keranizing type). 
L villous adenoma (insert: intesnal metaplasia).
Figure 3.6: Classiﬁcation of the bladder neoplasms with H&E staining (adapted from [Mont08]).
3.3.3 Disease evolution & progression
The exact progression pathway to invasive cancer remains partly unknown. In patients with low
grade Ta disease, it has been shown that the 15-year progression-free survival is 95% with no
cancer speciﬁc mortality. Patients with high grade Ta tumors had a progression-free survival of
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61% and a disease speciﬁc survival of 74%, whereas patients with T1 disease had a progression-
free survival of 44% and a disease-speciﬁc survival of 62%, lending support to the view that
invasion of the lamina propria is a prognostic indicator for risk of disease progression and reduced
survival [Drol05].
Droller et al. updated the schematic depicting the multiplicity of pathways in bladder cancer
development [Jone93, Drol05]. In Figure 3.7, the number of pathways and their likelihood of
occurrence as represented by the size of the arrows accounts for the diﬀerent types of bladder
cancer that are seen. The majority of bladder tumors present with a papillary conﬁguration
and are generally conﬁned to the mucosal layer. Resection of any visible lesion presumably
restores a normal transitional cell epithelium, although conceivably there are changes elsewhere
in the bladder not yet clinically detectable endoscopically. Although these generally low-grade
tumors conﬁned in the mucosa may recur, they generally do not follow a more aggressive,
potentially life-threatening pathway. Rarely, additional genetic changes may induce development
of a higher-grade papillary lesion. More commonly, however, high-grade lesions may develop
directly through diﬀerent genetic changes, suggesting a process termed dysplasia. Dysplasia
may also lead to the production of high-grade cells that do not assume a papillary conﬁguration
but instead maintain growth along the ﬂat plane of the urothelium, taking the form of carcinoma
in situ (CIS,Tis). Although these lesions may proliferate to produce high-grade papillary tumors
(rare), they are more often associated with a development of nodular tumors that become directly
invasive without necessarily protruding into the lumen of the bladder until much later in their
development. Solid tumors appear more commonly to be associated with lymphatic/vascular
permeation and the development of distant metastases.
The genetic changes occurring in bladder cancer are not treated in this manuscript, but they
are currently under research by many groups [Kiem09, Chen09b, Chen09a].
The classic way to categorize patients with TaT1 tumors is to divide them into risk groups
based on prognostic factors derived from multivariate analysis. Based on the 2596 patients
cohort using European Organization for Research and Treatment of Cancer (EORTC) risk tables,
Sylvester et al. derived a simple scoring system was derived based on six clinical and pathological
factors: number of tumors, tumor size, prior recurrence rate, T category, presence of carcinoma
in situ, grade [Sylv06]. The scoring system is described in details in Table B.3 in Appendix B).
The following endpoints were assessed: (1) time to ﬁrst recurrence (disease-free interval) and
(2) time to progression to muscle invasive disease. Depending on cancer stages, the probabilities
of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to
17%, respectively. At ﬁve years, the probabilities of recurrence and progression ranged from 31%
to 78% and from less than 1% to 45%. Detailed results are listed in Table B.4 in Appendix B.
The most important prognostic factor in patients with T1G3 tumors is the presence of
concomitant CIS. The probability of progression in T1G3 patients without CIS is 10% at one
year and 29% at ﬁve years; in T1G3 patients with CIS, the corresponding ﬁgures are 29%
and 74%, respectively. In such patients a cystectomy should be seriously considered very early
in their treatment since progression in patients with a history of superﬁcial bladder cancer is
associated with a very poor prognosis [Schr04].
3.4 Screening method
The most common presenting symptom of bladder cancer is painless haematuria. Additionally,
unexplained urinary frequency, urgency, or irritative voiding symptoms should alert the clinician
to the possibility of bladder cancer.
The clinical necessity for a non-invasive test for bladder cancer is two-fold, including the early
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Figure 3.7: Pathways in bladder cancer development [Jone93].
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detection of high grade bladder tumors before muscle invasion and monitoring tumor recurrence
or new onset. An ideal noninvasive test should be sensitive, speciﬁc, rapid, technically simple
and have low intra-assay and interassay variability [Loke01].
When a diagnosis of transitional cell carcinoma is suspected, the initial assessment consists
of voided urine cytology, cystoscopy, and radiological investigation of the upper tracts.
3.4.1 State-of-the-art : cytology
Urine sample can be collected in a sterile container in the outpatient facility or during a cys-
toscopy. The urine sample is processed in a laboratory and examined under a microscope by a
pathologist who looks for abnormal cells. This procedure is called cytology.
Urine cytology has high speciﬁcity but limited applicability due to its relatively low sen-
sitivity and subjective nature. In a recent review, van Rhijn et al. stated that the overall
speciﬁcity of urinary cytology has been high, with a range of 85%-100% for poorly diﬀerentiated
tumors [van 05]. This has enabled the cytologist to distinguish diﬀerences between malignant
and benign cells in the cytologic appearance of bladder wash specimens. In contrast, the over-
all sensitivity has been rather poor, especially for low-grade carcinoma, with a wide range of
13%-75% in reported in published studies.
3.4.2 New screening procedures
Therefore, several new screening tests have been developed based on biochemical markers found
in sampled urine. Examples are listed in Table 3.4. Their value is yet to be established in larger
clinical trials.
Mechanism Sensitivity Speciﬁcity
Cytology Tumors cells sloughed 7-17% PUNMLP G1 90-98%
in urine 53-90% high grade
BTA Stat Detects urothelial 50-80% 50-75%
and TRAK basement membrane
NMP-22 Nuclear proteins 50% in non-invasive disease 85.7%
released during apoptosis 90% in invasive disease
ImmunoCyt Immunoﬂuorescence 50-85% 62-73%
3 monoclonal antibodies
UroVysion FISH with probes to Chr3,7,17,9p21 70-86% 66-93%
Abbreviations:
BTA=bladder tumor antigen.Stat=signal transducer and activator of transcription.
TRAK=total reference air karma.NMP-22=nuclear matrix protein-22.
FISH=ﬂuorescence in-situ hybridisation.Chr=chromosome.
Table 3.4: Non-invasive diagnostic tests for transitional cell carcinoma [van 09]
3.5 Bladder cancer management
Up to 70% of newly diagnosed bladder tumors present as highly diﬀerentiated, superﬁcial tumors,
and can be readily treated with transurethral resection. Although up to 50% to 80% of patients
may have recurrent tumors, at worst 10–20% ultimately progress to invasive disease [Kurt00].
In contrast, although it is also a superﬁcial noninvasive lesion, CIS is a potentially aggressive
tumor due to its unpredictable nature [Sylv06]. By deﬁnition, CIS of the bladder is a ﬂat,
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high grade intraurothelial neoplasm [Epst98]. It may occur as focal lesions, in diﬀuse form or
concurrent with other high risk types of transitional cell carcinoma [Drol00]. Patients with
bladder CIS are at signiﬁcant risk for cancer progression and death from bladder carcinoma.
Therefore, the detection of CIS has signiﬁcant prognostic and therapeutic implications for the
patient [Schm04, Loid05].
Early detection of bladder cancer is a key to better prognosis for the patient [Babj08,
Oost02]. After a urothelial lesion is detected, the diagnosis and clinical stage is established
by transurethral resection of the bladder (TURB) . This resection should include muscularis
propria, especially if the lamina propria is aﬀected or the tumor is high grade. When the
transurethral resection shows lamina propria invasion but does not include suﬃcient muscularis
propria in the specimen a repeat resection should be done to rule out muscularis propria invasion.
TaT1 tumors recur frequently and progress to muscle-invasive disease in a limited number of
cases. It is therefore necessary to consider adjuvant therapy in all patients after TURB. It can
be Bacillus Calmette-Guérin (BCG) or chemotherapeutic agents (e.g. mytomicin or farmoru-
bicin) [Babj08, Drag10].
The high rate of recurrence is the feature of bladder cancer that makes follow-up a crucial
component in eﬀective management. After TURB of the tumor, early re-resection at 4-6 weeks
should be considered to minimize the risk of staging error and to ensure complete resection.
Moreover, patients should have cystoscopy and voided urine cytology every 3 months for 2
years, then 6-monthly for 2 years, and then once yearly indeﬁnitely [Kauf09].
3.5.1 TURB Procedure
TURB remains the gold standard for management of bladder cancer, but there is evidence
of a high rate of tumor recurrence after primary resection, and of variation between institu-
tions [Thom08]. The aim of initial TURB is to remove all visible tumor and obtain tissue
for histological diagnosis. The procedure is performed with the patient under general or loco-
regional anaesthesia to allow paralysis (if required by tumor location) and thereby minimize the
risk of stimulating the obturator nerve and subsequent adduction of the thigh muscles, which
can result in bladder perforation. Tumor resection occurs via a 26-28 Fr resectoscope with a 30-
degree telescope and diathermy loop using glycine or water irrigation [Solo97]. Video-endoscopy
is used routinely in most units and oﬀers the advantages of ergonomic ease for the surgeon,
better visibility, and more freedom of movement of the resectoscope, in addition to the teaching
opportunities it aﬀords. A continuous ﬂow sheath provides a clear visual ﬁeld while minimiz-
ing bladder overﬁlling, bladder perforation, stimulation of the obturator nerve, and obscuring
carcinoma in situ.
The tumor is resected using precise movements of the loop. Once the tumor is resected,
the base is either biopsied using cold-cup biopsy forceps or resected and sent for pathology
in a separate, appropriately labeled pot. Any suspicious areas should also be biopsied and
sent in separate, clearly labeled pots. Biopsy of normal mucosa is not routinely recommended
unless there is positive cytology or the presence of multiple tumors or T1 stage tumor [Solo97].
Hemostasis is then obtained using a rollerball electrode to fulgurate the resected area and obtain
biopsy.
After TURB alone, around 50-70% of patients develop recurrence due to incomplete TURB,
tumor cell implantation, or aggressive tumor biology [Sylv06]. Over a century ago, it was
postulated by Albarran and Imbert that bladder cancer recurrence was caused by implantation of
ﬂoating tumor cells. Hence the standard TURB approach may explain the high recurrence rates
for superﬁcial bladder cancer [Parm89]; a theory supported by the common sites of recurrence –
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90.6% of recurrent tumors occur in the dome, compared with 6.3% of primaries [Boyd74]. More
recently, molecular studies have demonstrated that multifocal tumors are monoclonal, indicating
a common origin [Hafn01].
Irrigation solution is used to distend the bladder, clear the surgical site, and remove blood
and resected tissue. During transurethral resection of the prostate (TURP), the so-called TURP-
syndrome was described. It is a real concern during electroresection, due to intravascular ab-
sorption of irrigating distilled water [Jens91]. Indeed, when excess ﬂuid collects in the body, the
concentration of sodium in the bloodstream is reduced, leading to the following common symp-
toms nausea, vomiting, fatigue, and confusion. That is similar in case of bladder resection, and
that is why other irrigating solutions (e.g. distilled water, saline solution, and glycine solution)
are used in the clinics. Indeed, this eﬀect, which was incidentally discovered during prostate
resection, is less marked with Glycine irrigation solution (due to its diﬀerent osmotic pressure).
During bipolar electroresection, saline (NaCl) solution is used, because it contains electrolytes
to conduct the electrical current from one electrode to another.
3.5.2 Socio-economical concerns
The economic burden of bladder cancer is well-characterized in the literature. Bladder cancer
(BC) has the highest lifetime treatment costs per patient (pp) of all cancers. Although most
patients present with NMIBC, the high rate of recurrence and disease progression necessitates
vigilant long-term monitoring for BC patients [Siev09]. Depending on the country, BC costs
from diagnosis-to-death range between $89’287 and $202’203 pp [Bott03] and will likely increase
as survival rates increase.
Sievert et al. reviewed several strategies for reducing BC’s economic burden that have been
proposed in the literature: (1) use of urine-based markers to identify incident or recurrent tumors
earlier; (2) use of outpatient facilities for TURB reducing hospitalizations if surgical risks can
be minimized; (3) improve eﬃcacy of intravesical treatments; (4) the use of photodynamic
diagnosis (PDD), instead of conventional white-light (WL) cystoscopy, to improve initial TURB
eﬃcacy and potentially reduce NMIBC’s residual risk [Siev09]. This topic paper concludes that,
while these new treatment options initially provoke higher costs after the initial diagnosis, long-
term cost beneﬁts can be achieved through reduced tumor recurrence and potentially reduced
progression rates.
Daniltchenko et al. compared the cost-eﬀectiveness of PDD vs. conventional WL cysto-
scopy [Dani05]. Fluorescence assisted TURB of superﬁcial bladder cancer signiﬁcantly improves
visualization of all malignant lesions and, thus, the completeness of resection. This advantage
of decreased tumor recurrence risk is maintained with statistical signiﬁcance for at least 5 years,
and eﬀectively reduces patient morbidity and costs for repeat operations. Additionally, the cost-
analysis presented in this study suggests a considerable economical advantage of ﬂuorescence
assisted TURB compared to the standard procedure.
3.6 Development of photodetection for bladder cancer
3.6.1 Historical perspective
Maximilian Carl-Friedrich Nitze (1848-1906) was a German urologist. In Dresden, he became
inspired by the work of Julius Bruck, a dentist, who performed diaphanoscopy of the bladder
by inserting a incandescent, water-cooled platinum wire in the rectum. The illumination of
the bladder was insuﬃcient, however, and the rectum was unfortunately burned in some cases.
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Attempts to examine the interior of the bladder were not new, having been undertaken ﬁrst by
Bozzini in 1807 using a reﬂected candle light source, which had also proved to be an insuﬃcient
light source and was too painful for patients owing to the size of the instrument.
Dr. Nitze got the intuition that the ﬁeld of view could be enlarged using an optical system,
and that the light source should be placed at the tip of the instrument in the same way that
“to light up a room, one must carry the lamp inside”. Along with Viennese instrument maker
Joseph Leiter (1830-1892), he is credited with the invention of the modern cystoscope. The
Nitze-Leiter cystoscope was ﬁrst publicly demonstrated in 1879 [Mout98]. Functionally, it used
an electrically heated platinum wire for illumination, a cooling system of ﬂowing ice-water, and
telescopic lenses for visualization (see Figure 3.8). Invention of the incandescent light bulb by
Thomas Edison allowed further improvements to the cystoscope; in 1887 Nitze constructed an
apparatus that no longer needed a cooling-system. Nitze is also credited with producing the
ﬁrst endoscopic photographs.
Joaquin Albarrán (1860-1912) was a urologist who was born in Cuba. In 1878, he went
to Paris, where he worked and studied under many renowned physicians. In 1906 he became
director of the Clinic of Urology at the Hôpital Necker. He is credited with the invention of
a device for adjustment of a cystoscope during the catheterization of the ureter. This device
was to become known as the Albarrán lever. He was nominated in 1912 for a Nobel Prize in
Medicine. He was one the ﬁrst to enlighten the mechanism of recurrence of bladder cancer, due
to cellular reimplantation in the bladder wall [Case06].
Figure 3.8: Maximilian Nitze and his cystoscope from 1877.
3.6.2 History of ALA-derivatives based photodetection
Porphyrins were identiﬁed in the mid-nineteenth century, but they were used in medicine until
the early twentieth century. Hematoporphyrin was ﬁrst produced by Scherer in 1841 during
experiments investigating the nature of blood. Dried blood was heated with concentrated sulfuric
acid, the precipitate was washed free of iron and then treated with alcohol [Sche41]. However,
the ﬂuorescent properties of hematoporphyrin were not described until 1867 and it was named
hematoporphyrin in 1871 [Ackr01].
The ﬁrst reports of attempts to localize human tumors with ﬂuorescent porphyrins appeared
in the early 1950s. In 1951, Manganiello and Figge studied the eﬀects of hematoporphyrin in
three patients with head and neck malignancies but ﬂuorescence was not detected, very likely
due to the lower doses of photosensitizer given to humans as compared with those in previous
animal experiments [Mang51].
As shown in section 2.2.2.1, 5-aminolevulinic acid (ALA) is a precursor of many ﬂuoresc-
ing porphyrins in the biosynthetic pathway for heme. In the following, we will simplify the
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legibility by speaking only about the protoporphyrin IX (PpIX). Pioneering in vitro studies
of ALA [Mali87] and the report of a successful ALA-based photodynamic treatment of skin tu-
mors [Kenn90] opened the way to novel research. The ﬁrst reports about ﬂuorescence cystoscopy
for the detection of bladder cancer were from the group of Munich in 1992 [Baum92, Krie94,
Krie95].
Indeed, Baumgartner et al. easily observed ALA-induced ﬂuorescence with the naked eye
during cystoscopy under violet light illumination. All tumor lesions were sharply marked with
brightly shining red ﬂuorescence. Correlation of ﬂuorescence and microscopic ﬁndings gave a
sensitivity of 100% and a speciﬁcity of 68.5% [Baum92, Krie94].
Following these ﬁrst tests, the group of Lausanne developed and optimized ALA-derivatives
for the detection of non-muscle invasive bladder cancers. The main motivations behind this
research were to increase the signal-to-background ratio (i.e. heighten the ﬂuorescence intensity)
and shorten the instillation interval to an acceptable time for clinical acceptance. Indeed, ALA
used to be instilled between 2–4 hours prior to examination, which is not practical for ambulatory
patients.
A collaboration between the Medical Photonics group (EPFL, Prof. van den Bergh), the
Institute of Physiology (Faculty of Biology and Medicine, University of Lausanne, Prof. Kucera),
and the Department of Urology (CHUV-University hospital, Lausanne, Profs. Leisinger and
Jichlinski) led to the development of hexyl-ester aminolevulinic acid (HAL) for the detection
of bladder cancer [Jich97]. The combined eﬀorts of in vitro, preclinical and clinical studies in
Lausanne eventually led to the phase II and III clinical trials undertaken together with Photocure
ASA [Uehl00, Mart99, Lang99].
Clinical measurements of the PpIX ﬂuorescence performed in human bladder cancers, with
a optical ﬁber-based spectroﬂuorimeter conﬁrmed a highly selective production of PpIX in the
urothelium as compared to the detrusor muscle, as well as a high speciﬁcity for malignant
urothelium. However, the PpIX ﬂuorescence intensity was found to vary strongly between
tumors [Chan96, Stei94, Forr95]. Consequently, the subsequent research program aimed at op-
timizing the conditions of PpIX accumulation and distribution within cancer tissue, by looking
at diﬀerent ways to improve the transfer of ALA (a hydrophilic molecule) through biologi-
cal membranes. Various approaches were investigated, namely ALA-esteriﬁcation, ALA com-
bined with the administration of dimethylsulfoxyde (DMSO), iontophoresis, and addition of iron
chelators like Desferal [Uehl00, Uehl06]. As clinical experience with iontophoresis was inconclu-
sive [Sten96], various ALA esters administered at diﬀerent concentrations were investigated.
The analysis of the PpIX accumulation kinetics and distribution across the photosensitized
urothelium in the pig bladder model demonstrated the superiority of HAL administered at
4-8 mM, when compared to all other tested conditions [Mart99]. Following these preclinical
studies, HAL was selected from the multitude of possible ALA-alkylesters because it represented
a good compromise between water-urine solubility and suﬃcient PpIX formation capacity at low
doses. Furthermore, HAL has been shown to lead to a homogenous distribution of PpIX-related
ﬂuorescence over the entire urothelium [Mart03]. The ﬁrst clinical investigation indicated a
signiﬁcant increase (>2x) of PpIX ﬂuorescence intensity could be observed with HAL using
20-fold lower concentrations as compared to ALA [Lang99]. Figure 3.9 shows some of the
historical results from the in vitro tests, which led to the selection of the HAL for this urological
application. Both ﬁgures describe the relationship of ALA-derivatives concentration and the
measured ﬂuorescence intensity on porcine mucosa and bladder cancer cells, respectively. It
appears clearly on both samples (porcine mucosa and cell culture), that HAL reaches a higher
level of ﬂuorescence with a much lower concentration that ALA. Additionally, Marti et al. showed
that instillation time required for HAL was much shorter than for ALA [Mart99]. Indeed, one
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Figure 3.9: Concentration dependence of PpIX accumulation for one culture of porcine bladder mucosa
and two diﬀerent cell lines with diﬀerent precursors (methyl-, ethyl-, butyl-, hexyl-, and octyl-ester of
ALA) [adapted from [Mart99, Uehl00]]
hour instillation was shown to be suﬃcient to build-up enough PpIX in cancer cells with HAL to
allow photodetection. This aspect was crucial in driving HAL as a standard method in clinical
environment, as compared to ALA instillation time (2–4 hours).
This technology has been licensed to an industrial partner, PhotoCure ASA1, leading to
the approval of hexylaminolevulinate (Hexvix R© as commercial name) in Europe in March 2005
for patients with known or suspected bladder cancer. Hexvix R© is the ﬁrst pharmaceutical
product on the market that improves visual inspection of the bladder. The performance of
this product is well recognized by the medical community since the European Association of
Urology (EAU) oﬃcially recommended this procedure in 2005 [Babj05, Babj08]. GE Healthcare
Inc.2 licensed the global marketing and distribution rights for Hexvix R© from Photocure in 2006.
The beneﬁt of Hexvix R© is also supported by the fact that increased detection of non-invasive
bladder tumors with Hexvix R© leads to a reduced rate of recurrence of the tumors. The Food &
Drug Administration (FDA) Advisory Committee agreed that Hexvix R© as an adjunct to white
light cystoscopy is a well-documented diagnostic procedure and has a favorable beneﬁt/risk
proﬁle in the detection of non-muscular invasive bladder cancer. The Committee voted in favor
of Hexvix R© on FDAs question end of December 2009. The ﬁnal approval for the new drug
application (NDA) is eﬀective since May 2010. Hexvix R© will be sold on the USA-market under
the name CysviewTM, and must be used with a blue light cystoscopy system from Karl Storz
GmbH.
3.6.3 False-positive predictors
The average speciﬁcity for PDD as reported by several groups is about 60% and ranges from
33 to 81%, mainly due to false-positive ﬂuorescence areas (i.e. ﬂuorescing lesions that are not
cancer). These false-positive spots have been investigated by many groups, that reported several
origins.
Dominicis et al. reported a learning curve for the procedure of about 15 patients [Domi01].
It will therefore not inﬂuence the sensitivity and speciﬁcity of the procedure in the large number
of patients studied.
1www.photocure.com
2www.gehealthcare.com and www.hexvix.com
66 Chapter 3. Introduction to Bladder Cancer
The degree of ﬂuorescence in the tissue might vary according to the observation angle; the
more tangent it is, the more the bladder mucosa may appear ﬂuorescent, even if healthy. The
use of a 30◦ or 70◦ lens is therefore recommended, and the mucosa should be observed as
perpendicularly as possible to reduce the possibility of false-positive results. For these reasons
false positive ﬂuorescence may be noted during the observation of the prostatic urethra, bladder
neck, and trigone [Grim03].
The ﬂuorescence of tissue by excitation of induced PpIX is not only speciﬁc for cancer; ﬂu-
orescence can also be detected in urothelial hyperplasia, squamous metaplasia, inﬂammatory
or granulation tissue. Several factors — such as drug uptake, enzymatic activity — have been
known to inﬂuence the production and conversion or depletion of PpIX after exogenous applica-
tion of ALA-derivatives [Krie00]. Filbeck et al. also showed that inﬂammation or scar formation
negatively inﬂuences the speciﬁcity of PDD within 6 weeks after transurethral resection [Filb99].
BCG is an important predictor for false positives in ﬂuorescence cystoscopy. Indeed, the
speciﬁcity of ﬂuorescence cystoscopy is reduced by BCG immunotherapy up to 12 weeks after the
last instillation, because it induces acute inﬂammatory reaction. In case of low and intermediate
risk bladder tumors, it is recommended postponing PDD until 9-12 weeks after the last BCG
instillation to optimally beneﬁt from the procedure [Grim03, Drag09a, Drag09b, Drag10].
As a matter of fact, inﬂammation of the bladder mucosa also displays an enhanced metabolic
activity, and accounts for most of the false-positive areas.
In about 90% of the cases, false positive ﬂuorescent locations appear to be benign. Properly
assessing false and true positive lesions should also incorporate genetic evaluation of false positive
lesions. Zaak et al. have shown that some false positive lesions, histologically classiﬁed as
normal urothelium, exhibit genetical changes identical to those of papillary tumors in the same
patient [Zaak02].
3.6.4 Characterization of ﬂuorescence positive-sites
Over the past years, new optical technologies have been integrated to the urological clinical
environment to characterize false-positive sites: Raman spectroscopy (RS), optical coherence
tomography (OCT) , and narrow-band imaging (NBI) [Caub09]. NBI was already described
in Section 2.1.2. One provides here an overview of the technology and diagnostic of Raman
spectroscopy and OCT, with a short explanation of the clinical signiﬁcance.
3.6.4.1 Raman spectroscopy
Raman Spectroscopy (RS) enables measurement of molecular components of tissue in a qualita-
tive and quantitative way. The principle of this optical technique is based on the Raman eﬀect,
discovered by Sir Chandrasekhara Venkata Raman in 1928 [Rao07].
Light that does not excite a molecule into one of the energy levels of the excited states
(as with ﬂuorescence) may still force it into a so-called virtual state (see Figure 3.10). This
virtual state will be extremely short lived and the energy of the incident photon will be quickly
reradiated, most likely as a photon with the same wavelength (elastic scattering). When nuclear
motion (e.g. vibration) occurs during the lifetime of the virtual state, the molecule can relax
to a higher vibrational level of the ground state while emitting a photon of longer wavelength.
This process is called Raman scattering. Each molecule has unique vibrational energy levels,
with their corresponding wavelength shifts. All of the shifted wavelengths from the diﬀerent
molecules in tissue, when combined, form the Raman spectrum, which is a function of the
molecular composition of the tissue investigated.
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Figure 3.10: Raman scattering, with vibrational and virtual energy states
A change of the vibrational energy states results from the interactions of photons of the
incident light interact with the tissue molecules. A new photon is emitted to account for the
energy diﬀerence between the initial and the ﬁnal states, resulting in a diﬀerent wavelength of
the scattered light. Each molecule has unique vibrational energy levels with their corresponding
wavelength shifts. All of the shifted wavelengths from the diﬀerent molecules in tissue combine
to form the Raman spectrum, which is a function of the molecular composition of the tissue
investigated. This molecular composition changes if pathologic transformations occur, and by
this means RS can provide an objective prediction of pathologic diagnosis. To assist with
interpretation of RS, a pseudocolor map of the tissue under examination can be created. Tissue
areas with similar spectra, and therefore with similar molecular composition, are depicted in the
same color, thus creating a picture comparable to histopathology.
Several groups have determined the diagnostic accuracy of RS by comparing ex vivo Raman
measurements of bladder samples with histology. De Jong et al. showed that in 15 bladder
tissue samples classiﬁcation between tumor and non-tumor was possible with a sensitivity and
speciﬁcity of 92% and 94%, respectively [deJ06]. Crow et al. demonstrated that diﬀerentiation
between normal, inﬂammatory, and malignant tissue was feasible with a sensitivity of 90-95%
and a speciﬁcity of 95-98% in 75 bladder tissue samples [Crow04].
3.6.4.2 Optical Coherence Tomography
Optical Coherence Tomography (OCT) produces high-resolution, cross-sectional images of tis-
sue. The principle of this optical technique is analogous to B-mode ultrasonography except that
infrared light is being used instead of sound.
The principle of optical time-domain reﬂectometry (OTDR) dates back in the 1980’s. This
method was developed for the diagnostics and optimization of ﬁber optic systems; in particular,
the determination of ﬁber attenuation, splice quality, and the location of defects were of great
interest. However, to investigate optical structures with dimensions in the submillimeter range,
the resolution of a ﬁber optic OTDR system which lies in the centimeter to meter range was
insuﬃcient. In the late 1980’s, an EPFL group led by René Salathé used an infrared subpicosec-
ond pulse source in conjunction with balanced heterodyne detection, and showed experimental
results demonstrating a sensitivity of more than 100 dB and a resolution of 60 µm in air. Tak-
ing advantage of the large tuning range of the laser system, it was even possible to improve the
resolution to less than 10 µm [Beau89, Gilg89].
In parallel, the principle was transferred to the optical tissue characterization. First tests
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of this new-called femtosecond optical ranging were performed in biological systems (the cornea
in rabbit eyes in vivo and the epidermal structure of human skin in vitro) [Fuji86]. A ﬁrst
two-dimensional in vivo depiction of a human eye fundus along a horizontal meridian based
on white light interferometric depth scans has been presented at the ICO-15 SAT conference in
1990 [Ferc90]. Cross sectional retinal imaging was also demonstrated in 1991 by a Massachusetts
Institute of Technology (MIT) team headed by James G. Fujimoto [Huan91].
The working principle of an OCT system is based on a laser oscillator (e.g. Ti:sapphire,
800nm) coupled into the ﬁber-based Michelson-type interferometer. The light is split into a
reference beam with variable path length and a probe beam, which is focused onto the sample.
The light backscattered from the sample is recombined with the light reﬂected from the reference
arm. The resulting interference between the recombined beams is detected as a function of the
reference arm path length. An interference signal is only observed if the path diﬀerence of
both arms is matched to within the coherence length of the light source, thus enabling depth
resolved imaging. The demodulated interference pattern – representing a depth proﬁle of the
backscattered intensity – is transferred to a grayscale map for graphic representation. Adjacent
A-scans are detected by scanning the laser beam across the sample resulting in a cross-sectional
image (B-scan).
The main contrast mechanism is elastic light scattering. The amplitude of the scattered
light, which is inﬂuenced by tissue type, is measured at diﬀerent tissue depths. Adjacent depth
proﬁles can be displayed in real time, resulting in an image comparable to histopathology, with
resolutions down to 10 µm and at depths of around 1-3 mm [Zysk07]. Ultrahigh resolution
systems even achieve an overall axial resolution of 3.6 µm in air (< 3 µm in tissue) [Herm08].
In non-diseased tissue, the three anatomic layers of the bladder wall can be well distin-
guished with OCT. This is feasible due to the diﬀerent scattering properties of each distinct
layer resulting in diﬀerent intensities within an image [Tear97]. Figure 3.11 shows the three
main layers (urothelium, lamina propria, muscularis mucosa). In bladder cancer tissue, these
layers are usually no longer distinguishable [Herm08]. Furthermore, probably due to the higher
nuclear-cytoplasm ratio, the OCT images can show diﬀerent backscattering properties. A broad-
ened urothelium is also seen in case of a papillary tumor. In contrast to ultrasonography, OCT
does not require a conducting medium or direct contact during imaging, which makes it easily
applicable in endourology [Many05].
Figure 3.11: Left: One of the current implementation of the optical ﬁber based OCT probe (diameter
2.7 mm). It easily passes through the working channel of standard cystoscopy equipment. Right: OCT
image of normal urothelium: Mucosa is dark and thin (A). Lamina propria is bright and clearly deﬁned
(B). Muscularis layer is dark with striated appearance (C).
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Two recent clinical studies demonstrated the potential of OCT in a clinical context.
Schmidbauer et al. performed a single-center study with same-patient comparison, patients
with suspected bladder cancer ﬁrst received an intravesical instillation of HAL [Schm09]. Cys-
toscopy was performed in WL, followed by blue-light inspection and OCT scanning. In 66
patients studied, 232 lesions were detected and scanned by OCT, and were subsequently re-
sected or biopsied. Additionally, 132 areas of normal-appearing urothelium were investigated
by all three methods and biopsied. On a per-lesion basis, sensitivity and speciﬁcity were re-
spectively 69.3% and 83.7% for WL, 97.5% and 78.6% for HAL, and 97.5% and 97.9% for HAL
combined with OCT. Overall, bladder cancer was diagnosed in 58 patients (87.9%), with a per-
patient sensitivity of 89.7% for WL and 100% for both HAL alone and HAL with targeted OCT.
Per-patient speciﬁcity for HAL alone and targeted HAL was 62.5% and 87.5%, respectively.
Goh et al. obtained 94 images in 32 patients undergoing bladder biopsy or transurethral
resection of bladder tumor [Goh08]. They correlated 38 suspicious areas with biopsy ﬁndings.
OCT imaging correctly identiﬁed tumors conﬁned to the mucosa with a sensitivity and speciﬁcity
of 90% and 89%, respectively. Muscle-invasive tumors were detected in 7 of 7 lesions with 100%
sensitivity, 90% speciﬁcity, and 92% accuracy.
3.6.4.3 Multiphoton endoscopy
Brieﬂy, multiphoton microscopy (MPM) or multiphoton endoscopy (MPE) involve the illumi-
nation of tissue by near-infrared light from a femtosecond pulsed laser, which is used to excite
ﬂuorescence from the naturally occurring ﬂuorophores residing at the focal volume. In addition
to cellular autoﬂuorescence, MPM allows the identiﬁcation of non-centrosymmetric structures
such as collagen by utilizing a higher order scattering phenomenon called Second Harmonic
Generation (SHG). MPE enables visualization of cellular layers and intracellular organs with
deep penetration depth (several hundred of microns), and can be used in vivo to directly observe
molecular mechanisms of life without the need for removing tissue from the body (biopsy).
The human bladder is an ideal candidate for MPM imaging and MPE methodology, since it
has a well-deﬁned architecture, whose perturbation by cancer can be easily detected at cellular
and tissue organization levels. MPM can identify the morphology of the umbrella cells very
well, as well as the perturbation of the urothelial layer is visible by MPM. Indeed, the layer of
connective tissue containing collagen and scattered smooth muscle cells, known as the lamina
propria, can be well resolved with SHG.
Multiphoton endoscopes allow real time, non-invasive biopsies of the human bladder, as well
as an up-close assessment of the resection margin. To demonstrate this principle, Mukherjee et
al. used a bench-top multiphoton microscope to identify cancers in fresh, unﬁxed human bladder
biopsies [Mukh09]. Multiphoton images were acquired in two channels: (1) broadband autoﬂuo-
rescence (420–530 nm) from cells, and (2) SHG (390±35 nm), mostly by tissue collagen. These
images are then compared with gold standard hematoxylin/eosin (H&E) stained histopathology
slides from the same specimen. These authors found excellent correlation between the multi-
photon and histopathological diagnoses. These results are conﬁrmed by Cicchi et al. [Cicc10].
Additionally, these latter authors showed that tumor cells appeared slightly diﬀerent in shape
and with a smaller cellular-to-nuclear dimension ratio with respect to corresponding normal
cells. Further diﬀerences between the two tissue types were found in both spectral emission and
ﬂuorescence lifetime distribution by performing temporal- and spectral resolved analysis of ﬂu-
orescence. This method may represent a promising tool to be used in a multi-photon endoscope
for in vivo optical diagnosis of bladder cancer.
Several factors must be considered for the extension of MPM imaging technology from ex
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vivo biopsies to endoscopic imaging in real patients. MPM has still a limited ﬁeld of view and
relatively slow image acquisition speeds, but can ideally combined with another high speciﬁcity
primary detection technique. ALA-derivatives based ﬂuorescence detection is a good candidate,
but no study to date has shown that the porphyrin content in cells does not interfere with the
autoﬂuorescence signatures in MPM.
MPE has been implemented in several explorative ﬁber-based probes, but no commercial de-
vice has been developed up to now. For instance, Myaing et al. report on the development of a
miniature, ﬂexible, ﬁber-optic scanning endoscope for two-photon ﬂuorescence imaging [Myai06].
The endoscope uses a tubular piezoelectric actuator for achieving two-dimensional beam scan-
ning and a double-clad ﬁber for delivery of the excitation light and collection of two-photon
ﬂuorescence. Bao et al. developed an other approach for three-dimensional (3D) in vivo cellular
imaging [Bao08]. Their device has a “large” ﬁeld of view (475×475 µm2), with 250 µm depth
imaging capability. Its lateral and axial resolutions are better than 1 and 14.5 µm, respectively.
This hand-held device can be easily adapted to an existing endoscopic imaging system. These
authors had improved the acquisition speed by a factor 10 as compared to [Myai06], but it
remains a important limitation for clinical use (0.4 mm2/s vs. 0.04 mm2/s).
Tang et al. developed a prototype based on a 1030 nm femto-second ﬁber laser, a two-
axis microelectromechanical system (MEMS) mirror and double-cladding photonics crystal ﬁber
[Tang09a, Tang09b]. The laser pulse duration is 150 fs, the average power is 200 mW, and the
repetition rate is 40 MHz. They achieve an image rate of 0.25 Hz (128 × 128 pixels2, with
3 µm resolution). They acquired sample images from rat tail tendon and human skin samples
(SHG), and two-photon excited ﬂuorescence from human skin tissues stained with exogenous
ﬂuorophore.
These multiphoton approach has shown great potential on bench-top microscopes regarding
resolution and “non-invasive staining”. However, the endoscopic approach is still under devel-
opment, and needs tremendous progresses before being integrating in the clinical routine.
3.7 Angiogenesis related to bladder cancer
Once a tumor grows beyond approximately 100-200 µm in diameter, passive diﬀusion is no longer
able to support malignant cell division, and neovascularization becomes essential [Carm00].
Charlesworth and Harris reviewed the mechanisms underlying urologic malignancies [Char06],
including vessel sprouting and bridge formation. These processes depend on endothelial cell
migration and proliferation.
In endoscopic imaging, we are interested to look at the new vessel formation and reorga-
nization, because this vascular information is likely to be discriminant between true and false
positive lesions in the bladder, and other organs.
3.7.1 General deﬁnitions
Angiogenesis is a physiological process involving the growth of new blood vessels from pre-
existing vessels. Though there has been some debate over terminology, vasculogenesis is the
term used for spontaneous blood-vessel formation, and intussusception is the term for new
blood vessel formation by splitting oﬀ existing ones.
Angiogenic vessels show several diﬀerences from mature vessels. They have a disorganized
and irregular structure. Angiogenic endothelial cells exhibit altered surface markers and cell
adhesion molecules that reﬂect their increased proliferation, protein expression and secretion.
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Angiogenesis related to bladder cancer may release proteins into the urine, that can be detected
externally (see Section 3.4.2).
Angiogenesis is mostly hypoxia driven. Hypoxia promotes the formation of blood vessels,
and is important for the formation of a vascular system. Indeed, hypoxia-inducible factors
(HIFs) are transcription factors that respond to changes in available oxygen in the cellular envi-
ronment, speciﬁcally, to decreases in oxygen. In particular, HIF-1, when stabilized by hypoxic
conditions, upregulates several genes to promote survival in low-oxygen conditions, including
vascular endothelial growth factor (VEGF) [Beni08]. Jain et al. highlighted that one speciﬁc
type of VEGF (also referred to as VEGF-A) appears to be the most critical of all the known an-
giogenic molecules. VEGF promotes the survival and proliferation of endothelial cells, increases
the display of adhesion molecules on these cells, and increases vascular permeability [Jain05].
Tumor blood vessels have diﬀerent morphology than the normal vasculature. Angiogenesis
in tumors causes excess recruitment of endothelial cells. However, VEGF over-expression leads
to formation of additional micronetworks connected to higher order vessels, rather than insertion
of individual capillaries into the existing vessels structure [Hein08]. In addition, tumor vessels
are tortuous, dilated, and can have dead ends. They are not organized into deﬁnitive venules,
arterioles and capillaries like their normal counterparts, but rather share chaotic features of all
of them [Berg03].
The ideal imaging tool for angiogenesis would need to have a resolution high enough to
demonstrate not only increased density of microvessels, but also to show the microscopic hall-
marks of angiogenesis as mentioned before. In addition, characterization of the angiogenesis
during the neoplastic process and monitoring of blood vessels, blood supply, and vessel archi-
tecture in vivo during ongoing therapy would be of interest. Within the last few years, certain
developments have been achieved in endoscopic imaging with the potential to enable these ob-
jectives.
The ﬁrst step was to enable magnifying endoscopy to get a deeper insight into tissue char-
acteristics and vascularization. An irregular microvascular pattern appears to be capable of
predicting the histologic characteristics of cancerous lesions in the GI tract [Yosh04, Curv08].
Meining et al. acquired images of blood vessels with the Cellvizio R© ﬁber-based confocal probe
(see Section 2.4). Here, again, an irregular vascular pattern with leakage of ﬂuorescein was
associated with neoplasia in the colon [Mein08]. In addition, this system can be combined with
a “vessel viewer” application software, which seems to be very helpful to objectively measure
vessel density and blood ﬂow.
3.7.2 Microvessel density (MVD)
Tumor angiogenesis can be assessed on histopathological slides by using an antibody to en-
dothelial cells, to identify tumor vasculature. Microvessel density (MVD) can then be measured
either as an average of counts over a number of randomly selected areas, or quantiﬁed in the
densest areas of neovascularization, termed hotspots. A variety of immunohistochemical tech-
niques have been used to assess MVD, based on antibodies to CD31, CD34 or factor-VIII-related
antigen [Char06]. The inconsistency between results from diﬀerent investigators has often been
partly blamed on variation in the methodology of measuring MVD.
High MVD was initially shown to be an independent predictor of survival [Dick94]. In-
creasing MVD has subsequently been shown to be associated with increasing incidence of tu-
mor recurrence, stage progression, lymph-node metastases and the presence of vascular inva-
sion [Boch95, Godd03].
There have been a number of reviews on MVD that summarize the growing body of evi-
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dence supporting MVD as a method of assessing urologic malignancies, but that also show the
pitfalls [Dick94, Kerb02, Fox04]. For instance, it was amply demonstrated in the study of Ax-
elsson et al. , where after an initial training period with Weidner, no association between MVD
and patient survival was observed [Axel95]. Hlatky et al. reviewed studies demonstrating the
value of using tumor MVD as a prognostic indicator for a wide range of cancers. In this context,
measurement of MVD facilitates assessments of disease stage and the likelihood of recurrence
and helps guide treatment decisions [Hlat02]. Recently, however, it has been assumed by some
investigators that measurements of MVD may also reveal the degree of angiogenic activity in a
tumor. Based on this assumption, quantiﬁcation of MVD is thought to constitute a surrogate
marker for the eﬃcacy of antiangiogenic agents as well as a mean by which to assess which
patients are good candidates for antiangiogenic therapy prior to treatment. In the same review,
Hlatky et al. showed that MVD is not by itself an indicator of therapeutic eﬃcacy, nor should
it be used to guide the stratiﬁcation of patients for therapeutic trials.
3.7.3 Signiﬁcance to bladder cancer
The vascular system of the urinary bladder wall eﬀectively performs its function in spite of
considerable spatial changes due to the ﬁlling/voiding cycle. However, only a few studies have
dealt with the microvascular architecture of the bladder wall: a classical description of its
histology including vascularization by von Möllendorﬀ (1930) and a microangiographic study by
Sarma (1981).
Miodonski et al. published two studies in which they described the microvasculature visu-
alized by scanning electron microscopy (SEM) of vascular corrosion casts [Miod98, Miod99].
Postoperative bladder specimens obtained from patients with advanced bladder tumors were
ﬁlled with small amount (80 ml) of saline and perfused via at least four largest arteries with
anticoagulant-containing saline followed by paraformaldehyde/glutaraldehyde ﬁxative and Mer-
cox resin. After polymerization of the resin, the vascular casts were macerated with potassium
hydroxide, cleaned with formic acid and water and freeze dried. Only regions of the bladder wall
distant to the tumor were examined in light and scanning electron microscopes. They explained
the adaptation of bladder mucosa to contraction of the muscularis by two mechanisms: 1) de-
crease in the epithelial surface by reorganization of the urothelium and 2) extensive folding of
the mucosa. Miodonski et al. also highlighted two major vascular plexuses (adventitial/serosal
and mucosal) and two distinct capillary networks (muscular and subepithelial) in the successive
layers of the wall (see Figure 3.12).
Larger branches of main extra-vesical arteries and veins formed the adventitial/serosal plexus
characterized by highly tortuous course of the vessels and numerous anastomoses. This plexus
supplied and drained the capillary network of the muscularis and also sent long, perpendicular
vessels, 100–300 µm in diameter, piercing the muscularis and communicating directly with the
mucosal plexus. The perpendicular vessels were almost straight, wavy, tortuous or tightly coiled,
depending on whether they joined the mucosal plexus near the top or near the base of the fold.
The mucosal plexus consisted of some capillaries, thin arteries (50–100 µm) and more numerous,
thicker veins (80–250 µm), showing a tortuous appearance and frequent interlacements; it formed
a distinct vascular layer parallel to the inner surface of the bladder and following the proﬁles of
mucosal folds [Miod98].
There is clear evidence that the features of angiogenesis (such as MVD) and expression of
angiogenic factors (such as VEGF) are related to adverse outcomes in bladder cancer [Char06].
Goddard et al. showed that MVD in superﬁcial bladder cancer is signiﬁcantly higher in those
cases that subsequently progress to muscle invasive disease [Godd03].
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Figure 3.12: Schematic representation of the vascular topography in the wall of empty (left) and ﬁlled
(right) human urinary bladder. SCP, subepithelial capillary plexus; MP, mucosal plexus; AP, adventitial
plexus ([Miod99]).
Figure 3.13: Vascular architecture of mucosa adjacent to a tumor. The yellow dashed line separates the
vasculature of the tumor (T). Note uneven surface of the subepithelial capillary network, with elevations
and depressions (asterisk) and palisade-like array of its supplying and draining vessels (white hands, left)
similar to that present in the tumor (yellow arrows, right). Bar 200µm(adapted from [Miod98])
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From a molecular point of view, thrombospondin-1 (TSP-1) is 430 kDa glycoprotein pro-
duced by normal urothelial cells that is strongly antiangiogenic. Campbell et al. showed that
downregulation of TSP-1 secretion is a key event in the switch from an anti-angiogenic to an
angiogenic phenotype, which occurs early in the development of bladder cancer [Camp98].
3.7.4 Imaging angiogenesis in the bladder
Zimmern et al. showed that ﬂuorescein angiography reveals markedly increased uptake in pap-
illary tumors and carcinoma in situ compared with normal urothelium [Zimm95]. Areas of
papillary transitional cell tumor and carcinoma in situ developed a brilliant yellow-green ﬂuo-
rescence, indicating that neovascularity is acquired relatively early during bladder tumorigenesis.
Adjacent normal urothelium was non-ﬂuorescent and provided a contrasting dark background
facilitating the detection of all lesions.
Several imaging techniques have been employed in vivo to analyze tumor vasculature, for
instance before and after the administration of antiangiogenic and antivascular drugs, in order
to assess (i) proof of principle, by demonstrating that a new drug has impacted on the tumor
vasculature, and (ii) proof of concept, to conﬁrm that the drug has achieved a clinically relevant
end point.
The main techniques that have been employed to image angiogenesis in the clinic are MRI,
CT and PET. Resection biopsy is the “gold standard” technique for the diagnosis and staging
of bladder cancer. Prior to resection, conventional CT and MRI are performed, demonstrating
equivalent high accuracy in staging of muscle-invasive (T2-T4) disease. However, their utility
in distinguishing superﬁcial (T1) from early muscle-invasive (T2) tumors is poor. Additionally,
they are unable to detect ﬂat lesions such as carcinoma in situ. Other techniques, such as
contrast-enhanced ultrasonography (CEUS) and optical imaging, might play an important role
in the future [Zee10]. CEUS allows imaging of vessels with diameters of 50-100 µm by combining
the use of Doppler ultrasonography with contrast agents in the form of gas-encapsulated micro-
bubbles under 10 µm in diameter [Nico08, Nico09].
Reiher et al. showed that the association of p53 status with microvessel density in their
patient population was weak, whether assessed by staining for CD31 or CD34 [Reih02]. How-
ever, this study conﬁrmed the strong association of p53 and microvessel density with the well
established prognostic factors of grade and stage in superﬁcial bladder cancer, supporting other
evidence of an important role for p53 and angiogenesis in the tumor biology of this disease.
Their data also suggested that p53 is not a primary regulator of angiogenesis in this patient
population. This suggested that other genetic or environmental factors may contribute to the
regulation of angiogenesis in superﬁcial bladder cancer.
Korkolopoulou et al. stated that the studies based on microvessel density (MVD) as the
only factor reﬂecting angiogenesis overlooked other parameters that might be signiﬁcant as
well, such as the complexity of the microvascular network, the size and shape of microvessels,
and the immunostaining intensity of endothelial cells [Kork01]. These authors concluded that
the prognostic signiﬁcance of neovascularization is better assessed by area and shape-related
morphometric characteristics, whereas MVD becomes inﬂuential only with regard to overall
survival of patients with invasive tumors.
Summarily, all these studies tend to show that an in situ observation of the vascularization
developing in early bladder cancer may give a useful information over tumor progression poten-
tial. Therefore, characterizing the vascularization underlying the ﬂuorescence positive spots is
of high interest. This thesis is an optical contribution to imaging angiogenesis in bladder cancer.
That is the purpose of the study presented in Chapter 5.
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Chapter 4
Optimization of the spectral design
for ﬂuorescence cystoscopy
4.1 Fluorescing metabolites present in urine
This study originates from the clinical observation that the images are somehow “blurred” by
a greenish screen between endoscope tip and bladder mucosa during ﬂuorescence cystoscopy,
especially with the PDD setup from Richard Wolf. This eﬀect is enhanced by the urine produc-
tion. Indeed, when the bladder is not ﬂushed regularly, greenish ﬂows coming out of the ureters
can easily be observed. For this reason, it is supposed that some ﬂuorophores contained in the
urine are excited by the photodetection excitation light, and appear greenish on the screen.
This eﬀect may impair the visualization of the bladder mucosa, and thus cancerous lesions, and
lowers sensitivity of the ﬂuorescence cystoscopy.
Surprisingly, the ﬂuorescence of urine has not received particular attention in the past,
although various attempts have been made to isolate and identify ﬂuorescent substances. Several
historical papers reported about metabolites present in urine, that may ﬂuoresce under certain
conditions [Bert01, Chas88, Hege93, Mans01].
Urine has frequently been reported to display a characteristic blue-green ﬂuorescence that can
change in case of pathological urine [Danc64]. This blue-green ﬂuorescence has been attributed
to the presence of two main groups of ﬂuorophores, most are metabolites of tryptophan as shown
in Figure 4.1.
Generally, the spectral characterization of a mixture of ﬂuorophores is not easy. Most urine
ﬂuorophores possess very similar ﬂuorescence parameters and may aﬀect each other in a mixture
by changing their individual spectra. Leiner et al. measured the total ﬂuorescence of human
urine at various excitation and emission wavelengths and presented it in 3-dimensional form,
the so-called excitation-emission matrices (EEMs). Despite the complexity of the composition
of urine, 3–5 distinct ﬂuorescence maxima could be observed. Eﬀects of pH were studied and
tentative assignments as to the species responsible for the peaks were evaluated. They are listed
in Table 4.1. Most likely, however, the peaks observed do not result from a single ﬂuorescent
urinary metabolite, but rather from several species having similar spectral properties and being
present in comparable concentrations.
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Figure 4.1: Localization of urine ﬂuorophores (A and B group) in the excitation-emission matrix (EEM).
The group A of ﬂuorophores represents the highest contribution to the whole urine ﬂuorescence. The group
B is characteristic with 4-6 times lower concentration than group A [Kusn05].
Description Excitation Emission Description of the Fluorophore-Chromophore
Peak 1 288.5±0.9 379±5.8 Indoxylsulphate
Peak 2 324.3±3.2 418.9±2.6 4-pyridoxic acid, very strong ﬂuorescence
Shoulders 280 315 Species ﬂuorescing at these wavelengths have been de-
tected in the urine, but none of them could as such
be assigned to this shoulder : (R-tryptophane,R1-acetic
acid,tyrosine). Characteristic concentration changes
were found in urine of cancer patients and newborn ba-
bies.
370 455 3 kynurenines and 2 pterins (neo- and bio-) are known to
ﬂuoresce much more intensely than both folic acid and
xanthurenic acid.
Peak 3-4 420,450,465 525 Riboﬂavin or one of its urinary metabolites or a combi-
nation thereof.
Shoulders 430 460 Sobel et al. reports that this peak is produced by an un-
known substance, present in all urine specimens, some-
times in high concentration [Sobe74]
490 535
Peak 5 They are rather weak in intensity. It is assumed that
they result from porphyrins which are known to be most
strongly ﬂuorescent in acidic solution.
405 596, 619, 653 3 emission maxima for uroporphyrin
400-405 595,618, 652, 671 4 emission maxima for coproporphyrin
Table 4.1: Main ﬂuorophores identiﬁed in urine as reviewed in [Lein87].
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Kusnir et al. showed that concentration of physiologically produced urine is very vari-
able [Kusn05]. It is a result of such various eﬀects as circadian rhythms, diet, amount of
consumed water, physical activity of the person, . . . Individual ﬂuorophore concentrations diﬀer
by orders. Since ﬂuorescence intensity is not a fully linear function of ﬂuorophore concentration
(auto-quenching eﬀect, energy transfer, and other phenomena), each change in urine concentra-
tion (mixture of ﬂuorophores) causes unpredictable changes in the shape and intensity of the
whole spectrum.
Additionally, these authors studied the eﬀect of dilution. Before ﬂuorescent measurements,
urine samples were centrifuged and supernatant was diluted via geometric progression. At the
dilution 1:500, ﬂuorophores of group A (as deﬁned in Figure 4.1) dominate in EEM. Urine diluted
by 1:30 is characterized by the quenching of group A and the rising ﬂuorescence of group B.
The EEM of urine diluted by 1:10 present only group B. The undiluted urine spectrum express
only those ﬂuorophores present in very low (trace) concentration because the ﬂuorescence of
both main ﬂuorophore groups, A and B, disappears and is not manifested at all. The EEMs
(not shown) clearly indicate principal concentration problem of multiﬂuorophore system – fully
diﬀerent ﬂuorescence spectra of the same material caused only by the dilution of the sample.
Individual ﬂuorophores in the mixture manifest themselves only in an appropriate concentration.
The dilution of the sample acquired during cystoscopy is depending on many factors: i) pa-
tient urine production varies strongly from one patient to an other; ii) patient’s diet also have an
inﬂuence on the metabolites present in the urine at the time of cystoscopy; iii) bladder ﬂushing
and/or rinsing is done when needed during the cystoscopy (so that the time interval between 2
ﬂushes ranges from 10 seconds up 10 minutes).
In the following section, we will present spectroﬂuorimetric results acquired on samples
relevant for cystoscopy (i.e. at diﬀerent times during examination). Prior to the clinical samples,
we measured each pure irrigation solution (NaCl, Aqua and Glycine). Figure 4.2 shows neither
signiﬁcant absorption peaks nor ﬂuorescence peaks in the emission range 350–700nm. The
shoulders observed around 400 nm, 600 nm, 635 nm, may be due to device-speciﬁc artifacts (e.g.
UV-Visible lamp transition in the Cary spectrometer). The absolute value of the absorbance for
these three liquid ranges between 0.1–0.17, at least 4-fold lower than hemoglobin absorption.
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Figure 4.2: Absorption spectra of the 3 solutions ﬁlling the bladder (Aqua, NaCl, Glycine) with (i) the
original values and (ii) normalized at their maximum.
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Abstract: During ﬂuorescence cystoscopy, it is observed that the acquired images are some-
times blurred by a greenish background originating from the bladder washout ﬂuid. Several
ﬂuorophores are involved in this overall liquid ﬂuorescence, and their exact origin and relative
contributions remain unknown. In this study, the bladder washout ﬂuid is sampled at diﬀer-
ent times during ﬂuorescence cystoscopy examinations. In total, 32 samples from 12 patients
are analyzed with a spectroﬂuorimeter (excitation range: 350-445 nm, emission range 380-700
nm). This study shows clearly that the position of the ﬂuorescence peaks (excitation/emission
wavelengths: 450/525 nm, 405/625 nm) and shoulder (440/525 nm) is reproducible between
diﬀerent patients. It also suggests that an excitation at wavelengths higher than 400 nm helps
to suppress this solution background ﬂuorescence. Additionally, the pH of the solution seems to
inﬂuence the position of the ﬂuorescence peaks, and this suggests that changing the pH of the
examination liquid could help in avoiding the greenish background.
4.2.1 Introduction
Bladder cancer is an important topic in oncol-
ogy. In the western world, it is the fourth most
common malignancy in men and the eight most
common in women [Kirk05]. White light cys-
toscopy has been established as a standard pro-
cedure for both detection and removal of blad-
der cancer. However, it has a limited sensitiv-
ity in particular for ﬂat lesions [Jich05, Lovi09].
Fluorescence cystoscopy has been developed to
enhance the detection of early bladder cancer.
This technique is performed using blue-violet
light to induce the ﬂuorescence of photoac-
tive porphyrins (PaPs) , mostly protoporphyrin
IX (PpIX). PaPs are selectively produced in
early lesions [Witj07] after an instillation into
the bladder of a precursor solution, typically
2 hours prior the examination. The resulting
ﬂuorescence image has a blue-green color if the
tissue is healthy while the cancer appears in
red.
The main purpose of this study is to ana-
lyze the ﬂuorescence characteristics of the blad-
der washout ﬂuid and thus to identify the ﬂuo-
rophores and absorbers responsible for this en-
vironmental ﬂuorescence.
4.2.2 Materials & Methods
Samples (typically 15 ml) of the blad-
der washout ﬂuid were collected during the
drainage of the bladder of 12 patients under-
going a transurethral resection of the bladder
(TURB) under ﬂuorescence cystoscopy. The
mean operation (detection and resection) du-
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ration was 45 minutes.
In order to reﬂect the alteration of the ﬂuo-
rescence properties over the course of examina-
tion and how diﬀerent irrigation ﬂuids and con-
centration inﬂuence ﬂuorescence spectra, the
content of the bladder was collected at four dif-
ferent points in time:
Just before the examination start –
PaPs-Urine sample In order to perform
ﬂuorescence cystoscopy, a 50 ml precursor so-
lution is instilled into the bladder 2 hours prior
the examination. With an average urine pro-
duction of 1-2 ml/min, the resulting precursor
solution concentration in the bladder ﬂuid af-
ter 2 hours instillation is 25-50%. In this phase,
the washout ﬂuid contains the remaining pre-
cursor (not ﬂuorescing), PaPs, and the urine
secreted in this interval. Measuring this type
of sample was of interest because it corresponds
to the initial conditions of the procedure with
the highest urine concentration.
After the bladder wash – NaCl-Urine
sample For cytological diagnosis, the blad-
der is rinsed with a 500 ml NaCl solution (NaCl
0.9%, B. Braun, Germany) to collect urothe-
lial cells. This solution remains only for a very
short time in the bladder (typically 5-10 sec-
onds), and urine concentration is very low (i.e.
diluted).
During the ﬂuorescence cystoscopy –
Aqua-Urine sample During the regular
photodetection procedure, the bladder is irri-
gated with a water solution (Aqua, B. Braun,
Germany) to ensure good visualization of the
bladder mucosa. Therefore, urine concentra-
tion in these samples depends on the elapsed
time after last ﬂushing.
During the resection phase – Glycine-
Urine sample During electro-resections, the
bladder is irrigated with a glycine solution
(Glycine 1.5% solution, Baxter, USA) to avoid
water intoxication due to irrigation ﬂuid enter-
ing the bloodstream, the so-called TURP syn-
drome. For short resection time, this risk is
minimal and the water irrigation solution can
still be used. In these samples, some blood
was present due to the on-going resection pro-
cedure. This sample was of particular relevance
since the greenish ﬂows were often visible dur-
ing this phase.
The number of samples of each type was not
the same due to clinical reasons (e.g. no cy-
tology requested, limited resection time with-
out glycine). Consequently, 10 PaPs-Urine,
5 NaCl-Urine, 10 Aqua-Urine, and 7 Glycine-
Urine were collected. Samples were stored at
low temperature (T = 4◦C) between collection
and measurement. Typical time interval be-
tween collection and measurement was 2 hours.
The 32 samples were analyzed with a spec-
troﬂuorimeter (LS-50B, Perkin Elmer, USA)
and the results are presented as assembled in an
excitation-emission matrix (EEM), as well as
ﬂuorescence-emission spectra with excitation
wavelengths ranging from 350 nm to 445 nm
(5 nm step) and emission wavelengths ranging
from 380 nm to 700 nm (see Figure 4.4). Flu-
orescence was collected with an angle of 90 de-
grees.
To identify possible sources of absorption,
an absorption spectrum between 350 nm and
700 nm was also acquired for each sample with
a spectrophotometer (Cary 500 UV/VIS/NIR,
Varian, USA). For all measurements, samples
were analyzed in a 1 cm thick quartz cuvette
(OS, Hellma, Germany) with improved trans-
mission in the near UV.
4.2.3 Results
We measured each pure irrigation solution
(NaCl, Aqua and Glycine) and observed nei-
ther signiﬁcant absorption peaks nor ﬂuores-
cence peaks in the emission range 350-700nm
(see Figure 4.2).
During the resection phase, the excitation
light is much absorbed by the bladder washout
ﬂuid due to the variable blood content, im-
pairing the PaPs ﬂuorescence excitation, and
thus, lowering the contrast between lesions and
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healthy mucosa. Figure 4.3 shows a typical
absorption spectrum of Glycine-Urine samples,
where oxyhemoglobin strong absorption peaks
can be clearly identiﬁed.
In the following, typical ﬂuorescence spec-
tra of the various samples are shown and de-
scribed. The scales on Figure 4.4 [a-h] are com-
parable, because the samples were measured in
the same conditions, but the color bars were
adjusted to help visualization. Great varia-
tions in ﬂuorescence intensities were observed
between patients. Numbers indicated in brack-
ets for each type of sample are the mean ﬂuo-
rescence intensity, the standard deviation and
the observed range.
PaPs-Urine samples – Figure 4.4 [a-b]
(290±95, range 160-420). Two main ﬂuores-
cence peaks are visible at excitation/emission
wavelengths of 360-380/450 nm (Peak 1) and
of 405/635 nm (Peak 2). A shoulder of a third
peak is also visible around 440/520 nm.
NaCl-Urine samples – Figure 4.4 [c-d]
(181±88, range 47-260). The NaCl bladder
wash has ﬂuorescence intensity well above the
NaCl background signal (1:30-1:50). In this
case, only one peak is present (excitation wave-
length < 350 nm and emission at 450 nm). The
excitation peak is shifted towards shorter wave-
lengths. The second peak and the shoulder do
almost disappear.
Aqua-Urine samples – Figure 4.4 [e-f]
(471±174, range 220-720). For these samples,
a small shift of the excitation maxima (re-
lated to Peak 1, from 365 to 340 nm) towards
shorter wavelengths is observed as compared
to PaPs-Urine samples, but the shift is smaller
than in NaCl. The other peak and shoulder
are still present but no variation in the excita-
tion/emission is observed.
Glycine-Urine samples – Figure 4.4 [g-h]
(120±69, range 32-220). The glycine back-
ground is also measured separately (data not
shown) and it is veriﬁed that intensities are
lower than the signal itself (1:30, 1:50), giving
a good signal to noise ratio. As in NaCl, only
one peak is clearly visible and its excitation is
shifted respect to that of Peak 1 in PaPs-Urine
sample.
4.2.4 Discussion
Many diﬀerent molecules may play a role in the
urine ﬂuorescence, and it is not straightforward
to identify all of them [Lein87]. These authors
classiﬁed peaks and shoulders that are match-
ing to our measurements. It is important to
underline that among the manifold substances
occurring in urine, only those having high val-
ues for the product ε · c ·φ will signiﬁcantly con-
tribute to the total ﬂuorescence, where ε is the
molar extinction coeﬃcient of the substance at
the relevant excitation wavelength, c is its con-
centration, and φ is its ﬂuorescence quantum
yield. This means that variation in the EEM
can be observed when we consider diﬀerent di-
lutions of the urine sample [Kusn05], because
the diﬀerent ﬂuorochromes have a spectral de-
pendence to the concentration.
The interaction of the ﬂuorochromes with
the diﬀerent physicochemical environment of
the solvent can also inﬂuence the ﬂuorescence
properties of the sample. In particular, the
pH of the solution seems to be important.
The pH of normal urine is generally in the
range 4.6–8, a typical average being around
6. Most of the variations are due to diet.
For example, high protein diet results in more
acidic urine, but vegetarian diet generally re-
sults in more alkaline urine. Many ﬂuorophores
present in the urine exhibit strong pH depen-
dence [Sare51, Sato58]. Indeed, their ﬂuores-
cence yield appears to be strongly related to
the pH [Dros02, Buen04].
Pyridoxic acid has been recognized as one
of the major ﬂuorescent metabolites in urine
with a maxima at 324/419 nm [Lein87, Sare51,
Greg79]. In our measurements, it probably
gives a large contribution to Peak 1. How-
ever, it should be noted that other substances
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Figure 4.3: Absorption of a Glycine-Urine sample. Three peaks can be identiﬁed at 414.7 nm, 542.7
nm, and 578 nm, which correspond to the main absorption peaks of hemoglobin (HbO2: 414 nm, 542 nm,
578 nm; Hb: 434 nm, 556 nm) in good agreement with http: // omlc. ogi.edu/
interfere at these wavelengths. In particular,
when the sample is undiluted, it seems that also
kynurenine and xanthurenic acid play an im-
portant role in the total ﬂuorescence [Kusn05,
Lein87]. A shift towards shorter wavelengths
of kynuretic acid ﬂuorescence is observed when
the solvent is less acidic [Sato58]. A similar
shift is also observed in our emission spectra
passing from PaPs-Urine sample (more acidic
due to the precursor) to the other samples.
Comparing our measurements with the lit-
erature [Kusn05, Lein87], Peak 2 is attributed
to porphyrins that are often present in urine
as a degradation product of bilirubin or uro-
bilin [Lein87]. Cancerous cells loaded with
PaPs or free PaPs released to the bladder (also
ﬂuorescing at these wavelengths) are also likely
to be present in the liquid. The shoulder is at-
tributed to riboﬂavins, which have a peak at
about 440/520 nm [Lein87].
For NaCl-Urine, Aqua-Urine, and Glycine-
Urine, the shift in the excitation wavelength of
Peak 1 and the almost total disappearance of
Peak 2 and its shoulder is probably due to the
fact that urine is more diluted than in PaPs-
Urine sample. Some of them, with high ﬂuores-
cence quantum yield, could be present in low
concentration and probably almost disappear
when urine is more diluted [Kusn05]. Another
possible explanation is that there is a quench-
ing of some ﬂuorochromes due to the solvent.
In the case of NaCl-Urine samples, the fact
that NaCl stays in the bladder for a short time
(typically less than 5 seconds) has also to be
considered. In fact, this could not allow a suf-
ﬁcient porphyrin accumulation in the bladder,
resulting in Peak 2 disappearance.
Hemoglobin absorption can inﬂuence ﬂu-
orescence measurements. Hence, it probably
contributes in deﬁning the shape of the peaks,
particularly in Glycine-Urine samples. For the
same reason, the presence of hemoglobin in the
washout ﬂuid can also impair the cancer de-
tection, since it lowers the intensity of the light
illuminating the bladder surface, and alters the
spectroscopy of the ﬂuorescence collected by
the cystoscope.
Finally, although the exact inﬂuence of
the alimentation over the urine composition
(and thus ﬂuorescence) remains unknown, it is
pretty obvious that the whole body metabolism
is aﬀected by the patient diet. In this study,
the patients are fasting over the night preced-
ing the examination, and the inter-patient vari-
ations remain limited.
4.2.5 Conclusions
In this study, the total ﬂuorescence of diﬀerent
liquids ﬁlling the bladder of patient subject to
ﬂuorescence cystoscopy is analyzed. Two main
factors inﬂuence our measurements: dilution
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Figure 4.4: Example of ﬂuorescence measurements of diﬀerent samples taken from the same patient:
PaPs-Urine (a, b), NaCl-Urine (c, d), Aqua-Urine (e, f), and Glycine-Urine (g, h). EEMs are reported
on the left, while emission spectra are reported on the right.
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and pH. A determination of the exact role of
these factors, in particular of the pH, in the
measurements can suggest the formulation of
a new washout solution, in order to avoid the
greenish background during ﬂuorescence cys-
toscopy.
For the moment, what we can deduce from
our measurements is that excitation wave-
lengths below 390 nm should be avoided in or-
der to reduce the excitation of the main ﬂu-
orophores of the urine. Additionally, in or-
der to suppress the secondary peak attributed
to riboﬂavins in the green spectral region
(ex440/em520nm), one should avoid excitation
below 450 nm, which is questionable, since we
would like to excite PpIX in the violet spectral
region.
92 Chapter 4. Optimization of the spectral design for ﬂuorescence cystoscopy
Bibliography
[Bert01] A. Bertazzo, E. Ragazzi, M. Biasiolo, C. V. Costa, and G. Allegri. Enzyme activities involved in
tryptophan metabolism along the kynurenine pathway in rabbits. Biochim Biophys Acta, 1527(3):167–
175, Aug 2001.
[Buen04] C. Bueno and M. V. Guerrero, J. andand Encinas. Spectroscopic properties of 4-pyridoxic acid as a
function of pH and solvent. Helvetica Chimica Acta, 87:940–948, 2004.
[Chas88] J. Chastain and D. Mccormick. Characterization of a new ﬂavin metabolite from human urine. Biochim.
Biophys. Acta, 967(1):131–134, 1988.
[Danc64] P. W. Danckwortt and J. Eisenbrand. Luminescenz-Analyse im ﬁltrierten ultraviolettern Licht. Akad.
Verlags-Ges, Leipzig, 1964.
[Dros02] P. Drossler, W. Holzer, A. Penzkofer, and P. Hegemann. pH dependence of the absorption and emission
behavior of riboﬂavin in aqueous solution. Chem. Phys., 282:429–439, 2002.
[Greg79] J. F. Gregory and J. R. Kirk. Determination of urinary 4-pyridoxic acid using high performance liquid
chromatography. The American Journal of Clinical Nutrition, 32:879–883, 1979.
[Hege93] Z. L. Hegedus and U. Nayak. Renal excretion of plasma soluble melanins by healthy human adults.
Arch Int Physiol Biochim Biophys, 101(6):417–423, 1993.
[Jich05] P. Jichlinski and H.-J. Leisinger. Fluorescence cystoscopy in the management of bladder cancer: a help
for the urologist! Urol Int, 74(2):97–101, 2005.
[Kirk05] Z. Kirkali, T. Chan, M. Manoharan, F. Algaba, C. Busch, L. Cheng, L. Kiemeney, M. Kriegmair,
R. Montironi, W. M. Murphy, I. A. Sesterhenn, M. Tachibana, and J. Weider. Bladder cancer: Epi-
demiology, staging and grading, and diagnosis. Urology, 66(6 Suppl 1):4–34, 2005.
[Kusn05] J. Kusnir, K. Dubayova, L. Leskova, and M. Lajtar. Concentration matrices-solution for ﬂuorescence
deﬁnition of urine. Analytical Letters, 38:1559–1567, 2005.
[Lein87] M. Leiner, R. Hubmann, and O. Wolfbeis. The total ﬂuorescence of human urine. Analytica Chimica
Acta, 198:13–23, 1987.
[Lovi09] B. Lovisa, P. Jichlinski, D. Aymon, B.-C. Weber, H. van den Bergh, and G. Wagnieres. Bladder
cancer detection by ﬂuorescence imaging with hexvix(r): optimization of the excitation light during
high magniﬁcation cystoscopy. In I. Georgakoudi, J. Popp, and K. Svanberg, editors, Clinical and
Biomedical Spectroscopy, volume 7368, page 73681I. SPIE, 2009.
[Lovi10] B. Lovisa, A. M. Novello, P. Jichlinski, H. van den Bergh, and G. Wagnieres. Fluorescence of the
bladder washout ﬂuid following cystoscopy: a preliminary study. In N. Kollias, B. Choi, H. Zeng, R. S.
Malek, B. J. Wong, J. F. R. Ilgner, K. W. Gregory, G. J. Tearney, L. Marcu, H. Hirschberg, S. J.
Madsen, A. Mandelis, A. Mahadevan-Jansen, and E. D. Jansen, editors, Photonic Therapeutics and
Diagnostics VI, volume 7548, page 75481J. SPIE, 2010.
[Mans01] A. Mansilla, I. Meras, and F. Salinas. Analysis of pteridines and creatinine in urine by hplc with serial
ﬂuorometric and photometric detectors. Chromatographia, 53:510–514, 2001.
[Sare51] H. P. Sarett. A study of the measurement of 4-pyridoxic acid in urine. J. Biol. Chem., 189:769–777,
1951.
[Sato58] K. Satoh and J. M. Price. Fluorometric determination of kynurenic acid and xanthurenic acid in human
urine. J Biol Chem, 230(2):781–789, Feb 1958.
[Sobe74] C. Sobel, C. Cano, and R. E. Thiers. Separation and quantitation of coproporphyrin and uroporphyrin
in urine. Clinical Chemistry, 20(11):1397–1402, 1974.
[Witj07] J. A. Witjes and J. Douglass. The role of hexaminolevulinate ﬂuorescence cystoscopy in bladder cancer.
Nature Clinical Practice Urology, 4(10):542–549, 2007.
Chapter 5
High magniﬁcation reﬂectance
imaging in the bladder
5.1 Introduction to HM cystoscopy
Fluorescence cystoscopy with Hexvix R© represents one of the major recent advances in urologic
oncology in the recent years (as described in details in Section 3.6). Hexvix R© allows to detect
early lesions with a very high sensitivity. Moreover, many clinical studies reported a very high
detection rate of ﬂat lesions (e.g. CIS, 92–95%) [Jich03a, Witj07], and a better identiﬁcation
of lesions that were overlooked with standard WL cystoscopy alone [Frad07, Gros07]. In ad-
dition, the precise staining and mapping obtained on the bladder mucosa give a direct visual
appreciation of the disease extension. Therefore, random biopsies of the mucosa become useless,
thus reducing the risk of unnecessary mucosal injury, one critical factor in bladder tumor recur-
rence [Theo03]. A secondary end-point that was demonstrated is the improved resection under
ﬂuorescence, contributing to the lower recurrence rate [Denz08].
However, tissue abnormalities such as inﬂammations, hyperplasia, metaplasia and scars may
sometimes induce false-positive results. Although most of these false positives can easily be
rejected under white light observation (see Section 3.6.3), inﬂammations are much more diﬃcult
to identify, resulting in supplementary biopsies. Therefore, the purpose of this research project
is to develop novel, fast, and convenient method to characterize ﬂuorescence positive spots
in situ during ﬂuorescence cystoscopy, thus reducing the false-positive rate and the cost of
supplementary biopsies. The developed instrumentation should be kept compatible with the
current PDD instrumentation in order to minimize the impact on the clinical routine.
As shown in Section 3.7, angiogenesis plays an important role in bladder cancer progression,
as it is a prerequisite for growth and metastasis [Char06]. In this project, we will use the
magniﬁcation and/or high-resolution cystoscopy to characterize the vascularization underlying
ﬂat lesions appearing as positive during ﬂuorescence cystoscopy. We will particularly focus on
the capillary/vessels patterns and the microvascular architecture. The objectives of this project
were: i) to identify the smallest value of the magniﬁcation, ii) to identify the optimal features
of these images (vessel or cellular structure) to characterize the lesions, and iii) to optimize the
spectral design of the imaging system to better visualize the identiﬁed patterns.
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Over the last years, high resolution and high magniﬁcation endoscopic observations were
applied to many diﬀerent organs. These technologies enhance the detection of the following
features: modiﬁcation of the vocal cords histology [Andr95a, Andr95b], cervical cancer on-
set with contact micro-colpohysteroscopy [Mats05], diagnostic improvement of Barrett’s esoph-
agus [Fort06], pit pattern classiﬁcation of the colon [Kudo96], characterization of small and
diminutive colonic polyps (pit pattern and vascular pattern intensity) [East08], observation of
the looped capillary vessels inside the papillae in the oesophagus [Inou97], subepithelial vascular
patterns in the bronchi, including increased vessel growth and complex networks of tortuous
vessels [Shib02, Shib03, Shib10], microvascular architecture of the surface epithelium like vessel
arborescence and interconnection in the upper gastro-intestinal tract [Kuma06]. In addition,
endocytoscopy systems (together with vital staining) allowed the microscopic observation at
the cellular level, including cellular density, pattern of the cellular arrangement, deformity and
enlargement of the nuclei, nuclear-cytoplasmic ratio [Sasa06]. In this manuscript, we always
bear in mind, that the magniﬁcation of our cystoscope should be kept into reasonable bounds
(30–150×) in order not to transform it into a microscope, incompatible with the conventional
surgical tools. In the following pages, to improve the legibility, we will call the range 80–120×
high magniﬁcation not to be confused with the high magniﬁcation necessary to acquire images
at the cellular level (>500×).
Since we were interested in transferring this magniﬁcation concept in urology, a dedicated
rigid cystoscope was adapted in collaboration with Richard Wolf GmbH. This cystoscope equip-
ped with a knob allowing to change the magniﬁcation in situ in both white light and ﬂuorescence
mode. The section 5.2 describes the optical properties of this cystoscope. A clinical study
was designed to assess the feasibility of characterizing the vascularization in situ. In a ﬁrst
phase, an image atlas was created to register the vascular patterns of interest. In a second
phase, 60 patients who were subject to “routine” ﬂuorescence cystoscopies were recruited at the
University Hospital in Lausanne, and their endoscopic ﬁnding were classiﬁed following the atlas.
Section 5.3 summarizes the clinical results. We then analyzed whether the vessel classiﬁcation
information was fully contained in the image skeletons in the section 5.4. Since our method for
the quantiﬁcation of blood vessels involved some elements of subjectivity, Section 5.5 deﬁnes
some algorithms to segment blood vessels and investigate the inﬂuence of color presentation. In
Appendix E, the spectral design of our setup is modiﬁed to enhance the contrast between the
tissue and the vessels.
5.2 Optical characterization of the HM cystoscope
The adapted rigid cystoscope is based on a Microview cystoscope (Richard Wolf GmbH, Knit-
tlingen, Germany) with a viewing direction of 25◦. It has a diameter of 4 mm, a working length
of 30 cm, and can be inserted into a dedicated 17.5 Fr sheath, equipped with an endoscope
bridge. This sheath is equipped with 2 ﬁxed stop cocks to allow permanent irrigation of the
bladder. The cystoscope itself is equipped with a knob allowing to change the magniﬁcation
in situ. Figure 5.1 depicts the proximal part of the HM cystoscope. This rigid cystoscope was
thought to be a measurement device rather than a ﬁnal product. The results of the studies
presented in this chapter will allow to deﬁne the “input design” of a new ﬂexible cystoscope
with integrated magniﬁcation.
In a quantitative approach, the main problem with a variable zooming instrumentation
is to determine the size of the observed patterns. In addition, operating the knob on the
rigid cystoscope results in a modiﬁcation of the ﬁeld of view (FOV), depth of ﬁeld (DOF) and
magniﬁcation. At the present time, the distance between the endoscope and the tissue cannot
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Figure 5.1: High magniﬁcation cystoscope. The magniﬁcation can be adjusted with a knob on the
optical device (range 30-650×).
be measured in vivo (except of course when in contact with the tissue). In the next section, we
will describe the calibration procedure with the help of a standardized target.
5.2.1 Useful deﬁnitions in geometrical optics
The ﬁeld of view (FOV) is deﬁned as the (angular or areal) extent of the real world being
observed by the cystoscope. The size of the ﬁeld of view and the size of the image detector
directly aﬀect the image resolution.
The depth of ﬁeld (DOF) is the portion of a scene that appears acceptably sharp in the
image. Although a lens can precisely focus at only one distance s, the decrease in sharpness
is gradual on each side of the focused distance, so that within the DOF, the unsharpness is
imperceptible due to the limited resolution of the detector (resp. display system). One usually
deﬁne the DOF with a short distance L1 and a long distance L2, the closest and farthest sharp
points, respectively (see Figure 5.2). The DOF calculation is not trivial, but many authors
describe it in details [Merk93].
Total 
depth of 
field
L1 L2
s
Figure 5.2: Deﬁnition of the DOF with parameters L1, L2, and s
In order to calculate the DOF, we need the following deﬁnitions:
The circle of confusion (CoC) is an optical spot caused by a cone of light rays from a lens
not coming to a perfect focus when imaging a point source. Thus, it is usual to deﬁne the
DOF as the region where the CoC is less than the resolution of the detector.
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The f-number (f/#) of an optical system expresses the diameter of the entrance pupil in
terms of the focal length of the lens; in simpler terms, the f -number is the focal length
divided by the “eﬀective” aperture diameter. The f -number (often also notated as N) is
given by
f/# = N = f
D
with D the diameter of the entrance pupil and f the focal length
The hyperfocal distance H is the distance beyond which all objects are acceptably sharp for
a lens focused at inﬁnity, and is given by
H 
f2
Nc

fD
c
with c is the diameter of the CoC for a given image format.
Let s be the distance at which the camera is focused (the “subject distance”). When s is
large in comparison with the lens focal length, the distance L1 from the camera to the near limit
of DOF and the distance L2 from the camera to the far limit of DOF are
L1 ≈ Hs
H + s and L2 
Hs
H − s for s < H
When the subject distance is the hyperfocal distance (i.e. s = H),
L2 = ∞ and L1 = H2
In general, the depth of ﬁeld L2 − L1 is
DOF  2Hs
2
H2 − s2 for s < H
For s ≥ H, the far limit of DOF is at inﬁnity and the DOF is inﬁnite; of course, only objects at
or beyond the near limit of DOF will be recorded with acceptable sharpness.
Substituting for H and rearranging, DOF can be expressed as
DOF  2Ncf
2s2
f4 − N2c2s2
Thus, for a given image format, depth of ﬁeld is determined by three factors: the focal length of
the lens, the f-number of the lens opening (the aperture), and the camera-to-subject distance.
5.2.2 Determination of the HM cystoscope resolution
A good way to determine resolution of an optical setup is to look at a pattern of known size
and see whether it is resolved or not. The USAF-1951 test target (abbrev. USAF-target) was
developed for this purpose. It contains patterns that get continuously smaller in order to measure
the actual resolution of an imaging system. The structure of the USAF-target and the size of
each element are standardized according to an American military standard [USAi51].
The USAF-target consists of a series of patterns decreasing in size, with a range depending
on the applications. It consists on several groups that are serially numbered with -2,-1,. . .,6,7.
Each group consists of six elements, which are progressively smaller. An element on the test
target consists on 3 horizontal and 3 vertical lines (see Figure 5.3). Each of the lines are 5 times
longer than wide; the distance between two lines is exactly equivalent to the width of a line.
The combination of a black and a white line is called a line-pair (lp).
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For a deﬁned group G, the element E has the following properties:
Resolution [lp/mm] x = 2G+
E−1
6
Line length [mm] L = 2.5/x
Line width [mm] l = L/5 = 0.5/x = 1/2x
l=0.5/x 1/x
0.5/x
0.5/x
1/x
2.5/x
L=2.5/x
Figure 5.3: Size of the elements on the USAF target
In Table 5.1, the resolution is stated in line pairs per millimeter (lp/mm). From element
to element(in a column downwards), the resolution increases by a factor 1.12. From group to
group (in a line to the right), the resolution doubles.
Group
Element -2 -1 0 1 2 3 4 5 6 7
1 0.25 0.50 1.00 2.00 4.00 8.00 16.00 32.00 64.00 128.00
2 0.28 0.56 1.12 2.24 4.49 8.98 17.96 35.92 71.84 143.68
3 0.31 0.63 1.26 2.52 5.04 10.08 20.16 40.32 80.63 161.27
4 0.35 0.71 1.41 2.83 5.66 11.31 22.63 45.25 90.51 181.02
5 0.40 0.79 1.59 3.17 6.35 12.70 25.40 50.80 101.59 203.19
6 0.45 0.89 1.78 3.56 7.13 14.25 28.51 57.02 114.04 228.07
Table 5.1: Resolution in lp/mm rounded to 2 decimals of the USAF-1951 test target
The endoscopic setup adapted for the HM study in the bladder (HM cystoscope coupled to the
PDD camera) is able to resolve patterns down to the element 5 of the group 7, corresponding
to a line width of 2.46 µm (see Figure 5.4).
Figure 5.4: Image of the USAF target acquired with the HM rigid cystoscope
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5.2.3 Calibration of the magniﬁcation
We performed calibration measurement for the HM rigid cystoscopes, with diﬀerent settings and
instrumentation :
• two HM cystoscopes (HM1 and HM2) built with the same architecture. Due to the ster-
ilization process that last more than 12 hours at CHUV, we needed two cystoscopes to
acquire images in two diﬀerent patients on the same day.
• two endoscopic cameras : ﬁltered (F) and non-ﬁltered (NF). Filter was removed in one
PDD camera to acquire blue-backscattered images to target hemoglobin absorption peak
(see Appendix E).
• focusing position of the camera, controlled by a small handle on the camera side : extreme
counter-clockwise (CCW) , inﬁnite (inf), extreme clockwise (CW). While rotating the
cystoscope knob, it is possible to acquire sharp images regardless if the camera is in CW
or CCW position.
• the same test were done with diﬀerent illumination light (WL, PDD blue light, green light).
Since the results were similar, we present only the results acquired in WL.
For that purpose, we translated the cystoscope in a plane perpendicular to the USAF target
plane, the cystoscope being tilted to compensate the viewing angle (25◦). Images of the USAF
target were then acquired at diﬀerent distances (i.e. diﬀerent magniﬁcation). The translation of
lens groups (inside the cystoscope ocular) is such that for each distance endoscope-target (≈ s),
this cystoscope model features two diﬀerent magniﬁcation that yield a sharp image while rotating
the knob : (i) “moderate”-magniﬁcation (< 400×); (ii) “high”-magniﬁcation (400–650×).
In “moderate”-magniﬁcation, we can track the diameter of the endoscopic circular mask
(i.e. ﬁeld of view), which is varying with the knob position (Figure 5.5) and link it to the
magniﬁcation since we can identify patterns of known size on the USAF target (Figure 5.6).
2 mm0.8 mm0 mm
Zooming knob HM cystoscope
Viewing angle
USAF target
Distance to adjust focus
Figure 5.5: Images of the same USAF element acquired at diﬀerent distances. As one has to rotate the
knob to stay in focus, one can observe the varying size of the circular mask around the image.
Figure 5.6 plot the magniﬁcation vs. diameter of the endoscopic circular mask, which was
measured in pixels, assuming that the whole image is extracted from a full PAL frame (720×576
pixels2). The linear ﬁtting parameters (y = a · x + b) plotted in Figure 5.6 are summarized in
Table 5.2 for each measurement conﬁguration.
We observe ﬁrst that the camera model has little inﬂuence over the ai coeﬃcients, whereas
a small oﬀset appears in the bi coeﬃcients. The oﬀset can result from small diﬀerences in the
measurement setup (position of the camera, angulation, etc.). Second, the inﬁnite focusing lies
between the two extreme position CW and CCW (except for HM1 NF), which means in the
clinical environment that the camera should be focused at inﬁnity before being clipped to the
HM cystoscope. Even if the two HM cystoscopes are built with the same architecture, we observe
variations when the camera is focused at inﬁnity. This may result from optical imprecisions in
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Figure 5.6: Magniﬁcation vs. diameter of the endoscopic circular mask for the “moderate”-magniﬁcation
regime.
the manufacturing process. Even if the standard deviations are acceptable in this context, the
measurements variations may result from the following imprecisions: (i) circle size measurement
(circle edges were not clear steps, but rather diﬀuse borders); (ii) since the DOF is not equal to
zero, errors may occur in ﬁnding the minimal distance at which the USAF target is sharp.
CCW a1x + b1 Inﬁnite a2x + b2 CW a3x + b3
a1 b1 a2 b2 a3 b3 ai (µ ± σ) bi (µ ± σ)
HM1 NF 0.97 -304.52 0.86 -251.40 0.90 -242.57 0.91±0.06 -266.16±33.51
HM1 F 1.02 -357.92 0.89 -260.85 0.83 -201.24 0.95±0.06 -295.82±53.92
HM2 NF 0.97 -269.29 1.02 -276.48 0.94 -231.68 0.96±0.05 -249.92±23.53
HM2 F 1.05 -318.17 0.98 -262.55 0.96 -238.39 1.00±0.05 -273.04±40.91
mean 0.99 -305.55 0.94 -262.82 0.94 -245.33
std dev 0.05 48.28 0.08 10.34 0.02 16.21
Table 5.2: Summary of the linear ﬁtting coeﬃcients for the relationship magniﬁcation vs. diameter
In the “high”-magniﬁcation regime, the diameter is not changing signiﬁcantly, and we thus
tracked the knob position with the help of a graduation. Figure 5.7 shows the relationship
between the knob position and the magniﬁcation. The quadratic ﬁtting has been added for
visual support. One unit corresponds to a rotation of 360◦/14  26◦.
5.2.4 Flexible HM endoscopes : optical speciﬁcations
Based on the results of the explorative study (see Section 5.3) which enabled us to deﬁne the
optimal magniﬁcation (ranging 80–100 ×), our industrial partner decided to integrate the high
magniﬁcation feature into the tip of a ﬂexible endoscope. At this point, it should be noted that a
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Figure 5.7: Magniﬁcation vs. knob position for the “high”-magniﬁcation regime for the HM1 cystoscope
with the ﬁltered camera at inﬁnite position.
similar approach was conducted in bronchoscopy to characterize the false-positive lesions result-
ing from autoﬂuorescence bronchoscopy (see Chapter 11). The ﬁrst prototypes were designed
with a ﬁxed focal length, so that the only way to perform magniﬁcation cystoscopy/bronchoscopy
was to get closer to the mucosa within the DOF.
The developed prototypes (broncho and cysto) are built following the same architecture.
Only the CCDs and color settings are modiﬁed to account for the diﬀerent ﬂuorescence modes
(AF vs. PDD).
Figure 5.8 plots the relationship between distance to the mucosa and magniﬁcation. The
HM ﬂexible scopes were compared to the non-modiﬁed ﬂexible scopes for both broncho- and
cystoscope. The dashed lines (located at 2 mm and 4 mm, respectively) represent the shortest
theoretical limit of sharpness; the points measured below this limit are irrelevant, because the
patterns of interest were not well resolved at these distances/magniﬁcations. The exponential ﬁts
are presented for visual support. Interestingly, we can observe the same optical characteristics
for the two non-modiﬁed scopes, as well for the HM scopes.
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Figure 5.8: Magniﬁcation on a 19 inches monitor of the ﬂexible broncho- and cystoscopes
In the bladder, we were able to show that the last ﬂexible prototype developed for HM
cystoscopy has a limit of sharpness, which prevents the imaging of the vessel of interests. Indeed,
when comparing the performances of the HM rigid cystoscope (which served for the clinical study
present in Section 5.3) and the ﬂexible HM cystoscope, we observe a decrease in resolution. The
ﬂexible HM cystoscope can not focus on objects closer than 2 mm, resulting in a blurring of
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the vessels even if the magniﬁcation would be suﬃcient to identify them. Figure 5.9 shows the
direct comparison of the rigid and ﬂexible HM cystoscopes, illuminated with green light (see
Appendix E). We observe a similar ﬁeld of view, but the resolution is higher with the rigid
cystoscope. The white arrows shows the small capillaries that help to discriminate FP from TP
on ﬂat lesions, but they remain undetectable with the ﬂexible HM scope.
Figure 5.9: Comparison of the ﬂexible and rigid HM cystoscopes. The white arrows shows the
capillary vessels that help to discriminate FP from TP on ﬂat lesions.
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Abstract: Fluorescence imaging for detection of non-muscle invasive bladder cancer is based
on the selective production and accumulation of ﬂuorescing porphyrins, mainly protoporphyrin
IX (PpIX), in cancerous tissues after the instillation of Hexvix R©. Although the sensitivity of
this procedure is very good, its speciﬁcity is somewhat limited due to ﬂuorescence false positive
sites. Consequently, magniﬁcation cystoscopy has been investigated in order to discriminate false
from true ﬂuorescence positive ﬁndings. Both white light and ﬂuorescence modes are possible
with the magniﬁcation cystoscope, allowing observation of the bladder wall with magniﬁcation
ranging between 30× for standard observation, and 650×. The optical zooming setup allows
adjusting the magniﬁcation continuously in situ. In the high magniﬁcation regime, the smallest
diameter of the ﬁeld of view is 600 microns and the resolution is 2.5 microns, when in contact with
the bladder wall. With this cystoscope, we characterized the superﬁcial vascularization of the
ﬂuorescing sites in order to discriminate cancerous from non-cancerous tissues. This procedure
allowed us to establish a classiﬁcation based on observed vascular patterns. 72 patients subject
to Hexvix R© ﬂuorescence cystoscopy were included in the study. Comparison of HM cystoscopy
classiﬁcation with histopathology results conﬁrmed 32/33 (97%) cancerous biopsies, and rejected
17/20 (85%) non-cancerous lesions.
Abbreviations: ALA aminolevulinic acid, HAL hexyl ester of aminolevulinic acid, PpIX proto-
porphyrin IX, WL white light, HM high magniﬁcation, TP true positive, FP false positive, TN
true negative, FN false negative
Keywords: non-muscle invasive bladder cancer, ﬂuorescence cystoscopy, PDD, high magniﬁca-
tion, Hexvix R©, vessel patterns, vasculogenesis, angiogenesis
5.3.1 Introduction
Bladder cancer is the fourth most common
cancer among men and the eighth most com-
mon malignancy in women in the Western
world [Kirk05]. Urothelial cell carcinoma com-
prises 90% to 95% of all bladder cancers,
with about 70% found initially as non-muscle-
invasive bladder cancer and the remainder as
invasive cancer [Oost01]. Flat lesions, such as
high grade dysplasia or carcinoma in situ, are
associated with a high risk of invasive progres-
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sion, and an even higher recurrence rate (50-
85%) [Drol05]. Therefore, there is a need for a
reliable early detection method.
Over the past decades, white light (WL)
cystoscopy was established as the standard di-
agnostic procedure to detect early bladder can-
cer. However, WL may lead to missing le-
sions, that are diﬃcult or impossible to visual-
ize [Joch05]. To overcome this limitation, ﬂu-
orescence cystoscopy based on aminolevulinic
acid (5-ALA) and its derivatives has now been
well established. The ﬂuorescence cystoscopy
is performed using blue-violet light that excites
the red ﬂuorescence of the porphyrins, mainly
protoporphyrin IX (PpIX) [Kenn90, Kenn92].
In the biosynthesis of heme, endogenous 5-
ALA is a natural precursor of the ﬂuorescing
PpIX [Uehl00]. The subsequent conversion of
PpIX into heme is relatively slow. The appli-
cation of exogenous ALA-derivatives, includ-
ing Hexvix R©, can thus lead to accumulation
of signiﬁcant concentrations of ﬂuorescing por-
phyrins. The latter are selectively produced
and accumulated in these early lesions upon
the instillation of the bladder with a solution
of Hexvix R© during about one hour [Jich03b,
Jich08]. With this method, the sensitivity
of cystoscopy for ﬂat lesions that are over-
looked in white light is improved to nearly
100% [Jich03b, Jich08, Schm04]. Thus, ﬂuores-
cence cystoscopy will reveal areas in the blad-
der that are suspicious for ﬂat lesions (dyspla-
sia, pTis) or small papillary tumor (pTa, pT1)
that can not always easily be seen with WL cys-
toscopy [Gros07, Frad07]. Furthermore, it has
been shown that ﬂuorescence cystoscopy re-
duces the tumor recurrence rate, probably due
to a more complete resection [Dani05, Witj07,
Denz07, Babj05].
Fluorescence cystoscopy has a high sensitiv-
ity, but still yields a relatively high percentage
of ﬂuorescence false positive lesions, typically
39% [Gros07, Frad07]. Histopathological diag-
nosis of the false positives showed that false
ﬂuorescence mostly occurred in tissues with
a high cell turnover such as metaplasia, hy-
perplasia, and chronic inﬂammation [Jich03b].
In 2005, the European Association of Urol-
ogy (EAU) has approved the ﬂuorescence cys-
toscopy as standard method for the detection
of non-muscle invasive bladder cancer [van 05].
The FDA positively reviewed this method as a
new drug application for Hexvix R© in 2009.
There is clear evidence that the features of
angiogenesis (such as microvessel density) and
expression of angiogenic factors are related to
adverse outcomes in bladder cancer [Char06].
Reiher et al. et al. conﬁrmed the strong asso-
ciation of microvessel density with the well es-
tablished prognostic factors of grade and stage
in non-muscle invasive bladder cancer [Reih02].
It is likely that developing new imag-
ing capabilities for vascular imaging will also
facilitate discriminating mucosal changes in
the bladder. Vascular patterns, like tor-
tuous vessels and vessel loops, are used to
identify neoplasia in several organs including
the bronchi, and the upper and lower gas-
trointestinal tract [East08, Kuma06, Shib02,
Shib03]. In bronchoscopic studies, Shibuya et
al. state that conventional white light broncho-
scopes observe only increased redness and local
swelling, whereas high magniﬁcation broncho-
scopes enable the vascular network to be visual-
ized in the bronchial mucosa [Shib02, Shib03].
Morphological features such as vessel growth
and complex networks of tortuous vessels help
these authors to identify this cancerization pro-
cess [Shib03]. Indeed, they were able to dis-
tinguish between inﬂammatory tissue and neo-
plastic lesion in the bronchi by observing the
complex neo-vascular structure and tortuosity.
Diﬀerent group showed that a zooming obser-
vation allows to observe changes in the in-
trapapillary capillary loops in the esophagus,
including dilatation, weaving, changes in cal-
iber and diﬀerences in shape [Kuma06, Inou97].
They also observed that the tumor vessels were
rearranged at the surface of the tumor. Sim-
ilarly, East el al. deﬁned the vascular pat-
tern intensity, which is directly related to the
microvessel density, in combination with the
Kudo pit pattern classiﬁcation, to assess the
malignancy of small colonic polyps [East08].
With the development of high magniﬁ-
cation (HM) cystoscopy presented in this
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manuscript, it is possible to visualize alter-
ations of the vascular organization at the sur-
face of the bladder mucosa. Thanks to its
optical zoom, our cystoscope allows to adjust
the magniﬁcation continuously between the low
and high magniﬁcation regimes by turning a
knob and changing the distance between the
cystoscope tip and the mucosa. As compared
to cellular imaging systems, the operator is able
to ﬁrst localize the area of interest with the help
of ﬂuorescence cystoscopy, and then to zoom in,
to characterize the superﬁcial vascularization,
using one and the same device. Therefore, HM
examination ﬁts easily into the clinical routine,
as it doesn’t require much extra time and in-
strumentation.
The present study evaluates this vascular
imaging technology on patients that were sub-
ject to routine ﬂuorescence cystoscopy. To our
knowledge, this is the ﬁrst time that vascular-
ization patterns are used as a discrimination
criterion on ﬂuorescence positive spots in the
bladder. A ﬂexible videoendoscope will be de-
signed based on the results of this study in or-
der to allow an observation of the whole bladder
in both low and high magniﬁcation regimes.
5.3.2 Materials & Methods
High magniﬁcation setup
The bladder was ﬁrst inspected with a con-
ventional ﬂuorescence cystoscope to localize
the ﬂuorescence positive sites under blue-violet
light. The accessible ﬂuorescing sites were
then observed with the rigid magniﬁcation
cystoscope (Lumina Microview 25◦, Richard
Wolf GmbH, Germany). This cystoscope (see
Figure 5.1) was ﬁrst operated in a “low-
magniﬁcation” regime to identify the ﬂuores-
cence positive lesions in ﬂuorescence mode, and
then in a HM regime to characterize the vascu-
larization under white light reﬂectance mode.
This approach is quite convenient, since it en-
ables to observe the bladder wall with magniﬁ-
cation ranging continuously between 30× and
650× under ﬂuorescence or white light obser-
vation, without changing the cystoscope.
The HM cystoscope has an external diam-
eter of 4 mm and is equipped with a knob al-
lowing alteration of the magniﬁcation in situ.
This continuous range is achieved by simulta-
neously adjusting the device’s focal length and
the cystoscope-tissue distance. The magniﬁca-
tion is deﬁned here as the ratio between the
sizes of the object on the image displayed on a
19 inches monitor and the corresponding real
object, given that our conventional cystoscope
yields a 30x magniﬁcation. The present de-
vice is able to resolve patterns down to the
element 5 of the group 7 on the USAF tar-
get 1951 (line width: 2.5µm, corresponding to
200 lp/mm, Figure 5.4).
Endoscopic image classiﬁcation
The whole procedure was recorded on a
DV recorder (DVCAM DSR 20MDP, Sony
Corporation, Japan) and digitized using the
IEEE1394 connection between the DV recorder
and a portable PC. In an explorative prelimi-
nary study (data not shown), individual frames
were extracted from the video sequences, and
image classiﬁcation was performed oﬄine based
on visual quantiﬁcation of the vessel patterns.
Images were classiﬁed in ﬁve categories: A)
“linear”, i.e. “normal”, vascularization B)
edema and/or vessel thickening C) tortuous
vessels and/or vessel loops D) dense mesh
and/or disorganized network E) no vascular-
ization visualized while probing the lesion. In
the latter, the images were excluded from the
statistics. Typical HM images on ﬂat ﬂuores-
cence positive sites are shown in Figure 5.10
according to the classiﬁcation.
In the study presented here, the vascular-
ization patterns were classiﬁed intraoperatively
based on the categories (A to E). DV recording
was only used for documentation purposes.
Patient population
78 patients (54 men, 24 women; mean age 67;
range 18-85) with suspected or veriﬁed blad-
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Figure 5.10: High magniﬁcation endoscopic images acquired under white light.
Non-malignant: A) normal vessels B) edema and vessel thickening
Malignant: C1) tortuous vessels C2) vessel loops D1) dense mesh D2) disorganized network
der cancer (by means of positive urinary cytol-
ogy, prior cystoscopy or a history of urothelial
cancer) were enrolled between September 2007
and August 2009. They underwent ﬂuorescence
cystoscopy with Hexvix R© at the CHUV Uni-
versity Hospital (Lausanne, Switzerland), un-
der loco-regional or general anesthesia. Pa-
tients were informed about the beneﬁts and
risks of the ﬂuorescence procedure and the
study was acknowledged by the local ethics
committee.
Endoscopic procedure
Hexvix R© (GE Healthcare, USA) was prepared
by reconstitution of 100 mg of hexaminole-
vulinate (HAL) hydrochloride powder, equiv-
alent to 85 mg of HAL, in 50 ml phosphate
buﬀered saline. Following hospitalization, pa-
tients received an intravesical instillation of
50ml (8mM) solution of Hexvix R© through a
standard catheter for about one hour. After
emptying of the bladder, inspection and map-
ping of all lesions and suspicious areas was done
by an urologist with experience in this method.
Imaging system
The endoscopic ﬂuorescence imaging system
basically consists of a ﬁltered light source
and a ﬁltered endoscopic camera, as shown
schematically in Figure 5.11. Fluorescence cys-
toscopy was performed using a commercial sys-
tem (Richard Wolf GmbH, Knittlingen, Ger-
many), which allowed bladder wall inspection
with both white light reﬂectance and blue-
violet light excited ﬂuorescence. The endo-
scopic light source is based on an IR ﬁltered
300 W Xenon lamp (Richard Wolf GmbH, Ger-
many) equipped with a ﬂip-ﬂop ﬁlter holder
containing a light-attenuation grid for conven-
tional white light illumination and a blue-violet
interference ﬁlter (390-440 nm) to excite the
ﬂuorescence of the porphyrins, mainly PpIX.
The camera collects the red ﬂuorescence and
the tissue autoﬂuorescence through a long-pass
ﬁlter (cut-on wavelength 450 nm). A foot
switch allows rapid changing between white
light illumination and blue-violet ﬂuorescence
excitation. The source light is delivered to the
cystoscope optics by a liquid light guide.
Histopathological analysis
Each ﬂuorescing positive site was cold-biopsied
and/or resected. Tissue samples were ﬁxed
in formalin and examined by an experienced
pathologist who was blinded to the high-
magniﬁcation description of the vasculariza-
tion. Urothelial carcinomas were graded ac-
cording to the World Health Organization
(WHO) 1973 classiﬁcation [Most73] and to the
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Figure 5.11: Fluorescence cystoscopy setup.
consensus WHO/International Society of Uro-
logical Pathology (ISUP) 1998 [Epst98]. Flu-
orescence positive biopsies were then grouped
into two classes: non-malignant (normal, meta-
plasia, hyperplasia, chronical inﬂammation),
malignant (dysplasia, pTa, pT1, pT2, pTis).
5.3.3 Results
Histopathology
A total of 179 biopsies taken on ﬂuorescence
positive (HAL+) spots were biopsied. They
were macroscopically classiﬁed as being 111
ﬂat, 51 exophytic, 17 scar tissues. In this study,
we retained the macroscopic description, i.e.
ﬂat vs. exophytic, given by the operator in-
traoperatively, even if it diﬀers from the patho-
logical description. 10 pTa and 4 pT1 appeared
ﬂat, whereas 3 pTis and 1 dysplasia appeared
exophytic.
The regions of interest that initially tested
as ﬂuorescence positive (HAL+) or white light
positive (WL+) but upon pathological anal-
ysis were described as non-cancerous biopsies
were characterized as false positives (HAL/FP
and WL/FP, respectively). Similarly, HAL+
and WL+ regions of interest that demonstrated
cancerous biopsies were characterized as true
positives (HAL/TP and WL/TP, respectively).
Table 5.3 shows the histopathological anal-
ysis of the 179 HAL+ biopsies, detected by
Hexvix R© and WL cystoscopy, respectively.
The additional columns list how many biop-
sies contained inﬂammatory tissue. Table 5.4
shows the same data for ﬂat lesions only.
We can observe that ﬂuorescence cys-
toscopy is much more sensitive to early lesions
than WL cystoscopy (see Table 5.3), even in
this case of a very experienced WL endoscopist.
Indeed, 39 additional lesions were discovered
with the help of Hexvix R© cystoscopy. Table 5.3
shows that inﬂammation is present in 41/68
(61%) of the HAL/FP, whereas it is only the
case in 17/111 (15%) of the HAL/TP. Table 5.4
shows that the same observation is valid for ﬂat
lesions; inﬂammatory tissue is present in 29/53
(55%) of the HAL/FP, whereas it is only the
case in 12/58 (21%) of the HAL/TP. 35 addi-
tional ﬂat lesions were discovered with the help
of Hexvix R© cystoscopy. It is interesting to note
that no inﬂammatory tissue was found in the
pT1 and pT2 cancers.
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No. detected on HAL+ sites
HAL+ with inﬂam. WL+ with inﬂam.
dysplasia 18 7
111 HAL/TP
8 5
72 WL/TP
pTa (G1-G3) 43 3 33 1
pT1 (G1-G2) 12 0 11 0
pT2 4 0 4 0
pTis 34 7 15 4
non-malignant 68 41 68 HAL/FP 27 17 27 WL/FP
Total 179 58 99 27
Table 5.3: Histopathological analysis of the 179 ﬂuorescence positive (HAL+) lesions
No. detected on HAL+ sites
HAL+ with inﬂam. WL+ with inﬂam.
dysplasia 15 5
58 HAL/TP
5 3
23 WL/FP
pTa (G1-G3) 10 1 5 0
pT1 (G1-G2) 4 0 3 0
pT2 0 0 0 0
pTis 29 6 10 3
non-malignant 53 29 53 HAL/FP 16 8 16 WL/FP
Total 111 58 99 27
Table 5.4: Histopathological analysis of the 111 ﬂat ﬂuorescence positive (HAL+) lesions
High magniﬁcation descriptive analysis
Among the 179 biopsies, 58 HAL+ sites from
which 45 ﬂat lesions were observed with high
magniﬁcation in order to try to decrease the
number of FP, and thus the number of biop-
sies taken. The HM clinically observed blood
vessels were classiﬁed into four categories, in-
cluding: A) normal or linear vascularization;
B) edema and vessel thickening; C) tortuous
vessels / vessel loops; D) dense mesh / dis-
organized network. Biopsies that were clas-
siﬁed as cancerous and could be attributed
with either HM classiﬁcations A and B are re-
ferred to as HM false-negative (HM/FN), while
HM classiﬁcations C and D are referred to as
HM true-positive (HM/TP). Conversely, biop-
sies that were classiﬁed as non-cancerous and
could be attributed with either HM classiﬁ-
cations A and B are referred to as HM true-
negative (HM/TN), while HM classiﬁcations
C and D are referred to as HM false-positive
(HM/FP).
Table 5.5 summarizes the result of the clas-
siﬁcation analysis of the 58 HAL+ lesions ob-
served with HM: 36 true positive (HAL/TP)
and 22 false positive (HAL/FP). With the help
of HM cystoscopy, 32/33 (97%) HAL/TP le-
sions with clinical in situ visualized vascular-
ization could be conﬁrmed and 17/20 (85%)
HAL/FP lesions with a visible vasculariza-
tion could be rejected. The cancerous lesion
that was not conﬁrmed by our HM method
(HAL/TP–HM/FN) was inﬁltrated by a sar-
comatoid carcinoma. Conversely, the 3 le-
sions with vascular irregularities that were de-
scribed as non-cancerous by the histopathol-
ogist (HAL/FP-HM/FP) had the following
histology: granulomatous inﬂammation, von
Brunn nests that mimic urothelial carcinoma
and lymphoid inﬁltration, respectively.
Table 5.6 summarizes the result of the vi-
sual classiﬁcation of the 45 ﬂat HAL+ le-
sions observed with high magniﬁcation: 24
true positive (HAL/TP) and 21 false positive
(HAL/FP). With the help of HM cystoscopy,
22/22 (100%) HAL/TP ﬂat lesions with visu-
alized vascularization could be conﬁrmed and
17/19 (89.5%) HAL/FP lesions with a visible
vascularization could be rejected.
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HM descriptive analysis 36 HAL/TP 22 HAL/FP
non-malignant (A) linear vascularization 0 1 HM/FN 15 17 HM/TN(B) edema and vessel thickening 1 2
non-malignant (C) tortuous vessels / vessel loops 22 32 HM/TP 2 3 HM/FP(D) dense mesh / disorganized network 10 1
Total 33 20
discarded (E) no visualized vascularization 3 2
Table 5.5: Visual classiﬁcation of the 58 ﬂuorescence positive lesions observed with high magniﬁcation:
36 true positive (HAL/TP) and 22 false positive (HAL/FP).
HM descriptive analysis of the ﬂat lesions 24 HAL/TP 21 HAL/FP
non-malignant (A) linear vascularization 0 0 HM/FN 15 17 HM/TN(B) edema and vessel thickening 0 2
non-malignant (C) tortuous vessels / vessel loops 12 22 HM/TP 2 2 HM/FP(D) dense mesh / disorganized network 10 0
Total 22 19
discarded (E) no visualized vascularization 2 2
Table 5.6: Visual classiﬁcation of the 45 ﬂat ﬂuorescence positive lesions observed with high magniﬁca-
tion: 24 true positive (HAL/TP) and 21 false positive (HAL/FP).
5.3.4 Discussion
Over the last years, ﬂuorescence cystoscopy
has been established as standard method for
early bladder cancer detection in the Euro-
pean Union [Witj07, Hall07]. Fluorescence
cystoscopy is particularly useful at improv-
ing the detection of ﬂat lesions, such as pTis
and pTa [Jich03b]. However, this technique
has been related to a relative high-number of
false-positive sites. Areas with a higher cellu-
lar turnover like metaplasia, hyperplasia, and
residual inﬂammation also accumulate PpIX
and in that sense ﬂuoresce similarly to malig-
nant tissue [Witj07]. Grimbergen et al. showed
that several factors including drug uptake, and
enzymatic activity have been known to inﬂu-
ence the production and conversion or deple-
tion of PpIX after exogenous application of the
ALA or ALA-esters [Grim03]. Jichlinski et al.
speculated that false positives can arise, in cer-
tain speciﬁc cases, from oblique illumination of
the mucosa if the distal end of the endoscope is
too close to the bladder wall [Jich97]. Indeed,
when the tissue is illuminated tangentially, it
may produce a high level of ﬂuorescence on
the normal mucosa, particularly at the bladder
neck and the trigone [Zaak08]. Additionally,
bladder mucosa exposed to intravesical therapy
in the weeks prior to ﬂuorescence cystoscopy
could also exhibit a higher rate of false-positive
lesions [Grim03, Drag10]. Draga et al. also
showed that the false-positive rate decreases
during the ﬁrst 12 weeks after the latest re-
section [Drag09].
In this study, we aimed to diﬀerentiate vas-
cular patterns between non-malignant, false-
positive, and malignant, true-positive changes
in the bladder. Several groups have previ-
ously developed systems able to acquire im-
ages at the cellular level in the gastro-intestinal
tract [Wang07], even in the bladder [Sonn09],
but it appears that this approach has several
limitations, particularly the microscopic ﬁeld
of view and the need for additional contrast
dyes [Sonn09]. Scanning of the whole organ
is thus not realistic in a clinical environment.
Therefore, we have focused our research on the
characterization of vascular patterns on suspi-
cious sites already localized by Hexvix R© ﬂu-
orescence cystoscopy. In this conﬁguration, a
ﬂuorescent site can easily be characterized with
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high magniﬁcation by turning the knob, ad-
justing the distance and switching to the ap-
propriate illumination light. This approach is
very convenient since it allows visualization of
the bladder using ﬂuorescence and white light,
both in the low and high magniﬁcation regime
without changing the cystoscope.
Bladder cancer is often multi-focal in na-
ture. In this study, due the bladder ovoid ge-
ometry, this rigid cystoscope prototype with
small viewing angle (25◦) doesn’t allow instru-
mental access to all parts of the bladder. In
particular, the anterior wall and dome could
not be imaged easily. Thus, in the statistics,
the number of sites that are observed with the
HM cystoscope is much smaller that the to-
tal number of ﬂuorescence positive sites ob-
served. We reviewed both ﬂat and papillary
ﬂuorescence positive sites. In each papillary
tumor, we have observed the so-called intra-
papillary loops, where the capillaries appear
like small rings of about 50µm in diameter close
to the surface. The shape of the vessels was in
good agreement with those observed in other
organs [Shib02].
All cystoscopy results can be more or less
aﬀected by the urologist learning curve. In par-
ticular, the rejection of false-positives highly
depends on the physician’s experience. The
non-perfect speciﬁcity of the well-established
drug Hexvix R© has also been observed in larger
HAL phase III studies [Gros07, Frad07]. Our
false-positive rate 68/178 (38%) is in fact in
good agreement to what has been obtained in
the latter (39%). In the present study, HAL
cystoscopy detects 57% (107/68) more non-
muscle invasive lesions such including dyspla-
sia, pTa, pT1, and pTis. Although there is
an increase in the number of false-positive le-
sions, this clearly indicates a major advantage
of HAL cystoscopy vs. conventional WL cys-
toscopy, because it will allow a more complete
resection [Babj05].
The three HM/FP (see Table 5.5) that
are not cancerous lesions are tissues of identi-
ﬁed types that may also induce modulation of
the superﬁcial vascularization that presumably
supports cellular changes at the surface of the
urothelium [Roma03]. Conversely, no vascu-
lar alteration could be observed with our setup
on the HM/FN lesion, even if it was protrud-
ing out of the bladder wall, probably because
this pathology was not originated in the blad-
der mucosa.
Our results were based on the urologist sub-
jective appreciation, whereas an image analysis
method for quantifying blood vessels could be
helpful to aim at greater objectivity. Experi-
ments on small blood vessels in the chorioal-
lantoic membrane (CAM) model have led to
the development of a multistep mathemati-
cal procedure to obtain a skeleton represen-
tation of the vessels and capillaries [N.-S10].
Similarly, software analysis of retinal vascula-
ture images highlighted the potential of deﬁn-
ing site-based parameters, such as local ves-
sel diameter, fractal dimension, and tortuos-
ity [Vick09]. We are currently working at the
integration of these quantiﬁcation algorithms
in our procedure. This may be of interest to
assess the status of sites appearing positive dur-
ing ﬂuorescence cystoscopy. The next genera-
tion of prototypes with a better image quality
may help algorithms to run with fewer artifacts.
Table 5.5 & 5.6 illustrates that HM im-
age acquisition may be impaired by missing
some vascular patterns while looking at the ﬂu-
orescence positive sites (5 for all lesions, 4 for
ﬂat lesions). Recent studies have targeted the
hemoglobin absorption peaks using the narrow-
band imaging technology [Herr08]. At present,
we are investigating the potential use of se-
lected excitation wavelengths (data not shown)
to improve the contrast between the vessels
and the surrounding mucosa. This may help
to point out the optimal vessels (depth and
size) to discriminate FP from TP ﬂuorescence
positive sites. Furthermore, an increase in the
cystoscope contact pressure may lead to a de-
crease in the superﬁcial blood ﬂow, and thus
a decrease in reﬂectance light absorption, and
hence the vessels close to the surface may dis-
appear from the ﬁeld of view. A spacer may be
added to the cystoscope in the future to avoid
this eﬀect.
The observations made on exophytic le-
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sions reveal a distinct pattern of vasculariza-
tion, with loops sprouting along the papillary.
In conjunction with a histochemical analysis of
the biopsies, this approach may serve as a vi-
sual method for staging and grading of the ex-
ophytic bladder carcinomas.
The rigid cystoscope used in the present
study prevents the visualization of the proximal
part of the bladder wall, and has evident draw-
backs regarding bladder accessibility. However,
this cystoscope prototype helped us to demon-
strate the proof-of-principle of this vessel char-
acterization technique to identify false-positive
lesions. This HM cystoscope approach can also
be used for the characterization of sites suspi-
cious under white light, or detected by other
diagnostic techniques, including hypericin ﬂu-
orescence cystoscopy [Bhuv10].
In summary, we claim that this “detect-
and-characterize” procedure based on a high-
magniﬁcation cystoscope is very convenient
since no change of endoscope is required to
switch between the ﬂuorescence detection and
tissue vascular characterization modes. There-
fore, with a rejection rate (97%) of FP lesions,
HM is likely to be a non-invasive, simple and
convenient approach to reduce the number of
biopsies and improve patient management.
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5.4 Evaluation of the vascular skeletonisation
The study of section 5.3 describes the classiﬁcation of vascular patterns based on high magniﬁ-
cation cystoscopy. As such, we acknowledge that the speciﬁcity and sensitivity depends on the
operator, as it is the case in many diagnostic methods routinely used in the clinics. However,
during this study, we observed that most of the vascular patterns could be correctly classiﬁed
after only a short learning period (2–3 HM cystoscopies).
This section estimated whether the whole information that allows the observer to classify the
vessel patterns in Section 5.3 is fully contained in the skeleton or not. Indeed, before spending a
lot of time in implementing various image processing algorithms to extract the vessels from the
background, it was worthwhile to see if the end result would contain the relevant information.
In addition, this preliminary study aimed to identifying the critical features that should be used
to discriminate the false-positive from the true-positive ﬂuorescence areas.
We present here an oﬄine classiﬁcation study, in which 11 ﬁrst-time observers were asked to
classify 27 endoscopic images and to choose the most appropriate description for the vascular
patterns they observed in the presented 27 HM pictures: linear, thickening, tortuous, dense
network or loops (see Figures 5.14 & 5.15). These 27 images were acquired on areas, that were
subsequently biopsied (11 non-cancerous, 16 cancerous). With these 27 images, the observers
(blinded to the histopathological results) were told to deﬁne two image sets with 11 False-Positive
(linear, thickening) and 16 True-Positive (Tortuous/Dense Network/Loops). This classiﬁcation
is the same one as that used in the publication (see Section 5.3.2). All images were acquired with
WL illumination, except images No. 5, 10, 21, 25 that were acquired with green light illumination
(derived from the spectral optimization described in Appendix E). The great variations in color
appearance is due to the diﬀerent tissue backscattering properties.
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In a second step, we manually segmented the 27 images of interests. With the pen/bucket
tool in ImageJ/Photoshop (NIH and Adobe Inc.), we divided the RGB image into two pixel
classes : (i) vessel (ii) tissue. It resulted in black&white (BW) images, that are also depicted
in Figures 5.14 & 5.15. The same 11 observers were asked to classify the 27 skeletons with the
same criteria.
The percentage of false classiﬁcation (PFC) is computed as the number of wrong answers
over the total number of answers. For each image couple in Figure 5.14&5.15, the numbers in
red indicate the PFC either for the original image or its skeleton (if = 0).
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Figure 5.12: Percentage of false classiﬁcation of the 27 HM images (original & skeleton)
Figure 5.12 shows the PFC for each image couple (original & skeleton). This small observer
population (n = 11) reached an accuracy of 94% for original endoscopic images, which shows
that a correct classiﬁcation is likely not to be observer-dependent.
The skeletons are more diﬃcult to classify than the original images (see Figure 5.12). Hence,
such a visual classiﬁcation based on the skeletons only would lead to a higher PFC. Indeed, the
average error was higher for the skeletons (17.8%) than for the original images (5.7%). This
may be explained by at least four factors :
• the depth information is lost in skeletons. Indeed, on conventional images, it is fairly easy
to evaluate if a vessel is coming to the surface and entering at an other spot. In others
words, if the vessel is fully contained in a plane parallel to the surface, or connected to
other with vertical bridges.
• the layered structure of the urothelial vasculature is also lost. Indeed, when acquiring
images in vivo, it is fairly easy to identify the diﬀerent vasculature layers, due to the fact
that some are altered when touching the surface with the endoscope (superﬁcial vessels),
whereas some remains unaﬀected (deeper vessels). In a skeletonized image, one perceives
only the 2D network without any information about how the layered architecture of the
vasculature.
• in the skeleton, the vessels appear as a uniform black tube, whereas in the original image,
the vessels do not have a uniform cross-section and their proﬁle can also contain information
for the operator.
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• in the skeleton, only the vessel tree is visible. All other structures (bubbles, mucosa
irregularities, . . . ) are erased by the segmentation procedure. This gives a hint that
extra-vascular patterns may also contain relevant information for the classiﬁcation.
In Figure 5.10, we observe three classes of images : i) 0% PFC (3, 4, 7, 8, 12, 13, 16, 19, 23, 24,
27) ; ii) misclassiﬁcation of original and/or skeleton (1, 9, 15, 17, 21, 25, 26); iii) only skeleton
misclassiﬁcation (2, 5, 6, 10, 11, 14, 18, 20, 22). Images with low density of vessels (7, 9, 12,
19, 23, 27) were classiﬁed mostly as TP (which is correct except for 9). This may be explain by
the fact that small capillary loops appear as sparse vessel patterns. Images with large thickened
vessels (5, 8, 13, 26) were mostly classiﬁed as FP. Vessel edema were often found on inﬂammatory
mucosa.
Table 5.7 shows the statistics for the classiﬁcation of the images (27 images for 11 observers
correspond to a total of 297 occurrences).
a) Classiﬁcation for original images
Histopathology
Cancer No cancer
Classiﬁcation Positive 173 14Negative 3 107
b) Classiﬁcation for skeleton images
Histopathology
Cancer No cancer
Classiﬁcation Positive 142 19Negative 34 102
Table 5.7: Classiﬁcation vs. Histopathology for both original and skeleton images.
Table 5.8 shows the compared values for sensitivity, speciﬁcity, positive and negative pre-
dictive value, likelihood ratio positive and negative. These terms are deﬁned in Table 2.6. It
appears clearly that the classiﬁcation with the original image is more sensitive and more speciﬁc.
It also displays a higher PPV and higher NPV.
Sensitivity Speciﬁcity PPV NPV LR + LR−
Original images 0.983 0.884 0.925 0.973 8.496 0.019
Skeleton images 0.814 0.843 0.887 0.75 5.185 0.22
Table 5.8: Summary of the statistical values for the classiﬁcation procedure.
Figure 5.13 shows the post-test probability for both original and skeleton images. The larger
the area between the blue and orange curves, the better the classiﬁcation method, meaning that
the classiﬁcation based on the original images has better prediction capabilities.
Interestingly, the images acquired with green backscattered (GBS) light yield a higher PFC
for the skeletons than the conventional images. Since, the small vessels are better resolved with
GBS, the skeletons are appearing with a higher density of vessel, sometimes leading the observers
to classify them as “dense mesh”.
The “hand-made” segmentation procedure may suﬀer from some limitations, although it is
often regarded as the “gold standard” for each vessel segmentation algorithms [M.-P07b, Sale10].
Since skeletons are more convenient to process with an automated image characterization pro-
cedure (vessel branching, areas, fractal dimension, . . . ), we also implemented an automated
version of the skeletonisation process (see Section 5.5.1).
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Figure 5.13: Plot of the post-test probability for both original and skeleton images.
In conclusion, based on the results of the visual classiﬁcation, we can say that some visual
information is lost after image skeletonisation. However, skeletonisation yields a binary image,
that is best suited for image morphologic analysis. The latter analysis yields some non-visual
parameters (number of branches, vessel mean length, fractal dimension) that can also be dis-
criminant on ﬂuorescence positive lesions.
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Figure 5.14: Atlas of HM images (original images and corresponding skeletons)
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Figure 5.15: Atlas of HM images (original images and corresponding skeletons)
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5.5 Image processing and analysis
We have shown in the clinical study (presented in Section 5.3) that the classiﬁcation of vessel
architecture may lead to a very good rejection of the false-positive lesions. However, it still
relies on the physician learning curve, since it is only a qualitative description. In order to
make this discrimination method even more robust, we made several attempts to implement
a reliable and quantitative method of vessel description, that would be valuable for the early
detection and characterization of morphological changes. This will allow the identiﬁcation of
the discrimination features.
In this section, we will present two methods. First, we will implement vessel segmentation
algorithm to extract the vessel information from the background (see Section 5.5.1), and then
we will try to extract global image information without the tedious extraction of each individual
vessel (see Section 5.5.2).
5.5.1 Vessel segmentation
Over the last years, vessel architecture has been studied over time to diagnose some disease
(e.g. in the eye). Retinal blood vessels have been shown to change in diameter, branching
angles or tortuosity, as a result of a disease, such as hypertension [Stan95, Wong05a], onset of
diabetes or diabetic renal disease [Wong05b]. Because of its diverse roles in key physiological and
pathological processes, angiogenesis is an important area of medical research, with a considerable
number of angiogenic and anti-angiogenic drugs currently undergoing clinical trials. Santos et
al. developed an integrated angiogenesis screening system, with vessel segmentation as part of
the work ﬂow [Sant08].
In this section, we present a method to automatically segment blood vessels based upon
multi-scale feature extraction. The input images are conventional endoscopic images converted
to grayscale (intensity images). This method overcomes the problem of variations in contrast
inherent in the endoscopic images by using the ﬁrst and second spatial derivatives of the inten-
sity image that gives information about vessel topology. Thus, this approach also enables the
detection of blood vessels of diﬀerent widths, lengths and orientations.
This algorithm is a multiple pass region growing procedure, limited by the gradient informa-
tion and the maximum principal curvature. It progressively segments the blood vessels using fea-
ture information together with spatial information about the eight-neighboring pixels, obtaining
in this way a segmented binary image. This method was adapted from a retinal image processing
algorithms, known as multi-scale analysis, developed by Martinez et al. [M.-P07b, M.-P07a].
5.5.1.1 Feature extraction
Since the blood vessels present in the bladder have diﬀerent sizes, it is convenient to introduce a
measure that varies within a certain range of scales. Multi-scale techniques have been developed
to provide a way to isolate information about objects in an image by looking for geometric
features at diﬀerent scales. Under this framework representing information at diﬀerent scales is
deﬁned by convolving the original image I(x, y) with a Gaussian kernel G(x, y; s) of variance s2:
Is(x, y; s) = I(x, y) ⊗ G(x, y; s) where G(x, y; s) = 12πs2 e
−x2+y2
s2 and s is a length scale factor
The eﬀect of convolving an image with a Gaussian kernel is to suppress most of the structures
in the image with a characteristic length less than s. The use of Gaussian kernels to generate
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multiscale information ensures that the image analysis is invariant with respect to translation,
rotation and size [Koen84].
To extract geometric features from an image, a framework based on diﬀerentiation is used.
Derivatives of an image can be numerically approximated by a linear convolution of the image
with scale-normalized derivatives of the Gaussian kernel.
∂nIs(x, y; s) = I(x, y) ⊗ sn∂nG(x, y; s) where n indicates the order of the derivative.
The normalization by scale makes the derivatives dimensionless which means that the derivatives
will have the proper behavior under spatial rescaling of the original image and that structures
at diﬀerent scales will be treated in a similar manner.
Detection of tube-like structures using multiscale approach has been carried out by other
researchers [Sato97, Lore97]. The main purpose of these works was to develop a line-enhancement
ﬁlter based on the eigenvalue analysis of the Hessian matrix. To make a proper feature extraction,
we will use these algorithms in combination with a gradient information to segment blood vessels
rather than to enhance them.
The ﬁrst directional derivatives describe the variation of image intensity in the neighborhood
of a point. The magnitude of the gradient represents the slope of the image intensity for a
particular value of the scale length factor s and is deﬁned as
|∇Is| =
√
(∂xIs)2 + (∂yIs)2
The second derivative information is derived from the Hessian of the intensity image I(x, y):
H =
(
∂xxIs ∂xyIs
∂yxIs ∂yyIs
)
Since ∂xyIs = ∂yxIs, the Hessian matrix is symmetrical with real eigenvalues and orthogonal
eigenvectors which are rotation invariant. The eigenvalues, λ+ and λ− (assuming λ+ ≥ λ−)
measure the convexity and concavity in the corresponding eigendirections. For an image with
white vessels over a dark background, λ+ ≈ 0 and λ− 	 0. Conversely, for an image with black
vessels over a light background, λ+  0 and λ− ≈ 0 [M.-P07b]. For the sake of simpliﬁcation,
we deﬁne here :
λ1 = min(|λ+|, |λ−|) and λ2 = max(|λ+|, |λ−|)
The maximum eigenvalue λ2 corresponds to the maximum principal curvature of the Hessian
tensor, which we will refer to as maximum principal curvature.
To illustrate the algorithm, we will use the same image throughout the text. Figure 5.16 de-
picts the original image, which shows the regular vascularization present in the bladder acquired
with 80× magniﬁcation.
Figure 5.16: Original image converted to grayscale.
We calculated the features for all integer values of s, assuming smin ≤ s ≤ smax, where smin
and smax are ﬁxed according to the approximate sizes of the smallest and largest vessel radius
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to be detected in the image. These two parameters have to be known a priori and will depend
on the pixel resolution of the original image as well as on the ﬁeld of view of the endoscopic
camera. Figure 5.17 shows the maximum principal curvature and magnitude of the gradient at
diﬀerent scales. For our endoscopic images, we chose s1 = 1 and s2 = 10. It clearly illustrate
that the size of the detected vessels is depending on s. Indeed, increasing s results in observation
of larger vessel structure.
s=2 s=3 s=4 s=5 s=10
Maximal
curvature
Gradient
magnitude
Figure 5.17: Maximum principal curvature λ2 and magnitude of the gradient at diﬀerent scales for
s = 2, 3, 4, 5, and 10.
At this point, we have to take into account that absorption properties of the large vessels
may diﬀer from small vessels due to the diﬀerent amount of red blood cells, and thus varying
hemoglobin concentration. Hence, we have to equalize our two parameters with a diameter-
dependent factor. Since our best approximation of vessel radius at this stage of the algorithm
is the scale factor s, we used this in our equalization. Thus, since vessels with diameter d  2s
are most strongly detected when the scale factor is s, we normalized each feature along scales
by d and then kept the local maxima over scales:
γ = max
s
[ |∇Is(s)|
d
]
and κ = max
s
[
λ2(s)
d
]
Therefore, the local maxima of the equalized gradient magnitude γ and the local maxima of
the equalized maximum principal curvature κ are the two features used to classify pixels in
the image into two region classes, background and vessel, using a multiple pass region growing
procedure. Figure 5.18 depicts the local maxima responses over the scales.
5.5.1.2 Region growing procedure
The region growing algorithm we use is based on an iterative relaxation technique. For each im-
age, all the parameters used in this algorithm are automatically calculated from the histograms
of the extracted features (see Figure 5.19). The classiﬁcation of pixels as vessel or background is
based primarily upon the maximum principal curvature κ, from which the criteria for determin-
ing seeds are deﬁned. Using spatial information from the classiﬁcation of the eight-neighboring
pixels, classes grow initially in regions with low gradient magnitude, γ, allowing a relatively
broad and fast classiﬁcation while suppressing classiﬁcation in the edge regions where the gradi-
ents are large. In a second stage, the classiﬁcation constraint is relaxed and classes grow based
solely upon κ to allow the deﬁnition of borders between regions.
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(a) maxs |∇Is(s)| (b) maxs λ2(s)
(c) γ (d) κ
Figure 5.18: Local maxima response over the scales for: (a) gradient magnitude |∇Is(s)|, (b) maxi-
mum principal curvature λ2, (c) diameter-dependent equalized gradient magnitude γ, and (d) diameter-
dependent equalized maximum principal curvature κ
0 0.1 0.2 0.3 0.4 0.5
0
2000
4000
6000
8000
 
 
0 0.1 0.2 0.3 0.4 0.5
0
5000
10000
15000
 
 
a) Histogram of the gradient magnitude strength γ
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γ/γmax
µg ± σg
b) Histogram of the maximal curvature strength κ
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Figure 5.19: Parameters used in the region growing algorithm. (a) Histogram of the local maxima of
the gradient magnitude strength, γ. One class: low gradient, γ < µg + σg. (b) Histogram of the local
maxima of the maximum principal curvature strength κ where t is the threshold. Two classes: background
κ/κmax ∈ [0, t] and vessel, κ/κmax ∈ (t, 1]
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The histograms of both features h(γ) and h(κ) are calculated. For h(γ), only one class is
used: low gradient, which is deﬁned as γ < µg + σg for the complete histogram, where µg is the
mean and σg is the standard deviation.
h(κ) is automatically divided into two classes using the Otsu’s threshold algorithm [Otsu79],
in which an optimal threshold is selected by discriminant criteria, where the separability between
the resulted classes in gray levels is maximized. It uses the zero and ﬁrst order cumulative
moments of the gray level histogram. The means and standard deviations of h(κ) for each class
are calculated: background, for κ/κmax ∈ [0, t] with mean µb and standard deviation σb; and
vessel, for κ/κmax ∈ (t, 1] with mean µv and standard deviation σv, where t is the threshold.
The size of the interval for each class varies depending on the value of a parameter a, which
changes during the iteration process. Intervals for each class are deﬁned as: µ ± aσ.
The algorithm begins by planting seeds for each region: background seeds are pixels for which
κ ≤ µb, whereas vessel seeds are deﬁned as γ ≥ µv. Figure 5.20 shows an example of the planting
stage where vessel seeds are shown in black, background seeds in white and unknown pixels in
gray. These conditions ensure that only those pixels in the inner areas of each region, with a
very high probability of belonging to the region, are labeled as seeds.
(a) original image (b) planting seeds
(c) ﬁnal segmentation (d) overlay image
Figure 5.20: Region growing algorithm. (a) Original image converted to 32-bits grayscale image
(b) Planting seeds: black, vessel seeds; white, background seeds and gray, unknown pixels; (c) Final
segmented image (d) Overlay image.
Region growing is an iterative process: an unlabeled pixel is classiﬁed as belonging to class j
if it has at least one neighbor of class j already classiﬁed and if it fulﬁls a speciﬁc condition
with initial parameters ai = 1. ai will specify the size of the class interval for the iteration i.
Figure 5.21 shows a case where the value of the pixel falls within the current interval for class 2
and will be classiﬁed as 2 since it also has nearest neighbors already classiﬁed as 2.
A gray value which may belong to two diﬀerent classes is assigned to the one to which most
of its neighbors belong. Growing is repeated from left to right and top to bottom until no more
pixels are classiﬁed. The constraints are relaxed by incrementing the parameters ai in steps of
0.5 and the growing is repeated. After the seeds are planted, the conditions for growing are
deﬁned as follows: in the ﬁrst stage, the growing for both classes is restricted to regions with
low gradients allowing rapid growth of regions outside of the boundaries, and allowing vessels
to grow where the values of j lie within a wide interval.
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Figure 5.21: From the histogram of κ, intervals for each class j are deﬁned as: µj ± aiσj, where ai will
specify the size of the class interval for the iteration i. An unlabeled pixel P is classiﬁed as belonging to
class j if it lies inside the interval j and if it has at least one neighbor of class j already classiﬁed
The condition for class vessel is :
(µv − avσv)  κ AND γ  (µg + agσg) AND Nv  1
and for class background:
κ  (µb + abσb) AND γ  µg AND Nb  1
where Nj is the number of neighbors already labeled as class j.
After alternating these two steps until no further classiﬁcations are found, the ﬁnal stage of the
algorithm grows vessel and background classes simultaneously without the gradient restriction.
Now the condition for class j is:
(µj − aσj)  κ  (µj + aσj) AND Nj  1
and again the condition is relaxed by increasing a from a = 1 by steps of 0.5 until all pixels
are classiﬁed. With this ﬁnal stage, borders between classes are deﬁned. Figure 5.20 shows the
result of the growing after this second stage. Interestingly, the non-relevant “deep” vessels were
ignored by this algorithm.
5.5.1.3 Limitations of the multi-scale algorithm
In order to yield good performance, the presented multi-scale algorithm needs input images
with good intrinsic contrast (i.e. a clear intensity variations between vessels and background),
because noise can be very disturbing in the gradient and maximal curvature measurement.
Indeed, noise impairs the detection of large vessels, because gradient variations are wrongly
detected in the middle of the vessel where the gradient should be ﬂat. It results a non-uniform
detection of large vessels (as to be seen in Figure 5.20d). Noise can also impair the detection of
small vessel. For instance, small intensity variations can be dissolved in the overall noise induced
by video compression algorithm.
With standard WL illumination, we reached a signal-to-noise (S/N) ratio close to 1.2 (when
converted to grayscale intensity) on endoscopic images. Figure 5.22 shows an example of vascular
patterns underlying a carcinoma in situ in the bladder. If one looks only at the image on the left,
one can distinguish the vessel network, whereas the gray level intensity plot on the right doesn’t
show a huge contrast out of the noise. A vessel displays only a 15-counts drop as compared
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to the background (when measured peak-to-peak, even less when measured at 50% intensity).
Interestingly, the human eye is able to accommodate for such small intensity variations and
can easily recognize the vessel structure (see Section 5.3), whereas the variations of gray level
intensities yields a poor numerical contrast.
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Figure 5.22: (a) left: vascularization underlying a bladder carcinoma in situ with the proﬁle drawn as
a black line; (b) right: intensity proﬁle of the image
Additionally, the non-uniform illumination of the endoscopic site may also result in wrong
behavior of this algorithm, even if it is more robust than standard thresholding methods. A pre-
processing routine (e.g. subtracting the image low frequencies) can be added to the algorithm
presented here in order to mimic a pseudo-uniform illumination patterns, similar to what is
available in microscopic studies.
In order to maximize this vessel-background contrast, we implemented some contrast maxi-
mization schemes (such as spectral optimization) described in details in Appendix E.
5.5.2 Global information extraction
As described in the section 5.4, the skeletonized image does not contain the full information
to allow discrimination of the true and false positive. In order to overcome this limitation, we
describe here a method to extract the global features of the images without extracting each
individual vessel.
For that purpose, we developed an algorithm to quantify the amount of variations in the
image spatial frequencies, and investigate whether it could serve as a discrimination basis be-
tween the observed vascular patterns. This framework was implemented as a simple software
prototype in ImageJ (National Institute of Science, NIH, Bethesda, MD).
The ﬂow chart of the algorithm is summarized in Figure 5.23. First, still images were
digitized using the IEEE1394 connection between the DV recorder (DVCAM DSR 20MDP,
Sony Corporation, Japan) and a portable PC. We ﬁrst convert the image from 24-bits RGB
color space to 32-bits grayscale intensity with a contrast maximizing method (developed at BIG
lab at EPFL). Then, to avoid artifact due to the endoscopic circular mask (i.e. variations of the
diameter of the FOV), whose size depends on the knob’s position (see Section 5.2), we deﬁned
a region-of-interest (ROI) (340x380 pixels2). The ROI was then blurred by a Gaussian ﬁltering
with a variance of 20, and subtracted to the original ROI in order to create a pseudo-uniform
illumination pattern.
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Open Image
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Figure 5.23: Image analysis ﬂow chart that describes ImageJ procedure
Fast-Fourier Transformation (FFT) was applied on the background-subtracted image following
the well-known transformation formula:
F (u, v) = 1
N2
N−1∑
x=0
N−1∑
y=0
f(x, y)e−2πj
ux+vy
N
In the Fourier domain image, each point represents a particular frequency contained in the
spatial domain image. The basis functions are sine and cosine waves with increasing frequencies.
F (0, 0) represents the DC-component of the image which corresponds to the average brightness
and F (N–1, N–1) represents the highest frequency. The low frequencies of the image are located
in the center of the power spectrum. As they should help to discriminate between linear and
tortuous vessels, we extracted this information by shrinking the size of the image down to 20x22
pixels2 with least-square method and cubic splines. We computed mean and standard deviation
of this new pixel distribution, and visualized it with the help of a histogram.
Figure 5.24 depicts the diﬀerent steps of this image analysis procedure. In this preliminary
study, the FFT yielded some interesting results. In Figure 5.24, we can clearly observe a variation
in the pixel distribution of the low frequencies (i.e. in the center of the image). The frequency
distribution around the center is larger for the carcinoma in situ than on the normal tissue,
suggesting that we will have to focus in low frequencies spectrum for the next experiments.
Indeed, the pixels in the reduced image has the potential to be a good indicator of the image
complexity. This could help to discriminate modiﬁed vascular structure from linear architecture,
thus between true and false positive lesions.
Moreover, this global approach is simpler to implement than a vessel segmentation procedure,
and could be complementary to the method presented in Section 5.5.1. A summary of this
approach has been published in [Lovi09].
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Figure 5.24: Image analysis results (background substraction, FFT, histogram plot)
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Chapter 6
Conclusions
and future prospects in urology
The main aims of the part of this manuscript dedicated to research performed in urology were to
optimize the photodetection instrumentation of bladder cancer, and to ﬁnd an eﬃcient method
to reduce the false-positive rate associated with ﬂuorescence cystoscopy. Several clinical and
ex vivo imaging and spectroﬂuorimetric studies were performed to gain insight on the optical
characterization of bladder carcinoma, deﬁning further possibilities to increase the sensitivity
and speciﬁcity of photodetection. These studies identiﬁed vascular patterns, whose shape and
organization were characteristics to diﬀerentiate false and true positive lesions.
Violet LEDs positioned at the distal end of the endoscopes will be used in the future as
excitation light source for endoscopic ﬂuorescence imaging. Since the spectral emission of these
LEDs will be narrower than the emission of light sources used at the present time for ﬂuorescence
cystoscopy, we have now the opportunity to improve the spectroscopy of this excitation light by
selecting relatively precisely the wavelength producing the best Tumor/Normal tissues (T/N)
contrasts and brightness. This concept is of particular relevance in the bladder where the
sharp ﬂuorescence excitation peak of PpIX interferes with the very strong and sharp absorption
peak of hemoglobin contained in the tissues and in the liquid ﬁlling the bladder. Therefore,
the determination of the wavelength corresponding to the optimal trade-oﬀ resulting from the
partial overlap between these PpIX excitation and hemoglobin absorption peaks is not trivial.
To address this issue, we have compared the endoscopic images resulting from a Krypton laser
(407, 413 nm) with a conventional ﬁltered light source (370–430 nm). With this very preliminary
study, we were able to show a possible increase of the tumor-to-background contrast using a
narrow excitation centered on the PpIX excitation peak. More detailed results are presented in
Appendix C.
Similarly, the value of the optimal excitation wavelength also depends on the spectroscopy
of the endogenous ﬂuorophores and/or absorbers that are present in the liquid used to ﬁll the
bladder. These liquid are producing a greenish background signal degrading the T/N contrast.
This eﬀect is particularly important with the Wolf system that detects the green tissue autoﬂu-
orescence to generate the background image. Therefore, the comprehensive determination of
the spectroscopy of this liquid will enable to identify the optimal excitation and, possibly, de-
tection wavelengths to be used to generate a minimal background and, consequently, an optimal
contrast.
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In Chapter 4, the main metabolites present in the urine mixture were identiﬁed, but their
exact interplay still needs to be investigated. In a second study, we showed that the ﬂuores-
cence of the bladder washout ﬂuid collected during the examination is strongly related to urine
production. We were able to identify the main metabolites that ﬂuoresce when excited with
blue-violet light. High variations were observed between samples and patients. We could show
that some spectral range have to be avoided in order to suppress the greenish appearance of the
ﬂows coming out of the ureters.
Not only the excitation but also the wavelengths to be detected need a speciﬁc optimization.
More precisely, it is still not known if the decrease in the green autoﬂuorescence — observed
between small papillary lesions and their normal surrounding tissues — is also present on ﬂat
carcinoma in situ (CIS). Since detecting CIS as early as possible is crucial in terms of patient
management, we can investigate this problematic in the future.
Even if the ﬂuorescence cystoscopy is a well established method for the detection of ﬂat
bladder carcinoma, the dedicated PDD instrumentation has still to be tested for its reliability
over time. Several parameters such as illumination light power, excitation spectrum, overall
transmission and integrity of the detection system are subject to variations over time. In the
clinics, a regular check of these parameters is necessary. It helps to prevent misinterpretation of
the obtained endoscopic images and avoid under/over diagnosis leading to an evident reduction
of patient beneﬁt. In the framework of this thesis, we designed some reference validation samples
to evaluate the system performances. They are described in Appendix D.
Since ﬂuorescence cystoscopy still suﬀers from limited speciﬁcity, we investigated in Chapter 5
the use of high magniﬁcation cystoscopy to characterize ﬂuorescence positive lesions in the
bladder. This method is convenient, since it ﬁts perfectly into the current clinical routine. We
were able to show in a clinical study that comparison of HM cystoscopy classiﬁcation with
histopathology results conﬁrmed 32/33 (97%) cancerous biopsies, and rejected 17/20 (85%)
non-cancerous lesions. In the future, we will have to transfer this magniﬁcation technology on a
ﬂexible platform to overcome the geometric limitations. At this point, it is to be noted that most
of the surgical tools are nowadays available for the rigid platform only (e.g. electro-resection and
cautery for TURB). A trade-oﬀ has to be found between the existing platform and the promising
HM characterization of false positive sites.
Since the HM classiﬁcation was based on subjective criteria in the clinical study, we wanted
to quantify the observed vascularization with more robust criteria. In Section 5.4, we evaluated
the pertinence of extracting vascular skeleton out of the endoscopic image. It resulted a clear
loss of visual information, when converting an original image into a skeleton. In Section 5.5,
we implemented an image processing algorithm to automatically extract the vessel information
based on a region-growing procedure. In the future, two approaches may be combined : 1)
a quantitative analysis of the image skeleton, so that non-visual parameters (e.g. branching,
fractal dimensions, concavity) can be evaluated with respect to their discrimination capability
of true vs. false positive spots; 2) an improvement of the visual classiﬁcation parameters as
to be observed with conventional endoscopic images. As ﬁnal stage, we analyzed global image
features (such as low frequencies spatial distribution) without extracting each individual vessel.
This approach also showed some potential to discriminate vascularization.
In order to better visualize the vessels, we may improve their contrast with respect to the
background. Since hemoglobin is a very strong absorber of green and blue light, it can be used as
an intrinsic marker of the vessel, because it is contained almost exclusively in the red blood cells.
Consequently, we moved towards a spectral optimization of our endoscopic observation system.
The ﬁrst preliminary results are presented in Appendix E, where we showed that images acquired
with a restricted excitation bandwidth targeting the hemoglobin absorption peaks yielded much
131
more contrasted vascularization pictures.
It is now clearly established that the chromatic presentation of the images on the TV mon-
itor observed by the endoscopist has an important impact on the visualization/detectability of
lesions during endoscopic ﬂuorescence imaging. In Appendix F, we reviewed the parameters
that inﬂuence the tumor detectability with respect to chromatic presentation of the contrast.
Indeed, foreground-to-background contrast (e.g. tumor-to-healthy) can be enhanced by giving
speciﬁc hue values to the relevant areas. Our preliminary tests showed that complementary
color presentation is likely to improve the tumor detectability. Nevertheless, the inter-observer
variations regarding optimal color presentation are very poorly documented. In the future, we
will quantify the impact of false-color allocation on lesion detectability.
In this manuscript, we have shown the great potential of high magniﬁcation vascular imaging
to reject false-positive lesions. We also showed that imaging of backscattered wavelengths has
a great potential to improve the vessel-to-background contrast. However, the combination of
reﬂectance and ﬂuorescence imaging in the same device remains a great challenge. Several
attempts have been made up to now (e.g. virtual ﬁltering, dual-CCD endoscope), but the optimal
device has still to be developed.
This high magniﬁcation procedure could be applied to virtually all hollow organs accessible
with endoscopy, as long as vascular characterization is relevant to discriminate false from true
positive lesions. Very preliminary tests were made on vocal cords to assess feasibility of this
observation in the larynx. We showed that this approach could be a useful tool to characterize
early lesions, as an adjuvant to the existing combined procedure that involves autoﬂuorescence,
endoluminal ultrasound and OCT.
In the bladder, only few groups are working on characterizing the false-positive lesions.
Schmidbauer et al. postulated that OCT is able to resolve the layered structure of the urothelium.
Recently, this group published a study characterizing the positive lesions detected by HAL
ﬂuorescence cystoscopy. They reported an increase speciﬁcity from 78.6% to 97.9% for HAL
with targeted OCT as compared to HAL alone. Sensitivity was not modiﬁed since they only
target HAL+ lesions. With a depth of penetration of 1-2 mm, this devices enables urothelium,
lamina propria, and muscularis propria to be distinguished. Current system has however only
a limited resolution (30 µm lateral resolution). Since urothelium does not exhibit the same
layer deﬁnition as the retina, the operator may need a special training before using this tool to
reduce discrepancies in interpretation of OCT images. After a dedicated training, these authors
claims to be able to reject 36/42 (86%) of the false-positive. Their 2.3 mm probe is also fully
compatible with the clinical routine since it can be inserted into standard surgical instruments.
Nowadays, several groups aimed to perform an in vivo “optical biopsy” to virtually replace
the histopathological analysis. For instance, Cicchi et al. used multiphoton endoscopes [Cicc10].
These authors showed that tumor cells appeared slightly diﬀerent in shape and with a smaller
cellular-to-nuclear dimension ratio with respect to corresponding normal cells. Further diﬀer-
ences between the two tissue types were found in both spectral emission and ﬂuorescence lifetime
distribution by performing temporal- and spectral resolved analysis of ﬂuorescence. Sonn et al.
used confocal laser endomicroscopy. This imaging technique requires the intravesical/intravenous
use of ﬂuorescein. These authors could highlight clear diﬀerences in the cellular between normal
mucosa, and low and high grade tumors.
Since it is not timely possible to scan the whole bladder with such a small ﬁeld of view,
both methods are promising only as characterization method. However, no combination of
endomicroscopy and/or multiphoton endoscopy with ﬂuorescence cystoscopy has been reported
up to now.
A new design trend that was reported recently in endoscopy is the “wireless” endoscope, with
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radio-communication from the CCD to the monitor, and LED-based integrated illumination.
An extreme example of this would be the technology called capsule endoscopy, where patients
swallow a vitamin-size camera that will acquire images throughout the GI tract (stomach, small
bowel and colon) and send them to the doctor for review (Pillcam from Given Imaging Inc.,
EndoCapsule from Olympus Inc.). With 6 LEDs built-in for illumination, these devices achieve
compactness (11 mm × 26 mm) with a wide ﬁeld of view (145◦) and enhanced depth of ﬁeld
(0–20 mm), but they still suﬀer from battery lifetime limitations. The power supply will remain
a crucial technical issue in the development of wireless endoscopy.
Since the cost of miniaturization are still decreasing, novel zooming setup (e.g. Optotune
AG) to perform high magniﬁcation endoscopy can now be integrated at the distal end of the
endoscope, in the same manner than confocal endoscopy was integrated as MEMS [Cham07].
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Part II
Bronchial cancer

Chapter 7
Introduction to Bronchial cancer
7.1 Bronchial Anatomy and Histology
External respiration (i.e. the gas exchange between air and blood) takes place in the lungs, where
the venous blood is oxygenized and sent back to the body blood circulation via the arteries. The
blood carbon dioxide (CO2) resulting from the body’s oxygen consumption is released to the
external environment and replaced by oxygen (O2). The human thorax holds two lungs (right
and left) that are subdivided into a total number of 5 lobes. Three lobes are in the right lung,
and two in the left lung. Indeed, the left lung’s architecture is slightly diﬀerent due to the heart’s
volume in the left part of the thorax (see Figure 7.1).
RUL
RML
RLL
Right Left
LUL
LLL
Trachea
Figure 7.1: Lobar structure of the lung. The right lung consists of 3 lobes, namely the right upper lobe
(RUL), the middle lobe (RML) and the right lower lobe (RLL). The left lung consists of the left upper
lobe (LUL) and the left lower lobe (LLL).
The human respiratory system may be subdivided into two parts: (i) the conducting portion
is a continuum of air passageways that conduct air from the environment into respiratory spaces
(and back out); (ii) the respiratory portion (gas exchange) consists of many interconnected air-
ﬁlled spaces with very thin linings which allow rapid gas exchange. The air ﬂows down the
so-called “tracheo-bronchial tree”, a tubular system dividing in bronchi, bronchioles, and alveoli
(see Figure 7.2). It starts with the trachea, which divides into the two primary or extra-lobar
bronchi. These primary bronchi further divide into the secondary or intra-lobar bronchi which
on their part divide into bronchi of decreasing size (segmental bronchi). The small bronchi
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Figure 7.2: The tracheo-bronchial tree viewed from the trachea. The trachea divides into a right and
a left main bronchus which further subdivide into the higher generation bronchi and bronchioli. The
“B-numbers” give the oﬃcial nomenclature of the bronchi (adapted from Pentax documentation).
subdivide into terminal and respiratory bronchioles and form the alveoli. Essentially all gas
exchange between air and blood occurs across the walls of alveoli.
The diameter of the trachea is typically 20 mm in adults. This diameter decreases to about
16 mm for the extra-lobar bronchi, 11 mm for the intra-lobar bronchi, and is less than 8 mm for
the segmental bronchi. The bronchioli have diameters smaller than 0.6 mm. The terminal alveoli
are less than 0.3 mm in diameter [Yeh80]. Due to the decreasing size of the bronchial diameter,
only the primary and secondary bronchi are accessible with conventional bronchoscopes. The
histology of the tracheo-bronchial tree is not uniform, and undergoes signiﬁcant changes from
the trachea to the alveoli.
The function of the conducting portion of the tracheo-bronchial tree, i.e. from the trachea
down to the terminal bronchioles, is to modify the incoming air by heating, increasing its relative
humidity, and puriﬁcation from particles. Indeed, the proximity of the rich vascularization of
the airway walls heats the incoming air before reaching the respiratory portion. Humidiﬁcation
and puriﬁcation are achieved by the so-called “mucociliary escalator” which results from the
interaction of the mucous and serous layers, and the cilia overlaying the epithelium. The serous
layer is in immediate contact with the epithelium and mostly contains water and proteins. A
viscous mucous layer sitting on the serous layer humidiﬁes the air and traps particles. The
cilia of the respiratory epithelium beat in concert, and moved the secreted mucous towards the
pharynx, for either expectoration or swallowing to the stomach where the acidic pH helps to
neutralize foreign material and micro-organisms. In smokers, the number of ciliated cells in the
epithelium is signiﬁcantly reduced. Thus, the eﬃciency of the mucociliary escalator is reduced,
resulting in irritations of the mucosa and an increased coughing reﬂex1.
1Department of Physiology and Biophysics, Suny Stony Brook University, The respiratory system,
http://www.pnb.sunysb.edu/hby531/chap11%20respiratory.pdf
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The principal histologic features of the trachea and the accessible bronchi are given in the
following section.
7.1.1 The trachea
The trachea is supported by 15 to 20 hyaline cartilaginous structures (C-shaped, open dorsally),
which are replaced by smooth muscle bundles in the posterior wall. The inner lining of the
trachea consists of 4 layers : the mucosa, the lamina propria (or tunica propria), the submucosa,
and hyaline cartilage, as depicted in the photomicrograph in Figure 7.32. The tracheal mucosa
forms a ciliated pseudo-stratiﬁed columnar epithelium. A very prominent basement membrane
separates the epithelium from the lamina propria. In contrast to the avascular epithelium,
the lamina propria is highly vascularized and contains numerous elastic ﬁbers and ﬁne, densely
packed collagen ﬁbers. The elastic ﬁbers are arranged in bundles that run along the longitudinal
axis of the bronchial wall giving it a stripe-like morphology. The thin layer of the lamina propria
separates the epithelium from the submucosa. It contains less elastic ﬁbers and only loosely
packed collagen ﬁbers. The secretory portions of exocrine glands are located in the upper part
of the submucosa.
Hyaline cartilage
LP
SM
Respiratory epithelium
Basement membrane
Tracheal glands
Figure 7.3: Histology of the trachea. The ciliated pseudo-stratiﬁed columnar epithelium (respiratory
epithelium) is separated from the lamina propria (LP) by the basement membrane. A portion of a cartilage
ring is visible in the submucosa (SM).
7.1.2 The bronchi
The histological appearance of the extra-lobar, intra-lobar, and segmental bronchi is similar to
that of the trachea. A photomicrograph of healthy bronchial wall tissue is shown in Figure 7.43.
The most superﬁcial layer of the bronchi is formed by a ciliated pseudo-stratiﬁed columnar
epithelium that lays on the lamina propria. The two tissues are separated by the thin basement
membrane. In the extra-lobar and ﬁrst segmentary bronchi, the epithelial thickness is ≈ 40–
60 µm. However, the epithelial thickness with successive branching, becoming a simple ciliated
epithelium close to the bronchioles. The lamina propria contains elastin and collagen ﬁbers as
well as blood vessels. The extra-lobar bronchi, and the trachea alike, contain smooth muscles
only on their posterior wall, whereas they are found right below the lamina propria in the
intra-lobar bronchi. They are arranged helically in crisscrossing bundles around the bronchi,
and become more prominent as one approaches the bronchioles. The cartilage arrangement and
shape change signiﬁcantly with successive branching. In particular, the cartilage rings found in
the trachea and the extra-lobar bronchi make room for isolated plates (islands) of cartilage in
2Indiana University School of Medicine [PERL] : http://pathology.iupui.edu/
3Institut für Pathologie der Universität Basel : http://alf3.urz.unibas.ch/pathopic
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Figure 7.4: Normal bronchial histology. The mucosa (M) consists of the ciliated respiratory epithe-
lium and the lamina propria (LP). Smooth muscle ﬁbers and small blood vessels are visible in the LP. The
submucosa (SM) contains serous glands and blood vessels. A portion of the hyaline cartilage is visible in
the lower part of the image
the intra-lobar and segmentary bronchi. A gradual transition is observed between the histologic
characteristics of successive branching.
7.2 Facts about bronchial cancer
Lung cancer is the deadliest cancer in the world with the highest incidence rates occurring in
North America and Europe4 (see Figure 3.1). However, over the past few years, lung cancer
incidence has dramatically increased in developing countries [Youl08]. Still, a clear demarcation
line is visible between the developed and the less developed countries5 (see Figure 7.5). The
mortality rate for lung cancer in Europe exceeds that of all other most common cancers, including
prostate, colorectal, stomach, bladder, and head and neck cancer, by a factor more than 2. In
European women, only breast cancer is associated with a higher mortality rate [Levi04]. In
2009, it was estimated that about 219’440 new lung cancer cases would occur in 2009 and about
159’390 lung cancer patients would die of their disease in the USA [Jema09].
Malignant and non-malignant tumors in the lung can develop from all tissues in the bronchi
and lung parenchyma. However, bronchial carcinoma represents about 90% to 95% of all malig-
nant lung tumors [Schu94]. About 60–70% of these lesions are centrally located, i.e. accessible
by bronchoscopic procedures [Auer91, Pari03b], and only 20–30% are peripheral. The central
bronchial lesions occur 25.6% in the RUL, 13.3% in the RML, 15.4% in the RLL, 30% in the
LUL, and 15.7% in the LLL [Schu94]. However, over the last decades, changes in patterns of
lung cancer were observed [Auer91] with an increasing incidence of peripheral and adenocarci-
noma [Gazd97, Thun97] principally due to modiﬁcation in the smoking behavior of individuals
and cigarette design (ﬁlters, light tobacco cigarettes, profound inhalation) [Fran99].
Among all central lesions, the squamous cell carcinoma (SCC) is the most frequent carcinoma
type; its prevalence ranging between 29% to 43% [Auer91, Kenn00]. Other types of bronchial
carcinoma are adenocarcinoma, large cell lung carcinoma, and small cell lung carcinoma (SCLC).
This thesis work will focus on the detection and characterization of squamous cell carcinoma
and its non-invasive stages.
The most important risk behavior for lung cancer is tobacco smoking, being responsible for
4SEER Cancer Statistics Review: 1975-2005. http://seer.cancer.gov/csr/1975_2005/
5GLOBOCAN 2008 http://globocan.iarc.fr/
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Source : GLOBOCAN 2008 (IARC)
Estimated age-standardized incidence rate per 100000
Lung, female, all ages
Estimated age-standardized mortality rate per 100000
Lung, female, all ages
Estimated age-standardized incidence rate per 100000
Lung, male, all ages
Estimated age-standardized mortality rate per 100000
Lung, male, all ages
< 5.1 < 12.2 < 26.2 < 42.4 < 79.3
< 1.5 < 4.0 < 7.1 < 14.3 < 36.3 < 1.5 < 4.1 < 6.5 <10.8 < 30.0
< 4.7 < 11.5 < 24.0 < 36.5 < 73.2
Figure 7.5: Age-standardized incidence and mortality rate for men and women in 2009 [Ferl10].
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85–90% of all bronchial carcinoma [Tycz03]. In 2005, it was estimated that around 1.25 billion
adults throughout the world were smokers (1 billion men and 250 million women) [Mack06].
This represented approximately 35% of men and 22% of women in more developed countries,
compared with 50% of men and 9% of women in less developed countries.
The relationship between smoking and lung cancer is one of the most thoroughly investi-
gated issues in biomedical research [Albe03], and compelling evidence has built up since the
middle of the twentieth century to indicate that smoking is the predominant causal factor for
lung cancer [Thun02, Sasc04]. Epidemiological studies show a clear dose-response relationship
between lung cancer risk and the number of cigarettes smoked per day, the degree of inhalation,
and the age at initiation of smoking [Enge96, Agud00]. Odds Ratios (OR) of lung cancer are
estimated at 23.9 (19.7–29) for male current smokers vs. never smokers, and at 7.5 (6.2–9.1) for
male former smokers vs. never smokers [Simo01]. In other words, smokers have a 15- to 30-fold
increased risk of developing lung cancer compared with nonsmokers [Sasc04]. This excess risk of
lung cancer is lower in women, with an estimated OR of 8.7 (7.4–10.3) for female current smokers
vs. nonsmokers and 2.0 (1.6–2.4) for female former smokers vs. never smokers [Agud00].
Clinical characteristics and risk factors of nonsmoker patients with lung cancer are still de-
bated. To evaluate the consequences of exposure to second-hand smoke (commonly known as
“passive smoking”), more than 1600 key articles were reviewed in 2007 by the Surgeon General
oﬃce6. They concluded that exposure to second-hand smoke can also cause lung cancer, cor-
related by other authors [Wake07]. In a recent meta-analysis [Khud01], all histological types
were found to be associated with tobacco smoking, the relationship being stronger for squa-
mous cell carcinoma (OR: 25.4 [18.4–35.1]) and small cell carcinoma (OR: 42.0 [21.7–81.2]) than
for adenocarcinoma (OR: 6.18 [4.59–8.32]). In two recent studies, Clément-Duchêne and Paris
demonstrated that some risk factors, such as duration of smoking and certain occupational
exposures but not gender or age, have a more important inﬂuence on the incidence of lung
adenocarcinomas than on other histologic types [C.-D10, Pari10]. However, they also showed
that neither occupational nor exposures suﬃce to explain the occurrence of such disease in never
smokers. Their ﬁndings suggest that a sizeable fraction of lung cancer cases, both in male and
female never smokers, may share common characteristics, and possibly underlying biological
mechanisms, as recently suggested by Toyooka et al. [Toyo07].
Other factors are occupational exposure to carcinogens like asbestos, some metals (e.g. chro-
mate, nickel, arsenic, cadmium), radon, and ionizing radiation [Albe07]. However, these factors
account for less than 9% of bronchial carcinoma [Stee96, Dris05]. This is also true for envi-
ronmental factors, principally air-pollution, which is estimated to be responsible for less than
5% of the cases [Schu94]. However, occupational factors seem to be only secondary to the
formation of bronchial cancer in smokers. A clinical AF bronchoscopy study on high risk pa-
tients by Paris et al. showed that deﬁnite occupational respiratory exposure to carcinogens
and active smoking were independently associated with the presence of high grade bronchial
pre-neoplastic lesions [Pari03a]. In this study, 9% of all patients showed high grade dysplasia,
whereas low grade dysplasia were detected in 45%. Similar data have been reported by Lam et
al. [Lam93, Hawk99].
7.2.1 Carcinogenesis and staging of bronchial cancer
Bronchial carcinogenesis is a multi-step process, that usually begins with alterations of the
squamous epithelium under the eﬀect of inhaled harmful components. The individual steps were
classiﬁed by the World Health Organization (WHO) and the International Association for the
6http://www.surgeongeneral.gov/library/smokeexposure/index.html
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Study of Lung Cancer (IASLC) in the WHO/IASLC histological classiﬁcation of pulmonary and
pleural tumors that was revised in 1999 [Trav99, Bram01, Nich01]. This updated classiﬁcation
was developed with the aim to adhere to the principles of reproducibility, clinical signiﬁcance, and
simplicity in order to minimize the number of unclassiﬁable lesions as compared to the previous
one [Worl81], including e.g. the addition of two pre-invasive lesions to squamous dysplasia and
carcinoma in situ.
The staging of squamous cell carcinoma is described by the International System for staging
of lung cancer. In this classiﬁcation system, lung cancer stages are grouped according to their
TNM (T – primary tumor, N – regional lymph nodes, and M – metastasis) anatomical subsets
(similar to bladder cancer classiﬁcation, see Section 3.3.2.1). Table 7.1 & 7.2 show an overview
of the TNM descriptors and the stage grouping (adapted from [Moun00]).
T – Primary tumor
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Non-invasive papillary carcinoma
Tis Carcinoma in situ: ﬂat tumor
T1 Tumor ≤ 3 cm in greatest dimension, no invasion more proximal than the lobar
bronchus
T2 Tumor with any of the following features: > 3cm in greatest dimension; ≥ 2 cm
distal to the carina; invading pleura; associated with atelectasis or local obstructive
pneumonitis
T3 Tumor of any size directly invading any of the following: chest wall, diaphragm,
mediastinal pleura, parietal pericardium; or < 2 cm distal to the carina; or atelectasis
or obstructive pneumonitis of entire lung.
T4 Tumor of any size with invasion of mediastinal organs (e.g., heart, trachea, oesopha-
gus, mediastinum) or vertebral body
N – Lymph nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Ipsilateral peribronchial and/or ipsilateral hilar lymph node meatastasis
N2 Ipsilateral mediastinal and/or subcarinal lymph node metastasis
N3 Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral
scalene, or supraclavicular lymph nodes
M – Distant metastasis
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Table 7.1: The international TNM descriptor system for the staging of lung cancer (1997 revision).
The steps of early carcinogenesis in the epithelium are deﬁned as (1) reactive changes (include
basal cell or goblet cell hyperplasia, and squamous metaplasia); (2) low-grade squamous dysplasia
(LGD); (3) high-grade squamous dysplasia (HGD); (4) microinvasive carcinoma and (5) invasive
carcinoma. Microphotographs showing the 5 principal WHO classes are shown in Figure 7.6,
that depicts hematoxylin and eosin (H&E) stained slides.
Hyperplasia is characterized by increased proliferation of basal or goblet cells, increasing the
number of cell layers in the epithelium to 3-10 [F.-E98, Chha05]. In squamous metaplasia, the
ciliated pseudo-stratiﬁed normal epithelium is replaced by a stratiﬁed cell structure of variable
thickness [F.-E98]. Reactive changes frequently show spontaneous regression and are not consid-
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Stage TNM subset
0 Carcinoma in situ
IA T1 N0 M0
IB T2 N0 M0
IIA T1 N1 M0
IIB T2 N1 M0
T3 N0 M0
IIIA T3 N1 M0
T1-3 N2 M0
IIIB T4 N0-3 M0
T1-3 N3 M0
IV any T any N M1
Table 7.2: Stage Grouping. International deﬁnition of the TNM subsets for lung cancer staging.
Figure 7.6: H&E stained photomicrographs of the principal WHO classes: basal cell hyperplasia, meta-
plasia, mild dysplasia, moderate dysplasia, severe dysplasia, carcinoma in situ (CIS), microinvasive carci-
noma and invasive squamous cell carcinoma (courtesy from S. Andrejevic-Blant, Institute form Pathology,
CHUV University Hospital, CH-Lausanne)
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ered as pre-neoplasia, but they can occasionally turn into low-grade squamous dysplasia (mild
and moderate dysplasia). In mild dysplasia, the microscopic architectural and cytological distur-
bance of the epithelium is minimal. The epithelial cells exhibit a mild increased in size and show
pleomorphism. A continuous progression of maturation from the base to the luminal surface
and variations in nuclei-cytoplasma (N/C) ratio are observed. Moderate dysplasia is character-
ized by a moderate increase of the epithelial thickness with a superﬁcial ﬂattening of the cells.
The N/C ratio is higher than in the mild dysplasia and mitosis can be detected in the lower
third of the epithelium. The changes in the N/C ratios and mitosis are even more marked in
high-grade dysplasia, where cells are markedly increased in size and show strong pleomorphism.
High-grade dysplasia includes severe dysplasia and carcinoma in situ (CIS), considered as equiv-
alent by several authors. Low and high grade dysplasia are referred to as pre-neoplasia. They
are limited to the epithelium and do not break through or inﬁltrate the basement membrane. If
the epithelial changes extend over the basement membrane and invade the subepithelial layers,
they are referred to as neoplasia. If the inﬁltration into the subepithelial layers is less than
3 mm, the lesion is considered a microinvasive carcinoma. Neoplasia that penetrate into deeper
tissue layers are referred to as invasive carcinoma. More details on the microscopic features of
squamous cell dysplasia and higher grade epithelial neoplasia are listed in Table 7.3.
Reactive, pre-neoplastic and neoplastic changes of the epithelium are often associated with
inﬂammatory reactions in the bronchial mucosa and submucosa. Eosinophils are often considered
as inﬂammation ﬂag in H&E images. They do stain as characteristic black dots well demarcated
in the micrographs.
The exact prevalence of severe dysplasia and CIS in the bronchial tree is unknown. In a review
of ﬂuorescence bronchoscopy data in a selected population of smokers and former smokers with
sputum atypia, prevalence rates of 6% and 1.6% were reported for severe dysplasia and CIS,
respectively [Lam00].
7.3 Management of bronchial cancer: an overview
Lung cancer survival depends of the disease stage at presentation [Pari03b]. The extremely high
mortality rate of lung cancer is strongly attributed to the general late detection and diagnosis of
the disease. Indeed, stage I and II are often asymptomatic and consequently, less than 25% of
lung cancer patients will present with an early stage cancer [Pari03b]. On the other hand, the
yield of curative therapy for advanced stage (III - IV) is still low [Bepl03]. Indeed, the overall
5-year survival rate for lung cancer is only 14%. This rate is about 25–1% for stage III and IV,
but can reach 25–67% when the lung cancer is detected at an early stage (I or II) [Moun97].
Thus, eﬃcient detection of early stage bronchial carcinoma is crucial for a successful therapeutic
outcome and survival. This is particularly true for the detection of ﬂat, small pre-neoplastic
lesions such as dysplasia and CIS, because those lesions have a high probability for growing into
invasive lesions within a short period of time [Bota01, Venm00, Lam98].
Clinical studies have shown that approximately 10% of moderate dysplasia and 19% to 83%
of severe dysplasia will progress to invasive lesions [Venm01, Shes00]. Monitoring the progres-
sion of pre-neoplasia to neoplasia is especially important in the context of the management
and follow-up (interval between control bronchoscopies, chemoprevention) of patients diagnosed
with a primary cancer in the bronchi and/or in any ear-nose-throat (ENT) localization, be-
cause these patients are at particularly high risk for secondary or second primary bronchial
neoplasia [Mart95, Anta95, Jone95, John98, Levi99, Stoe01].
The incidence of second primary bronchial neoplasia for lung cancer patients ranges from
0.5% to 10% [Anta95]. Sixty percent (60%) of all second primary bronchial cancers are meta-
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chronous (i.e. developing at diﬀerent times), and 40% are synchronous (i.e. at the same time).
The prevalence of second primary bronchial neoplasia in head and neck (H&N) cancer patients
has been reported to be 7–32% [Dele97, León99]. In a clinical autoﬂuorescence (AF) bron-
choscopy study, Venmans et al. found pre-neoplastic central bronchial lesions in 25% of patients
with a history of H&N SCC [Venm01]. Long-term studies on patients with secondary or sec-
ond primary lung cancers showed that resection of early metachronous lesions improved the
long-term survival rate [Anta95, Asap00]. However, most patients (68%) are asymptomatic at
the time of diagnosis of the second primary cancer [Asap00], which is frequently detected only
“by accident” during a follow-up examination. Since secondary and second primary bronchial
cancers may occur several years after the ﬁrst cancer diagnosis [Anta95], patients surviving
treatment of a ﬁrst primary carcinoma (bronchi or H&N) require lifelong screening of second
primary bronchial lesions [Dodd01]. Further high-risk populations that should be considered
for screening for bronchial cancer include long-term survivors of small cell lung cancer, occupa-
tionally exposed groups, and subgroups of smokers (heavy smoker, lung cancer history in the
family) [Batt95].
7.3.1 Screening and detection of bronchial cancer
The most common detection methods for lung cancer are sputum cytology, chest X-ray (CXR),
computed tomography (CT), low-dose spiral CT, positron emission tomography (PET), mag-
netic resonance imaging (MRI) and bronchoscopy (white light or AF).
Sputum analysis is currently a widely used screening tool in high risk populations [Thun03].
It involves microscopic examination of the cells that are either coughed up from the lungs, or
collected through a bronchoscope. It has a high speciﬁcity especially for bronchial SCC, but
only a limited sensitivity of 65% [Thun03, Depp04]. This percentage is likely to be much smaller
for dysplasia and squamous cell carcinoma. DNA analysis, automated quantitative cytome-
try and methylation of the sputum samples have shown promising results to improve sensitiv-
ity [McWi03]. Sputum analysis is the least invasive and least costly of the detection methods
mentioned so far, and can easily be used in wide range screening programmes. However, it does
not allow localization of the lesion within the tracheo-bronchial tree. Indeed, bronchoscopy is
the only established method that allows detection and localization of central bronchial lesions
and parallel tissue sampling for histological diagnosis.
Chest x-ray is a projection radiograph of the chest and is a very common procedure of diag-
nostic. It helps physicians to diagnose pneumonia, emphysema, and lung tumors of important
size. Unfortunately has only a limited resolution and thus, has only poor sensitivity for the
detection of early bronchial lesions.
Low-dose CT scan is a computerized x-ray procedure that produces cross-sectional images
of the body. This procedure is widely used for screening of high-risk patients, because it is non-
invasive and brief. Several studies showed that multi-detector spiral CT has a higher sensitivity
to early and small sized lung cancer than CXR [Bepl03, McWi03]. Its detection rate is about
3-fold higher than with CXR attributed to better resolution and volume rendering capability.
Indeed, spiral CT can detect lesions as small as 2-3mm in size [Kenn00], but at the price of a low
speciﬁcity [Hens99, Hens03]. Moreover, CT is not sensitive to superﬁcial, pre- or microinvasive
central lung cancers [McWi03].
PET is a nuclear medicine imaging technique which produces a three-dimensional image
or picture of functional processes in the body with the help of a radio-active sugar. With
this technology, cancer areas with increased metabolism can be highlighted. In lung cancer
management, PET with 18-ﬂuorodeoxyglucose has to be considered as a diagnostic and staging
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tool, rather than a screening tool [vanZ02, Port02]. Pastorino et al. demonstrated that the
combined use of low-dose spiral CT and PET improves the speciﬁcity of early stage lung cancer
detection [Past03].
Several attempts were made in the last years to establish breath test as a valid tool for lung
cancer screening, since it is non-invasive and totally painless. It was pioneered by Dr. Michael
Phillips et al. in 1999 [Phil99], an Autralian physician located in New York. These tests were
reﬁned by several groups. For instance, Peng et al. showed with gas chromatography/mass
spectrometry studies that several volatile organic compounds (VOC) , which normally appear
at levels of 1-20 ppb in healthy human breath, are elevated to levels between 10 and 100 ppb
in lung cancer patients. In this study, 42 volatile organic compounds that represent lung cancer
biomarkers were indentiﬁed [Peng09]. Bajtarevic et al. assessed the performance of two meth-
ods : proton transfer reaction mass spectrometry (PTR-MS) vs. solid phase microextraction
with subsequent gas chromatography mass spectrometry (SPME-GCMS) [Bajt09]. These au-
thors showed that isoprene, acetone and methanol are compounds appearing in everybody’s
exhaled breath, whereas potential marker compounds are alcohols, aldehydes, ketones and hy-
drocarbons. They also claimed that PTR-MS gives much more reliable quantitative results then
GCMS-SPME, since it does not need pre-concentration. Sensitivity for detection of lung cancer
patients based on presence of (one of) 4 diﬀerent compounds not arising in exhaled breath of
healthy volunteers was 52% with a speciﬁcity of 100%. Using 15 (or 21) diﬀerent compounds for
distinction, sensitivity was 71% (80%) with a speciﬁcity of 100%. These approaches have often
2 classes of patients : healthy and cancer-bearing. In this studies, no description is available
about the stages of the cancer, and it is diﬃcult to ﬁgure out whether their conclusion are also
valid for early non-invasive cancers.
Finally, bronchoscopy is a technique of visualizing the inside of the airways. The ﬁrst bron-
choscopy was performed in 1897 by a German, Gustav Killian. For this examination, an instru-
ment bronchoscope is inserted into the airways, usually through the nose or mouth, or occa-
sionally through a tracheostomy. This allows the practitioner to examine the patient’s airways
for abnormalities such as foreign bodies, bleeding, tumors, or inﬂammation. Specimens may be
taken from inside the lungs: biopsies, ﬂuid (known as broncho-alveolar lavage), or endobronchial
brushing. The practitioner may use either a rigid bronchoscope or ﬂexible bronchoscope. A rigid
bronchoscope is a straight, hollow, metal tube. Doctors perform rigid bronchoscopy less often
today, but it remains the procedure of choice for removing foreign materials, as its increased
thickness allows instruments to be more easily inserted through it. Rigid bronchoscopy also
becomes useful when bleeding interferes with viewing the examining area, and allows for more
interventions, such as cautery to stop the bleeding. A ﬂexible bronchoscope is a long thin tube
that contains small clear optical ﬁbers that transmit light images as the tube bends. Its ﬂexi-
bility allows this instrument to reach further into the airway. The procedure can be performed
easily and safely under local anesthesia. Nowadays ﬂexible videobronchoscopes are introduced
on the market. The optical ﬁbers inside the tube are replaced by a CCD-detector placed at the
distal tip of the endoscope. Drawbacks related to the ﬁbers (e.g. loss of transmission, breakage)
are voided.
Conventional white light bronchoscopy has a high sensitivity and speciﬁcity for early stage,
invasive, central bronchial cancer, but is limited in the detection of small pre-neoplastic lesions.
Indeed, in the central airways, less than 40% of high grade dysplasia is detectable by conven-
tional white light bronchoscopy [Lam00, Wagn03]. Autoﬂuorescence bronchoscopy (AFB) has
been introduced as a tool for the detection of ﬂat pre-neoplastic central bronchial lesions. Its
sensitivity for pre-invasive squamous lesions is about twice that of conventional white light bron-
choscopy [Lam98, Gouj03]. AFB will be discussed in Chapter 7.5 of this thesis in more detail.
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Some trials involving virtual bronchoscopy have been carried out. Data set acquired with CT
scan can be process with computer-generated, three-dimensional reconstruction techniques. It
can render surfaces or endoluminal images. These approaches could be added to the conventional
imaging technique to enhance visualization.
7.3.2 Treatment of bronchial cancer
Surgery is the preferred curative therapy of localized non-small cell lung cancer (NSCLC) at
stage III and below. Depending on the stage and the extent of the lesion, surgery is performed
as pneumectomy (surgical removal of a lung), or lobectomy (surgical removal of a lobe). The
overall 5-year survival rate for complete surgical resection of stage I and II NSCLC is about
40% [Dien01]. Limited resection such as segmentectomy or wedge resection reduce mortality
and morbidity, but are associated with a 3 times higher local recurrence rate and a decrease in
5-year survival [Dien01].
Post-operative radiotherapy and (neo-)adjuvant chemotherapy can improve survival [PORT98,
Stew00]. However, about 30% of all patients with localized NSCLC don’t undergo surgery due
to presentation at an advanced stage, unresectability of the carcinoma, medical comorbidities, or
advanced age [Baum01]. In these cases, radiotherapy (alone or in combination with chemother-
apy) oﬀers the only curative possibility. However, the mean 5-year survival rates for those
treatments are below 27% for stage I–II lung cancer [Zimm03] and around 10% for stage III–IV
disease [Souh98].
For localized pre-neoplasia, i.e. squamous dysplasia and CIS, (micro-)invasive carcinoma,
and early stage bronchial carcinoma, minimal-invasive bronchoscopic therapies provide alter-
native treatment options [Shes00, Hert05]. Most common therapies include PDT [Mach95],
endobronchial brachytherapy (EB) [Mach95, Nag01], cryotherapy [Deyg01], argon plasma co-
agulation (APC) [Cros01], laser therapy with Nd:YAG laser and electrocautery [vanB01]. The
endoscopic treatment of early-stage bronchial cancer has been reviewed by Sheski [Shes00] and
Herth [Hert05]. PDT for the treatment of early stage bronchial cancer and pre-neoplastic en-
dobronchial lesions has been widely investigated. Clinical studies have shown that the response
rate of PDT is highest for CIS and microinvasive SCC sized < 1 cm. 5-year survival rates in
patients treated with PDT for early stage bronchial carcinoma or bronchial pre-neoplasia vary
between 43% and 72% [Mazi04]. The most common photosensitizer used for bronchial PDT is
Photofrin R© [Monn90, Kato98], but clinical studies using m-THPC [Sava97] and mono-L aspartyl
chlorin e6 [Kato03] have also been reported.
In a 3-year follow up study, Monnier et al. [Monn90] and Savary et al. [Sava97] reported
a local recurrence rate after PDT for dysplasia and CIS inferior to 15%. However, the use of
bronchoscopic therapies for the treatment of bronchial cancer demands accurate delineation and
staging of the lesion, especially the determination of the lesion’s inﬁltration into the bronchial
mucosal layers and the exclusion of nodal extension [Sute01].
7.4 Angiogenesis
Carcinogenesis in the bronchial wall is associated with an increased growth of new blood vessels,
called angiogenesis, as reported by Fisseler-Eckhoﬀ et al. [F.-E96, F.-E98] and Fontanini et al.
[Font99]. These groups investigated the micro-vessel density (MVD) in the tunica propria of
normal, metaplastic, dysplastic and early cancerous human bronchial tissue. The morphometric
ﬁndings reported by the two groups are summarized in Table 7.4. Both groups reported an
increase in the MVD with increasing degrees of tissue degeneration. High grade dysplasia and
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CIS were found to have a 3 to 4 times higher MVD than normal tissue. In samples with advanced
dysplasia, increased angiogenesis was found in the vicinity of the basement membrane. In a more
recent work, Keith et al. observed the presence of capillary blood vessels closely juxtaposed to
and projecting into dysplastic squamous epithelium of bronchial biopsy specimens [Keit00].
The MVD in this so-called angiogenic squamous dysplasia (ASD) was increased in comparison
with normal mucosa, but comparable to the MVD in other forms of dysplasia. Figure 7.7
illustrates the angiogenic squamous dysplasia and angiogenesis in bronchial neoplasia (adapted
form [Keit00]). Shibuya et al. also reported an increase in MVD and the presence of ASD
in bronchial pre-neoplasia and early cancerous lesions in a clinical in vivo study using a high
magniﬁcation bronchoscope [Shib02, Shib03]. Shijubo et al. reviewed tumor angiogenesis of non-
small cell lung cancer, showing recent evidence suggesting that angiogenesis is related to poor
prognosis in many solid tumors [Shij03]. All aforementioned changes in the vascularization of
pre-neoplastic tissue are associated with an increased blood (thus, haemoglobin) concentration
in this type of tissue relative to normal tissue.
Fisseler-Eckhoﬀ et al. Fontanini et al.
0.4 mm below the basement membrane in the lamina propria
in the lamina propria (depth not speciﬁed)
Measured Value Microvessel Density Vessel Cross section Microvessel Density
[mm−2] [10−4 mm2] [mm−2]
Healthy Bronchial Wall 33 9.04 12
Chronic Inﬂammation 55 14.4 -
Acute Inﬂammation 43 11.3 -
Hyperplasia 40 5.38 11 ± 5
Squamous cell Metaplasia 55 15.3 11 ± 5
Mild Dysplasia 83 2.95 13.5
Moderate Dysplasia - - 28 ± 20
Severe Dysplasia/ CIS 101 9.08 56 ± 14
Invasive SCC 105 7.61 77 ± 10
Table 7.4: Morphometric data for vascularization of healthy and neoplastic bronchial mucosa, derived
from Fisseler-Eckhoﬀ [F.-E96, F.-E98] and Fontanini [Font99]. Though the absolute values for the vessel
density in the subepithelial layers of the bronchial wall are diﬀerent, both reports show an increase in the
vessel density with increasing grade of pre-neoplasia and neoplasia.
As already stated in Section 2.2.1.1, Gabrecht et al. recently showed that hemoglobin content
in the tissue is likely to be responsible for the AF chromatic contrast [Gabr07a]. These obser-
vations were the rationale that allows us to observe the vascularization that lies “under” the
early lesions with a dedicated high magniﬁcation bronchoscope. Preliminary results are shown
in Chapter 11.
7.5 Autoﬂuorescence bronchoscopy development
Conventional diagnostic procedures have a low sensitivity for intra-epithelial lesions. This may
be attributed to several factors. First, the small size of these lesions (usually only a few mm
in diameter, with an extension over only a few cell layers) [Lam00]. As a result, they cannot
always be distinguished from surrounding healthy tissue by their form; in other words by their
size and elevation. Second, diﬀerentiation based on color reﬂectance is very restricted or even
impossible for early lesions. As a result, only approximately 30% of existing carcinomas in situ
could previously be made visible [Kenn01].
Autoﬂuorescence (AF) endoscopy was a great improvement in the detection and localization
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Figure 7.7: Photomicrographs of ASD. a) capillary tufts (arrows) are projecting into the dysplastic
squamous epithelium of the bronchial wall. The epithelium is thickened. b) Thickening of the basement
membrane is frequently observed in ASD lesions.
of intraepithelial lesions as compared to white light bronchoscopy [Horv99, vanR01, Gouj03].
By exciting bronchial tissue by exposing it to violet and blue light at a deﬁned wavelength,
autoﬂuorescence light is induced in the endogenous ﬂuorophores of the bronchial wall (see Sec-
tion 2.2.1.1).
Several advantages of AF bronchoscopy vs. WL bronchoscopy were acknowledged over the
last years : (i) bronchial carcinoma can be visualized and treated at a stage at which the
chances of healing are still very good; (ii) margins of the tumor can be clearly demarcated; (iii)
and the extent of a tumor is much easier to recognize than under white light allowing more
accurate staging; (iv) in contrast to PDD (photodynamic diagnosis), no medication is required
to produce the ﬂuorescence. This avoids a number of potential problems such as the approvals
for the medication (known as photosensitizers), the method of administering the medication and
the dose, toxicity, bleaching of the tumor marker, etc. (iv) the change over between conventional
white light and AF endoscopy is simple and fast by pressing a foot switch. No bronchoscope
changes is required.
Autoﬂuorescence bronchoscopy (AFB) was introduced by Stephen Lam’s group, in Vancou-
ver, and was ﬁrst reported in the early 1990’s [Hung91, Lam93]. Several endoscopic AF imaging
systems have been developed and are commercially available [Wagn03]. Instruments from the
following companies are currently on the market: the LIFE system by Novadaq (ancient Xillix
Technologies, Vancouver, BC, Canada), the SAFE system by Pentax (Tokyo, Japan), the D-
Light system by Karl Storz GmbH (Tuttlingen, Germany), the DAFE system by Richard Wolf
GmbH (Knittlingen, Germany), and the Evis Lucera Spectrum by Olympus Inc. (Tokyo, Japan)
(see Table 7.5).
Over the last years, several photodetection system have been developed at EPFL (in collabo-
ration with Richard Wolf GmbH) in the framework of diﬀerent PhD thesis (see Figure 7.8 [Wagn92,
Zell00, Step02, Uehl05, Gabr06]). In 2002, the ﬁrst generation of DAFE (Diagnostic AutoFluo-
rescence Endoscopy) was commercialized by Wolf. Since then, the device has been updated with
the addition of backscattered light (blue and red) following the prospective work of Gabrecht et
al. [Gabr07b, Gabr08]. The color presentation (lesion vs. background) was adapted with the
diﬀerent system generations (red vs. green, red vs. pinkish, blue vs. gray).
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Manufacturer Excitation Emission &Image presentation
Xillix I Helium-Cadmium
laser (442 nm) &
separate WL source
2 spectral regions : 500–575 nm (green) and 615–
630 nm (red). Lesions as reddish brown zones on
a greenish background [Lam90, Lam93]
Xillix Oncolife Xenon light source
for WL & AF
[Stri08, Edel09]
SAFE-3000, Pentax 408 nm laser diode One green spectral domain (490–590 nm). Tis-
sue background (light green), lesions (dark green)
with simultaneous display of WL and AF [Lee07]
D-Light, Storz Xe lamp WL & AF
exc. (380–460 nm)
3-CCD camera [Häuß05]
DAFE, Richard Wolf Xe lamp WL & AF
exc. (370–430 nm)
1-CCD camera with LP ﬁlter at 455nm. Red le-
sions over pinkish background [Gouj03, Gabr07c]
DAFE II, Richard
Wolf
Xe lamp WL & AF
exc. (370–430 nm)
1-CCD camera with LP ﬁlter at 455nm. Blue
lesions over grayish background after intelligent
Color Balance7.
Evis Lucera Spec-
trum, Olympus
Xe lamp WL & AF
exc. (395–475 nm)
AF 490–625 nm, reﬂected light (550,610 nm).
Normal mucosa (light green), tumor (pinkish),
vessel (dark green) [Chiy05, Ueno07]
Table 7.5: Development of the ﬂuorescence detection setup over the last years.
Bertha Anna DAFE I
Figure 7.8: Diﬀerent generations of the endoscopic ﬂuorescence imaging system developed at EPFL:
Berta (1992), Anna (1998-99), DAFE I (2002)
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Chapter 8
Narrow-band excitation
in the bronchi
As already mentioned in Chapter 7, all commercially available AFB systems show high sensi-
tivity, but only limited speciﬁcity for the detection of early cancerous and precancerous lesions
in the bronchi.
A fundamental understanding of the origins of the mechanisms underlying the AF contrast is
essential for a better diﬀerentiation between true and false positive results. It has been described
elsewhere (Section 2.2.1.1) that the autoﬂuorescence (AF) contrast between (pre-)neoplastic
lesions and healthy tissues in the bronchi results from (i) an overall decrease in AF intensity
(“intensity contrast”) and (ii) a stronger decrease in the green (450–600 nm) relative to the red
(600–800 nm) (“spectral contrast”), i.e. a distortion of the AF spectral shape. The purpose of
the present chapter was to investigate the inﬂuence of the excitation bandwidth on the healthy-
to-lesion AF contrasts in AFB.
In a spectroﬂuorometric study, Zellweger et al. demonstrated in vivo that the excitation
wavelengths producing the highest healthy-to-lesion contrasts (intensity and spectral) are be-
tween 400 nm and 430 nm with a peak around 405 nm [Zell01]. The authors concluded that this
wavelength range would be optimal to discriminate between healthy tissue and (pre-)neoplastic
lesions. Since it corresponds to the absorption peak of hemoglobin, it is very likely that light
absorption due to tissue hemoglobin is playing a major role in the build-up of AF contrasts.
This is in good agreement with Bard et al. , who showed that bronchial tumors are characterized
by a lower blood oxygen saturation and a higher blood content than normal mucosa. No diﬀer-
ences were observed between normal and metaplastic/mild dysplastic mucosa [Bard05]. Since
blue-violet light at wavelength around 405 nm does not penetrate deeply in bronchial tissue,
these results also suggest that the contrast mechanisms are located in the superﬁcial layers of
the bronchial walls. This is conﬁrmed by the data of Qu et al. , who showed that the main
contribution of bronchial AF arises from the upper part of the sup-epithelial layer while no
signiﬁcant AF is observed form the superﬁcial epithelium [Qu94, Qu95].
Nevertheless, we should stress at this point the inﬂuence of the measurement geometry.
Indeed, point measurement is more sensitive to chromophores and absorbers present in the
vicinity of the mucosa, whereas imaging covers a larger surface, and collects information from
deeper layers. Thus, ﬁber-based measurements are very sensitive to epithelium thickening – from
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about 40µm in normal tissue up to more than 100µm in CIS [Qu94, Häuß99]–, and displays often
an intensity contrast between pre-cancerous lesions and healthy tissue [Qu94]. Autoﬂuorescence
imaging has been shown to be less sensitive to surface modiﬁcation. Conversely, the ﬂuorescence
signal originating in the submucosa can be better collected with AFB, since epithelium in itself
is not ﬂuorescing (i.e. being almost transparent). Therefore, the chromatic contrast (green AF
is much more lowered than red AF) has been almost exclusively demonstrated with imaging
studies.
Gabrecht et al. reported previously on the addition of blue and red backscattered light to
enhance the contrast [Gabr07, Gabr08]. In this chapter, we are comparing the contrast obtained
with a narrow-band excitation around 410 nm from a laser light source (superﬁcial excitation,
< 100µm) and a broadband excitation around 430 nm (deep excitation, 100–300µm) from a
ﬁltered lamp.
Some optical tricks were investigated to achieve an homogenous illumination at the distal
end of the endoscope, necessary for good endoscopic image quality. Problems occurred at the
interface between the laser extension ﬁber and the liquid light guide that conveys light to the
endoscope. Indeed, the ﬁber has a numerical aperture (NA) of 0.4 and a diameter of 400 µm and
the guide had a NA of 0.53 and a diameter of 4 mm. We designed a coupler having a SMA plug
on one side and custom made plug for the light guide on the other side, as shown in Figure 8.1.
The part containing the SMA plug could be rotated in the x-y plane around a central axis in
order to change the injection angle between the extension ﬁber and the light guide. Perpen-
dicular injection resulted in a “forward peaked” light output (i.e. inhomogeneous illumination
of the endoscopic site). A slight rotation of the SMA connector results in a bell-shaped light
distribution which ﬁts the angular distribution of the illumination with the broadband light
source [Gabr06].
Figure 8.1: The custom-made light guide coupler. The optical quartz ﬁbre and the endoscopic
light guide are plugged at opposite sites. The coupling angle can be adjusted by the screws at either side
of the unit.
In the article reproduced hereinafter [Lovi07], only the green channels of the relevant images
were reproduced, because they contain the contrast information. Indeed, some red backscattered
light was collected in the red color channel, so that the pure AF contrast could not be observed
in this channel. Figure 8.2 displays the white light reﬂectance image, and both AF images,
excited with DAFE and Kr+, respectively.
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A biopsy was taken on each suspicious site, and the analysis revealed the following histopatho-
logical status:
A 60-year old female patient. CIS located in the inferior bronchus. The lesion is clearly
visible at the “11 o’clock” position on the cardiac wall of the bronchus. The intensity
decrease on the lesion relative to the healthy surrounding is clearly enhanced with the
narrow band Kr+ excitation.
B 59-year old patient. High grade squamous dysplasia on the division of the middle lobe.
The spur exhibits strong red ﬂuorescence in DAFE. The grayscale images reveal a strong
intensity decrease of the green AF on the lesion.
C 70-year old patient. CIS in the left lower bronchus. Hardly suspect with WLB, the spur
exhibited a dark red ﬂuorescence with both DAFE and Kr+ excitation.
A
B
C
Figure 8.2: White light, autoﬂuorescence (DAFE) and Krypton (Kr+) images from three patients.
A CIS located in the inferior bronchus.
B High grade squamous dysplasia on the division of the middle lobe.
C CIS in the left lower bronchus.
In this study, we can conclude that narrow-band excitation improves the intensity contrast.
Indeed, for each site, the healthy/tumor ratio in the green channel (Gh/Gt) for the narrowband
excitation exceeds Gh/Gt for the broadband excitation, with a mean ratio equal to 1.43±0.20. As
described in previous studies [Gabr05], the bandwidth of the excitation light has no detectable
inﬂuence on the spectral contrast, i.e. the intensity ratio between the red and green channels.
In this study, since no red ﬂuorescence intensity can be measured due to the red backscattered
light, no valid statement about spectral contrast can be made.
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Chapter 9
Calibration and optimization
of the AF imaging system
This chapter present two studies aiming to quantify the intra- and inter-patient variations in the
AF intensities in order to optimize the spectral response and the settings of the DAFE imaging
system (manufactured by Richard Wolf GmbH). These variations can negatively aﬀect the image
quality of AF bronchoscopy (AFB) and, thus, the learning curve of the clinician. Moreover, some
knowledge about the magnitude of these variations can help to scale the dynamic range of future
AFB systems.
Variations in the AF intensity have already been described in spectrometric study [Zell01a],
as well as in imaging study [Hirs01, Kenn01, Gouj03], where bronchial AF is investigated, but to
our knowledge, this is the ﬁrst reported quantitative analysis of the inter-patient variations of AF
intensity and reﬂectivity of endobronchial tissue. Zellweger et al. demonstrated that the intra-
patient variations were signiﬁcantly smaller than the inter-patient variations (approximately
50%) [Zell01b]. Compared to this value, the inter-patient variations found in our study were
surprisingly small: approximately 25% on the healthy carina in the green part of the spectrum
(490–580 nm) and only slightly higher (32%) in the red part of the spectrum. The depth-probing
issue has to be taken into account when comparing imaging and spectroscopic studies, but it
has been already addressed in the Introduction of the Chapter 8).
The quantiﬁcation of the AF intensities with routinely used endoscopic imaging systems is
not trivial. Indeed, these systems often feature camera gain control, frame integration, or shut-
ter time adjustment to dynamically react to the varying imaging conditions during endoscopy
(thoroughly described in [Gabr06]). Therefore, the quantiﬁcation of the tissue AF requires the
use of an optical reference allowing normalization of the intensity levels. We designed this refer-
ence so that it can be placed in the patient’s bronchi during bronchoscopy. Having the reference
and the bronchial mucosa in the same ﬁeld of view (i.e. the same camera settings) allows us to
normalize the images oﬀ-line.
In the ﬁrst article (published in Physics in Medicine and Biology [Gabr07]), the design
and characterization of a reference for AFB is presented. The second article (published in
Lasers in Medical Science [Gabr09]) presents a preliminary clinical study aiming to quantify the
inter-patient variations during AFB with the help of the developed reference. Both studies are
reproduced in their published format.
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The experiments were mainly realized in the framework of Tanja Gabrecht’s PhD the-
sis [Gabr06]. The contributions of the author of this thesis manuscript were the following:
Design of an endoscopic reference I prepared the measurement set up and characterized
the reference’s optical properties (i) R∞, the total diﬀuse reﬂectance, (ii) µeﬀ, the eﬀective
attenuation coeﬃcient (and calculation of µa and µ′s), (iii) the ﬂuorescence properties (emission
spectrum) with an optical ﬁber-based spectroﬂuorimeter, and (iv) the photostability of the
material.
Quantiﬁcation of the inter-patient variations I performed image acquisitions in the clin-
ical environment in order to enlarge the patient cohort, and obtain representative sampling. I
was also involved in the oﬀ-line analysis of the images in order to compute the red/green ratios
on the tissue and reference. This latter work was realized in parallel with Ms. Gabrecht, in
order to lower bias due to the observer.
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Chapter 10
Clinical evaluation
of the AF imaging system
This chapter presents a clinical evaluation of a version of the AF-based imaging prototype,
manufactured by Richard Wolf GmbH to detect early bronchial cancers. It implements the con-
clusions of Gabrecht et al. [Gabr08], that optimized the amount of detected blue backscattered
light to improve speciﬁcity of AF detection method.
A second prototype — which allows online image analysis (e.g. thresholding based on the
green/red ratio) — has also been evaluated clinically. The results are presented in Appendix A.
This second study shows that an optimal thresholding procedure allows to dramatically reduce
the false positive rate in head& neck (H&N) cancer patients.
10.1 Introduction
As mentioned in Chapter 7, lung cancer accounts for about 30% of the cancer deaths in the
world, and the overall 5-year patient survival is less than 15%. Patient survival is strongly
linked to the early detection of bronchial lesions. For instance, 5-year survival for stage Ia
is 60%. Unfortunately, lung cancer is often asymptomatic. Consequently, about 66% of the
patients already present a stage III/IV cancer at the time of diagnostic, which predicts a poor
prognostic. Thus, a reliable detection method for early cancer would help to improve the patient
prognostic.
Systematic screening by chest X-ray and sputum analysis has been proposed, but it is cur-
rently not implemented because it does not lower mortality [Cort83]. “Molecular screening”
has undergone encouraging progresses in the recent years, but this procedure is not yet es-
tablished in the clinical environment. The cancer guidelines advise the following : if atypical
or cancerous cells are found during sputum analysis in absence of radio-visible lesions, a de-
tailed examination of the full respiratory tract is strongly advised [Søre09]. Even if a primary
cancer is already detected in the H&N region, one should not cancel the bronchoscopic exami-
nation, since these lesions are often multifocal [Sava91]. About 60% of radio-occult cancer are
(pre-)neoplastic cancers (dysplasia, CIS, and micro-invasive carcinomas), but unfortunately only
30% of the CIS and 60% of the microinvasive carcinomas are visible in conventional white light
bronchoscopy [Lam93].
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Endoscopic ﬂuorescence imaging (EFI) systems have been developed in order to improve
the sensitivity of WL endoscopy. Indeed, AF bronchoscopy (AFB) has been shown to have a
twice better sensitivity than conventional WL bronchoscopy (WLB) [Häuß05]. However, the
AFB speciﬁcity remains limited, mainly due to high number of false positive. The AFB working
principle has been described elsewhere in this manuscript (see Section 2.2.1.1).
In collaboration with Richard Wolf GmbH, a new ﬂexible DAFE video-bronchoscope pro-
totype had been developed. The chip-on-the-tip technology, that integrates a CCD detector
at the distal end of the endoscope, had been implemented in this device. With this technical
modiﬁcation, the optical ﬁbers for the image transmission could be spared, avoiding that ﬁber
breakage and aging had an impact on image quality.
This clinical study aimed to assess the performances of this new prototype in a multicentric
clinical study with a larger cohort of patients (about 150), since this system was already tested
by the ENT unit in CHUV hospital with promising results.
The primary goal of this study was to determine the relative sensitivity and speciﬁcity of
AFB with respect to WL bronchoscopy. The gold standard remained histopathological analysis
of bronchial biopsies. AF photodetection served as a biopsy guide on patients with suspected
early lesions.
The second goal was the determination of tumoral markers on pre-cancerous lesions. Ge-
netic anomalies are observed in the course of neoplasia development. It is likely that an early
detection of such alterations would be a diagnostic tool discriminating pre-neoplastic lesion with
a proliferation rate. Thus, a molecular analysis was performed on 30 selected patients.
The oﬃcial documents (study protocol, patient information sheet, and patient consent form)
received approval by the local ethics committee.
10.2 Materials & Methods
10.2.1 Imaging system
The bronchoscopies were performed with the DAFE II prototype (6 mm diameter, Richard
Wolf GmbH, Knittlingen, Germany). The system consists of a DAFE/PDD light projector
(type 5138), a 1 CCD camera controller (type Endocam 5520) and a ﬂexible DAFE video-
bronchoscope (type 7270, outer diameter 6.0 mm, 2.2 mm working channel). The light projector
is infrared-ﬁltered and delivers both white and blue light (370–430 nm, see Figure 2.12). The
video-bronchoscope is equipped with a long-pass ﬁlter that rejects most of the excitation light.
In this device, some of the backscattered blue light is collected through the emission ﬁlter.
The same bronchoscope allows to perform WLB and AFB. The images are recorded by a DVD
recorder and displayed on a 19" LCD monitor, both also provided by Richard Wolf. Two of these
systems (serial numbers 456145,456146) were delivered to Lausanne in November 2006. Before
the start of the study in 2007, both light projectors were returned to Richard Wolf for technical
revision and update. The revised light projectors arrived in Lausanne at the end of March 2007.
A third one was delivered (serial number 5738) in March 2008.
With this setup, the lesions appear in blue over a greyish background. An intelligent color
balance (iCB) procedure is performed at the beginning of each examination on healthy bronchial
mucosa (e.g. main carina). It allows the camera controller to compensate for inter-patient AF
variations (see Chapter 9). This procedure implements what will be discussed in Appendix F,
namely that one option to achieve the best contrast would be to present a saturated color for
the foreground over a greyish background.
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Figure 10.1 shows a typical example, with a carcinoma in situ that is well-demarcated in AF
mode, whereas it is nearly invisible with conventional white light illumination.
Figure 10.1: Example of a CIS on a spur, with white and blue light illumination. The tumor margins
are well-demarcated in AF mode.
10.2.2 Patient population
The study was conducted in two medical locations: the CHUV university hospital in both
pneumology (PNE) and ear-nose-throat (ENT) departments, as well as at Dr. François Heinzer’s
private practice. At the CHUV hospital, the study was supervised by Dr. Alain Sauty (PNE) and
Dr. Philippe Pasche (ENT). At the end of 2008, Dr. Heinzer’s setup was moved to Clinic Cecil in
Lausanne for practical reasons (bronchoscopic examination sometimes require total anesthesia).
At this point, we would like also to thank Marie Hofer for helping in collecting patient data and
informed consent forms in CHUV hospital.
144 patients (mean age 61 years old, range 41–87) were recruited for this study between May
2007 and December 2009. Figure 10.2 shows the timeline of patient recruitment, with a mean
patient number of 4–5 per month.
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Figure 10.2: Timeline of the patient recruitment in this clinical study.
Most of the patients recruited for this study were at high risk of developing dysplasia or
carcinoma in situ, because of their smoking history.
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Inclusion criteria Patients older than 18 years old, that were subject to bronchoscopy or
panendoscopy (before being recruited in the study) were recruited if they had :
• known endobronchial lesions suspicious for neoplasia
• pulmonary or ENT lesions suspect for neoplasia (as seen in chest X-ray or CT scan)
• post therapeutic control (follow-up of oncologic cases)
• pre therapeutic control (before laser, PDT, . . .)
• samples (sputum, broncheoalveolar lavage, bronchial biopsy/brush) suspect for neoplasia
• previous suspect examination with/without AF
• smoker > 20 UPA suspicious for endobronchial lesions
Exclusion criteria Patients were excluded from the protocol if they had, apart from the
conventional contraindications for bronchoscopy:
• administration of a photosensitizer less than 4 weeks before
• treatment with chemo- or radiotherapy 3 months prior to the examination
• coagulation problems
• suspicion of carcinoid (because of high bleeding probability)
• severe hypoxemia
• pregnancy
• not signed the written informed consent.
10.2.3 Investigation protocol
All patients were examined following the same clinical protocol approved by the local ethics
committee. Control biopsies sampled on healthy tissues allowed to determine relative sensitivity
and speciﬁcity of the detection method.
The patients recruited for the study underwent endoscopic examination (ﬂexible and/or
rigid) following usual procedure, with local or general anesthesia. After the vocal cords, the
tracheo-bronchial tree was reviewed for each lobe sequentially, ﬁrst with WL, then with blue
light, so that the suspicious lesions were recorded ﬁrst in WL, and then in AFB. The physician
proceeded with the remaining procedures (biopsy, brush, broncho-alveolar lavage) at the very
end of the examination.
As a convention, it was stated in the protocol that the operator would take 2–3 biopsies per
site if 1–2 sites were described to be suspicious (WL or AF), and 1 biopsy per site if more than
3 sites were described as suspicious. Additionally, he would take 2–3 biopsies on AF negative
(AF−) tissue, with a maximum of 10 biopsies.
Suspicious regions in white light were described as areas where the bronchial mucosa lost
his normal aspect (hyperemia, non-smooth mucosa with some surface irregularities, thickening
and/or discoloration). The control biopsies on AF− tissues were sampled on interlobar or seg-
mental spurs (because of easy access). The examination was recorded on DVD for documentation
purpose.
Biopsies originating from areas suspects only under WL were excluded from this protocol
(i.e. they were analyzed but simply labeled as excluded from the protocol in the Results part).
Similarly, biopsies coming for exophytic masses were not considered because AF was irrelevant
in this situation. A case report form summarized the patient information, the localization of the
lesions, and their endoscopic appearance : ﬂuorescence (AF+/AF−) and/or WL (WL+/WL−).
If a biopsy was found to be as CIS or a micro-invasive carcinoma, the patient was informed and
a local treatment was proposed (such as cryotherapy, brachytherapy, photodynamic therapy, or
CO2 laser cauterization).
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10.2.4 Histopathological analysis
Each ﬂuorescing positive site was cold-biopsied. Tissue samples were ﬁxed in formalin and ex-
amined by experienced pathologists (Dr. Snezana Andrejevic Blant and Dr. Hanifa Bouzourene)
who were blinded to the endoscopic result (AF+ or AF−) in order not to bias the examination.
The slides were reviewed independently by both pathologists, until they reached a consensus.
The biopsies were cut in 5 µm slides and stained with hematoxylin/eosin. Bronchial biopsies
were graded according to the World Health Organization (WHO) classiﬁcation 1999 [Bram01].
Fluorescence positive biopsies were then grouped into ﬁve categories: 1) normal bronchial mu-
cosa; 2) reactive modiﬁcations (basal hyperplasia, squamous metaplasia); 3) low-grade dysplasia
(light and moderate); 4) high grade dysplasia, carcinoma in situ; 5) micro-invasive carcinoma. In
this study, classes 1, 2, and 3 are considered as non-cancerous lesions (Histo−), whereas 4 and 5
are cancerous (Histo+). Complementary observations (presence of inﬂammation, angiogenesis)
were reported for each biopsy.
The biopsies that were taken on ﬂuorescence positive (AF+) or white light positive (WL+)
sites, but upon pathological analysis were described as non-cancerous biopsies (1,2,3), were
characterized as false positives (AF/FP and WL/FP, respectively). Similarly, AF+ and WL+
regions of interest that demonstrated cancerous biopsies (4,5) were characterized as true positives
(AF/TP and WL/TP, respectively).
10.3 Results
10.3.1 Histopathological results
As mentioned above, 144 patients were recruited in the study, among them 115 patients (80%)
were not diagnosed with any ﬂuorescence positive sites. In the following, an occurrence is deﬁned
as either a patient recruited in the study with no biopsy, or a biopsy taken in one particular
patient (so that a patient with several biopsies could account for more than one occurrence).
Similarly, an occurrence was said to be excluded from the study protocol, if either 1) no ﬂu-
orescence positive (AF+) site was found in this particular patient, or 2) the histopathological
analysis was unsuccessful (e.g. limited volume of biopsy, abraded epithelium).
The 144 patients recruited in the study yielded 175 occurrences, whose endoscopic appear-
ance is listed in Table 10.1.
AF+ AF– total
WL+ 9 8 17
WL– 23 135 158
total 32 143 175
Table 10.1: Endoscopic appearance of the 175 occurrences
The 143 AF– occurrences were described as follows: excluded from protocol study (n=126),
normal (n=9), reactive modiﬁcations (n=6), low-grade dysplasia (n=2). All occurrences are
true-negative.
The 32 AF+ occurrences were described as follows: excluded from protocol (n=8), nor-
mal (n=8), reactive modiﬁcations (n=8), low-grade dysplasia (n=2), high-grade dysplasia/CIS
(n=3), micro-invasive carcinoma (n=1), non-small cell carcinoma, invasive (n=2). 18/24 (75%)
of the AF+ are false-positive, whereas 6/24 (25%) are true-positive.
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The 158 WL– occurrences were described as follows : excluded from protocol (n=128), nor-
mal (n=15), reactive modiﬁcations (n=11), low-grade dysplasia (n=2), high-grade dysplasia/CIS
(n=2).
The 17 WL+ occurrences were described as follows: excluded from protocol (n=6), nor-
mal (n=2), reactive modiﬁcations (n=3), low-grade dysplasia (n=2), high-grade dysplasia/CIS
(n=1), micro-invasive carcinoma (n=1), non-small cell carcinoma, invasive (n=2).
Table 10.2 summarizes the histopathological status of the 175 occurrences. The presence of
inﬂammatory tissue in the biopsy is indicated in brackets.
AF– AF+ WL– WL+
excluded from protocol 126 8 (2) 128 (2) 6
normal 9 8 (6) 15 (5) 2 (1)
reactive changes 6 8 (3) 11 (2) 3 (1)
low-grade dysplasia 2 2 (1) 2 (1) 2
high-grade dyplasia/CIS 0 3 (2) 2 (1) 1 (1)
micro-invasive carcinoma 0 1 0 1
invasive carcinoma 0 2 0 2
total 143 32 158 17
total (included) 17 24 30 11
Table 10.2: Histopathological status of the 175 occurrences. Number in brackets indicate the number of
occurrences containing inﬂammation.
Inﬂammation is present in 10/18 (56%) of the AF+ false-positive sites. Table 10.3 summarizes
the classiﬁcation of the 41 occurrences that were not excluded from the protocol.
AF– AF+ total
Histo– 17 18 35
Histo+ 0 6 6
total 17 24 41
WL– WL+ total
Histo– 28 7 35
Histo+ 2 4 6
total 30 11 41
Table 10.3: Summary of the 41 retained occurrences presented with respect to their endoscopic appear-
ance.
No false-negative (AF−/Histo+) were observed with AFB. Consequently, all the cancerous
lesions were detected by AFB, whereas only 4/6 (66%) were detected with WLB only. The
higher stage carcinomas (micro-invasive, invasive) were visible with both imaging modalities.
AFB was more sensitive to pre-neoplastic changes of the bronchial mucosa than WLB (10/5).
10.3.2 Technical review
Since this instrumentation was an improved prototype, we also asked the physicians to com-
ment about the new device. They positively reviewed the image quality in AF mode. The
endobronchial stripes were well-deﬁned, which can be of great help for the operator. Indeed,
disruption in the stripes could be a hint for a pre-cancerous lesion. The bronchoscope handling
was convenient (e.g. navigation was easy), even if the videobronchoscope was a little bit more
rigid (less bendable) than the Olympus currently used in CHUV. The initial devices suﬀered
from a lack of suction, which could impaired the broncho-alveolar lavage (e.g. diﬃculties to
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recollect the ﬂuid after it was squirted into the lung). This issue had been partly solved with
Wolf’s detailed explanations.
The intelligent color balance (iCB), as well as the non-intuitive false-color presentation,
was not easy to teach to the operators. Secretions appearance was bright blue and could be
disturbing to identify ﬂuorescence positive lesions. A mucosa clearance with NaCl solution was
sometimes required.
10.4 Discussion
In a review of ﬂuorescence bronchoscopy data in a selected population of smokers and former
smokers with sputum atypia (i.e. patients having a proﬁle corresponding to the patients of the
present study), prevalence rates of 6% and 1.6% were reported for severe dysplasia and CIS,
respectively [Lam00]. The prevalence in the present clinical study is 6/144 (4.2%).
The number of biopsies taken on (WL+/AF−) sites with non-cancerous histopathological
analysis is 3/7. Hence, AFB can potentially reduce the number of biopsies by 43%.
The number of false-negative is always diﬃcult to assess extensively, because one could not
take biopsies everywhere in the whole lung. In this study, the “theoretical” negative predictive
value of AFB (directly linked to the numbers false-negative) is 100%. For this reason, some
physicians do not take any biopsies on AF– areas, because they are pretty conﬁdent that a
ﬂuorescence negative area (AF–) won’t turn out to be histopathologically positive [Ramo10].
The positive predictive value is only 25%, due to the high number of FP (n=18), which may
be partly attributed to the high number of physicians involved in the study. It was foreseen
that only 2-3 clinicians would be recruited as operators, but at the end, more than 20 physicians
were active in this study due to rotations in the assistant team. Since they need a few patients
to “steep” their learning curve, we can imagine that about 20% of the false positive could be
discarded.
Despite the fact that they were built with the same architecture, some tiny diﬀerences in color
rendering were observed between the three devices used in this study. However, we reviewed all
the cases, and we could not show a signiﬁcant diﬀerence in sensitivity and speciﬁcity between
the three devices. However, it can not be excluded that some FPs may be attributed to these
variations.
We observed a high number of inﬂammations associated with false-positive results (56%).
It is likely that morphometric parameters (e.g. vascularization patterns underlying these AF+
areas) can reject a high proportion of these false-positive lesions [Shib10]. For that purpose, we
developed e.g. high-magniﬁcation bronchoscopy (see Chapter 11) to help decreasing the false-
positive rate.
Another source of AFB false positives is related to the biopsy sampling. Whenever possible,
biopsies are taken in the ﬂuorescence mode to ensure that the tissue sample is coming from a
ﬂuorescence positive area. Nevertheless, it cannot be excluded that a certain number of tissue
samples are not taken from the ﬂuorescence positive regions, but from ﬂuorescence negative
(AF−) neighboring tissue. Last, histopathologic examination is deemed as the “gold standard”
for comparison with bronchoscopic ﬁndings in nearly all clinical studies reporting on autoﬂuores-
cence bronchoscopy. Nevertheless, some authors report on signiﬁcant inter-observer variability
in histopathologic analysis [Kuri98, Venm00]. In a retrospective study of 343 bronchial tissue
samples from AFB, Venmans et al. revealed inter-observer variability by a factor of 2 in the
number of diagnosed preinvasive bronchial neoplasia [Venm00].
In this study, we used a strict deﬁnition of cancerous, resp. non-cancerous lesions. However,
in a preventive examination, the ﬁrst steps of carcinogenesis (such as reactive changes, squamous
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metaplasia, low-grade dysplasia) can also be of interest, because the diagnosed patient can be
told to avoid carcinogen exposure (e.g. smoking) to allow self-regression of the lesion.
Many patients have extra-bronchial lung tumors that can be visualized on the CT-scan, but
since these tumors are not protruding in the endoluminal space, they remain invisible with bron-
choscopic examination (even with AF). In the recent years, a new technology has been developed
by Olympus Inc, namely the transbronchial needle aspiration guided by an endobronchial ultra-
sound (EBUS-TBNA) [Came10]. It allows the physicians to sample mediastinal lymph nodes
and peribronchial lesions, and to stage the extrabronchial carcinoma.
Since bronchial cancer is an evolutive disease, we had in mind to follow-up the patients over
the study timeline, in order to see if a pre-neoplasia (Histo−, but detected as AF+ with our
device) could have been seen later on either with a self-regressed or a cancerous lesion. We
reviewed all the patients ﬁles available at CHUV. Unfortunately, only few patients came back
to the CHUV hospital for oncological treatment (chemo- or radiotherapy often for other non-
bronchial primary cancer), but none of them were subject to a second bronchoscopy until end
of 2009.
Summarily, we conclude that this new prototype is highly sensitive to pre-cancerous modiﬁ-
cations of the bronchial wall. It also detects carcinoma in situ and micro-invasive lesions. Since
it adds virtually no time to the conventional examination – barely a few minutes when used in
parallel with WL examination –, it can be a great help for the physician.
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Chapter 11
High magniﬁcation endoscopy
in the bronchi
11.1 Introduction
Since several decades, the physicians are able to access hollow organs with endoscopic meth-
ods, which serve both as diagnostic and surgical means in a wide range of disciplines of the
modern medicine (urology, gastroenterology, pneumology,. . .). Over the last years, various en-
doscopic instrumentations were developed. The original rigid optics were gradually replaced with
new devices, including ﬁbroscopes, videoendoscopes, and recently high magniﬁcation and high-
resolution endoscopes. White light (WL) endoscopy displays a poor sensitivity to (pre-)neoplastic
lesions. Autoﬂuorescence bronchoscopy (AFB) was developed to overcome this limitation. Cur-
rent endoscopic methods based on the detection of autoﬂuorescence achieve high sensitivity, but
still lack speciﬁcity.
High rates of false positive results negatively aﬀect the outcome of the AF diagnostic tech-
nique, in particular in the tracheo-bronchial tree [Verm99, Venm99, Lam00]. This issue has
already been addressed by other authors using commercial systems based on violet autoﬂuo-
rescence excitation [Häuß99, Horv99, Iked99]. Some categories of atypical but noncancerous
tissues (such as scar tissue, inﬂammation, and bruised mucosa) often appear positive under
AFB [Häuß99].
Section 2.2.1.1 present the origins of AF contrast in the bronchi between healthy tissue and
early neoplastic lesions. Summarily, this contrast is mainly due to the epithelium thickening and
the increased vessel density below the AF+ lesions [Kenn01, Chha05, Gabr07, Gabr08]. Indeed,
several authors have reported increased microvessel density in the sub-epithelial layer of bronchial
squamous dysplasia and carcinoma in situ (CIS) [F.-E96, Font99]. Vascular changes are also
found in pre-neoplastic, i.e. inﬂammatory and metaplastic lesions, but are characterized by ves-
sel sizes and distribution patterns diﬀerent from those observed in neoplastic and early cancerous
lesions [F.-E96]. Therefore, inﬂammation and metaplasia exhibit a minor increase in the number
of vessels along with increased vessel cross section surface, while angiogenesis in dysplasia and
CIS is characterized by a signiﬁcant increase in the number of small diameter vessels [F.-E96].
Moreover, in a high number of dysplastic lesions, the presence of capillaries being closely jux-
taposed or even projecting into the bronchial epithelium have been reported [Keit00, Hirs01].
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These lesions, termed angiogenic squamous dysplasia (ASD), are suspected to have a higher
probability to become squamous cell carcinoma than dysplasia or CIS.
All diﬀerences in the neovascularization pattern are associated with diﬀerences in blood
volume, and thereby hemoglobin concentration in the tissue. This is also true for bronchial
tissues, as described by Qu et al. [Qu94]. Therefore, it is likely that developing new imaging
capabilities (including vascular imaging) will facilitate discriminating mucosal changes.
Gabrecht et al. showed that hemoglobin content of the tissue has a dramatic impact on
spectral contrast [Gabr07]. Indeed, after formalin ﬁxation, neither spectral measurements nor
imaging revealed spectral contrast between healthy bronchial tissue and (pre-)neoplastic lesions
in formalin. These results indicate that epithelial thickening and blood supply in the adjacent
lamina propria are likely to play a key role in the generation of the AF contrast in bronchial
tissues.
These results are conﬁrmed by Uehlinger et al. , who performed time-resolved measurements
of tissue autoﬂuorescence excited at 405 nm with an optical-ﬁber-based spectrometer in the
bronchi of 11 patients [Uehl09]. No signiﬁcant change in the AF lifetimes was found, suggesting
that the spectral contrast might be due to an enhanced blood concentration just below the
epithelial layers of the lesion. The intensity contrast probably results from the thickening of the
epithelium in the lesions.
Yamada et al. observed many ramifying subepithelial microvessels of large airways in in-
tercartilage and membranous portions, whereas only a few microvessels were seen in cartilage
portions. Histologically, these subepithelial microvessels were thought to be distributed within
approximately 800 and 500 µm beneath the surface of the intercartilage portions and membra-
nous portions, respectively [Yama05].
Shibuya et al. report the characterization of vessels with high magniﬁcation, using either
narrow-band imaging or autoﬂuorescence as a detection method [Shib02, Shib03]. All the biopsy
specimens from 16 normal ﬂuorescence sites were found to consist of normal bronchial epithe-
lium. Biopsy specimens from 43 abnormal ﬂuorescence sites were diagnosed as 22 bronchitis and
21 dysplasia. Of the 21 bronchial dysplasia specimens, 17 lesions had morphological changes
characteristic of angiogenic squamous dysplasia reported by Keith et al. [Keit00]. Immunohisto-
chemical stains for CD34 conﬁrmed the presence of endothelial cells lining the capillaries in the
core of the papillary projections and subepithelial lamina propria. In this study, they observed
subepithelial vessels L1, L2, and L3 of calculated size 42.2–84.3 µm, 41.4–82.7 µm, and 50.3-
100.6 µm, respectively, at an observation depth of 1-3 mm. In histopathological analysis, the
diameter of capillary blood vessels C1, C2, C3, and C4 in ASD were 49.9 µm, 47.6 µm, 34.4 µm,
and 26.5 µm, respectively. Thus, the actual diameters seen in the histopathological samples
roughly matched the vessel diameters seen by high magniﬁcation bronchoscopy, especially at an
observation depth of 1 mm.
In a very recent report, the same authors repeated the measurements on various histopatho-
logical types (ASD, CIS, microinvasive, and invasive carcinoma) [Shib10]. First, high-resolution
bronchovideoscopy with WL was performed. Observations were repeated using NBI light to
examine microvascular structures in the bronchial mucosa. Spectral features of the RGB (red/
green/ blue) sequential videoscope system were changed from a conventional RGB ﬁlter to the
new NBI ﬁlter. The wavelength ranges of the NBI ﬁlter were: 400–430 nm (blue), 400–430 nm
(green), and 520–560 nm (red). Increased vessel growth and complex network of tortuous ves-
sels of various sizes were clearly observed in ASD, whereas some additional dotted vessels were
observed in squamous cell carcinoma. Capillary blood vessel and/or tumor vessel mean di-
ameters of ASD, CIS, micro-invasive and invasive carcinoma were 41.4±9.8 µm, 63.7±8.2 µm,
136.5±29.9 µm, and 259.4±29.6 µm, respectively. These results indicated a statistically signif-
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icant increase of mean vessel diameters in the four groups (p < 0.0001). These authors even
described a vessel morphology evolution during lung cancer pathogenesis.
Squamous dysplasia ASD CIS Micro-invasive Invasive
Tortuous vessel networks + + – – –
Dotted vessels – + + ++ +++
Spiral and screw type vessel - - + ++ +++
Table 11.1: Vessel morphology during lung cancer pathogenesis established by NBI imaging using high-
resolution bronchovideoscope (adapted from [Shib10].
At this point, we can draw a parallel with urology, where we also performed high magniﬁca-
tion vascular imaging. The observed vascular patterns were used to discriminate the false from
the true positive lesions in the bladder (see Chapter 5, published in [Lovi10]).
In collaboration with Richard Wolf GmbH, we developed a new prototype to integrate high
magniﬁcation capability in AF and standard bronchoscopes. Due to the high false-positive
rate related to AFB, there is a high interest in characterizing positive spots observed during
autoﬂuorescence bronchoscopy. In this chapter, we present a clinical evaluation of the modiﬁed
AF bronchoscope to provide a proof-of-concept for its future clinical usage. For this study, we
recruited patients belonging to high risk groups, in order to have a higher probability of ﬁnding
ﬂat lesions.
The main objectives of the clinical evaluation were the following:
1. To determine the appropriate magniﬁcation to see the small vessels located at the surface
of the bronchial wall.
2. To determine the optimal spectral design for the detection of backscattered light between
WL, green light and violet light.
3. To determine if the found magniﬁcation is compatible with the standard DAFE or WL
macroscopic observations.
11.2 Materials and Methods
11.2.1 HM bronchoscope optical and mechanical characteristics
Two slightly diﬀerent bronchoscopes were tested in the clinics :
Bronchoscope A HM DAFE bronchoscope, ﬁltered, outer diameter 6 mm.
Bronchoscope B HM bronchoscope, non-ﬁltered, outer diameter 5.3 mm, used to detect
backscattered violet light.
For comparison purpose, we used two regular DAFE bronchoscopes :
Bronchoscope C DAFE bronchoscope, ﬁltered, outer diameter 6 mm.
Bronchoscope D DAFE bronchoscope, ﬁltered, outer diameter 5.3 mm.
The CCD detector used in both endoscopes has a diagonal size of 1/10 inch with 330’000 pixels.
It is equipped with a cyan-magenta-yellow-green (CMYG) mosaic ﬁlter. A dedicated video
processing unit, that delivers RGB-PAL signals to a monitor, is attached to the CCD. The CCD
itself is placed in bronchoscope A behind a long-pass ﬁlter (LP455nm, Richard Wolf GmbH,
proprietary ﬁlter) to allow ﬂuorescence visualization, and in bronchoscope B behind a neutral
density glass window to protect it during machine cleaning process.
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Figure 11.1: Description of the HM bronchoscope assembly
The two light channels convey the illumination light onto the tissue with the helps of em-
bedded optical ﬁbers. Both are placed symmetric relative to the CCD window.
The biopsy channel (2mm in diameter) allows the operator to: (i) spray liquid drug to
induce local anaesthesia in the tracheo-bronchial tree (including pharynx, larynx, vocal cords
and trachea); (ii) suck any secretion to avoid image blurring by mucous; (iii) insert instruments
(e.g. biopsy forceps and brush) to assess histopathological status of the observed mucosa.
Similar to what was done in urology in order to enhance the contrast (see Appendix E),
we placed bandpass ﬁlters in the light source in order to target the two hemoglobin absorption
peaks. Sequentially, the ﬂip-ﬂop ﬁlter holder (with 3 positions) can be rotated to place the
appropriate ﬁlters in front of the Xenon bulb. The three positions are ﬁlled with the following
characteristics: a grid for white light (370–700 nm), a blue ﬁlter (405 nm FWHM 50 nm,
proprietary AF ﬁlter, Richard Wolf GmbH) to excite AF and collect blue backscattered (BBS)
images, and a green ﬁlter (550 nm, FWHM 50 nm, Chroma Technologies Inc.) to acquire green
backscattered images (GBS). Images were collected either with the ﬁltered (WL and GBS) or
non-ﬁltered HM bronchoscope (WL, GBS, and BBS).
Figure 11.1 depicts the HM bronchoscope with its connectors and valves, and Figure 11.2 depicts
the main optical components at the distal end of the HM bronchoscope.
The resolution of the HM bronchoscope was assessed with the help of USAF target, in a similar
manner to HM cystoscopy described in Section 5.2. Table 11.2 shows the comparison between
conventional and HM bronchoscope. Unfortunately, the resolution is impaired when looking
at the USAF target with blue light illumination (maybe due to chromatic aberrations in this
wavelength range).
A direct comparison of the 5.3 mm and 6 mm bronchoscopes yields approximately the same
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Figure 11.2: Distal end of the high magniﬁcation bronchoscope. The white arrows show the
main components (CCD, light channels, biopsy channel).
USAF Group & Element line width [µm] lp/mm
Conventional DAFE bronchoscope C
White light 3-6 35.1 14.25
Blue light 3-3 49.6 10.08
HM bronchoscope B
White light 5-1 15.6 32
Blue light 4-3 24.8 20.16
Table 11.2: Resolution of the bronchoscopes
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FOV, despite the fact that they produce diﬀerent apparent diameter on the screen (see Ta-
ble 11.3). A full frame is assumed to be 720 pixels wide in the PAL video standard. The
endoscope’s magniﬁcation was increased by only shifting a lens inside the objective in order
to get closer to the mucosa, without changing the focal length of the system [Webe10]. The
relationship between the distance and the magniﬁcation is depicted in Figure 5.8 on page 100.
The magniﬁcation — deﬁned as the ratio between the real size and the size on 19" screen —
ranged between 20–60× when the mucosa observed at 8 mm and 2 mm, respectively.
The angle of view is deﬁned as follows, where the distance endoscope-USAF δ is 8.3 mm:
α = 2 ∗ arctan
(FOV/2
δ
)
Endoscope type Scope diameter [mm] Screen diameter [pixels] FOV [mm] Angle of view
DAFE II D 5.3 331 11.86 71.10o
DAFE II C 6 403 15.04 84.36o
HM non-ﬁltered B 5.3 513 15.14 84.73o
HM ﬁltered A 6 514 16.52 89.72o
Table 11.3: Field of view (FOV) of the bronchoscopes acquired at the same distance endoscope-USAF.
11.2.2 Patient population
11 patients were recruited (mean age 68 years old, range 51–85). They were subject to routine
ﬂuorescence bronchoscopy (as a post-operative follow-up or pre-operative extension assessment).
They were observed with the prototypes A and/or B in order to perform AFB and characterize
the subepithelial vessels.
This clinical tests were hosted in CHUR Lille’s endoscopy unit (lead by Dr. Philippe Ramon)
and held on a two-days measurement campaign in April 2010. The procedure was done under
local anesthesia to relax the throat muscles and diminish the coughing reﬂex. If needed, some
relaxing medicine were given per os as a premedication (e.g. benzodiazepins). The patient
remained sat for the whole procedure. The bronchoscope was usually inserted via the nose
(exceptionally via the mouth when the nostrils were too small).
Unfortunately, no ﬂuorescence positive areas were detected during this campaign. Therefore,
the acquired images are not relevant for the characterization of any AF positive areas, but they
can serve as a proof-of-principle of the high magniﬁcation bronchial imaging with our prototypes.
11.3 Results obtained in the clinics
The in vivo resolution is lower than that measured on the USAF target, but is suﬃcient to
visualize small vessels. Indeed, the smallest observed vessel size was approximately 35 µm (see
Figure 11.3). This lower resolution may be attributed to the non-ideal contrast observed between
the bladder mucosa and the vessels, contrary to that measured on the USAF target’s alternating
black&white patterns observed (see Section 5.2.2).
We also directly compared the WL, DAFE, GBS, and BBS images (see Figure 11.4). The
best contrast between the vessels and the extravascular tissues is obtained with green light,
which is likely to be the optimal spectral design with the Wolf’s bronchoscopes. WL images are
not as contrasted but still “reasonable”. Violet images are very bad due to the problems already
identiﬁed in urology (see Appendix E). The latter are likely to be speciﬁc to this generation
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Figure 11.3: Vessel resolution calculation based on the mean diameter of the main bronchi (2 cm). The
images were acquired with green backscattered illumination, and are presented in grayscale.
of the Wolf’s instrumentations (poor overall sensitivity in the violet, optical aberrations, stray
light, reﬂections on optical coatings . . .).
We obtained similar results in all the patients that were investigated. Only few images are
presented here, but the conclusions regarding resolution remain valid for all the observed areas.
11.4 Discussion
As it can be seen in the images presented above, the resolution is suﬃcient to visualize the
reshaping of the vessel architecture due to early carcinogenesis. The observed vessel sizes are
fairly compatible with those observed by Shibuya et al. [Shib10]. These preliminary encouraging
results are clearly suggesting that, in the near future, we will be able to collect images on tissues
corresponding to all kind of hystopathologic status to generate an “atlas” of images. In this
atlas, we will record the optimal blood vessel features to be observed (tortuosity; vascular
mesh density, loops, . . . and other Shibuya’s criteria) in order to diﬀerentiate true and false
positives. The image analysis software developed for similar images obtained in the bladder
will also be customized to describe qualitatively the observed vascularization patterns in the
tracheo-bronchial tree.
Although the optical design is not the same between the 6 mm and 5.3 mm bronchoscopes,
we observed that the ﬁeld of view of bronchoscope B is almost the same than that of the
bronchoscope DAFE C. In a next generation, we may implement a higher resolution chip to let
the vessels be even better demarcated (due to the higher pixel density).
The color presentation has still to be improved in order to avoid intensity saturation in the
color channels, since saturated channels do not contain any information. Color reallocation and
digital scaling of the dynamic range may be eﬀective in order to improve the vessel visualization.
For instance, the two images presented in Figure 11.5 are two subsequent frames illuminated
with green light. The two images diﬀers by the camera controller mode. On the left part, the
image is still in DAFE mode with the corresponding color balance. On the right part, the image
is now in WL mode with a clear dazzling in the green channel (i.e. loss of information due
to intensity saturation). One can clearly see the better vessel deﬁnition when the image color
channels are not saturated. In the future, when design the color intensiﬁcation patterns, we may
bear this in mind.
These preliminary results with GBS and BBS showed a more contrasted and more superﬁcial
vascularization that is hardly invisible with standard WL. Therefore, we came to the conclusion
that an objective of crucial importance is to identify the optimal wavelength to be used for this
characterization of positive sites.
In conclusion, although this project was postponed to the last end of my thesis due to a
manufacturing delay, we showed that this magniﬁcation is suﬃcient to identify vessel of interests,
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Figure 11.4: Comparison of diﬀerent illumination modes while looking at the same suspi-
cious site. (i) BBS (bronchoscope B), WL mode; (ii) WL (A), WL mode; (iii) Blue light (A), DAFE
mode; (iv) GBS (A), DAFE mode; (v) GBS (A), WL mode
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Figure 11.5: Comparison of camera intensiﬁcation mode. On the left, green illumination in WL mode.
On the right, green illumination in DAFE mode.
and that targeting hemoglobin peaks is a good approach the enhance the contrast vessel-to-
background. Additionally, the physician did appreciate the better resolution as compared to the
regular DAFE bronchoscope and was pleased to use the higher magniﬁcation, showing that this
HM bronchoscope is fully compatible with the clinical routine.
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Chapter 12
Conclusions
and future prospects
in bronchoscopy
The main aims of the second part of this manuscript were to optimize the photodetection instru-
mentation of bronchial cancer, and to ﬁnd an eﬃcient method to characterize the false-positive
lesions associated with autoﬂuorescence bronchoscopy. It consists basically of a translation into
the tracheo-bronchial tree of the methods used successfully in the urinary tract. Despite the fact
that the chromatic contrasts between the tumor and healthy background do not have the same
origin (exogenously induced porphyrin ﬂuorescence vs. autoﬂuorescence), similar improvement
methods can be implemented in bronchoscopy. For instance, high magniﬁcation vascular imag-
ing is likely to be a reliable characterization method to evaluate the vascular patterns underlying
(pre-)early neoplasia in the bronchi.
In this manuscript, several clinical and ex vivo imaging and spectroﬂuorimetric studies were
performed to gain insight on the optical characterization of bronchial carcinoma, deﬁning further
possibilities to increase the sensitivity and speciﬁcity of photodetection.
In Chapter 8, we ﬁrst evaluated whether a violet narrow-band (with a Krypton laser) exci-
tation would improve the intensity contrast in the AF green spectral region. For each observed
site in vivo, we showed that the healthy/tumor ratio in the green channel for the narrow-band
excitation exceeds that for the broadband excitation, with a mean ratio equal to 1.43±0.20.
However, in this study, since no red ﬂuorescence intensity could be measured due to the red
backscattered light, no valid statement about spectral contrast could be made. However, we
may speculate that the red AF excited more superﬁcially with narrow-band excitation is less
absorbed by the epithelial thickening as would be the case with the broadband excitation. Sim-
ilarly, the narrow-band violet light would not reach the increased vessel density, and would not
yield a spectral contrast. Consequently, the red AF may not be modiﬁed by the excitation band-
width. Since violet LEDs will be used in the future as endoscopic light source (see Chapter 6),
this statement can be of interest for a technology transfer in the clinical environment.
In Chapter 9, we presented two studies aiming to quantify the intra- and inter-patient vari-
ations in the AF intensities in order to optimize the spectral response and the settings of the
endoscopic ﬂuorescence imaging (EFI) system. For this purpose, we developed a ﬂuorescence
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reference – with optical properties similar to the bronchial AF – to be placed endoscopically
near the bronchial mucosa. The observed inter-patient variations for the AF intensity measured
on the carina were in the order of 25–30%, which is less marked than in previously published
spectroscopic studies (∼50%). Nevertheless, with this study, we obtained this good estimation
of the AF variations, that helped to scale the dynamic range of future AFB systems.
Even if ﬂuorescence endoscopy is a well established method for the detection of early car-
cinoma, instrumentation has still to be tested for its reliability over time. In Appendix D, we
developed some ﬂuorescence validation samples to assess the performance of the instrumentation.
Several phantoms were developed. In the future, a validation procedure should be implemented
on endoscopic clinical devices, because if a device is not functioning properly, it may reduce the
clinical outcome of this imaging technology.
In Chapter 10 and Appendix A, we evaluated two generations of EFI prototypes. In Ap-
pendix A, we speciﬁcally reviewed what AFB can bring to H&N cancer patients. We were able
to show that the additional use of AFB procedure induced a change of management in about
15% of the patients in our cohort of high-risk H&N cancer patients. Additionally, we showed
that adding an online thresholding algorithm to the AFB procedure results in a rejection of
about 90% of the AF false positive. In Chapter 10, we evaluated the clinical performance of
the DAFE II prototype. No false-negative were observed with this AF bronchoscopy proto-
type. Additionally, more CIS were detected with AFB as compared with WL bronchoscopy.
Since it has a negative predictive value close to 100%, this prototype can eﬀectively reduce the
number of biopsies on WL suspicious areas, that do not appear suspicious in autoﬂuorescence
(WL+/AF−). This new prototype has been shown to be very sensitive to early modiﬁcations of
the bronchial mucosa, and may be considered as a serious candidate for an implementation in
the clinical routine. Several physicians have reported that many biopsies can be spared thanks
to AFB’s very high negative predictive value. Additionally, the images acquired with the new
system have a better texture than conventional WL images. For instance, when observing the
alternating light and dark longitudinal stripes in the bronchial wall, they can better distinguish
discrete irregularities, invisible in WL. Consequently, AFB can eﬀectively serve as a guidance
tool, even for the experienced bronchoscopist.
Lastly, we conducted some preliminary works in order to implement high magniﬁcation re-
ﬂectance imaging in the tracheo-bronchial tree to characterize the false-positive lesions resulting
from autoﬂuorescence bronchoscopy. Chapter 11 shows some optical characterization of our
high magniﬁcation bronchoscope. The preliminary measurement campaign showed that vessels
with a diameter of about 30 µm could be resolved with this HM bronchoscope. This is likely
to be suﬃcient to identify Shibuya’s criteria (loops, meshes, dotted vessels) on AF positive
lesions [Shib10]. In the future, we will characterize early cancers to see if this HM imaging
procedure also allows to reject false positive lesions as it is the case in the bladder.
Concurrent groups have also added some backscattered light to their EFI system. It allows
better discrimination of mucus, blood and mucosal alteration, but lowers the intrinsic red-green
contrast.
All technical improvements already discussed in Chapter 6 will obviously also have an impact
on bronchoscopy. Recent developments in OCT identiﬁed microstructures of normal bronchial
mucosa, including epithelium and lamina propria. OCT features of malignancy included loss
of normal, identiﬁable microstructures and subepithelial "optical fracture" of tissues [Mich10].
This OCT probe is also limited in resolution (10–20 µm, depth resolution, and 20–25 µm, a
lateral resolution), but the imaging depth of 2.2 mm allow penetration through the upper layers
of exposed tissues on airway surfaces, where many airway neoplasms may present, and are
equivalent to the tissue sampling depth of conventional endobronchial forceps.
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At this point, it should be noted that the development of patient screening procedures will
have a dramatic impact on EFI’s patient population. Indeed, current AFB inclusion criteria
include smoking or ex-smoking patients, with known or suspected H&N lesions and/or known
or suspected lung cancer. They may be narrowed down by an eﬀective screening procedure (such
as second generation sputum analysis, genetic testing or breath test). It is likely that patient
beneﬁt related to AFB will be even higher in high risks patients.
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Appendix A
Clinical experience
in H&N cancer patients
Head and neck (H&N) cancer patients have a high incidence of second primary tumors in the
tracheobronchial tree, which aﬀects the patient prognosis and management [Sava91]. The preva-
lence of second primary lesions in H&N cancer patients is estimated to be between 7% and 21%,
and about 63% of the metachronous second primary tumors are located in the lung and the
esophagus [Stoe01].
Glanzmann et al. reviewed three diﬀerent types of application of early cancer detection can
be distinguished [Glan03]: (1) Large scale screening studies in high risk population; (2) tumor
demarcation prior to surgery, and (3) patient follow-up in order to detect lung cancer recurrence
and second primaries. The latter will be treated in this chapter with a special dedication on
patients with a primary cancer in the H&N area.
Indeed, this chapter reviews the medical and therapeutic impact of AFB in a population of
21 (H&N) patients. This study showed that management of patients with H&N cancers can be
dramatically altered using AFB. Indeed, 11 lesions in 8 patients were found with the combined
autoﬂuorescence-thresholding method. Two of these patients discontinued the medical follow-up
in our medical facility. In the remaining six patients presenting a total of nine AF+ lesions,
the clinical management was changed as a consequence of the observations with AFB. More
precisely, all these patients were proposed additional treatment options for their second primary
cancers in the tracheo-bronchial tree. Treatments proposed were radical surgery (n=2), CO2
laser resection (n=1) and photodynamic therapy (PDT) (n=3). Of the nine lesions, four were
invisible with the WL bronchoscopy. These four lesions were found in 3 patients. Consequently,
the additional use of AF/T procedure induced a change of management in three of 19 (21-2
patients not followed up), i.e. about 15% in our cohort of high-risk H&N cancer patients.
Summarily, in addition to screening procedure in pneumology unit, AFB can be of great help
also for patients with a primary H&N cancer, since the probability to develop a second meta-
or synchronous bronchial cancer is high for these patients.
The work presented in the published article was mainly done by Tanja Gabrecht. The main
role of the author of this manuscript was to help for clinical data acquisition, collect the patients
data, and some oﬄine statistical work to quantify the variations related the receiver-operator
characteristics (ROC) curve.
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Appendix B
Bladder cancer histopathology
B.1 Morphological criteria for bladder cancer classiﬁcation
Tables B.1&B.2 give the histological characteristics (cell architecture, shape, . . . ) for both ﬂat
(reactive atypia, hyperplasia, dysplasia, CIS) and exophytic lesions (papilloma, PUNLMP, low-
and high-grade papillary carcinoma) derived from [Mont08].
Table B.3 describes the weights used to calculate probability of recurrence and progression
(Table B.4), ﬁrst presented in [Sylv06]. It gives the physician a simple decisional help for
bladder cancer management (e.g. whether to proceed to radical cystectomy or not, whether to
give adjuvant chemotherapy).
Features Reactive atypia Hyperplasia Dysplasia CIS
Cell layers Variable >10 Variable Variable
Polarization Slightly abnormal Normal Disordered Disordered
Cytoplasm Often vacuolated Homogeneous Variable, homogeneousto granular Variable
N/C ratio Normal to slightlyincreased
Normal to slightly
increased Slightly increased Increased
Nuclear size Enlarged Normal Enlarged Enlarged withvariation in size
Nuclear borders Regular/smooth Regular/smooth Notches/creases Pleomorphic
Chromatin Fine/dusty Fine Slight hyperchromasia Coarse
Nucleoli Large, single Small/absent Small Large, oftenmultiple
Mitotic ﬁgures Variable Absent Rare, basal Frequent, alllevels
Umbrella cells Uniformly present Present Present May be present
Denudation Variable No No Variable
Table B.1: Comparison of reactive atypia, hyperplasia, dysplasia and carcinoma in situ (CIS) [Mont08]
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Factor Recurrence Progression
Number of tumors
Single 0 0
2 to 7 3 3
≥8 6 3
Tumor size
<3 cm 0 0
≥3 cm 3 3
Prior recurrence rate
Primary 0 0
≤1 rec/yr 2 2
>1 rec/yr 4 2
T category
Ta 0 0
T1 1 4
CIS
No 0 0
Yes 1 6
Grade
G1 0 0
G2 1 0
G3 2 5
Total score 0-17 0-23
Table B.3: Weights used to calculate the recurrence and progression scores [Sylv06]
Recurrence Score Prob Recurrence
1 Year (95% CI)
Prob Recurrence
5 Years (95% CI)
0 15 (10, 19) 31 (24, 37)
1-4 24 (21, 26) 46 (42, 49)
5-9 38 (35, 41) 62 (58, 65)
10-17 61 (55, 67) 78 (73, 84)
Progression Score Prob Progression
1 Year (95% CI)
Prob Progression
5 Years (95% CI)
0 0.2 (0, 0.7) 0.8 (0, 1.7)
2-6 1.0 (0.4, 1.6) 6 (5, 8)
7-13 5 (4, 7) 17 (14, 20)
14-23 17 (10, 24) 45 (35, 55)
Table B.4: Probability of recurrence and progression according to total score. 95% Conﬁdence Interval
(CI) is indicated in brackets [Sylv06].
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Appendix C
Narrow-band excitation
in the bladder
During ﬂuorescence cystoscopy, the sharp ﬂuorescence excitation peak of PpIX often interferes
with the very strong and sharp absorption peak of hemoglobin contained in the tissues and in
the liquid ﬁlling the bladder (see Figure 2.2&2.11). In the context of integrating a LED at the
distal end of the endoscope, we have to investigate the best excitation wavelength to be chosen
in the next endoscope generation.
To address this issue, we have injected light from a Krypton laser working in the multiline
mode (407 nm and 413 nm) in the light guide attached to a ﬂexible cystoscope (new prototype,
PDD ﬂexible cystoscope, Richard Wolf GmbH). We have then compared on the same ﬂat le-
sions (n=2) the chromatic and visual contrast between the conventional ﬁltered (370–430 nm)
broadband Xenon light source (see Figure 2.12) and the narrowband excitation from the laser.
PpIX has an excitation peak at around 405 nm. Therefore, the excitation spectral power
(in the violet range) was higher in the violet with the Krypton laser (20 mW violet light at the
endoscope tip) than with the Xenon light source (30 mW for the whole bandwidth), leading to
a better ﬂuorescence excitation.
Images acquired with the narrow-band excitation (almost matching the PpIX excitation
peak) showed an increased visual contrast between ﬂuorescing lesions and healthy tissue. Typical
images are shown in Figure C.1. Illumination pattern on the tissue is not homogenized yet and
will be improved for clinical applications.
Regions of interest (ROIs) were deﬁned as selected areas of pixels on tumors and normal
tissues. Figure C.2 shows the red/green ratio (R1 = Ired/Igreen) and red/blue ratio (R2 =
Ired/Iblue) with both illumination modes on the selected ROIs.
Figure C.2 depicts the color channels ratio (R/G, R/B, G/B). It is likely that narrowband ex-
citation improves the red/green contrast on tumors, whereas the red/blue ratio remains constant
with both illumination modes. The green/blue ratio is close to 1 on healthy tissues with both
narrow- and broadband excitation light. On cancers, this ratio lowers to 0.76 with broadband,
and to 0.58 with narrowband. It suggests that the green autoﬂuorescence alteration depends on
the excitation bandwidth. More precisely, the use of shorter wavelength close to 405 nm will
increase the tumor-to-background contrast.
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If this trend is conﬁrmed by other cases, the narrow-band excitation can be implemented in
the next endoscope generation with the help of light-emitting diodes (LEDs) at the distal end
of the endoscope.
PDD light PDD light
Krypton lightKrypton light
ROI on Fluo+ ROI on Fluo-
Figure C.1: Comparison of broadband (PDD ﬁltered Xe lamp) and narrow-band (Krypton laser) exci-
tation in 2 patients
0
0.5
1
1.5
2
2.5
normal tumor normal tumor
PDD Krypton
Red/Green
Red/Blue
Red/Blue
Figure C.2: Red/green and red/blue ratios with the two illumination modes.
Appendix D
Fluorescence validation sample
to validate endoscopic imaging
D.1 Introduction
Even if ﬂuorescence cystoscopy is a well established method for the detection of ﬂat bladder
carcinoma, instrumentation has still to be tested for its reliability over time. The same is valid
for AF bronchoscopy. Several parameters such as illumination light power, excitation spectrum,
overall transmission and detection system integrity are subject to variations over time. In the
clinics, a regular check of these parameters is necessary. It helps to prevent misinterpretation
of the obtained endoscopic images and avoid under/over diagnosis leading to an evident patient
beneﬁt.
In order to make it user-friendly, the validation procedure should be kept as simple as
possible. It is not yet decided whether this validation routine will be implemented in the camera
ﬁrmware with an integrated post-processing of the collected test pictures or if it has to be checked
by an external technician. This issue has to be addressed separately, but it will undoubtedly
play an important role on the design procedure.
Many phantoms mimicking tissue optical properties have been designed over the last 20
years, in parallel to the development of optical diagnostic and therapeutic applications. For
instance, Bays et al. have design a three-dimensional (3D) optical phantom to characterize the
PDT response of the tracheo-bronchial tree [Bays97]. Indeed, a very small isotropic light detector
can be introduced into this phantom at several strategic positions to measure the radiant energy
ﬂuence rate. To produce the lung phantom, a negative imprint of the tracheo-bronchial tree
was cast in wax. This imprint was then immersed in the silicone. After curing, the wax was
removed by melting. With this technique, three-dimensional shapes can be accurately produced
with only one mold (see Figure D.1). This phantom can also be used by physicians to practice
the introduction and placement of the light distributor prior to clinical PDT to obtain an
homogenous light distribution in the tissue.
Wagnieres et al. developed an optical phantom with tissue-like properties in the visible [Wagn97].
This phantom was designed to mimic the tissue ﬂuorescence properties. Indeed, this phantom
was built with an agarose base, in which several ﬂuorophores were embedded: ink and blood as
optical absorbers, silica powder and Intralipid as scatterers, bovine serum to mimic binding to
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A B
Figure D.1: A Negative imprint in wax of the bronchial tree B endoscopic view of the lung phantom
[Bays97].
proteins. Interestingly, some penicillin were also added to ensure conservation of the phantoms
over 2–3 weeks.
With the development of optical tomography, diﬀusely scattering and absorbing phantoms
were required for developing experimental techniques as well as theoretical models of photon
transport in biological tissues. Furthermore, phantoms with well-deﬁned spatially varying optical
properties are needed to compare diﬀerent experimental methods of optical tomography. Firbank
and Delpy reported on diﬀusely scattering solid phantoms made from titanium dioxide particles
as scatterers embedded in polymer [Firb93]. Several authors improved the design of this ﬁrst
phantom by substituting monodisperses quartz glass spheres for the non-spherical titanium
dioxide particles [Suko96].
In a recent paper, de Bruin et al. present the design and characterization of silicone elastomer-
based optical phantoms [deB10]. Absorption is included by adding a green dye and scattering by
adding TiO2 or SiO2 particles. They build up a layered phantoms (with thicknesses as small as
50µm) to mimic the human retina, and also embedded gold nanoparticles to assess the resolution
of their optical coherence tomography (OCT) device. These homogenous phantoms exhibit well-
deﬁned and controllable thickness, refractive index, absorption, and scattering coeﬃcients.
The tissue equivalent phantoms are also important for calibration and standardization of the
new technique before putting it into clinical practice. For this purpose, many materials have
been used as optical phantoms for optical imaging studies. Beck et al. reviewed the fabricating
process of tissue phantoms [Beck98]. The most common tissue phantom system is based on
Intralipid (Kabivitrium,Stockholm,Sweden) as a scattering medium, a standardized aqueous fat
emulsion. It is usually combined with black Indian ink as absorber which itself contributes to
scattering [Wagn97]. The scattering properties of diluted Intralipid correspond to those of tissue,
apart from a relatively low scattering anisotropy of about g = 0.8. Other common scatterers
are milk or micron-sized latex spheres.
While it is important to mimic the organ shape, semi-rigid and solid phantoms were built
over time with diﬀerent mechanical properties. Solid phantom samples have been made using
either transparent hosts, like polymers, silicone or gelatin, or using inherently light-scattering
materials such as wax. Polymer-based phantoms have been reported to crack if they are too large
or to shrink during polymerization, which limit their applicability. Gels contain a solvent which
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evaporates, changing the dimensions and optical properties of the sample within a short period.
Steps towards realistic complex geometries have been layered samples, inserted inhomogeneities,
and phantoms mimicking whole organs. Additionally, some phantoms have realistic properties
over a wide wavelength range, and not only for laser-speciﬁc peaks.
We have prototyped some ﬂuorescence charts ready to be used by technical staﬀ in the
hospital as so-called validation charts. They provide a visual test checking the correct functioning
of the whole instrumentation chain. Our phantoms are based on a silicone matrix, loaded with
diﬀerent dyes to mimic absorption, scattering and ﬂuorescence properties of the bladder wall.
The overall goal of this subproject was 2-fold:
 Develop a validation/calibration chart to routinely assess the correct functioning of the
endoscopic system in bronchoscopy (autoﬂuorescence) and PDD system in urology (PpIX
ﬂuorescence).
 Design a reference sample for the PpIX ﬂuorescence and the tissue autoﬂuorescence, re-
spectively.
D.2 Validation sample speciﬁcations
In the following, we designed solid phantoms to test one or more of the following parameters:
Power and spectroscopy of the excitation/emission light, RGB balance and ﬂuorescence contrast.
Power and spectroscopy : illumination and image acquisition
• leakage of the excitation ﬁlter (mechanical break, changes in the optical transmission
characteristics);
• variation of the light power output of the Xenon bulb;
• transmission of the optics (aging of the light guide designed for violet light transmis-
sion, illumination optical ﬁbers, image guide)
RGB color contrast (wrong settings, distorted visual appearance)
• individual channel intensiﬁcation;
• leakage of the emission ﬁlter;
• contrast balance check between RGB channels (RG/RB/GB);
• distortion of the channel balance occurring during white and/or color balance (ACB)
Detectability of the ﬂuorescence contrast
• AF contrast : the validation sample has to be designed with a drop in the green
spectral region (to mimic AF drop on tumors).
• PpIX contrast : a ﬂuorophore (that emits red when excited with blue light) should
be present in the validation sample to check that the PDD setup can highlight the
pseudo-tumor information.
D.3 Phantom Design
The assumptions in the next paragraph and the two next sections Bronchoscopy and Urology are
depending on the endoscopic ﬂuorescence imaging device. They are based on the commercial
endoscopy setup manufactured by Richard Wolf GmbH, because it was part of our on-going
research collaboration. Obviously, the test chart can be sized depending on the endoscope it is
designed for.
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During the test procedure, the endoscopic camera should operate with maximal intensiﬁ-
cation gain regulated by the automatic gain control (AGC) unit, even if ampliﬁed noise may
interfere with a good visual check. Chromophores and ﬂuorophores concentration in the matrix
will have to be adapted to keep ﬂuorescence signal and backscattered light intensities at a level
similar to tissue. Additionally, it was assumed that frame integration time is continuously cal-
culated to adapt for illumination variations. This calculation is based on the intensity of the
pixels that are centrally located in the endoscopic images. It is to be noted that in the AF mode,
tissue (or chart) appearance is seriously aﬀected by the reﬂectance of the area illuminated at
the time of intelligent color balance (iCB). iCB is an internal software procedure that creates
a false color appearance to help visualization of the tumors with the DAFE II system. It sets
the normal tissue to grayish appearance, whereas tumors are looking bluish, when illuminated
in blue light.
D.3.1 Bronchoscopy
The bronchoscopic calibration chart is designed with 4 distinct areas: (i) white reﬂecting area
to perform white balance procedure; (ii) a substrate backscattering blue light (10%), but non-
ﬂuorescing, that should appear blue with a normal functioning system; (iii) the same substrate
loaded with a supplemental green ﬂuorochrome, mimicking normal tissue autoﬂuorescence (to
check RGB color balance). iCB will be performed on this area, which should also backscatter
the same amount of green light to visually detect green leakage; (iv) ﬂuorescence contrast can
be checked with two areas containing the same substrate, one of them containing less green
ﬂuorescent pigment to reproduce AF drop in the green spectral region.
Figure D.2 depicts a simpliﬁed version of the bronchial validation sample (without white
reﬂecting coating). The spectral curves on the left show the good agreement between bronchial
AF and sample emission spectra.
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Figure D.2: Example for the bronchi. [left] 7.5µl ﬂuorol 7GA (10−3M) and 5µl DCM (5 · 10−4M).
Additive : (1) no ink; (2) 12µl ink solution 2; (3) 48µl ink solution 2. iCB was performed on well 1.
[right] comparison of the ﬂuorescence emission spectra of normal bronchial mucosa and validation sample
normalized at their maximum.
D.3.2 Urology
This urologic calibration chart is similar to the one provided for bronchoscopy. However, the
contrast tumor/normal is related to the PpIX detection (and the corresponding red channel
intensiﬁcation). The tissue AF is in this case used as a background image. The calibration
chart is also designed with 4 distinct areas:(i) white reﬂecting area to perform white balance
procedure; (ii) 10% grey reﬂecting area, non-ﬂuorescing, to check color channels cross-talks;
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Figure D.3: Example for the bladder. [left] 5µl cyclamred. Additive : (1) no ink; (2) 6µl ink
solution 2; (3) 12µl ink solution 2. [right] comparison of the ﬂuorescence emission spectra of PpIX and
validation sample normalized at their maximum.
(iii) red ﬂuorescing area to mimic tumor appearance and control red channel intensiﬁcation;
(iv) green AF to check level of background detection.
Figure D.3 depicts an early version of the urological sample with bright ﬂuorescing spots. The
emission was attenuated in the ﬁnal version to drive the camera into the maximal intensiﬁcation
mode. Despite the non-exact overlap of the ﬂuorescence peaks between PpIX and Cyclamred
(as shown in Figure D.3), both display similar brightness and color appearance with the PDD
imaging setup.
D.4 Phantom preparation
The silicone base material is transparent with a refractive index of about 1.4. The refractive
index of soft tissues has been reported to be between 1.35 and 1.5 [Boli89] for soft tissues.
In order to mimic absorption, scattering, and ﬂuorescence properties of the tissue, we added
chromophores, ﬂuorophores, and scattering particles to the transparent matrix.
These phantoms were prepared in the framework of a Céline Dutruel’s semester thesis. A
detailed report about the recipes and the sample optical characterization (ﬂuorescence, trans-
mittance, reﬂectance) can be found in [Dutr07].
Our ﬁrst matrix was built out of silicon A & B (100/10 for RTV 141 and 100/5 RTV121,
Silitech AG, Switzerland). This material is very convenient to handle on workbench. A second
variant was to include the dyes either in a metacrylate solution and to polymerize it into poly-
methylmetacrylate (PMMA, acrylic glass), or in a polyester matrix (Esprit Composite, France).
The two latter materials are not easy to polymerize smoothly with standard lab equipment. The
epoxy resin was also excluded because it emits a too strong autoﬂuorescence signal in the green.
As compared to other matrices (PMMA, polyester, epoxy), silicone was found to be the best
candidates to incorporate various components with a spatially homogeneous distribution.
Scattering particles have to be added to the liquid solution (before polymerization) to mimic
tissue optical properties (µs, scattering coeﬃcient, µa, absorbing coeﬃcient, and g, anisotropy).
Candidates were TiO2 and/or Al2O3 (1/1000 w/w with respect to silicone). Other variants
included BaSO4, ZnO, MgO.
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We reviewed several ﬂuorescing particles, also to be homogenously added before polymerization:
• SpheroTM ﬂuorescent particles (Spherotech Inc., USA). These ﬂuorophores, once incorpo-
rated into the particles, do not bleach and their color and ﬂuorescence remains stable for
long periods of time under proper storage conditions. Not available at the time of testing.
• Dyes used for lasers : DCM C19H17N3O (emitting in the red when dissolved in MetOH)
and Fluorol7GA (an eﬃcient yellow-green dye for ﬂashlamp-pumped laser). We retained
them for the bronchoscopy validation model.
• PerspexTM ﬂuorescent PMMA (Lucite International Inc., USA) Diﬀerent types of this ma-
terial have been visually tested within the framework of the endoscopic reference design.
They mimic the tissue optical properties (reﬂectance, eﬀective attenuation coeﬃcient, ﬂu-
orescence spectrum) in a relatively good agreement (as shown in Chapter 9).
• Doped crytals with rare eath dopants (e.g. NaYF4:Yb,Er), as for solid-state lasers, and
ﬂuorescent minerals (crystals), (e.g. FA-2036, Photon Technology International Inc., USA).
Not tested.
• Industrial dyes for plastic like Hostasol red and Polysynthren blue (Clariant Inc., Switzer-
land). Used to backscatter blue and red light in urology and bronchoscopy samples.
• LeutaluxTM (Leuchtstoﬀwerk GmbH, Germany) as proposed by F. Borle [Borl06]. The
main advantage of Leutalux pigments is that they all can be excited in the blue-violet and
they have a broad band emission. We retained them to mimic the bright PpIX ﬂuorescence.
In the following, we describe the modus operandi shortly, since it was thoroughly described in
[Dutr07]. The components were ﬁrst dissolved or dispersed in ethanol and the solution was
carefully mixed with the silicone base. Ethanol was then removed by evaporation either in a
fume hood or by gentle heating. Finally, after allowing the base to cool, the catalyst was added
and the curing process could take place. A vacuum pump was used to extract air bubbles
(due to mixing procedure) prior to curing. Methanol, dimethyl sulphoxide (DMSO), and water
were also used successfully as solvents or dispersants instead of ethanol. The same technique of
evaporation was been performed to remove these before the curing. Water appeared to be the
most diﬃcult liquid to mix with silicone though. Consequently, an homogeneous distribution of
dye in the phantom was obtained only after complete evaporation of the water. Other solvents
can certainly be used, but have not been tested so far.
Beside of their wide availability, liquid ﬂuorescent dyes have the main disadvantage to photo-
bleach rapidly and could thus not be considered as a stable reference. Therefore, solid pigments
have been preferred until now.
D.4.1 Final recipes for the ﬂuorescence phantoms
Various solid ﬂuorescence phantoms were fabricated during this thesis work. The chosen shape
was an epoxy mold (Polytec, Polymere Technologien, Germany) with 3 wells containing 3 diﬀer-
ent concentrations of pigments (ﬂuorescing and non-ﬂuorescing) embedded in a silicone matrix.
Since it was a fully iterative process, we do not describe here all the attempts in details, but
rather present the ﬁnal mixture’s recipe.
Three main components were separately prepared and then mixed at diﬀerent concentrations:
• Substrate A: 5g of mixture with the proportions 10:1:1 (silicon/hardener/TiO2)
• Solution B: 4ml Ink diluted in 7.5ml EtOH
• Solution C: 0.4g Cyclamred diluted in 10ml EtOH
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Bronchial reference
3 epoxy molded wells with a basic substrate of 5 g of A with the following adjuvants:
1st well: 5 µl green Leutalux solution
2nd well: 7.5 µl de Fluorol7GA 10−3M, 5 µl DCM 5.10-4M, 48 µl B solution
3rd well: 5 µl Polysynthren blue and 12 µl B solution.
Figure D.2 depicts the bronchial validation sample. The bluish appearance in the 3rd well
mimic the real tumor in vivo.
Bladder reference
3 epoxy molded wells with a basic substrate of 5g of A with the following adjuvants:
1st well: 5µl C solution
2nd well: 5µl C solution and 12µl B solution
3rd well: 20µl Hostasol red and 12µl B solution
Figure D.2 depicts one version urological validation sample (without the red backscattering
part). The strong red emission can be further attenuated with Indian ink.
This mixture was also implemented in a “real” looking bladder model to serve as a demon-
strator for ﬂuorescence photodetection (see Figure D.4).
Figure D.4: Bladder model with red ﬂuorescing spots, invisible in WL illumination
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Appendix E
Spectral optimization
for HM endoscopy
In order to better visualize the vessels, we may improve their contrast with respect to the back-
ground. Since hemoglobin is a very strong absorber of green and blue light (see Section 2.1.1.1),
it can be used as an intrinsic marker of the vessel, because it is contained almost exclusively in
the red blood cells. Consequently, we moved towards a spectral optimization of our endoscopic
observation system. This implementation is less invasive than the intravenous injection of a
contrast dye (such as ﬂuorescein or indocyanine green).
Since we did not exactly know which vessels at which depth to look at, we based our approach
on the lesion depth proﬁling with diﬀerent wavelength. Indeed, due to the tissue optical prop-
erties, diﬀerent excitation wavelengths penetrate down to diﬀerent tissue depths. For blue light
excitation, only the ﬁrst cell layers of the lesion emit ﬂuorescence, because the light is not pen-
etrating deeper. For green light excitation, several hundred microns in depth emit ﬂuorescence,
and for red light several millimeters [Dögn01].
In this study, we will adapt this principle to the blood vessels. Indeed, vessels located at
diﬀerent depths absorbs light of diﬀerent wavelengths. The long penetrating wavelength may
probe the whole depth, whereas the short wavelength may probe only the superﬁcial vessels. It
means that it is possible to follow a vessel with long wavelength to deeper layers of the mucosa,
whereas we may observe vessels with abrupt ending at the penetration depth of blue violet light.
In the ﬁnal image, the vessel appearance may be aﬀected by (i) the scattering and absorption
characteristics of mucosa at diﬀerent wavelengths, (ii) the oxygenation state of blood, which
aﬀects its absorption properties, (iii) the diameter and the depth of the vessels, and (iv) the
visual perception process [Kien96].
To exploit this contrast, we placed bandpass ﬁlters in the light source in order to target the
two hemoglobin absorption peaks. Sequentially, a grid for white light attenuation (370–700 nm),
a blue ﬁlter (405 nm FWHM 50 nm, proprietary PDD ﬁlter, Richard Wolf GmbH), and a green
ﬁlter (550 nm, FWHM 50 nm, Chroma Technologies Inc.) were placed in front of the Xenon
bulb. Images were acquired with the unﬁltered endoscopic camera (Telecam, Karl Storz GmbH
& Co KG,Tuttlingen, Germany).
The original video sequences were digitized via IEEE1394. Individual frames were extracted
with Adobe Premiere Pro. The 24-bit RGB color images were then split in three 8-bit grayscale
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images, one for each color channel (ImageJ, NIH). Figure E.1 shows typical images acquired with
this setup and the corresponding decomposition in the three video channels R(red), G(green),
and B(blue). In this ﬁgure, the contrast and brightness were adjusted for legibility purpose.
Whenever possible, images in the three excitation modes (WL, blue, green) should be acquired
on the same lesion to allow direct comparison. However, for historical reasons, the number of
patients observed with each illumination mode is not equivalent : WL (n60), GBS (n15),
BBS (n5).
Blue backscattered 
405 nm (50 nm FWHM)
Green backscattered
550 nm (50 nm FWHM) 
White light
370-700 nm
Original image Red channel Green channel Blue channel
A
C
B
Figure E.1: RGB channel decomposition for the three excitation modes (WL, blue backscattered, green
backscattered). The white dashed line represent the place where intensity proﬁle from Figure E.2 were
measured. Grayscale intensities were adjusted to allow better visualization.
First, we measured intensity proﬁles (4-pixels wide to minimize noise) in each individual
color channel on a small portion of the image representative for vessel-background contrast (see
the white dashed line in Figure E.1). These intensity proﬁles are shown in Figure E.2 with two
columns. On the left part, ﬁgures A1, B1, C1 presents the overall intensity of each channel
for each illumination light, whereas the mean intensity is subtracted from the overall intensity
in ﬁgures A2, B2, C2. The dashed lines represent the position of the vessels. Obviously, the
channel containing the highest intensity is depending on the excitation mode. Consequently, it
yields a reddish (Fig.A under WL), a bluish (Fig.B under blue light), a greenish (Fig.C under
green light) appearance to the RGB composite image.
If one observes these curves in details, it appears that the white light illumination yields
poorly contrasted image. Indeed, the peak-to-peak intensity variation between vessel and back-
ground is less that 10 counts, and the vessel information is not really channel-speciﬁc (i.e. more
important in one channel that in the two others). Conversely, the blue light illumination yields
good contrast in all the channels (twice as high as with WL illumination). A major drawback
would be the overall lower intensity of the image, but this may be compensated by electronic
means. The green light illumination also yields a good contrast.
An other mean to evaluate the contrast is the evaluation of the color diﬀerence of the back-
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Figure E.2: Intensity of the RGB channels for the three excitation modes (WL, blue backscattered, green
backscattered). On the left, without mean substraction. On the right with mean substraction. The dashed
lines represent the position of the vessels.
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ground vs. vessels. The color representation most commonly used in computers and other elec-
tronic systems is red-green-blue (RGB) color channels. However, there exist other color spaces
that can be more eﬀective in the context of reaching a speciﬁc goal, such as closeness to human
perception (e.g. CIE-Lab) [Bosm10].
Consequently, we calculated the color diﬀerence in CIE 1976 (L∗, a∗, b∗) color space (CIELAB)
[Kueh76]. In this color space, the color of endoscopic images was expressed in terms of three
coordinate values (L∗, a∗, b∗), which located the object in a three-dimensional (3D) space. L∗
is deﬁned as lightness, a∗ as the red-green component and b∗ as the yellow-blue component.
Regions-of-interest were selected on several zones appearing as background (resp. vessels).
Typically, six analysis zones (three of each type) were selected per site to accommodate the
illumination artifacts due to the bladder geometry. We deﬁned here the Euclidean distance in
the color space as follows, with Li,ai,bi being acquired on background (b-index), resp. vessel
(v-index):
∆(L, a, b) =
√
(Lv − Lb)2 + (av − ab)2 + (bv − bb)2
Figure E.3 shows the (L, a, b)-color space visualization for the 3 illumination lights (white,
green, blue) for the background (resp. vessels) areas. The error bars represent variations across
the image. A general trend that can be observed is that vessels have a lower lightness than
background. This may be attributed to hemoglobin absorption, that results is less backscattered
light. We observe high variations in the hue components (a and b) in the diﬀerent illumination
modes, originating from variations in channel intensities (see Figure E.2).
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Figure E.3: (L, a, b)-color space visualization and representation of the Euclidean distance ∆(L, a, b) for
the 3 illumination lights (white, green, blue).
The last histogram presents the value of the color distance (∆(L, a, b) for the three illumi-
nation modes. It results that blue and green illuminations yield a much better contrast than
white light illumination. It conﬁrms the observed results on the intensity proﬁles.
Bibliography 241
Bibliography
[Bosm10] H. H. W. J. Bosman, N. Petkov, and M. F. Jonkman. Comparison of color representations for content-
based image retrieval in dermatology. Skin Res Technol, 16(1):109–113, Feb 2010.
[Dögn01] N. Dögnitz. Characterization of Vascular and Cancerous Lesions by Multispectral Excitation Fluores-
cence Imaging. PhD thesis, EPFL Thesis Nr 2450, 2001.
[Kien96] A. Kienle, L. Lilge, A. Vitkin, M. Patterson, B. Wilson, R. Hibst, and R. Steiner. Why do veins appear
blue? a new look at an old question. Applied Optics, 35(7):1151–1160, 1996.
[Kueh76] R. Kuehni. Color-tolerance data and the tentative CIE 1976 Lab formula. J Opt Soc Am, 66:497–500,
1976.

Appendix F
Color presentation in endoscopy
F.1 Introduction
The capability of an observer to take full advantage of a chromatic contrast presented on a
monitor highly depends on its ability to diﬀerentiate colors and color patterns, depending on
the background and surrounding environment.
With the help of his retinex model, Ewdin Land tried to sort out the mechanisms of color
perception [Land64, Land71]. He described that the spectral composition of the light will depend
on two factors: (i) the spectral reﬂectance of the object, its tendency to reﬂect some wavelengths
more than others, and (ii) the spectral composition of the illuminate, the relative proportions of
diﬀerent wavelengths in the light that falls on the object. As we view an object under diﬀerent
conditions (distances, angles, and illuminations), important changes occur in the physical image
on our retina, but our sensations prove much more stable than would be expected from our
changeful retinal image [Land77, Land86].
One of the several ‘constancies’ that characterize our sensory experience is color constancy.
Land et al. provided a particularly impressive and instructive demonstration of color constancy.
He performed an experiment in which a single mixture of red, green, and blue light produced
many diﬀerent color sensations. Observers reported white, pink, green, red, brown, yellow,
purple, blue, and black sensations from identical mixtures of red, green, and blue lights [Land77].
Land used his “Mondrians” cells to show that nearly the full gamut of color sensations can be
produced from a single mixture of red, green, and blue light. In particular, he puts forward the
fact that the foreground perception is mostly inﬂuenced by the color surrounding. For instance,
in a famous experiment, he was able to adjust the illuminants so that a green and a white
area were sending exactly the same triplet of radiant energies (RGB) to the eye. Under actual
viewing conditions, white area continues to look white and green area continues to look green
even though the eye was receiving the same ﬂux triplet from both areas.
Humans perceive the three-dimensional (3D) world by a pair of two-dimensional (2D) retinas
that react to visible light with a peak sensitivity near 550 nm. In a recent review, Cuschieri
linked the physical and psychological aspects of visual perception [Cusc06]. After preliminary
processing of the stimuli (including color) in the photoreceptors, the next event in the chain of
visual perception involves transfer of electrical signals (retinal image information) via the optic
nerves for resolution in the lateral geniculate nucleus and in the V1 region of the visual cortex.
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Downstream, further secondary processing occurs in specialized areas of the visual cortex (e.g.,
V4 [color] and V5 [motion]). The resulting image recognized by the subject in the cognitive pro-
cess is known as a percept, which determines the interpretation of the visual stimulation [Brid06].
Thus, the reality perceived is not absolute, but individual. Visual psychologists distinguish be-
tween two kinds of perception: direct (perception of objects in three-dimensional space) and
indirect (perception of pictures/images of objects rather than the objects themselves).
Humans have trichromatic color vision based on three color receptors on the retinal cone
cells: blue (β), or short wave (450 nm); green (γ), or medium wave (540 nm); and red (ρ), or
long wave (580 nm) [Stoc99, Stoc00]. Hering was the ﬁrst to suggest that the nature of the
color perception process is the product of the opponent interaction between stimuli from the
rods (respond to black and white) and the color sensing cones [Heri64].
It has been shown that diﬀerent observers may observe the scene with a diﬀerent perception
due to the relative sensitivity of their color processing chain. Small perception are often negligi-
ble, but some form of color-blindness aﬀects 1 in 12 individuals (8% of males and 0.4% females).
Color-blindness (often called daltonism) types are classiﬁed after the involved cone types and the
importance of visual trouble: (a) Monochromatism: no perception of colors (b) Dichromatism:
absence of gene, thus lack of pigmentation. Only 2 colors are perceived. (c) Trichromatism:
perception of 3 colors with abnormal intensity, due to gene hybridization, leading to important
variations in chromatic sensitivity.
Even if the proportion of genetic daltonism is rather low, some subtle variations could have
a great inﬂuence on the way physicians evaluate color contrast on a display. With ﬂuorescence
imaging, color presentation optimization is of high interest, since the information source is the
color contrast itself.
In the endoscopic context, and thus in ﬂuorescence cancer detection, color diﬀerentiation
is the basis of every diagnostic approach. Indeed, ﬂuorescence contrast often displays as a
chromatic diﬀerence to be seen either directly through the eye piece of the endoscope or on the
screen if a camera is connected to the endoscope. The latter allows a false-color presentation,
which can be of great help to improve the contrast, but it has to be studied carefully before
implementation. Little work has been done on aspects of visual perception and related defects
as they aﬀect the proﬁciency level for endoscopic surgery, in which the surgeon must operate
from images rather than reality.
Unfortunately, little is known on the proﬁciency level of color-blind surgeons (anomalous
trichromats and dichromats) in endoscopic surgery. Koningsberger et al. designed a study to
assess the prevalence of color vision deﬁciencies amongst Dutch GI endoscopists and to determine
whether color vision deﬁciency aﬀects an endoscopist’s diagnostic skill [Koni94]. The study did
not show any eﬀect of color vision deﬁciencies on endoscopic skills, nor does it show any deviant
prevalence of color vision deﬁciencies amongst Dutch GI endoscopists.
In this preliminary study, we would like to identify which color presentation is best suited
for endoscopic images. Observers were asked to classify images with diﬀerent color settings for
the foreground (tumor) and background. In a near future, the objective would be to implement
in the endoscopic display a user-deﬁned color presentation.
F.2 Color optimization in endoscopic ﬂuorescence imaging
Preliminary tests performed by our group on charts designed for color blindness detection have
been performed on a limited number of volunteers. The well-known Ishihara’s tests can eval-
uate color blindness in individuals. Inter-observer variations lead us to the conclusion that an
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observer-customized appearance is likely to increase observation comfort, and thus to beneﬁt
the diagnostic capability.
The current color presentation in endoscopic imaging devices is based on empiric observa-
tions. From a user point-of-view, it would be desirable to choose among a set of color presets
corresponding to the eye’s optimal color sensitivity. The latter could be determined with the
help of pseudoisochromatic tests. It would result diﬀerent color appearance independent from
the raw spectral information. Figure F.1 depicts typical color appearance of endoscopic images.
a) Storz imaging system (tumor in red, background in blue)
b) Wolf imaging system (tumor in magenta, background in blue-green)
Figure F.1: Comparison of the color presentation of two commercial devices
In collaboration with Cédric Paulou, we performed some preliminary work on the visual
sensitivity of chromatic contrasts [Paul10]. Basically, 11 naive subjects were asked to rank 8
images showing the same site, but with diﬀerent color appearances, i.e. variations for the tumor
and background, as depicted in Figure F.2. A small ﬂat tumor is present in the middle of the
picture; the ranking was based on tumor detectability.
A B C D
E F G H
Figure F.2: Images submitted to 10 observers
246 Appendix F. Color presentation in endoscopy
Figure F.3: Simpliﬁed color wheel adapted from ArtFactory
The colors in the images A, B, C and D were allocated with “arbitrary” color. Multiplicative
factors of the Photoshop color balance procedure are listed in Table F.1. The images E, F , G,
H were produced in such a way that the tumor and the normal tissues were presented in
complementary colors (i.e. with opposite value in the color wheel, see Figure F.3).
The total score was computed as the ranking position (rank) weighted by the numbers of
answers (n) : S =∑i ranki ·ni .
Arbitrary images S Complementary colors S
A blue 100 56 E yellow vs. blue 12
B green 100 72 F green vs. magenta 33
C original image 57 G red vs. cyan 37
D green100 blue50 81 H orange vs. green 48
Table F.1: Color allocation of the 8 images
Figure F.4 clearly shows that images presented in complementary colors increased the de-
tectability of lesions vs. background. The lowest score is obtained by E, maybe due to the fact
that human’s eye sensitivity is highest in the yellow-green spectral region. Additionally, the
image F — which is classiﬁed in the 7th and 8th position for only one observer — illustrates
that the most convenient color presentation for a majority of operators (yellow over blue, red
over green) remain unsatisfactory for speciﬁc types of color sensitivity.
The diagonal in Figure F.4 is almost free of any point, meaning that their is a clear de-
marcation between complementary and arbitrary colors. For most of the images (even with
the small sample size), we observe a Gaussian-like distribution, but, as already mentioned, the
bi-modal distribution for image F suggests that color sensitivity is deﬁnitely not the same for
each observer.
Brown et al. suggest that the perceived color at each point in a visual scene depends on the
relationship between light signals from that point, and light signals from surrounding areas of
the scene [Brow97]. In the well known phenomenon of simultaneous color contrast, changing the
overall brightness or hue of an object’s surround induces a complementary shift in the perceived
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Figure F.4: Graphical representation of the survey results. The circle sizes represent the number of
answers corresponding to the choice.
brightness or hue of the object’s color. These authors also demonstrated a strong compression of
the gamut of perceived colors depending on the background color. In other words, when a low-
contrast rectangle is embedded in a high-contrast mosaic of richly colored squares, it appears
as indistinct, washed-out shade of gray. But the same physically identical rectangles, when
embedded in a uniform 50% gray background, appeared much more distinct and colorful.
For our endoscopic approach, it would mean that the best contrast would be achieved by
setting the background to a complementary color related to foreground. In the bladder, the
current color implementation with magenta-green is not too far from the ideal situation, except
for people with speciﬁc red deﬁciency. An other option would be to set a grayish appearance
for the background, and the tumor in a high-contrast saturated color. In collaboration with our
industrial partner, we have implemented this approach in the bronchi (see Section 7.5).
In the future, we would like to implement color contrast adjustment directly in the imaging
system. This would allow the system to be adapted to the subjective color perception of the
user (this can to some extent combat color weaknesses of the user). Moreover, the color will
also be adjusted in critical situations, when the initial tissue diﬀerentiation is not as clear as
required, achieving the best possible distinction between healthy and diseased tissue.
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